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THESIS ABSTRACT  33 
 34 
Whilst exercise training can improve aspects of metabolic health (e.g. increasing 35 
insulin sensitivity), there can be some apparent variability between people in their 36 
response to supervised exercise training. Exercise studies typically do not control 37 
for the nutrient status of participants pre-exercise and this may, at least partially, 38 
explain this variable response. Performing a single bout of exercise before versus 39 
after eating breakfast can alter substrate metabolism during- and energy balance 40 
post-exercise. This includes increasing the utilisation of fat as a substrate during 41 
exercise, augmenting the activation of intramuscular signalling pathways relating 42 
to substrate metabolism and when breakfast is omitted, lowering energy intake 43 
on the day that the exercise is performed. These acute exercise-responses may 44 
be important for metabolic health when regularly accrued with training, especially 45 
for humans with obesity, for whom impairments relating to lipid metabolism and/or 46 
a low turnover of endogenous lipid pools (muscle and adipose tissue) may explain 47 
the association between obesity, physical inactivity and insulin resistance. The 48 
studies in this thesis first showed that when healthy men performed a bout of 49 
endurance-type exercise, substrate utilisation during exercise, plasma glucose 50 
flux at a meal consumed after the exercise, post-exercise intramuscular signalling 51 
responses and 24 h energy balance were dependant on whether breakfast was 52 
consumed before the exercise or omitted (Chapters 3 and 5). Nutrient-exercise 53 
timing was then shown to mediate training responsiveness in men classified as 54 
overweight or obese, with exercise before versus after breakfast increasing oral 55 
glucose insulin sensitivity, which was linked to increased lipid utilisation during 56 
exercise and augmented skeletal muscle adaptations (Chapter 6). These 57 
findings have implications for future research and clinical practice. For example, 58 
both acute and training exercise studies should control for nutrient-timing as a 59 
potential confounding variable when measures of postprandial metabolism are 60 
outcome measures and for populations at risk of metabolic diseases, endurance-61 
type exercise should be recommended before versus after nutrient consumption 62 
(breakfast) to increase the health benefits acquired from training. 63 




THESIS LAY SUMMARY 65 
 66 
Obesity prevalence in adults from the UK rose from 23 % to 29 % from 2000 to 67 
2016 (1) and similar trends were apparent worldwide, meaning that now ~ 2 billion 68 
humans can be classified as overweight (2). Obesity is associated with a higher 69 
risk of type 2 diabetes (T2D) and cardiovascular disease (CVD) (3) and incurs 70 
costs equating to ~ 3 % of total global spending (4). Bariatric surgery can achieve 71 
sustained weight loss and remission from metabolic diseases, but the costs and 72 
the risks involved, means that surgery is unlikely to be a solution to obesity at a 73 
population level (5). Lifestyle modifications such as exercising more frequently 74 
are also recommended to help prevent and treat metabolic diseases and obesity. 75 
However, many people fail to achieve current exercise guidelines, partly due to a 76 
perceived lack of time (6). For these people and for people who cannot increase 77 
the intensity or duration of exercise beyond a limit (e.g. due to a low fitness level), 78 
increasing the health benefits from any exercise that is performed is important. In 79 
addition, there is evidence of variability between people in their response to the 80 
same supervised exercise training, for some important health outcomes (7). The 81 
timing of food intake in relation to the exercise may be important in this regard, 82 
as exercising before versus after eating breakfast alters metabolism during- and 83 
after-exercise and some of the adaptive responses in exercised muscle (8). 84 
 85 
An infrequent use of fat stores in skeletal muscle and adipose (fat) tissue and/or 86 
a low capacity for using fat as a substrate for energy metabolism might, at least 87 
partially, explain a link between obesity and metabolic diseases, such as T2D (9). 88 
Most health-related research that has studied the effects of consuming breakfast 89 
before versus after exercise, or exercising and omitting breakfast altogether, has 90 
been conducted in a laboratory, in healthy men, and over a short (< 24 h) time 91 
frame (8). Exercising before breakfast increases fat use during exercise and also 92 
alters the magnitude of some adaptations that are important for health in muscle 93 
and fat tissue compared to exercising after- (and particularly a carbohydrate-rich) 94 
breakfast (10-14). In theory, this may enhance the health benefits of the exercise. 95 




diet over six weeks, exercising before, but not after, consuming a carbohydrate-97 
rich breakfast increased estimates of insulin sensitivity (a predictor of T2D risk) 98 
compared to a non-exercise group (11). Other research has also shown that the 99 
energy deficit created from omitting breakfast before exercise is not compensated 100 
for with a higher energy intake after exercise over 24 h (15, 16), which may create 101 
the conditions for a negative energy balance and greater long-term weight loss, 102 
compared to when breakfast is eaten before exercise. This finding is line with the 103 
theory that people who use less carbohydrate and more fat to fuel exercise may 104 
be less likely to compensate for the energy deficit from the exercise by eating 105 
more afterwards (17). However, an assessment of energy intake and expenditure 106 
over 24 h has not been reported in this context. Training studies in humans with 107 
obesity are also required to develop the current research in healthy men.  108 
 109 
As such, the research in this thesis aimed to investigate the effects of breakfast 110 
consumption versus omission before exercise or altered breakfast timing, for the 111 
short- and longer-term regulation of energy metabolism and energy balance. The 112 
research in Chapter 3 showed that glucose metabolism and adaptive responses 113 
in skeletal muscle differ after a single bout of exercise performed after breakfast, 114 
compared to if breakfast is omitted. Some methodological considerations were 115 
then explored in Chapter 4 and insights were provided into how different methods 116 
of sampling blood can alter the concentrations of measured metabolites. Then, in 117 
Chapter 5, an assessment of all behavioural components of energy balance was 118 
completed over 24 h, with exercise and breakfast consumption versus omission. 119 
In that study, we showed that breakfast omission versus consumption before 120 
exercise creates a more negative daily energy balance in healthy men, and that 121 
rates of carbohydrate use from the liver may help to explain differences in energy 122 
intake after exercise. Finally, in Chapter 6, thirty middle-aged and sedentary men 123 
classified as either overweight or obese, were allocated to either a no-exercise 124 
group, a breakfast before exercise group or an exercise before breakfast group 125 
for a six-week intervention. The exercise groups completed 30-50 min cycling, 126 
three times weekly and ate the same breakfast, but either before or after they did 127 




with exercise training before versus after breakfast and this was accompanied by 129 
augmented adaptations that relate to metabolic health in the exercised muscle. 130 
This response also occurred despite no clear differences between the groups for 131 
changes in body mass or behavioural components of energy balance in response 132 
to the intervention. That study therefore suggested that for some important health 133 
outcomes, people classified as overweight or obese should consider exercising 134 
before versus after eating breakfast. Overall, the research in this thesis provides 135 
insights into how exercise performed during fasting (i.e. with breakfast omission 136 
or with breakfast consumption but after exercise) alters the short- and the longer-137 
term regulation of energy metabolism and energy balance relative to exercising 138 
after eating. In Chapter 7, the results from all of the studies and their implications 139 
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COMMON ABBREVATIONS USED 170 
 171 
Throughout this thesis abbreviations are defined upon first use in each chapter. 172 
This list only details the abbreviations that are most commonly used:  173 
 174 
Akt = protein kinase B (also known as PKB) 175 
AMPK = 5′‐ adenosine monophosphate activated protein kinase  176 
AS160 = Akt substrate of 160 kDa 177 
AUC = area under the curve (iAUC = incremental area under the curve) 178 
AV = arterialised-venous  179 
BE (or BR-EX) = breakfast before exercise 180 
BHB = β-hydroxybuturate 181 
β-HAD = β-hydroxyl-coenzyme A-dehydrogenase 182 
BMI = body mass index 183 
C = carbon  184 
CS = citrate synthase 185 
CPT = carnitine palmitoyltransferase  186 
CVD = cardiovascular disease 187 
DEXA = dual energy x-ray absorptiometry 188 
ETC = electron transport chain 189 
EX-BR = exercise before breakfast 190 
FE = fasted exercise (breakfast omission) 191 
FGF21 = fibroblast growth factor 21 192 
GNG = gluconeogenesis 193 
GLP-1 glucagon-like peptide-1 194 
GLUT4 = glucose transport-4 proteins 195 
HDL = high density lipoprotein (LDL = low density lipoprotein) 196 
H = hydrogen  197 
HGP = hepatic glucose production 198 
HR = heart rate 199 
IFAB-P = intestinal fatty acid binding protein  200 
mRNA = messenger ribonucleic acid 201 
N = nitrogen  202 
NEFA = non-esterified fatty acids 203 
O = oxygen 204 
PL = phospholipid 205 
PPO = peak power output 206 
RER = respiratory exchange ratio 207 
RPE = rating of perceived exertion  208 
TCA cycle = tricarboxylic acid cycle 209 
T2D = type 2 diabetes 210 
TAG = triglyceride 211 
TCA = tricarboxylic acid  212 
V̇O2 = oxygen uptake (V̇O2 peak = peak oxygen uptake) 213 
V̇CO2 = carbon dioxide production 214 




CHAPTER 1 - LITERATURE REVIEW 216 
 217 
OBESITY AND METABOLIC DISEASE 218 
Obesity can be defined as the excessive expansion of primarily white adipose 219 
tissue depots, which can be largely attributed to a long-term energy imbalance, 220 
where daily energy intake exceeds the energy requirements of an individual (18). 221 
Worldwide, it is estimated that ~ 2 billion adults can be classified as overweight 222 
(with a body mass index (BMI) of between 25 and 29.9 kgm-2) and 600 million 223 
adults classified as obese, with a BMI > 30 kgm-2 (2). In the UK, the number of 224 
adults classified as obese increased from 23 % to 29 % between 2000 and 2016, 225 
with the prevalence in 11-15 year olds also rising from 19 % to 23 % during that 226 
period (1). These data are reinforced by reports that 39 % of adults in the UK can 227 
be classified as having a ‘very high’ waist circumference [i.e. > 102 cm for men 228 
and > 88 cm for women (1)]. The prevalence of obesity in young people is 229 
worrying, as it will likely result in a greater number of adults living with the 230 
comorbidities of obesity for the majority of their lives, reducing their quality of life 231 
and overall life expectancy. Indeed, the Global BMI Mortality Collaboration 232 
estimated that the risk of all-cause mortality is 45 % higher in people with class I 233 
obesity (BMI: 30.0 to 34.9 kgm-2) and 176 % higher in people with class III obesity 234 
(BMI: 40.0 to 59.9 kgm-2), relative to people with a BMI in the healthy range (19).  235 
 236 
Although obesity is reported to have directly accounted for < 1 % of deaths from 237 
1995 to 2006 (20), it is associated with a clustering of metabolic diseases, such 238 
as type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD) and 239 
cardiovascular disease (CVD) and these increase mortality risk (3). In line with 240 
the obesity trends, the number of people diagnosed with T2D in the UK has risen 241 
> 4 fold since 1980 (21). It is also estimated that in the UK, there will be a further 242 
11 million cases of obesity, 600,000 cases of T2D and 400,000 cases of coronary 243 
heart disease and stroke by 2030 (22). Another concern is that the average health 244 
care expenditure in the UK is estimated to be 10 %, 23 %, 45 % and 81 % higher 245 
for individuals classified as overweight, or with class I, II or III obesity respectively, 246 




~ £6 billion in direct medical costs for obesity (> 5 % of their yearly budget) and 248 
obesity also incurs productivity losses of ~ £3.3 billion, costs due to absenteeism 249 
of ~ £1.3 billion and costs associated with treating metabolic diseases associated 250 
with obesity, for example ~ £14 billion for T2D (24). As such, the overall costs of 251 
obesity to the UK economy are estimated to be in the region of £50 billion per 252 
year or ~ 3 % of gross domestic product and worldwide obesity is estimated to 253 
cost ~ £1.32 trillion per year (4). As such, interventions that can successfully 254 
reduce obesity prevalence at a population level and/or prevent the development 255 
of the associated metabolic diseases are still urgently required. Indeed, reducing 256 
obesity and metabolic disease prevalence was one of the primary targets outlined 257 
in the ‘Global Action Plan for the Prevention and Control of Non-Communicable 258 
Diseases: 2013-2020’, that was produced by the World Health Organisation (25).  259 
 260 
FASTING AND POSTPRANDIAL METABOLISM 261 
Metabolic health is an umbrella term that has been used to describe the ability of 262 
the body to maintain homeostasis of substrates from a whole-body to a molecular 263 
level in response to physiological challenges such as exercise or nutrient intake. 264 
The consequences of a sustained positive energy balance (i.e. adiposity) and the 265 
individual components of human behaviour that are primarily responsible for the 266 
development of obesity (excessive energy intake and/or a sedentary lifestyle) are 267 
independent risk factors for many chronic diseases such as T2D and CVD, in part 268 
by impairing normal fasting and postprandial substrate metabolism (26-28).  269 
 270 
Glucose metabolism  271 
When plasma volume remains unchanged, blood glucose concentrations depend 272 
on endogenous and meal-derived rates of glucose appearance versus rates of 273 
glucose disposal primarily into the liver and peripheral tissues (29). The regulation 274 
of blood glucose is primarily coordinated by the actions of the liver, the adipose 275 
tissue and skeletal muscle. In a resting overnight fasted state, blood glucose 276 
concentrations are maintained at ~ 4-5 mmol·L-1 (or ~ 4.6 g for a 70 kg man) in 277 
healthy humans (30). This is despite a relatively high rate of blood glucose 278 




adipose tissue (31). If the glucose extracted from the blood into peripheral tissues 280 
was not replaced, brain and metabolic dysfunction would quickly develop (30). 281 
The liver has a key role in regulating blood glucose levels during fasting and 282 
extracted blood glucose is largely replaced via hepatic glucose production (HGP) 283 
from glycogenolysis (breakdown of glycogen to glucose) and gluconeogenesis 284 
[GNG; formation of glucose from non-glucose substrates (30)]. Two hormones 285 
primarily regulate blood glucose concentrations and these are insulin and 286 
glucagon. Glucagon is released from the α-cells in the pancreas when systemic 287 
glucose concentrations are low and upon reaching the liver, glucagon promotes 288 
glycogenolysis and inhibits glycogen formation, thus increasing the net secretion 289 
of glucose into the systemic circulation (32-34). This response to increased 290 
systemic glucagon concentrations helps to prevent hypoglycaemia during fasting. 291 
The degradation of glycogen occurs via the coordinated action of glycogen 292 
phosphorylase (acting on the terminal α-1, 4-glycosidic linked glucose residues 293 
of glycogen) and glycogen debranching enzyme (acting on α-1, 6-branchpoints) 294 
to form glucose and glucose-1-phosphate, which can then be converted to 295 
glucose-6-phosphate by hexokinase (HK) or phosphoglucomutase, respectively 296 
(35). The glucose-6-phosphate can be used in tissues where the glycogenolysis 297 
occurred as a substrate for glycolysis (35) or in gluconeogenic tissues (mainly the 298 
liver but also the kidneys and intestines) glucose-6-phosphate can be transported 299 
to the endoplasmic reticulum, where it can be dephosphorylated to form glucose 300 
for secretion into the systemic circulation (35). The breakdown versus synthesis 301 
of glycogen is primarily regulated by a hormone-triggered cAMP cascade acting 302 
via protein kinase A [PKA; (35)]. The main substrates for GNG are lactate and 303 
pyruvate, but glycerol and amino acids such as alanine can contribute (31).  304 
 305 
The consumption of food provokes a complex endocrine and paracrine response 306 
(31), resulting in a profound shift in hepatic and whole-body metabolism from net 307 
glucose production to net storage. The carbohydrate content (75-100 g) of meals 308 
typically consumed in developed countries could, theoretically, increase blood 309 
glucose concentrations by > 8 fold (31). However, at least in metabolically healthy 310 




meals, which is only a 50-60 % increase above normal fasting concentrations 312 
(31). In healthy humans, blood glucose concentrations above typical fasting 313 
levels are detectable for up to ~ 2 h after 75-100 g of carbohydrate is ingested, 314 
although plasma glucose flux can be increased for longer than this (36).  315 
 316 
A primary hormone with respect to postprandial blood glucose regulation is insulin 317 
(37). An increase in blood glucose concentrations stimulates insulin synthesis in 318 
the β-cells of the pancreas (38) and its secretion into the systemic circulation (39). 319 
As blood glucose concentrations rise after carbohydrate consumption, the β-cell 320 
glucose concentration also increases and this phosphorylates pancreatic and 321 
duodenal homeobox 1 (PDX1), which upregulates insulin gene transcription (38). 322 
Insulin messenger ribonucleic acid (mRNA) is then translated as preproinsulin. 323 
Cleaving of the N-terminal of preproinsulin upon its insertion into the endoplasmic 324 
reticulum forms proinsulin, which consists of an amino-terminal β-chain, a 325 
carboxyl-terminal α-chain and a C-peptide molecule. Within the endoplasmic 326 
reticulum, proinsulin is exposed to endopeptidases such as PC1 and PC2 which 327 
cleave C-peptide to generate a mature form of insulin. An increase in glucose 328 
concentrations in the pancreatic β-cells also increases adenosine triphosphate 329 
(ATP) production. As a consequence, ATP-sensitive potassium (K+) channels at 330 
the plasma membrane close, which disrupts the resting membrane potential and 331 
opens the voltage-sensitive calcium (Ca2+) channels. An influx of Ca2+ ions into 332 
the β-cell triggers the exocytosis of secretory vesicles and thus facilitates insulin 333 
secretion into the systemic circulation (39). Gastrointestinal-derived peptides 334 
such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 335 
peptide (GIP) are also secreted from intestinal enteroendocrine cells after meal 336 
ingestion and potentiate this glucose-stimulated insulin secretion response (40).  337 
 338 
After meals, a proportion of the exogenous glucose is taken up by the liver in the 339 
first-pass extraction from the portal vein and uptake from the hepatic artery (41) 340 
the kidneys and the intestine (42), but the remaining meal-derived glucose enters 341 
the systemic circulation, before being disposed of by the peripheral tissues (43). 342 




(44) and by increasing blood glucose disposal. Skeletal muscle accounts for up 344 
to 90 % of insulin-stimulated blood glucose disposal during a hyperinsulinaemic-345 
euglycemic clamp (43) compared to < 5% for adipose tissue (45). However, with 346 
oral glucose ingestion, the relative contribution of skeletal muscle to whole-body 347 
blood glucose disposal is lower than during a hyperinsulinaemic-euglycaemic 348 
clamp at ~ 30-40 % of the ingested glucose, which is broadly similar to the uptake 349 
from splanchnic tissues, with the remainder accounted for by the brain, kidneys, 350 
heart and the adipose tissue (46, 47). Insulin increases glucose disposal into 351 
skeletal muscle by stimulating a translocation of the glucose transporter proteins 352 
(GLUT4) from specialised intracellular storage compartments to the cell plasma 353 
membrane and also by increasing intrinsic GLUT4 activity (Figure 1.1).  354 
 355 
At rest and without insulin stimulation up to 90 % of the GLUT4 remain within their 356 
intracellular vesicles (48). However, if insulin binds to the extracellular α-subunit 357 
of the insulin receptor at the cell plasma membrane, tyrosine residues located in 358 
the β-subunit are auto-phosphorylated (i.e. insulin receptor tyrosine kinase [IRTK] 359 
activation) and can be recognised by a phosphotyrosine-binding domain on the 360 
insulin receptor substrate (IRS) proteins (49, 50). As a result the tyrosine residues 361 
on the IRS proteins [IRS-1 and IRS-2 are the most important in skeletal muscle 362 
and adipocytes (50)] are phosphorylated by IRTK and in turn will bind to the p85 363 
regulatory subunit of Class IA phosphatidylinositol-3-kinase [PI3K; (49, 50)]. At 364 
the plasma membrane, the p110 catalytic subunit of PI3K then phosphorylates 365 
phosphatidylinositol 4,5-bisphosphate [PtdIns-(4,5)-P2] resulting in the formation 366 
of phosphatidylinositol (3,4,5)-triphosphate [PtdIns-(3,4,5)-P3] (49, 50). Protein 367 
kinase B (Akt/PKB) is then recruited to the cell membrane with the higher cellular 368 
PtdIns-(3,4,5)-P3 concentration via its pleckstrin homology domain (PH domain). 369 
In skeletal muscle and adipose tissue, Akt2 is the isoform of Akt implicated in the 370 
subsequent signalling pathway for GLUT4 translocation and exocytosis (51). 371 
 372 
The increased intracellular PtdIns-(3,4,5)-P3 levels produced by PI3K also 373 
recruits 3-phosphoinositide-dependent kinase-1 (PDK1), which phosphorylates 374 




by mammalian target of rapamycin complex 2 (mTOR-C2). Activated Akt in turn 376 
phosphorylates many downstream proteins such as the Rab GTPase activating 377 
proteins Akt substrate of 160 kDa (AS160/TBC1D4) and TBC1D1 (52, 53). AS160 378 
and TBC1D1 activity promotes the hydrolysis of GTP to GDP by the Rab proteins 379 
on GLUT4 storage vesicles, thereby keeping the GLUT4 vesicles inside the cells. 380 
However, if AS160 and TBC1D1 are phosphorylated they become deactivated, 381 
leading to increased GTP loading of the Rab proteins on the GLUT4 vesicles, 382 
which increases GLUT4 trafficking to the plasma membrane (51, 54). The binding 383 
of insulin to the insulin receptor can also phosphorylate a protein known as c-Cbl, 384 
which exists as a complex with catabolite activator protein (CAP) (49). There is 385 
evidence that with insulin stimulation, this complex is recruited to the plasma 386 
membrane and stimulates GLUT4 translocation in the adipose tissue through this 387 
pathway, independently of insulin-stimulated PI3K activation (49). Specifically, 388 
tyrosine phosphorylated c-Cbl recruits a complex of an adaptor protein - CrkII - 389 
and C3G (which is a guanine-nucleotide exchange factor for the GTPase TC10), 390 
which then activates TC10 and thereby stimulates GLUT4 translocation (49, 55). 391 
 392 
After glucose is transported into the myocyte through the GLUT4 transporter, it is 393 
irreversibly phosphorylated by hexokinase (HK) before being stored as glycogen 394 
or entering the glycolytic pathway for oxidation (Figures 1.2 & 1.3). The HK 395 
isoenzymes have a high affinity for glucose but are also inhibited by glucose-6-396 
phosphate, which is the first product formed in the conversion of glucose to 397 
pyruvate (32). With increased blood insulin concentrations, skeletal muscle HK 398 
(and particularly HK-II) mRNA levels, protein content and activity increases (32). 399 
During fasted rest, glucose entering skeletal muscle is directed towards glycogen 400 
synthesis versus glycolysis in roughly equal proportions and ~ 90 % of glucose 401 
entering the glycolytic pathway is oxidised (aerobic glycolysis) with the remainder 402 
converted to lactate (anaerobic glycolysis). However, with higher blood insulin 403 
levels (after carbohydrate ingestion) glycogen synthase is increasingly activated 404 





Insulin activates glycogen synthase through PI3K signalling, by phosphorylating 407 
site 1 on a subunit of protein phosphatase 1 (PP1), in a reaction that is catalysed 408 
by insulin-stimulated protein kinase-1 (57). Phosphorylation of site 2 on PP1 by 409 
PKA inactivates the protein and insulin also decreases PKA activity by activating 410 
phosphodiesterase (PDE3B), which converts cyclic adenosine monophosphate 411 
(cAMP) to adenosine monophosphate (AMP) (58). Insulin may also increase 412 
glycogen synthase activity by inhibiting glycogen synthase kinase-3 (57). Finally, 413 
insulin promotes glucose uptake via increased GLUT4 trafficking (Figure 1.1) 414 
and the consequent increase in glucose 6-phosphate production allosterically 415 
activates glycogen synthase (57). Some rodent models suggest that inhibition of 416 
glycogen synthase kinase-3 is not rate-limiting for muscle glycogen synthesis and 417 
that allosteric regulation of glycogen synthase activity by glucose-6-phopshate 418 
may play the more important role in insulin-stimulated muscle glycogen synthesis 419 
(59). Therefore, to summarise, insulin promotes net glucose storage as glycogen 420 
in skeletal muscle by (a) increasing intracellular GLUT4 trafficking (b) increasing 421 
HK activity/glucose phosphorylation and (c) stimulating glycogen synthesis (32).  422 
 423 
Insulin can also influence blood glucose concentrations by decreasing hepatic 424 
glucose production (HGP). Since it is secreted in the portal vein, the liver is the 425 
first tissue encountered by endogenous insulin and HGP can be lowered by a 426 
suppression of glycogenolysis via signalling pathways that are activated with the 427 
binding of insulin to its hepatic receptor (60). Hepatic insulin action begins with 428 
insulin receptor tyrosine kinase (IRTK) activation which, as described previously, 429 
leads to PI3K and PDK1/mTORC2 activation to phosphorylate Akt, which in turn, 430 
regulates aspects of hepatic glucose and lipid metabolism. Glycogenolysis starts 431 
with a formation of glucose-1-phosphate from glycogen, which is catalysed by the 432 
phosphorylated ‘a’ active form of glycogen phosphorylase. The inactive ‘b’ form 433 
of glycogen phosphorylase is converted to the ‘a’ form by PKA (32). Insulin can 434 
supress glycogenolysis by activating PP1 (which converts the ‘a’ to the ‘b’ form 435 
of glycogen phosphorylase) and by inhibiting PKA. However, insulin infused 436 
peripherally can also be as effective for suppressing HGP as intra-portal insulin 437 




(61). Glucagon stimulates HGP but systemic glucagon concentrations decrease 439 
with insulin infusions (62), because insulin inhibits glucagon secretion from the 440 
pancreatic α-cells (63). This effect of insulin may contribute to a suppression of 441 
HGP, because when blood glucagon concentrations are maintained during an 442 
insulin infusion, the suppression of HGP is lessened (64). Insulin also decreases 443 
the mobilisation of non-esterified fatty acids (NEFA) and glycerol from the adipose 444 
tissue and amino acids from skeletal muscle, reducing their availability for GNG 445 
in the liver (61). Insulin-mediated changes in adipokine secretion (61) and at least 446 
in rodents, a signalling pathway from the brain to liver may also help to regulate 447 
a suppression of HGP with higher blood insulin concentrations (65). Therefore, 448 
direct hepatic signalling and indirect (i.e. peripheral) effects likely contribute to an 449 
insulin-induced inhibition of HGP following nutrient ingestion. 450 
 451 
Fatty acid metabolism  452 
The amount of energy stored in the human body as glycogen is limited at around 453 
100 g in the liver and 350-700 g in skeletal muscle, with smaller depots in the 454 
brain, heart, kidneys and the adipose tissue (66). This limited storage capacity is 455 
mainly due to the low energy density of carbohydrates and the implications this 456 
would have for the mass that would need to be moved during physical activity. 457 
Humans can also utilise lipids as a fuel for energy metabolism and compared to 458 
glucose, fatty acids have a higher energy density [~ 40 kJg-1 for palmoyl-stearol-459 
oleoyl glycerol [PSOG] which is representative of triglyceride [TAG] from adipose 460 
tissue relative to ~ 15 kJg-1 for glucose (31, 67)]. As such, the capacity of the 461 
human body for storing lipids is greater than carbohydrates at ~ 10 kg for a lean 462 
75-80 kg man (66). In humans, lipids are mostly stored as TAG, which are formed 463 
from 3 fatty acids and 1 glycerol molecule, primarily in the subcutaneous adipose 464 
tissue, although skeletal muscle (~ 300 g for a lean 75-80 kg man) and the liver 465 
also have their own smaller, stores (31). The adipose tissue is mostly comprised 466 
of adipocytes, which exist in a matrix of blood vessels, immune cells, collagen 467 
and fibroblasts. A delivery of fatty acids to the adipose-tissue is mainly from 468 
chylomicrons derived from the intestine after the ingestion of a meal, and very 469 




the synthesis of TAG can be obtained either from glycerol-3-phosphate which is 471 
derived from glycolysis, or from oxaloacetate via glycerolneogenesis (68). 472 
 473 
Lipids are insoluble in aqueous solutions, but are soluble in organic solvents and 474 
therefore in order to be transported in the plasma, the majority of lipids are bound 475 
to albumin for non-esterified fatty acids (NEFA) or carried in lipoprotein particles. 476 
Depending upon the methodology used and participants studied, plasma NEFA 477 
concentrations range between ~ 300-600 μmol·L-1 in the overnight fasting state, 478 
to ∼ 1,300 μmol·L-1 after a 72-h fast (69). Cholesterol is not a metabolic energy 479 
source but is an essential component of plasma membranes and a precursor for 480 
steroid hormones and a variety of other specialised molecules (32). Cholesterol, 481 
TAG and phospholipids (molecules containing 2 fatty acids with a water-soluble 482 
phosphate end) are transported in the systemic circulation as complexes called 483 
lipoproteins, which are made from lipids and proteins and are classified according 484 
to their size and lipid content (32). VLDL and low-density lipoproteins (LDL) are 485 
TAG- and cholesterol-rich particles respectively, which are transported from the 486 
liver to the peripheral tissues, whereas high-density lipoproteins (HDL) remove 487 
excess cholesterol from the periphery and return it to the liver for excretion (32).  488 
 489 
When humans ingest a meal containing fat, the dietary fat is digested and broken 490 
down into NEFAs and monoglycerides, before being re-esterified in the intestine. 491 
Dietary lipids enter the systemic circulation as apolipoprotien B48 (ApoB48)- 492 
TAG-rich chylomicrons, which transport lipids from the intestine to the peripheral 493 
tissues for utilisation or storage (32). Blood TAG concentrations typically increase 494 
steadily after the ingestion of a meal containing fat and peak at ~ 5 h post-meal, 495 
whereas (especially if the meal elicits an insulin response), NEFA concentrations 496 
are decreased, often to negligible levels (70, 71). The ingestion of 20-30 g of 497 
dietary fat causes smaller perturbations to systemic TAG concentrations (often 498 
not > 1.0 mmolL-1) relative to the changes in blood glucose concentrations that 499 
can occur after a carbohydrate-rich meal is ingested (31). In skeletal muscle and 500 
the adipose tissue, TAG derived from chylomicrons, VLDL and LDL is hydrolysed 501 




TAG resynthesis can then occur (32). If a mixed-macronutrient meal is consumed 503 
by healthy humans, insulin also plays a role in dietary fat trafficking, diverting TAG 504 
towards storage in the adipose tissue by up-regulating LPL activity in the adipose 505 
tissue, down-regulating LPL activity in muscle and supressing the mobilisation of 506 
adipose-tissue derived fatty acids and liver-derived lipid [as discussed later in this 507 
literature review (32)]. In humans, the primary depot from where fatty acids are 508 
liberated for energy metabolism is the subcutaneous adipose tissue, due to the 509 
larger size of this store compared to visceral adipose tissue (72).  510 
 511 
The lipolysis of TAG occurs in 3 main stages (Figure 1.4). The first hydrolysis is 512 
catalysed by adipose triglyceride lipase (ATGL) and hormone sensitive lipase 513 
(HSL) and this forms diacylglycerol (DAG) and releases a non-esterified fatty acid 514 
chain (NEFA). DAG can be further hydrolysed by HSL to release a second NEFA 515 
molecule and a third NEFA can be released with a hydrolysis of monoacylglycerol 516 
(MAG) by monoacylglycerol lipase (MAGL). Adipose-tissue derived NEFA can be 517 
transported to skeletal muscle for metabolism, where they undergo β-oxidation, 518 
before the tricarboxylic acid cycle (TCA) and the electron transport chain (ETC) 519 
occur (Figures 1.5 & 1.6). Alternatively they can undergo re-esterification and 520 
remain in the adipocyte (73) and during prolonged fasting > 40 % of NEFA can 521 
be recycled back into TAG in this manner (74). However, as glycerol kinase is not 522 
present in human adipose tissue, glycerol is still released into the systemic 523 
circulation despite fatty acid re-esterification. As such, the rate of appearance of 524 
glycerol into the systemic circulation has been used to assess rates of lipolysis.  525 
 526 
During fasting, β-adrenergic receptor activation in the adipose-tissue stimulates 527 
adenylyl cyclase activity and the increased production of cAMP (75). The cAMP 528 
molecule binds to and activates PKA, which in turn, increases the activation of 529 
proteins that regulate lipolysis, including HSL (75). Perilipins form a protective 530 
barrier for TAG against intracellular lipase activity, but with the activation of PKA, 531 
a conformational change occurs, which permits greater access to the lipid within 532 
the droplet (76). Whilst not a main focus of this review, other hormones stimulate 533 




(58) and interleukin 6 (IL-6) (77). AMPK (5′‐ adenosine monophosphate activated 535 
protein kinase) is also activated under conditions of lower energy availability and 536 
promotes catabolic pathways in part due to its inhibitory effects on acetyl-CoA 537 
carboxylase (ACC); the enzyme responsible for catalysing the carboxylation of 538 
acetyl coenzyme A (acetyl-CoA) to malonyl coenzyme A (malonyl-CoA), in the 539 
first committed step of lipogenesis (78). Thus, in healthy humans the contribution 540 
of NEFA to metabolism is higher than glucose in a fasted, rested state (31, 79). 541 
 542 
However, following the ingestion of a carbohydrate-rich meal, higher blood insulin 543 
concentrations reduce the net mobilisation of adipose-derived fatty acids (80). In 544 
healthy humans, the EC50 of insulin (the concentration to facilitate a half-maximal 545 
response) to supress lipolysis is ~ 50 % of the EC50 of insulin for supressing HGP, 546 
showing the sensitivity of adipose tissue to insulin (81). As stated previously, the 547 
binding of insulin to the insulin receptor results in the tyrosine phosphorylation of 548 
IRS proteins and binding of PI3K. The consequent activation of PI3K inhibits PKA 549 
activity via Akt signalling (Figure 1.4). Insulin also increases net glucose disposal 550 
into the adipose tissue by increasing GLUT4 trafficking (via Akt signalling) and in 551 
the presence of insulin, hydrolysed NEFA are increasingly re-esterified, using 552 
glycerol-3-phosphate from glucose entering the adipocyte to re-form TAG (31). 553 
Insulin can also stimulate enzymes involved in the esterification of fatty acids to 554 
glycerol, including glycerol-3-phosphate acyltransferase, which catalyses the rate 555 
limiting step in TAG synthesis in adipose tissue (82). This effect of insulin partly 556 
occurs via sterol regulatory element binding proteins, such as SREPB-1c, which 557 
activate the transcription of genes encoding lipogenic enzymes (83). In contrast, 558 
in the absence of insulin, lipogenic pathways are suppressed and ATGL and HSL 559 
(which are inhibited by insulin via PKA signalling), liberate fatty acids from their 560 
glycerol base, allowing them to be secreted into the systemic circulation.  561 
 562 
The glucose-fatty acid cycle (Randle cycle) 563 
In a transition from fasting to feeding, insulin stimulates increased blood glucose 564 
disposal and carbohydrate utilisation by skeletal muscle and supresses rates of 565 




NEFA for metabolism (84). In addition, higher rates of lipid availability reduces 567 
glucose utilisation in skeletal muscle. When TAG are infused intravenously and 568 
in concert with heparin (which activates LPL, thus allowing it to interact with the 569 
infused TAG to release NEFA) peripheral blood glucose disposal is decreased 570 
(85). This regulation of metabolism according to systemic substrate availability 571 
and the co-ordination between the liver, skeletal muscle and the adipose tissue 572 
in this regard, reduces competition for substrate utilisation in skeletal muscle (84).  573 
 574 
A regulation of metabolism according to substrate availability also occurs within 575 
skeletal muscle. NEFA taken up into skeletal muscle are first transported across 576 
the mitochondrial membrane before they undergo β-oxidation, to form acetyl-CoA 577 
for the TCA cycle (31). An accumulation of acetyl-CoA, NADH and citrate can 578 
supress pyruvate dehydrogenase (PDH) and phosphofructokinase (PFK) activity 579 
respectively (86) and these enzymes have roles in pathways that convert glucose 580 
to pyruvate and the decarboxylation of pyruvate to acetyl CoA (Figure 1.2). This 581 
results in glucose-6-phosphate accumulation, an inhibition of HK and ultimately 582 
a reduction in glycolysis (86). In turn, an increased utilisation of glucose increases 583 
malonyl-CoA production, which inhibits the carnitine palmitoyltransferase (CPT) 584 
mediated transport of lipids across the mitochondrial membrane (86). An ability 585 
to adjust metabolism to substrate availability and energy demands is a key aspect 586 
of metabolic health (87). For example, in response to eating a carbohydrate-rich 587 
meal, metabolic flexibility represents the efficient transition in substrate utilisation 588 
in favour of carbohydrates from mostly lipids during fasting. The purpose of this 589 
response is to move from a catabolic state where glycogenolysis and lipolysis 590 
meet energy demands during fasting, to a more anabolic state where the ingested 591 





Figure 1.1.  Insulin-stimulated GLUT4 translocation in skeletal muscle and the 594 
adipose tissue. Insulin binding to the insulin receptor at the plasma membrane 595 
results in the phosphorylation (and activation) of Akt. In turn, this results in the 596 
phosphorylation (and deactivation) of proteins downstream of Akt such as AS160 597 
and TBC1D1, which regulate the processes involved in GLUT4 translocation from 598 
their intracellular vesicles to the plasma membrane. The activation of a Cbl-CAP 599 
complex is also thought to mediate insulin-stimulated GLUT4 trafficking in the 600 
adipose tissue. Drawn using information provided in (49, 50).  601 
 602 
Abbreviations:  603 
GLUT4 = glucose transporter 4 604 
IRTK = insulin receptor tyrosine kinase 605 
IRS = insulin receptor substrate 606 
PI3-K = phosphoinositide 3-kinase 607 
PtdIns-(3,4,5)-P3 = phosphatidylinositol (3,4,5)-trisphosphate  608 
PDK1 = 3-phosphoinositide-dependent kinase-1 609 
mTOR-C2 = mammalian target of rapamycin complex 2  610 
Akt = protein kinase B 611 
AS160 = Akt substrate of 160 kDa 612 
CAP = Cbl-associated protein 613 










































Figure 1.2. The formation of Acetyl-CoA from glucose (i.e. glycolysis) for the 616 
tricarboxylic acid cycle (TCA cycle). As fructose 1,6, bisphosphate is unstable, it 617 
splits into two 3 carbon products, so two 3 carbon (Pyruvate) molecules are 618 
produced for each glucose molecule. Drawn using information provided in (32).  619 
 620 
Abbreviations:  621 
TCA cycle = tricarboxylic acid cycle or the Krebs cycle (see Figure 1.6) 622 
LDH = Lactate dehydrogenase 623 
PDH = Pyruvate dehydrogenase 624 
NAD+/NADH = nicotinamide adenine dinucleotide (oxidised/reduced form) 625 
ATP = adenosine triphosphate 626 





Figure 1.3. Pathways by which glucose can be oxidised (glycolysis) or converted 629 
to glycogen (glycogenesis) after it has been transported into skeletal muscle and 630 
phosphorylated by hexokinase. Drawn using information provided in (32).  631 
 632 
Abbreviations: 633 
TCA cycle = tricarboxylic acid cycle or the Krebs cycle (Figure 1.5) 634 
LDH = Lactate dehydrogenase 635 





Figure 1.4. The lipolysis of triglycerides (TAG). Catecholamines stimulate- and 638 
insulin inhibits lipolysis, primarily acting via pathways which regulate the activity 639 
of protein kinase A (PKA). In this figure the red arrow denotes an inhibitory effect 640 
of Akt signalling (decreasing cAMP concentrations) on PKA activity. Drawn using 641 
information provided in (75).  642 
 643 
Abbreviations:  644 
IRTK = insulin receptor tyrosine kinase 645 
IRS = insulin receptor substrate 646 
PI3-K = phosphoinositide 3-kinase  647 
 Akt = protein kinase B  648 
PDE3B = phosphodiesterase 3B 649 
PKA = protein kinase A 650 
TAG = triglyceride or triacylglycerol 651 
DAG = diacylglycerol 652 
MAG = monoacylglycerol 653 
ATGL = adipose triglyceride lipase 654 
HSL = hormone-sensitive lipase 655 
MGL = monoacylglycerol lipase 656 
NEFA = non-esterified fatty acid 657 



































Figure 1.5. The β-oxidation of fatty acids. This occurs until the original fatty acyl 660 
chain is separated into Acetyl-CoA molecules for the tricarboxylic acid cycle (TCA 661 
cycle). Drawn using information provided in (32). 662 
 663 
Abbreviations: 664 
CAT = carnitine-acylcarnitine translocase (responsible for transporting carnitine-665 
fatty acid complexes and carnitine across the inner mitochondrial membrane) 666 
FACS = fatty-acyl-CoA synthase 667 
CPT1 = Carnitine palmitoyltransferase I 668 
CPT2 = Carnitine palmitoyltransferase II 669 





Figure 1.6. The tricarboxylic acid cycle (TCA cycle). This is a series of reactions 672 
that utilises the Acetyl-CoA molecules that have been derived from carbohydrates 673 
(Figure 1.2) and lipids (Figure 1.5) to form substrates for the electron transport 674 
chain (and the production of ATP). Drawn using information provided in (32). 675 
 676 
Abbreviations: 677 
NAD+/NADH = nicotinamide adenine dinucleotide (oxidised/reduced form) 678 
FAD/FADH2 = flavin adenine dinucleotide (oxidised/reduced form) 679 
CO2 = carbon dioxide 680 
GTP = guanosine-5'-triphosphate 681 





Figure 1.7. NEFA transport within muscle cells (for glucose see Figure 1.1). 684 
Various transporter proteins (and passive diffusion) facilitate NEFA transport 685 
across the cell plasma membrane. Transport across the mitochondrial membrane 686 
occurs via the carnitine palmitoyltransferase (CPT) system. Also see Figure 1.5 687 
for the β-oxidation of fatty acids and Figure 1.6 for the TCA cycle. Drawn using 688 
information provided in (32, 84). 689 
 690 
Abbreviations: 691 
GLUT4 = glucose transporter 4 692 
FATP = fatty acid transport protein 693 
FAT/CD36 = fatty acid translocase/cluster of differentiation 36 694 
FABPm = fatty acid binding protein 695 
FACS = fatty-acyl-CoA synthase 696 
HK = hexokinase 697 
PFK = phosphofructokinase-1 698 
PDH = pyruvate dehydrogenase 699 
CPT1 = carnitine palmitoyltransferase I 700 
CPT 2 = carnitine palmitoyltransferase II 701 
CAT = carnitine-acylcarnitine translocase 702 
TCA cycle = tricarboxylic acid cycle (or the Krebs cycle) 703 
NEFA = non-esterified fatty acid 704 




METABOLIC FLEXIBILITY AND INSULIN SENSITIVITY 706 
Impaired fasting metabolism 707 
The respiratory exchange ratio (RER) can be used to assess rates of substrate 708 
oxidation (88). The RER is an indirect measure of the respiratory quotient (RQ), 709 
which is the quantity of carbon dioxide (CO2) produced relative to oxygen (O2) 710 
consumed by a given tissue at any specific time (88). At the whole-body level, 711 
the ratio of CO2 produced to O2 consumed depends on the ratio of substrates 712 
being oxidised (88). The first reported limb balance study was in 1956, with 713 
measures of glucose and lipid utilisation via the RQ of the forearm muscle in 714 
healthy humans (89). This showed the transition in substrate utilisation in skeletal 715 
muscle from mainly lipids during fasting, towards carbohydrates after feeding. 716 
However, it has since been shown that the resting, fasted RQ of skeletal muscle 717 
can be higher in humans with obesity and T2D versus healthy humans (90, 91). 718 
This has also been shown at a whole body level using the RER (92). 719 
 720 
These results therefore suggests that at least some people with obesity display 721 
abnormalities in the ability to use lipids as a main substrate for energy metabolism 722 
in a resting, fasted state. This may be due to a reduced mitochondrial oxidative 723 
capacity (~ 20-40 %) in humans with versus without obesity (90, 93) and/or an 724 
increased presence of hyperinsulinemia and consequent suppression of lipolysis 725 
in the adipose tissue (as discussed later in this review). However, a difference in 726 
resting, fasting substrate utilisation in humans with versus without obesity is not 727 
always shown (94). Skeletal muscle has a capacity to increase O2 uptake per kg 728 
of tissue by ~ 150-fold during exercise (95) and at the whole body level, O2 uptake 729 
can increase by > 10 fold in the transition from rest to exercise (96). Thus, the 730 
relatively small decrease in mitochondrial oxidative capacity (~ 30 %) shown in 731 
some humans with obesity may be insufficient to impair lipid metabolism during 732 
resting conditions [with any inter-individual variability also potentially attributable 733 
to differences in their cardiorespiratory fitness levels (97)]. However, obesity is 734 
also associated with other impairments in energy metabolism, including in the 735 
ability to switch from predominantly lipid utilisation during periods of fasting to 736 




Impaired postprandial metabolism 738 
As early as 1931 it was proposed that insulin resistance - the reduced action of 739 
insulin - was instrumental in the onset and development of T2D (98). It has since 740 
been proposed that increased peripheral insulin resistance may also explain any 741 
link between the metabolic risk factors that characterise obesity, T2D and CVD 742 
(99). In skeletal muscle, insulin resistance primarily manifests as impairments in 743 
insulin-stimulated blood glucose disposal (99). Studies using hyperinsulinaemic-744 
euglycemic clamps have shown that obesity and T2D are associated with ~ 50 %  745 
lower rates of insulin stimulated blood glucose disposal versus healthy humans  746 
(100) and this has been mainly attributable to skeletal muscle (43). Humans with 747 
obesity but with normal glucose tolerance also show increased insulin resistance 748 
in skeletal muscle compared to lean, age- and sex-matched controls and the 749 
severity of this impairment has also been correlated with BMI (101, 102).  750 
 751 
A lower rate of insulin-stimulated peripheral glucose disposal in obesity has been 752 
attributable to defects that impair glucose transport, glucose phosphorylation and 753 
glycogen synthesis in skeletal muscle (100). However, muscle from humans with 754 
obesity or T2D does not show a reduced GLUT4 mRNA expression or GLUT4 755 
protein content compared to muscle from healthy humans, suggesting that the 756 
transcriptional or translational regulation of GLUT4 is not primarily responsible for 757 
this impairment (103). Instead, reduced insulin-stimulated GLUT4 translocation 758 
(104) and impaired HK and glycogen synthase activation (105) are more likely to 759 
be responsible. Some studies show a reduction in insulin binding to myocytes 760 
from humans with obesity or T2D (106). However, a reduction in insulin receptor 761 
number is not present in many insulin-resistant humans and does not correlate 762 
with the severity of insulin resistance (107). As such, impaired intramuscular 763 
insulin signalling may not be primarily related to defects in insulin binding (100). 764 
Some (106) but not all (108) studies report an impaired phosphorylation of the 765 
tyrosine residues on IRS proteins in T2D that is not explained by insulin receptor 766 
number or insulin binding affinity. Others have also shown that the severity of the 767 
defect (relating to impaired P13K activation) can be correlated with the decrease 768 




(109). An increased serine phosphorylation of IRS-1 in insulin resistant muscle 770 
may impair the tyrosine phosphorylation of IRS-1, but the factor(s) responsible 771 
for this effect in obesity is currently unclear (100). An increased activity of protein 772 
kinase C (PKC) is also present in insulin resistant muscle and may have a role in 773 
disrupting insulin signalling (100), as discussed subsequently. 774 
 775 
Whilst this review has a primary focus on skeletal muscle as the primary site of 776 
postprandial blood glucose disposal, insulin resistance can also occur in other 777 
tissues with obesity. In the liver, insulin resistance impairs (insulin-stimulated) 778 
glycogen synthesis and the suppression of HGP (110). Gene knock-out models 779 
suggest that in rodents this is due to increased hepatic DAG concentrations which 780 
activates PKC and impairs IRTK activation (111, 112). In humans, the hepatic 781 
DAG content and heightened PKC activation (but less so the ceramide content), 782 
can also predict hepatic insulin resistance (113). Hepatic steatosis can however 783 
develop without detectable impairments in hepatic insulin sensitivity (111). In 784 
some instances, hepatic TAG synthesis may be driven by increased fatty acid or 785 
carbohydrate (especially fructose) delivery (111). This can manifest as increased 786 
TAG synthesis and storage in the liver (as reported in non-alcoholic fatty liver 787 
disease), which can then worsen insulin resistance (111). In the adipose tissue, 788 
insulin resistance impairs (insulin-stimulated) glucose and fatty acid disposal and 789 
the suppression of lipolysis (99). Although insulin-stimulated glucose disposal in 790 
adipose-tissue is minor relative to skeletal muscle (~ 5 % of whole-body glucose 791 
disposal), glucose metabolism in adipocytes may alter fatty acid secretion via 792 
transcription factors including carbohydrate response element binding protein, 793 
which co-ordinates the transcriptional regulation of enzymes that traffic glycolytic 794 
end-products towards lipogenesis (111). Finally, around 120 pmol·L-1 of insulin 795 
results in a half-maximal suppression of lipolysis in healthy adipocytes but around 796 
300 pmol·L-1 is needed for the same effect in insulin-resistant adipose tissue 797 
(114). In insulin-resistant adipose tissue, a higher rate of fatty acid secretion then 798 
increases the likelihood of lipid synthesis occurring in the liver (111). Defective 799 
glucose disposal in skeletal muscle also increases glucose availability to the liver, 800 




Therefore, peripheral insulin resistance across multiple tissues results in fasting 802 
and postprandial hyperglycaemia (due to lower blood glucose disposal rates and 803 
impairments in the suppression of HGP) and hyperlipidaemia (due to an impaired 804 
suppression of lipolysis in adipose tissue but maintenance of fatty acid synthesis 805 
in the liver) (99). Studies in rodents suggest that hepatic insulin resistance may 806 
precede insulin resistance in other tissues (115). Nonetheless, in humans, insulin 807 
resistance in the liver has been suggested to occur concomitantly with insulin 808 
resistance in skeletal muscle (116). Despite some uncertainly in that regard, the 809 
consequent hyperglycaemia and hyperlipidaemia are important in the continual 810 
development of T2D and CVD, despite an initial increase in β-cell function (i.e. 811 
insulin secretion) initially compensating for defects in insulin action (100, 111).  812 
 813 
Lipid metabolism and insulin resistance 814 
With a sustained positive energy balance an expansion of the adipose tissue 815 
occurs via an increased number of adipocytes (i.e. hyperplasia) and hypertrophy 816 
of existing adipocytes. In particular, visceral adipose mass seems to be important 817 
for insulin sensitivity (117). The exact mechanisms underpinning any association 818 
between an increased fat mass and insulin resistance are still unclear. However, 819 
because energy metabolism is primarily regulated by the liver, adipose tissue and 820 
skeletal muscle and because insulin has effects across all of these tissues, it is 821 
unlikely that insulin resistance is attributable to one single factor. Nonetheless, 822 
since the work of Randle et al. (84) a specific role of impairments relating to lipid 823 
metabolism in the aetiology of insulin resistance has been investigated. Insulin 824 
sensitivity is impaired in myocytes exposed to adipocyte-derived lipids (118), 825 
which supports the theory that increasing lipid availability to skeletal muscle may 826 
worsen insulin resistance (119). Skeletal muscle sampled from humans with 827 
obesity often has a higher lipid content than humans without obesity, which has 828 
been demonstrated using muscle biopsy samples (120), histological staining 829 
(121), computed tomography (122) and magnetic resonance spectroscopy [MRS; 830 
(123)]. In insulin-resistant humans, the lipid content of skeletal muscle can also 831 
be correlated with the severity of insulin resistance, even after an adjustment for 832 




intramyocellular- (IMCL; lipid droplets within myocytes) versus extramyocellular-834 
lipid (EMCL; lipid located between myocytes) studies using MRS now suggest 835 
that IMCL can be more strongly correlated with peripheral insulin resistance, 836 
despite representing a small proportion of the intramuscular lipid pool (124-126). 837 
However, people who regularly exercise and often have high levels of insulin 838 
sensitivity, also have higher muscle lipid contents than sedentary people matched 839 
for body fat (127). Thus, for insulin sensitivity, the intramuscular lipid content 840 
should be interpreted in a context of factors such as the mitochondrial oxidative 841 
capacity of the muscle and how often intramuscular lipid stores are used (119).  842 
 843 
Any negative effect of lipid accumulation on insulin sensitivity (lipotoxicity) occurs 844 
when some of the lipid entering the mitochondria is only partly degraded. Lipid 845 
species such as DAG, fatty acyl-CoA esters and ceramide can then accumulate 846 
and have been proposed to interfere with insulin signalling (128-130), ultimately 847 
manifesting as impairments in insulin-stimulated glucose disposal (Figure 1.8). 848 
Increased intracellular DAG concentrations may increase PKC activity and impair 849 
IRS-1 activation (131), with ceramide acting on more distal steps within the insulin 850 
signalling cascade by inhibiting Akt2 and glycogen synthase kinase activation 851 
(132). However, the evidence linking the lipid intermediates to insulin resistance 852 
has mostly been derived from rodent models and in humans a mediating role for 853 
DAG or ceramide in the onset of insulin resistance is not always clear (133).  854 
 855 
Another factor that may, at least partly, be responsible for a link between obesity, 856 
lipid metabolism and insulin resistance is alterations to the phospholipid (PL) 857 
content of skeletal muscle (134). Although demonstrating causality is difficult, an 858 
increased saturated fatty acid content and decreased polyunsaturated fatty acid 859 
[PUFA; and in particular n-3 PUFA] content of skeletal muscle has been shown 860 
in metabolic disease states, including T2D (135). In addition, when rats are fed a 861 
high-fat diet they become insulin resistant, but the inclusion of n-3 PUFA in the 862 
diet can alleviate insulin resistance, if PUFA derivatives are incorporated into the 863 
intramuscular PL pool (136). Cross-sectional research in humans also suggests 864 




rectus abdominis and fasting blood samples were taken from coronary artery 866 
disease patients and vastus lateralis samples collected and a hyperinsulinaemic-867 
euglycaemic clamp was performed in healthy men (137). In the patients, fasting 868 
insulin concentrations were negatively correlated with the PUFA content of the 869 
intramuscular PL pool (independently of age, sex or whole-body adiposity) and in 870 
healthy men, the PUFA content of the PL pool was positively correlated with 871 
insulin sensitivity. These results were explained by the theory that properties of 872 
cell membranes are determined by their PL composition as increasing the PUFA 873 
content of cultured cells increases membrane fluidity, insulin receptor number 874 
and insulin action (138-140), and this effect is reversed if the saturated fatty acid 875 
content of the membranes is increased (140). The PL content of muscle may also 876 
alter insulin sensitivity via signalling molecules derived from C20 PUFAs (141).  877 
 878 
Whilst this review has a focus on skeletal muscle, it should be acknowledged that 879 
the systemic concentration of adipose-tissue derived hormones and inflammatory 880 
cytokines that can also impair peripheral insulin sensitivity, increases with the 881 
expansion of visceral fat mass in humans with obesity (142). For example, 882 
adipocytes from humans with obesity overexpress TNF-α, which is associated 883 
with disrupted glucose uptake in skeletal muscle and adipose tissue (143, 144). 884 
Further evidence that low-grade inflammation contributes to insulin resistance in 885 
obesity is that anti-inflammatory treatments can lower blood glucose 886 
concentrations and increase peripheral insulin sensitivity (145, 146). In addition, 887 
some inherent characteristics of the adipose-tissue are altered in obesity, for 888 
example a reduction in blood flow can occur, which reduces the capacity for 889 
nutrient and O2 delivery (147). This effect is believed to play an important role in 890 
the development of a pro-inflammatory state and may also impair the ability of 891 
the adipose-tissue to store lipids (and by doing so, increase the likelihood of 892 
ectopic storage in the liver and skeletal muscle) (148). Consequently, an 893 
association between obesity and insulin resistance is unlikely to be completely 894 
attributable to defects in skeletal muscle. However, changes in skeletal muscle 895 




Hyperinsulinemia via primary insulin hyper-secretion might also occur ahead of 897 
peripheral insulin resistance and drive increases in body mass and decreases in 898 
insulin sensitivity (149, 150). For example, hyperinsulinemia suppresses lipolysis 899 
within the adipose tissue and can inhibit the CPT-mediated transport of lipids into 900 
the mitochondria in skeletal muscle, primarily by increasing intracellular malonyl-901 
CoA concentrations (86). At an individual level obesity can be attributed to a 902 
sustained, positive energy balance (151). There is evidence in humans that when 903 
endogenous carbohydrate stores are increasingly utilised to provide energy for 904 
metabolism, appetite and energy intake are stimulated, with a higher rate of 905 
carbohydrate utilisation acting as the biological cue to replenish glycogen (17). It 906 
is therefore possible that a suppression of lipolysis and lipid utilisation in obesity, 907 
may increase the likelihood of a positive energy balance occurring via pathways 908 
relating to increased carbohydrate utilisation. Some indirect support for this 909 
theory comes from findings that fasting insulin concentrations predict body mass 910 
gains in Pima Indian children (152) and that adipose-tissue specific insulin 911 
receptor knockout mice show protection from obesity (153, 154). In mice, the 912 
genetic prevention of hyperinsulinemia during a high-fat diet also increases 913 
uncoupling protein 1 expression in adipose tissue and energy expenditure, which 914 
may also explain why these mice were protected against obesity (155). Cause-915 
and-effect relationships between hyperinsulinemia, insulin resistance and obesity 916 
are therefore complex, but common characteristics of these disease states are 917 
defects associated with lipid metabolism, a low energy flux and a low lipid flux.  918 
 919 
In obesity an accumulation of lipid species in muscle may originate from excess 920 
supply of lipid and/or a reduced rate of lipid utilisation. The intramuscular lipid 921 
content increases after a TAG and heparin infusion (increased lipid supply) and 922 
this can impair insulin sensitivity (156). There is also evidence of blood NEFA 923 
concentrations being increased in humans with versus without obesity (increased 924 
lipid supply), but these differences are not always present and/or are small and 925 
appear to be unrelated to fat mass (69). This is because with an increasing fat 926 
mass, the release of NEFA per kg of adipose tissue is reduced, due to increased 927 




Any accumulation of lipid species in skeletal muscle may also arise due to defects 929 
relating to lipid utilisation. A reduction in mitochondrial oxidative capacity of ~ 30% 930 
has been reported in skeletal muscle from humans with obesity and increased 931 
insulin-resistance versus healthy humans (90, 93). The mitochondrial oxidative 932 
capacity of skeletal muscle depends on both the mitochondrial content and the 933 
functional capacity of existing mitochondria. A reduction in mitochondrial density 934 
of ~ 40 % has been reported in muscle from humans with obesity versus lean, 935 
insulin-sensitive controls (157), but this is not always clear (100). Nonetheless, a 936 
reduction in electron transport chain (ETC) activity (157) and decreased rates of 937 
ATP synthesis in the mitochondria (158) have also been shown in muscle from 938 
humans with obesity and insulin-resistance, even if normalised to mitochondrial 939 
density, suggesting the presence of a functional defect. Muscle sampled from 940 
humans with obesity or T2D also typically has a reduced activity of CPT1, citrate 941 
synthase (CS), cytochrome c oxidase subunit I (COX1; a subunit of respiratory 942 
complex IV of the ETC) and β-hydroxyl-coenzyme A-dehydrogenase (β-HAD) 943 
compared to muscle from healthy humans (93, 159). These are enzyme markers 944 
for the capacity for lipid transport into the mitochondria, the TCA cycle, the ETC 945 
and for β-oxidation respectively. More evidence that mitochondrial deficiencies 946 
may have a role in the onset of insulin resistance is that decreasing peroxisome 947 
proliferator activated receptor γ co-activator 1α levels (PGC1α; a master regulator 948 
of mitochondrial biogenesis) in skeletal muscle increases insulin resistance (160). 949 
As such, mitochondrial defects may increase the likelihood of lipid accumulation 950 
in skeletal muscle and help explain a link between obesity and insulin resistance.  951 
 952 
However, mitochondrial defects may occur secondary to a development of insulin 953 
resistance in obesity (161). Studies have shown that feeding mice a high-fat diet 954 
(162) or raising plasma NEFA concentrations (163) can increase the content of 955 
mitochondrial enzymes in skeletal muscle and the capacity of muscle to utilise 956 
lipids, despite the development of insulin resistance. Similarly, if mice are grown 957 
to have a deficiency of PGC-1α in skeletal muscle, mitochondrial enzyme activity 958 
and the capacity of muscle to utilise lipids is reduced, but glucose tolerance can 959 




rodent muscle was often reduced to the extent that cellular ATP concentrations 961 
decreased (161). This increased intramuscular AMPK activation, which may have 962 
improved glucose tolerance by increasing GLUT4 translocation, which might not 963 
occur with a less severe mitochondrial defect (165). Nonetheless, mitochondrial 964 
deficiencies and insulin resistance might be traits of obesity without a causal link.  965 
A low energy and/or lipid flux due to physical inactivity (166) might also explain a 966 
link between obesity and an increased presence of peripheral insulin resistance. 967 
A regular utilisation of lipids derived from the adipose tissue has been linked to 968 
better metabolic health (167, 168) and decreasing lipid utilisation during exercise 969 
blunts changes in the expression of many genes relating to insulin signalling and 970 
glucose disposal in the adipose tissue (14). Similarly, stimulating IMTG utilisation 971 
has been associated with improved insulin sensitivity (169). Thus, taken together, 972 
current evidence suggests that defects relating to lipid metabolism contributes to 973 
the onset and/or development of peripheral insulin resistance in human obesity 974 
and that this impairment may be explained by defects relating to the mitochondria 975 





Figure 1.8. Pathways by which an accumulation of lipid metabolites may interfere 978 
with insulin signalling in skeletal muscle. Increased diacylglycerol (DAG) 979 
concentrations heightens the activation of protein kinase C (PKC). Ceramide and 980 
long chain fatty acyl-CoA have also been proposed to inhibit downstream proteins 981 
within the insulin signalling cascade. In this figure red arrows denote an inhibitory 982 
effect (on insulin signalling) Drawn using information provided in (32, 84, 86). 983 
 984 
Abbreviations: 985 
GLUT4 = glucose transporter 4 986 
IRTK = insulin receptor tyrosine kinase  987 
IRS = insulin receptor substrate 988 
PI3-K = phosphoinositide 3-kinase  989 
PtdIns-(3,4,5)-P3 = phosphatidylinositol (3,4,5)-trisphosphate  990 
PDK1 = 3-phosphoinositide-dependent kinase-1  991 
mTOR-C2 = mammalian target of rapamycin complex 2  992 
Akt = protein kinase B  993 
AS160 = Akt substrate of 160 kDa 994 
CPT1 = carnitine palmitoyltransferase I 995 




LIFESTYLE MODIFICATIONS 997 
In order to reduce rates of obesity without surgically removing adipose tissue, a 998 
negative energy balance must be created and sustained, with energy expenditure 999 
exceeding energy intake. If impairments relating to lipid metabolism and/or a low 1000 
lipid flux are important in the development of insulin resistance, interventions that 1001 
also increase the capacity of skeletal muscle for utilising lipids and/or stimulate a 1002 
frequent turnover of endogenous lipid pools should also prove beneficial in the 1003 
alleviation or prevention of metabolic diseases including T2D. Impairments in 1004 
insulin signalling in skeletal muscle do not seem to be explainable by mutations 1005 
in the insulin receptor or GLUT4 genes in humans with obesity or T2D (170-172). 1006 
Mutations in the HK and glycogen synthase genes can occur, but these are also 1007 
uncommon and are not related to insulin sensitivity or glycogen synthase activity 1008 
(173-176). Importantly, peripheral insulin resistance and mitochondrial defects 1009 
associated with obesity can be (at least partially) reversed with lifestyle changes.   1010 
 1011 
Dietary modifications 1012 
Sustained periods of dietary calorie restriction, when energy intake is reduced by 1013 
15-40 %, can facilitate body and fat-mass losses and increase peripheral insulin 1014 
sensitivity (177). A large body of literature supports the benefit of this approach 1015 
for improving blood glucose control, reducing inflammation in the adipose-tissue 1016 
and improving blood lipid profile, across a range of populations (178). Long-term 1017 
calorie restriction can also alleviate lipid accumulation in skeletal muscle, but this 1018 
effect is greater if the same weight loss is achieved through exercise in humans 1019 
with obesity (179). Moreover, regular exercise (and not just weight loss) may be 1020 
required to alleviate some of the defects relating to intramuscular lipid metabolism 1021 
in obesity. For example, when insulin-resistant humans with obesity are allocated 1022 
to diet-induced weight loss or the same weight loss but via exercise and diet, only 1023 
the exercisers experienced clear increases in the intramuscular mitochondrial-1024 
content or -enzyme activity (180). As such, if defects relating to lipid metabolism 1025 
are important for the onset or development of insulin resistance in obesity then 1026 





Another approach that has been studied in the context of obesity and metabolic 1029 
disease is adjusting the macronutrient composition of the diet, either with or 1030 
without a reduction in energy intake. One of the main rationales for this approach 1031 
is the proposed role of hyperinsulinemia in the aetiology of obesity and T2D and 1032 
that insulin is mainly secreted in response to carbohydrate ingestion. Ingesting a 1033 
low carbohydrate (< 2.5 gkg-1d-1), relatively high fat (~ 70 % of kcal) diet during 1034 
exercise training increases the capacity of skeletal muscle for utilising lipids over 1035 
just two weeks and has also been associated with an increased activation of lipid 1036 
metabolism proteins in skeletal muscle in healthy men (181). However, if exercise 1037 
is not performed, a high-fat, low carbohydrate diet can increase the IMCL content 1038 
of skeletal muscle and, in some cases, impair insulin sensitivity (182). Although 1039 
a carbohydrate-restricted diet can increase lipid utilisation (183, 184) this may 1040 
occur at a slower rate than the rate of lipid flux into muscle, thus resulting in an 1041 
increased accumulation of lipid metabolites and disrupted insulin signalling (128). 1042 
Thus, when improving insulin sensitivity is a goal for an intervention, replacing 1043 
dietary carbohydrate with dietary fat may not be the most efficacious strategy, 1044 
especially if exercise is not performed. This research has been examined in detail 1045 
elsewhere (185), and it is proposed that altering the macronutrient composition 1046 
of the diet does not induce clear metabolic benefits for glycaemic control, blood 1047 
lipid profiles or greater weight loss beyond those achieved with caloric restriction. 1048 
  1049 
Whilst creating a negative energy balance through a reduction in energy intake 1050 
can be an effective short-term strategy for managing the metabolic dysfunction 1051 
associated with obesity, a consistent body of evidence also suggests that weight 1052 
loss is often not sustainable in the long-term, with evidence of weight regain when 1053 
assessed at 1-2 years post-intervention (186). Compensatory metabolic and/or 1054 
behavioural adaptations can occur, including reductions in energy expenditure 1055 
attributable to a decrease in the resting metabolic rate (adaptive thermogenesis) 1056 
and changes to the secretion of appetite-regulating hormones (as discussed in 1057 
Chapter 5). This is in line with the thrifty gene theory, which speculates that the 1058 
body defends energy balance and fat stores, because our genotype was primarily 1059 




of energy abundance and energy conservation during periods of energy shortage 1061 
would favour long-term survival (186). It is proposed that following weight loss, 1062 
neuroendocrine signals including low systemic leptin and insulin concentrations 1063 
from the periphery convey messages regarding energy depletion to the brain, 1064 
which stimulates appetite and enhances metabolic efficiency. Along with a loss 1065 
of body- and fat-free mass and a decreased thermic effect of feeding, this narrows 1066 
the gap between energy intake and expenditure (187). This is reflected in a meta-1067 
analysis which showed that for weight loss, a plateau often occurs at ~ 6 months, 1068 
before regressing to baseline in the ensuring years with only some of the weight 1069 
loss retained (188). Importantly, it has also been suggested that being regularly 1070 
physical active might aid weight loss maintenance (189, 190). This is because 1071 
exercise can alter the nutrient and neuroendocrine signals that feedback to the 1072 
brain to regulate appetite and energy balance and because exercise can preserve 1073 
fat-free mass during weight loss (191). This also supports the role of exercise as 1074 
a long-term preventive strategy for obesity and associated metabolic diseases.  1075 
 1076 
Exercise 1077 
A sedentary lifestyle is considered to be a primary risk factor for T2D and CVD 1078 
(28, 192) and exercise is recommended as a strategy to prevent and treat T2D 1079 
(193). Exercise guidelines suggest that exercise should be performed regularly 1080 
at 40-70 % V̇O2 peak (peak oxygen uptake), for a minimum of 150 min·week-1. 1081 
This is grounded on findings that both an acute bout of endurance-type exercise 1082 
and exercise training can increase blood glucose control and insulin sensitivity in 1083 
humans with obesity or T2D (194, 195). This insulin sensitising effect of exercise 1084 
training can also be superior to those observed in response to drugs or insulin 1085 
therapy (196, 197). The beneficial effects of exercise on blood glucose control 1086 
and insulin sensitivity is attributed to two main effects: an acute phase which is 1087 
during and immediately after each bout of exercise performed and the enduring 1088 
training adaptations that then develop in response to repeated exercise bouts. In 1089 
addition, regular exercise training also increases the total amount of time that is 1090 





During exercise there is a marked increase in energy expenditure above rest and 1093 
blood glucose provides an important fuel source for active skeletal muscle (199). 1094 
Each bout of exercise activates contractile pathways in the exercising muscle, 1095 
which (and independently of insulin) translocate the glucose transporter, GLUT4, 1096 
to the plasma membrane and t-tubules for increased transmembrane glucose 1097 
transport (200). This is largely due to the increased activation of AMPK and 1098 
calcium-mediated pathways involving Ca2+/calmodulin-dependent protein kinase 1099 
kinases (CAMKKs) and serine/threonine kinase 11 (LKB1) (Figure 1.9) as well 1100 
as other cellular stressors, including increased nitric oxide and reactive oxygen 1101 
species (ROS) production (198, 200).  Importantly, even when insulin-stimulated 1102 
glucose uptake is impaired, the exercise-induced glucose uptake response can 1103 
remain intact (201). In line with that finding, the pharmacological activation of 1104 
AMPK stimulates glucose uptake in non-human primates and mice displaying 1105 
insulin resistance (202). Whilst not a focus of this review, each bout of exercise 1106 
also increases the secretion of circulating factors such as apelin and IL-6 that act 1107 
in an autocrine and/or paracrine fashion and have other benefits for metabolic 1108 
health, further supporting a role of exercise over other treatments for T2D (198).  1109 
 1110 
After exercise there is also an increase in insulin sensitivity for ~ 48 h in skeletal 1111 
muscle (198). Increased insulin sensitivity in the exercised muscle can manifest 1112 
as higher whole-body insulin-stimulated blood glucose disposal rates, although 1113 
this insulin-sensitising effect of a single bout of exercise (at the whole-body level) 1114 
is not always apparent in metabolically healthy, physically active humans (198). 1115 
Therefore, the acute insulin-sensitising effect of exercise is best thought of as a 1116 
localised effect, mostly restricted to the muscle(s) that were active during exercise 1117 
(198). Following exercise, meal-derived glucose is largely used to restore muscle 1118 
glycogen (203). The rate-limiting step in this process is the conversion of uridine 1119 
diphosphate-glucose to glycogen (Figure 1.3). This reaction is catalysed by 1120 
glycogen synthase, which is increasingly activated after exercise (204). However, 1121 
net glycogen formation can remain elevated after exercise, even when glycogen 1122 
synthase activity has returned to basal levels (205). This suggests that increased 1123 




exercised muscle for disposing of blood glucose. The plasma membrane GLUT4 1125 
content also returns to basal levels in ~ 2 h of exercise cessation (206) despite a 1126 
transient increase in muscle insulin sensitivity for ~ 48 h after exercise in healthy 1127 
humans (207) and for ~ 15 h in humans with T2D (208). After the immediate post-1128 
exercise period, an increased capacity of skeletal muscle for glucose disposal 1129 
can be largely explained by the GLUT4 response to subsequent insulin secretion 1130 
(209). Indeed insulin-stimulated GLUT4 translocation is increased in vitro if the 1131 
muscle has been pre-treated with insulin (without differences in Akt activation) 1132 
compared to muscle that was not pre-treated (210). Prior exercise can augment 1133 
this pre-treatment effect, as insulin and exercise stimulate the translocation of 1134 
GLUT4 via different signalling pathways and possibly from distinct intracellular 1135 
stores (211). Although insulin and exercise active different proximal signalling 1136 
pathways in skeletal muscle, they do converge at distal proteins (i.e. AS160 and 1137 
TBC1D1), with exercise acting via an AMPK signalling cascade (Figure 1.9).  1138 
 1139 
People who regularly exercise normally have lower blood insulin concentrations 1140 
during fasting, glucose infusions (212) and after oral glucose ingestion (213) than 1141 
sedentary controls. This is supported by evidence that exercise training increases 1142 
insulin sensitivity, even after a week of detraining, which suggests an adaptation 1143 
and not just an acute effect of exercise (214). In humans with impaired glucose 1144 
tolerance, regular exercise can lower blood glucose concentrations, although this 1145 
depends on the degree of glucose intolerance at baseline and the specific training 1146 
protocol used (215). Mechanisms behind the increases in insulin sensitivity with 1147 
exercise training are multifactorial (200). Some in vitro studies report a higher 1148 
expression of IRS proteins following exercise training, but this is not always clear 1149 
(200). Instead, increases in insulin sensitivity with exercise training are more likely 1150 
to be attributable to altered downstream insulin signalling (216, 217), which may 1151 
be due AMPK signalling (218). Increased AMPK activity after each exercise bout 1152 
performed may account for the higher GLUT4 expression and protein content in 1153 
exercised muscle after training (165), which has been linked to an increased 1154 
capacity for blood glucose disposal (219, 220). Exercise training also increases 1155 




and insulin to skeletal muscle (221). Although intramuscular blood flow does not 1157 
normally limit blood glucose disposal in healthy humans, this effect of exercise 1158 
may be important in humans with obesity, where a reduction in skeletal muscle 1159 
permeability has been shown (222). Alterations in body composition such as a 1160 
reduced fat mass and an increased fat-free mass can also occur (223) but are 1161 
not required for changes in insulin sensitivity with exercise training (224).  1162 
 1163 
Figure 1.9. Pathways by which insulin and muscle contractions (exercise) result 1164 
in increased GLUT4 translocation. Redrawn from a figure produced in (51). 1165 
 1166 
Abbreviations: 1167 
GLUT4 = glucose transporter 4  1168 
IRTK = insulin receptor tyrosine kinase 1169 
IRS = insulin receptor substrate  1170 
PI3-K = phosphoinositide 3-kinase  1171 
PDK1 = 3-phosphoinositide-dependent kinase-1  1172 
mTOR-C2 = mammalian target of rapamycin complex 2 1173 
Akt = protein kinase B  1174 
AS160 = Akt substrate of 160 kDa 1175 
AMPK = 5' AMP-activated protein kinase 1176 
CAMKK = alcium/calmodulin-dependent protein kinase kinase 2 1177 




Adaptive responses to exercise training may also be specifically related to lipid 1179 
metabolism. With each exercise bout, there is an acute increase in the turnover 1180 
of intramuscular triglyceride (IMTG) and adipose-tissue derived NEFA (225, 226). 1181 
A regular utilisation of NEFA derived from the adipose tissue has been associated 1182 
with an increased ability to buffer subsequent lipid flux (167, 168). The regular 1183 
utilisation of IMTG has also been positively associated with insulin sensitivity, 1184 
potentially due to an alleviation of the toxic lipid intermediates (169). Importantly, 1185 
humans with obesity can stimulate lipid metabolism during exercise and whole-1186 
body lipid utilisation rates can even be higher in men (227) and women (228) with 1187 
versus without obesity, when matched for cardiorespiratory fitness (Figure 1.10). 1188 
Thus, if the regular turnover of endogenous lipid pools is important for metabolic 1189 
health, then any effect of exercise training on insulin sensitivity may be partially 1190 
accounted for by spending more time in the ‘acute phase’ of exercise (198).  1191 
 1192 
In addition, following exercise training there is also evidence of an increase in the 1193 
capacity of skeletal muscle to utilise lipid substrates subsequently (10, 229, 230). 1194 
PGC1-α is a protein that may be important in this regard, because it is proposed 1195 
to be the master regulator of mitochondrial adaptations (231, 232) and can be 1196 
activated by AMPK (233). With a repeated increase in the activity of AMPK and 1197 
other cell kinases with regular exercise training, mitochondrial volume, enzyme 1198 
activity (234-236) and the content of proteins involved in lipid metabolism is 1199 
increased (237, 238). This may reduce the likelihood of toxic lipid intermediates 1200 
accumulating in skeletal muscle and contribute to increases in insulin sensitivity 1201 
(200). In support of this theory, in one study a strong predictor (~ 50 % of the 1202 
variance), for changes in insulin sensitivity following 16 weeks of exercise training 1203 
in humans with obesity was increases in lipid utilisation during rest (239). It has 1204 
also been shown that humans who regularly exercise store intramuscular lipid in 1205 
intramyofibrillar droplets, but humans with T2D have large subsarcolemmal lipid 1206 
droplets (240). Exercise training may therefore increase the storage of IMTG in 1207 
pools that are more easily accessible for metabolism without causing lipotoxicity. 1208 




with increments in mitochondrial oxidative capacity, this effect of exercise training 1210 
may help alleviate any lipid-related defects associated with metabolic diseases.  1211 
 1212 
The total volume of exercise performed (duration x intensity x frequency) is a key 1213 
determinant of the magnitude of many adaptations to exercise training (242). 1214 
However, many people fail to achieve current exercise guidelines, partly due to a 1215 
perceived lack of time (6, 243). For these people, and for people who cannot 1216 
increase the intensity or duration of exercise beyond a certain limit (for example 1217 
due to a low level of fitness) any optimisation of exercise efficacy is important. In 1218 
addition, some individuals may not always achieve the full potential benefits of 1219 
exercise training. For example, the HERITAGE family study reported that on 1220 
average exercise training increased insulin sensitivity, but 40 % of participants 1221 
showed negligible changes to- or decreased-insulin sensitivity (7). This inter-1222 
individual variability for postprandial insulinemia following exercise training has 1223 
also been shown to be greater than that of a control group (244). This suggests 1224 
that some of the variability is true inter-individual variability and not intra-individual 1225 
variability and/or measurement errors (245). These studies did not control for the 1226 
nutrient status of participants before exercise. If a regular turnover of endogenous 1227 
lipid pools or adaptations relating to lipid metabolism are important for changes 1228 
in metabolic health, this lack of a control for nutrient-exercise interactions may 1229 
partly explain any inter-individual variability in response to the exercise training.  1230 
 1231 
SUBSTRATE METABOLISM DURING EXERCISE 1232 
The increase in energy demands in the transition to exercise from rest is met by 1233 
increased carbohydrate and lipid oxidation, but the relative contribution of these 1234 
substrates depends on the exercise intensity (225). Henceforth, low- moderate- 1235 
and high-intensity exercise describe physical activity that is performed at < 50 %, 1236 
50-65 % and > 65 % V̇O2 peak respectively. The research used to inform this part 1237 
of the literature review was also mostly conducted in healthy, fasting humans. 1238 
Four main energy sources are utilised by skeletal muscle for energy metabolism 1239 
during exercise, as protein utilisation does not make a meaningful contribution in 1240 




blood glucose (derived from the liver) and for lipids these are intramuscular 1242 
triglyceride (IMTG) and blood NEFA derived from the adipose tissue (225, 226). 1243 
During fasting and at low exercise intensities a large proportion of the energy for 1244 
metabolism can be derived from lipids (Figure 1.11). In the transition from rest to 1245 
exercise the increased net mobilisation of NEFA from the adipose tissue is partly 1246 
due to the ~ 3-fold increase in blood catecholamine concentrations (247). Visceral 1247 
adipose tissue is very responsive to adrenergic activation, but subcutaneous 1248 
adipose tissue is a greater contributor to plasma NEFA flux during exercise, due 1249 
to its larger size (247). Exercise also increases plasma IL-6 concentrations (248), 1250 
which may contribute to the exercise-induced increase in lipolysis in the adipose-1251 
tissue (77). When the exercise intensity increases from low to moderate intensity, 1252 
lipid utilisation increases and, as an absolute rate, is highest at 45-65 % V̇O2 peak 1253 
(249). This is due to a greater rate of net IMTG utilisation, as the mobilisation of 1254 
NEFA from the adipose tissue decreases with this increment in exercise intensity 1255 
(250). As such, for fasted-state moderate-intensity exercise, NEFA and IMTG are 1256 
roughly equal contributors to whole-body lipid utilisation (Figure 1.11). In the 1257 
transition from moderate- to high-intensity exercise lipid utilisation then markedly 1258 
decreases (249) and to account for this, whole-body carbohydrate utilisation rates 1259 
are increased (225, 226). During low intensity exercise, a greater proportion of 1260 
the carbohydrate utilised for metabolism is from blood glucose, which is largely 1261 
derived from the liver when fasting (67). However, during high intensity exercise 1262 
muscle glycogen is increasingly utilised to provide energy for metabolism and can 1263 





Figure 1.10. The contribution of substrates to energy metabolism during exercise 1266 
in humans with/without obesity. Lipid utilisation represents plasma non-esterified 1267 
fatty acids (NEFA) and intramuscular triglyceride (IMTG & plasma lipoproteins). 1268 
Carbohydrate utilisation represents plasma glucose (GLU) and muscle glycogen 1269 
(MGLY). Study A was 60 min of fasted cycling at 50 % V02peak in men matched 1270 
for fitness levels (227). Study B was 90 min of fasted cycling at ~ 55 % V̇O2peak 1271 
in women matched for cardiorespiratory levels (228) * is p<0.05. 1272 
 1273 
Figure 1.11. A contribution of substrates to energy metabolism during exercise 1274 
in (healthy) humans without obesity. Lipid utilisation is plasma non-esterified fatty 1275 
acids (NEFA) and intramuscular triglyceride (IMTG & plasma lipoproteins) and 1276 
carbohydrate utilisation represents plasma glucose (GLU) and muscle glycogen 1277 




Limitations to lipid utilisation 1279 
Relative to carbohydrates, lipid stores in the body are vast [> 100,000 kcal for a 1280 
75 kg man without obesity compared to < 3000 kcal for carbohydrates (251)]. 1281 
Indeed, carbohydrates stores typically represent ~ 1-3 % of the energy in fat 1282 
stores, even in exercise-trained humans who have an increased capacity to store 1283 
glycogen. However, during exercise lipids are not always the greatest contributor 1284 
to energy metabolism. The utilisation of blood lipids for metabolism may be at 1285 
least partly regulated by lipid availability, as when blood NEFA concentrations are 1286 
reduced with nicotinic acid analogues (252) or elevated using TAG and heparin 1287 
infusions (253) lipid utilisation in skeletal muscle is decreased or increased, 1288 
respectively. Exercise can stimulate lipolysis in the adipose tissue by increasing 1289 
adrenergic β-receptor activation (254) and for low-intensity exercise, splanchnic 1290 
blood flow increases by > 4 fold versus rest (255), facilitating a higher net NEFA 1291 
mobilisation. However, at higher exercise intensities, splanchnic blood flow is 1292 
reduced as respiratory and exercising muscles are increasingly prioritised (255). 1293 
As a result, NEFA become trapped in adipose tissue and systemic concentrations 1294 
increase when blood flow is redistributed post-exercise (and at a greater rate than 1295 
glycerol), which suggests that lipolysis is not limiting NEFA mobilisation (250).  1296 
 1297 
In theory, another potential limiting factor for lipid utilisation during exercise is the 1298 
transport of NEFA into the myocyte, which is facilitated by fatty acid transport 1299 
proteins, although passive diffusion of NEFA across the plasma membrane is 1300 
possible (Figure 1.7). However, lipids can accumulate in skeletal muscle during 1301 
high-intensity exercise, suggesting that transport across the plasma membrane 1302 
is not limiting their utilisation (256). In addition, IMTG do not need to cross the 1303 
endothelium or the sarcolemma, so transmitochondiral membrane is a more likely 1304 
site for any transport-related limitation to lipid utilisation. In this process, long 1305 
chain fatty acid acetyl-CoA (from an esterification of fatty acids and CoA with ATP 1306 
in the cytosol), forms a complex with L-carnitine which is catalysed by CPT-1 1307 
(Figure 1.7). The complex is transported into the mitochondria, where CPT-2 can 1308 
then catalyse its transesterification back to free-carnitine and long chain fatty acid 1309 




high-intensity exercise, this may explain the decrease in rates of lipid utilisation 1311 
(226). Finally, lipids have a lower energy production rate per unit of time and 1312 
require more O2 to yield a given amount of energy versus carbohydrates (30). As 1313 
such, the oxidative capacity of the mitochondria in skeletal muscle is a potential 1314 
limiting factor for lipid utilisation (88). When oxidative metabolism cannot meet 1315 
the energy demands of exercise, anaerobic glycolysis is increased (257). Along 1316 
with a decreased intracellular pH, this can inhibit the CPT-transport system (258). 1317 
 1318 
Variation in lipid utilisation during exercise 1319 
Rates of lipid utilisation during fasted-state exercise also shows some apparent 1320 
inter-individual variation. If untrained men exercise at a moderate intensity during 1321 
fasting, the RER can range from 0.83 to 0.95 (259). Similarly, the measured RER 1322 
of trained cyclists has been reported to range from 0.72 to 0.93 during fasting at 1323 
rest, with a similar variation persisting during exercise (260). Training status, fat- 1324 
or fat-free mass, physical activity and sex differences appear to explain a small 1325 
amount (~ 35 %) of this variance (e.g. from 0.18 to 1.01 g·min-1 (97)]. Fasting 1326 
before laboratory-based exercise trials is a common procedure to help control for 1327 
baseline metabolic status, but this may also preclude the application of results to 1328 
situations most representative of daily living. For many humans in developed 1329 
countries, exercise is often performed in the evening (261). In concert with a high 1330 
carbohydrate diet consumed by many people living in developed countries (186), 1331 
it follows that most exercise sessions are undertaken after eating carbohydrates. 1332 
Since at least 1920, we have known that meal timing in relation to exercise alters 1333 
metabolism during exercise (262). Indeed, consuming carbohydrates 30-180 min 1334 
before exercise lowers whole-body lipid utilisation and increases carbohydrate 1335 
utilisation relative to when exercise is performed in a fasted-state (Figure 1.12). 1336 
The highest absolute rate of lipid utilisation during exercise in a fasted-state and 1337 
the biggest difference in lipid utilisation with exercise performed before versus 1338 
after nutrient ingestion occurs during moderate-intensity exercise (Figure 1.13).  1339 
 1340 
A decrease in lipid utilisation during exercise that is performed after consuming 1341 




between the meal [if < 6 h (263)] and the exercise (264) and is partly due to insulin 1343 
supressing NEFA mobilisation from the adipose tissue, by inhibiting lipolysis and 1344 
stimulating NEFA re-esterification (10). A higher intramuscular glucose flux and 1345 
decreased HSL activity (due to a lower blood catecholamine: insulin ratio), might 1346 
also inhibit IMTG utilisation with exercise performed in a carbohydrate-fed state 1347 
(265, 266). An overnight fast typically lowers liver glycogen concentrations by 1348 
around 40 % [350 ± 18 mmolL-1 4 h after a 60 % carbohydrate and 650 kcal meal 1349 
compared to 207 ± 22 mmolL-1 the morning after (36)], as liver glycogen helps to 1350 
maintain blood glucose concentrations during the overnight fast (30). Two hours 1351 
after a carbohydrate-rich breakfast is consumed, the liver glycogen content can 1352 
then be increased by > 20 % (36). As such, a lower hepatic glycogen content with 1353 
exercise performed during morning fasting (versus after breakfast) might also 1354 
increase adipose tissue lipolysis via liver-brain-adipose tissue signalling (267).  1355 
 1356 
Consuming carbohydrates before and/or during exercise can delay the onset of 1357 
fatigue by sparing muscle glycogen stores (268) and can improve performance 1358 
(269). Theoretically, this may enhance some adaptations to exercise by allowing 1359 
training to be performed at a higher intensity or maintained for longer, increasing 1360 
the overall exercise dose (242). However, a lack of time is often cited as a main 1361 
barrier to exercise (6, 243), so for many people, fatigue due to muscle glycogen 1362 
depletion is not likely to be limiting to the exercise dose performed, as glycogen 1363 
depletion only occurs after ~ 2 h of moderate-intensity exercise (225). For these 1364 
people augmenting exercise adaptations when the exercise is time- and intensity-1365 
matched will be of greater importance. Instead, if increasing lipid flux is important 1366 
for alleviating insulin resistance in obesity, eating carbohydrates before and/or 1367 





Figure 1.12. Substrate utilisation during exercise performed before (FED) versus 1370 
after (FAST) consuming breakfast. In Study A participants cycled for 30 min at 1371 
60 % V̇O2peak after a 12-h fast or 3 h after a carbohydrate rich breakfast (249), in 1372 
Study B participants ran for 60 min at 60 % V̇O2peak after a 12-h fast or 2 h after 1373 
a carbohydrate rich breakfast (15) and in Study C participants cycled for 60 min 1374 
at 55 % V̇O2peak after a 12-h fast or 1 h after a carbohydrate rich breakfast (10). 1375 
 1376 
Figure 1.13. The contribution of lipids to energy metabolism (A) and whole-body 1377 
lipid utilisation (B) during cycling exercise performed after breakfast (FED) or 1378 




BREAKFAST, EXERCISE AND GLYCAEMIA 1380 
Glycaemia during- and post-exercise (acute) 1381 
The focus of this review is nutrient-exercise interactions and glucose metabolism 1382 
after exercise. However, consuming versus omitting breakfast before exercise 1383 
also alters glycaemia during exercise (270). Comparing this research is difficult 1384 
due to differences in study designs, including the timing and the composition of 1385 
meals, but most studies have compared moderate intensity endurance-type 1386 
exercise before versus after (60-120 min) consuming a meal containing ~ 100 g 1387 
of carbohydrate. If exercise is performed pre-meal, blood glucose concentrations 1388 
during the activity are similar to- or are even slightly higher than rest, although 1389 
lower blood glucose concentrations have been shown versus rest after > 60 min 1390 
of fasted-state exercise (270). Despite similar blood glucose concentrations 1391 
during exercise versus rest, blood glucose flux is still increased during exercise 1392 
in the fasted state (271). Consuming versus omitting breakfast prior to exercise 1393 
further increases rates of whole-body blood glucose appearance and disposal 1394 
during exercise, with increased glucose oxidation contributing to higher whole-1395 
body carbohydrate utilisation rates (272). Exercising immediately after a high-1396 
glycaemic index, carbohydrate-rich meal can induce acute hypoglycaemia as 1397 
exercise and insulin (secreted in response to the meal) both stimulate GLUT4 1398 
translocation and blood glucose disposal (273). However, if moderate-intensity, 1399 
endurance-type exercise is undertaken 30- to 120-min after a carbohydrate-rich 1400 
meal, blood glucose excursions from the meal are lowered relative to when 1401 
exercise is not performed beforehand (274, 275), which might reduce CVD risk 1402 
by alleviating hyperglycaemia, if this stimulus is repeated regularly (276-278). 1403 
 1404 
Each bout of endurance-type exercise typically increases insulin sensitivity in the 1405 
exercised muscle (194). However, blood glucose concentrations following post-1406 
exercise meals are not always lowered relative to rest (279). This is because an 1407 
exercise-induced increase in postprandial blood glucose disposal rates can be 1408 
offset, or even superseded, by higher endogenous or meal-derived blood glucose 1409 
appearance rates (279). During rest, consuming a carbohydrate-rich meal lowers 1410 




underlying mechanisms for this second-meal effect include delayed gastric 1412 
emptying [with a 50 % increase in the time to clear 50 % of the stomach content 1413 
at the second meal (282)], which may be due to higher GLP-1 secretion (283). 1414 
GLP-1 also stimulates insulin secretion (40) and along with any priming of the 1415 
pancreatic β-cells due to prior insulin secretion, this can potentiate early phase 1416 
insulinemia after the second meal (284). Any potentiation of the insulin response 1417 
to feeding could further suppress HGP and increase peripheral blood glucose 1418 
disposal rates at the second meal (285). An increase in blood glucose disposal 1419 
rates may also be attributable to a priming of skeletal muscle by prior insulin 1420 
exposure (210). Finally, insulin-stimulated hepatic glucose disposal can also be 1421 
increased by prior exposure to insulin in dogs (286), so if this occurs in humans, 1422 
a priming of the liver might also contribute to increased blood glucose disposal 1423 
rates and/or a greater supression of HGP at subsequent meals consumed at rest.  1424 
 1425 
When breakfast is consumed before 60 min of running at 60 % V̇O2 peak, blood 1426 
glucose concentrations are higher in response to a post-exercise mixed-1427 
macronutrient meal versus breakfast consumption at rest (15). The postprandial 1428 
area under the curve (AUC) for blood glucose was 15 % higher with breakfast 1429 
consumption before exercise versus breakfast consumption at rest, but this 1430 
difference with exercise versus rest was not clear when breakfast was omitted. 1431 
Although confirmatory research is required, it is likely that higher postprandial 1432 
blood glucose appearance rates from the meals and/or HGP after exercise with 1433 
breakfast consumption before exercise was responsible for that finding. Gastric 1434 
emptying rates are not clearly altered during moderate-intensity endurance-type 1435 
exercise versus rest (287). However, performing exercise increases splanchnic 1436 
blood flow at subsequent meals by ~ 15-35 % (203) and eating prior to exercise 1437 
increases splanchnic blood flow during the exercise (10). This may raise blood 1438 
glucose appearance rates at meals that are consumed post-exercise, especially 1439 
when breakfast is consumed before the activity. Intestinal absorptive cells can 1440 
become damaged during exercise due to increased splanchnic hypoperfusion 1441 
(288). Splanchnic hypoperfusion is not always evident during low- or moderate-1442 




mechanical stress in the GI tract and higher systemic adrenaline concentrations 1444 
can also increase the intestinal damage response to exercise (289-291). This 1445 
intestinal damage response to exercise may depend on the presence of nutrients 1446 
in the GI tract via increased mechanical stress, which may also explain increased 1447 
post-exercise blood glucose appearance rates with breakfast consumption 1448 
versus omission before exercise (292). Finally, the liver glycogen content can be 1449 
increased after breakfast consumption (36), so residual post-exercise HGP may 1450 
contribute to higher postprandial post-exercise blood glucose appearance rates 1451 
compared to rest, or exercise with breakfast omission. A higher muscle glycogen 1452 
content decreases net muscle glucose disposal rates, due to reduced GLUT4 1453 
translocation and decreased HK activity (194). However, even if muscle glycogen 1454 
concentrations were increased before exercise with prior breakfast consumption 1455 
(versus omission) the utilisation of glycogen during exercise could, in theory, be 1456 
increased in that condition (293), to the extent that post-exercise concentrations 1457 
might not clearly differ. However, these mechanisms are speculative and further 1458 
research is required to investigate post-exercise postprandial glucose flux with 1459 
prior breakfast consumption versus omission. This research demonstrates that 1460 
performing exercise alters the glycaemic responses to the first meal post-exercise 1461 
compared to rest, and that this response may be altered by the prior provision (or 1462 
omission) of nutrients. It should however also be acknowledged that studying the 1463 
effects of exercise-nutrient interactions over a longer time is important as exercise 1464 
increases insulin sensitivity over a period spanning many meals (294, 295).  1465 
 1466 
Exercise training and glycaemia 1467 
Training studies with exercise performed before versus after breakfast either 1468 
report no change in fasting blood glucose or insulin concentrations (265), or lower 1469 
fasting concentrations after training, but with the magnitude of this change versus 1470 
no-exercise not clearly differing between exercise groups (11, 12). However, if 1471 
healthy men consume a hypercaloric (+ 30 % kcal of habitual diet) fat-rich (50 % 1472 
of kcal) diet, postprandial oral glucose tolerance is improved and the ISIMATSUDA 1473 
index of insulin sensitivity [an estimate of peripheral insulin sensitivity typically 1474 




is performed during morning fasting, but not when breakfast is consumed before- 1476 
and carbohydrates consumed during-exercise (11). In that study, participants ran 1477 
and cycled for 300 min·week-1 over 6 weeks and either had a 675 kcal (70 % 1478 
carbohydrate) breakfast 90 min before- and consumed 1 g·kg-1 of carbohydrate 1479 
during-exercise or exercised in the fasted-state (eating breakfast and the extra 1480 
carbohydrate post-exercise). Relative to a non-exercise control group, the blood 1481 
glucose AUC in response to an oral glucose tolerance test (OGTT) decreased if 1482 
exercise was performed fasted (238 ± 22 to 173 ± 11 mmolmin−1L-1; p <0.05) but 1483 
not after breakfast (263 ± 43 to 250 ± 36 mmolmin−1L-1 p >0.05) and the 1484 
ISIMATSUDA index also increased only if exercise was performed before breakfast. 1485 
Although a high-fat diet is not most representative of the diet consumed by many 1486 
people living in developed countries (186), this suggests that the timing of nutrient 1487 
ingestion in relation to exercise may be important for exercise-induced changes 1488 
in oral-glucose insulin sensitivity. However, it is possible that increases in body 1489 
mass in the control- and exercise after breakfast-groups (and not in the exercise 1490 
before breakfast group) might explain the differences in insulin sensitivity in that 1491 
study. Despite this, other studies report that exercise training before versus after 1492 
breakfast increases basal muscle glycogen concentrations (11, 12, 297). Defects 1493 
associated with muscle glycogen synthesis are shown in insulin-resistant states 1494 
(298) and an increased ability to store carbohydrate as muscle glycogen after 1495 
exercise training has been associated with increased insulin sensitivity (294). As 1496 
such, higher basal muscle glycogen contents reported following exercise before 1497 
versus after breakfast also suggests increased insulin sensitivity in that condition.  1498 
 1499 
Regularly exercising before versus after breakfast may offer a greater stimulus 1500 
for increasing peripheral insulin sensitivity. If this is the case, the acute increase 1501 
in whole-body lipid and/or IMTG utilisation (265) performed before versus after 1502 
breakfast may be responsible. A regular utilisation of NEFA derived from the 1503 
adipose tissue has been associated with an increased ability to buffer subsequent 1504 
lipid flux (167, 168). Consuming breakfast prior to exercise also blunts effects 1505 
seen after exercise during morning fasting for the expression of genes relating to 1506 




utilisation of IMTG has also been associated with increased insulin sensitivity, 1508 
potentially due to an alleviation of toxic lipid species (169). However, in the work 1509 
by Van Proeyen et al. (11), insulin sensitivity increased with exercise before 1510 
breakfast, but ceramide and DAG concentrations in exercised muscle remained 1511 
largely unaltered. Nonetheless, their participants were healthy, so excess lipid 1512 
influx to skeletal muscle due to the high-fat diet may have been partitioned into 1513 
IMTG preventing any accumulation of these lipid species (299). Indeed, the IMTG 1514 
content of type I and IIa fibres in the vastus lateralis was increased by ~ 50 % 1515 
and ~ 75 %, respectively. As the ability to synthesise IMTG is suggested to be 1516 
impaired in humans with obesity (300), this IMTG-synthesis pathway may be less 1517 
effective in buffering lipid flux into muscle in those populations. Regular exercise 1518 
in humans with obesity has been reported to decrease the intramuscular DAG 1519 
and ceramide contents and increase insulin sensitivity (301). Whether nutrient-1520 
exercise interactions alters the magnitude of this effect warrants investigation.  1521 
 1522 
Manipulating aspects of carbohydrate metabolism during exercise also alters 1523 
some adaptations relating to the capacity of skeletal muscle for utilising lipid 1524 
substrates (Figure 1.14). In one study, healthy men completed knee-extensor 1525 
exercise for 60 min at 75 % peak power output (PPO) over 10 weeks, with one 1526 
leg training daily and the other leg twice daily every second day, with a 2-h fasted 1527 
rest between the sessions (302). Ingesting 7-10 g·kg-1 of carbohydrates post-1528 
exercise favours the restoration of muscle glycogen (303) and the diet given in 1529 
that study (~ 675 g) would have been sufficient to (at least partially) restore 1530 
muscle glycogen in the leg training daily after each bout of exercise. In contrast, 1531 
the leg training twice daily would have completed the second session with a lower 1532 
muscle glycogen content. Post-intervention, the increase in the activity of CS in 1533 
exercised muscle was greater in the leg training twice daily. In a design more 1534 
readily applicable to a mode of exercise often performed, cyclists ate a diet 1535 
providing 8 gkg-1day-1 carbohydrate and alternated daily for 6 dayweek-1 1536 
between moderate- (100 min at 63 % PPO) and high-intensity cycling (8 x 5 min) 1537 
or completed both sessions on the same day every second day, separated by a 1538 




exercise, the maximal activity of both CS and β-HAD and the content of the ETC 1540 
protein COX-IV in the vastus lateralis were increased to a greater extent in the 1541 
men training twice daily (with some exercise sessions started with a low muscle 1542 
glycogen content). It has since been confirmed that training with a reduced 1543 
muscle glycogen content (~ 35-45 % of resting values) can increase whole-body 1544 
lipid utilisation during subsequent exercise in the fasted-state and also augment 1545 
mitochondrial adaptations compared to the same exercise commenced with a 1546 
higher muscle glycogen content (305, 306) [although the extent to which muscle 1547 
glycogen is depleted pre-exercise may be important in this regard (307)].  1548 
 1549 
Although training twice daily might not be sustainable people exercising primarily 1550 
for health reasons, exercise training (at a lower dose) performed before versus 1551 
after ingesting carbohydrates also results in greater increases in the content or 1552 
the mRNA expression of proteins in exercised muscle such as CD36 and CPT-1 1553 
that are involved in lipid metabolism, over a period of just 4-8 weeks (12, 13, 308). 1554 
Markers of mitochondrial biogenesis can also be increased after exercise training 1555 
before versus after breakfast (297) although this effect is not always evident (11). 1556 
These adaptations may increase the capacity of skeletal muscle for utilising lipids 1557 
which might then have implications for insulin sensitivity (309). Although exercise 1558 
training before versus after breakfast does not always increase whole-body lipid 1559 
and/or IMTG utilisation during subsequent fasted-state exercise (11, 297, 310), it 1560 
should be noted that the workload of the exercise tests used to measure this were 1561 
typically not adapted to account for any changes in the capacity for lipid utilisation. 1562 
 1563 
The exercise-induced activation of intramuscular energy sensing pathways can 1564 
be augmented when exercise is performed with a reduced relative to high muscle 1565 
glycogen content (311, 312). Together with evidence of a glycogen-binding site 1566 
on AMPK (313), this suggests that glycogen availability during exercise may 1567 
regulate some adaptations to exercise (314). Aside from AMPK, other proteins 1568 
regulate mitochondrial adaptations, such as p53, which is activated by exercise 1569 
and to a greater extent when muscle glycogen availability is decreased (315). 1570 




muscle glycogen) also augments mitochondrial adaptations (297) and consuming 1572 
carbohydrate during exercise commenced with a reduced muscle glycogen 1573 
content blunts greater increases in mitochondrial biogenesis otherwise observed 1574 
(306). This suggests that adaptations to exercise with a reduced carbohydrate 1575 
availability cannot be completely explained by muscle glycogen availability.  1576 
 1577 
Breakfast omission before exercise results in greater net NEFA mobilisation from 1578 
adipose tissue and increased lipid utilisation, relative to when carbohydrates are 1579 
consumed before and/or during exercise (264). Raising (163) or lowering blood 1580 
NEFA concentrations (316) increases and supresses the expression of proteins 1581 
involved in intramuscular mitochondrial biogenesis, respectively. This might be 1582 
because fatty acids are ligands for peroxisome proliferated activator receptors 1583 
(PPARs) which alter the expression of lipid metabolism proteins in muscle (317). 1584 
PPAR-δ regulates the expression of CPT1 (318) and enzymes in the fatty acid 1585 
oxidation pathway (319) and the exercise-induced increase in PPAR-δ activity 1586 
can be augmented by performing the activity with a low carbohydrate availability 1587 
(320). Although mitochondrial biogenesis is regulated by many transcription 1588 
factors, this is largely co-ordinated by PGC-1α, and PPAR-δ and AMPK help to 1589 
regulate PGC-1α expression (321). A higher intramuscular AMPK activity also 1590 
stimulates GLUT4 biogenesis, which may have implications for exercise-induced 1591 
changes in insulin sensitivity (165). Carbohydrate consumption during exercise 1592 
inhibits the increase in GLUT4 mRNA abundance (322) and after training, the 1593 
GLUT4 content of muscle is often (11, 308) [although not always (13)] increased 1594 
with exercise before versus after breakfast. Thus, an acute increase in the activity 1595 
of energy sensing proteins and/or a higher lipid flux during each bout of exercise 1596 
performed before versus after breakfast may stimulate key adaptations in muscle.  1597 
 1598 
Finally, alterations to the phospholipid (PL) composition of skeletal muscle have 1599 
been associated with obesity and insulin resistance (134). In healthy men, six 1600 
weeks of daily (> 30 mins) moderate intensity exercise at 55% V̇O2 peak alters 1601 
the PL content of skeletal muscle (323). In that study, peripheral insulin sensitivity 1602 




group the proportion of the saturated fatty acid - palmitic acid - in the PL pool in 1604 
the vastus lateralis decreased and the proportion of oleic acid - an unsaturated 1605 
fatty acid - was increased. That result may be important in light of associations 1606 
between insulin sensitivity and the palmitic acid content of the PL pool in skeletal 1607 
muscle (324). The training also decreased the total sum of n-6 poly-unsaturated 1608 
fatty acids (PUFAs) but there was no clear change in the sum of the n-3 PUFAs, 1609 
which resulted in a trend for a lower n-6-to-n-3 ratio in the intramuscular PL pool 1610 
(p<0.13). However, changes to specific PUFA species must be interpreted more 1611 
cautiously as they may be accounted for by errors associated with assessing the 1612 
content of fatty acids that represent a small proportion of the total PL pool (134). 1613 
Understanding if the changes in the PL pool were important for insulin sensitivity 1614 
in that study was also difficult because insulin sensitivity was assessed 24 h after 1615 
the last exercise session (so the changes may be due to an acute exercise effect).  1616 
 1617 
In another study, 8 men completed single-leg training for 30 min·day-1 for 4 weeks 1618 
at 70 % V̇O2 peak (325). That study did not detect clear changes in individual PL 1619 
fatty acids in the vastus lateralis post-exercise versus no-exercise but the PUFA 1620 
content of the PL pool tended to be higher after training (p<0.06) and the sum of 1621 
C20-22 PUFAs was correlated with insulin sensitivity from a hyperinsulinemic-1622 
euglycemic clamp (r=0.574; p=0.04). However, these relationships were not clear 1623 
mid-intervention, despite insulin sensitivity increasing from baseline in the 1624 
exercise group. Since this PL remodeling was also independent of dietary intake, 1625 
the reduction in the saturated fatty content of the PL pool was potentially due to 1626 
an upregulation of saturated fatty acid oxidation attributable to the increase in 1627 
energy expenditure (326). However, as all prior work has involved changes in 1628 
energy expenditure (i.e. exercise versus no-exercise) a role of nutrient-exercise 1629 
interactions independent of energy expenditure for PL remodelling is currently 1630 
unclear. Nonetheless, as PGC1α activity may regulate changes to the PL content 1631 
(327) and exercise with a reduced carbohydrate availability increasingly activates 1632 
energy sensing proteins such as AMPK (311, 312), it could be speculated that 1633 
exercising before versus after breakfast may stimulate PL remodeling to a greater 1634 




There is evidence to suggest that exercise training before versus after breakfast 1636 
may increase oral glucose insulin sensitivity (Figure 1.15). However, this may not 1637 
be the case when breakfast is completely omitted. If lean humans omit breakfast 1638 
at rest over 6 weeks, interstitial glucose concentrations are more variable in the 1639 
afternoon, relative to when breakfast is consumed (328). In humans with obesity, 1640 
the insulinemic response to an OGTT is also lower with breakfast consumption 1641 
versus omission over 6 weeks (329). As such, the effects of omitting breakfast 1642 
but performing exercise training now warrants investigation. In addition, whilst 1643 
nutrient-exercise interactions may regulate some adaptive responses to exercise 1644 





Figure 1.14. The effect of nutrient-exercise timing on mitochondrial adaptations 1647 
following exercise training. After consuming carbohydrates, higher blood insulin 1648 
and glucose concentrations decrease NEFA and IMTG utilisation during exercise. 1649 
This may blunt the activation of adaptive signalling pathways and contribute, 1650 
(along with the lower lipid flux during exercise) to the suppression of mitochondrial 1651 
adaptations in skeletal muscle. In this figure red arrows show an inhibitory effect. 1652 
Redrawn from a figure produced in (330). 1653 
 1654 
Abbreviations:  1655 
GLUT4 = glucose transporter 4 1656 
FATP = fatty acid transport protein 1657 
FAT/CD36 = fatty acid translocase/cluster of differentiation 36 1658 
FABPm = fatty acid binding protein 1659 
NEFA = non-esterified fatty acid 1660 
IMTG = intramuscular triglyceride 1661 
AMPK = 5' AMP-activated protein kinase 1662 
P53 = tumour protein p53 1663 
P38 MAPK = P38 mitogen-activated protein kinases 1664 
PGC1α = peroxisome proliferator activated receptor gamma coactivator 1 alpha 1665 



































Figure 1.15. Potential pathways linking nutrient-exercise interactions to changes 1668 
in peripheral insulin sensitivity. These include alterations in the exercise-induced 1669 
increase in the accumulation (or activation) of key energy sensing proteins (e.g. 1670 
AMPK), changes to the phospholipid content of plasma membranes, adaptations 1671 
relating to the glucose transporter proteins and/or an increased capacity for lipid 1672 
utilisation (see Figure 1.14). In this figure red arrows show an inhibitory effect. 1673 
 1674 
Abbreviations:  1675 
NEFA = non-esterified fatty acid 1676 
IMTG = intramuscular triglyceride 1677 
AMPK = 5' AMP-activated protein kinase 1678 
PGC1α = peroxisome proliferator activated receptor gamma coactivator 1 alpha 1679 


























BREAKFAST, EXERCISE AND ENERGY BALANCE  1681 
As energy cannot be created or destroyed (i.e. the first law of thermodynamics), 1682 
energy balance can be calculated as metabolisable energy intake minus energy 1683 
that is expended (151). As such, the long-term storage of excess energy, which 1684 
manifests as obesity, must reflect either a sustained increase in energy intake, a 1685 
sustained decrease in energy expenditure, or both when relative to a prior state 1686 
of energy balance. Metabolisable energy intake represents the energy that is 1687 
consumed in the diet in the form of carbohydrates (~ 4 kcal·g-1) fat (~ 9 kcal·g-1), 1688 
protein (~ 4 kcal·g-1) and alcohol (~ 7 kcal·g-1) minus energy that is not absorbed. 1689 
In humans, the energy that is not absorbed (lost in stools or urine) is around 5 % 1690 
of ingested calories. Indeed, across a variety of diets it was shown that ~ 4.5 % 1691 
and ~ 3.6 % of the energy ingested by healthy humans was lost in faeces or in 1692 
urinary excretion, respectively (331). However, this percentage does depend on 1693 
diet composition (332) and body composition, which may alter the gut microbiome 1694 
and as a consequence, the energy harvesting capacity of the gastrointestinal tract 1695 
(333). One further complication is that absorption of ingested energy can also be 1696 
influenced by other factors, such as food preparation. For example, freezing and 1697 
toasting bread increases the recrystallization of resistant starch reducing the 1698 
fraction of the carbohydrate that is liberated into the systemic circulation and the 1699 
ingestion of beef mince versus steak results in a higher availability of systemic 1700 
amino acids (334, 335).  1701 
 1702 
Daily energy expenditure is the summation of (a) resting metabolic rate (RMR; 1703 
the energy required to maintain various cellular and tissue functions during rest 1704 
such as fuelling sodium/potassium pumps, facilitating neuronal firing in the brain 1705 
and maintaining core body temperature), (b) diet-induced thermogenesis (DIT; 1706 
the increment in energy expenditure above the fasted-state required to process 1707 
ingested food and drink) and (c) physical activity energy expenditure (PAEE; the 1708 
energy attributable to the metabolic cost of exercise and non-exercise physical 1709 
activity) (151). For the majority of people living in developed countries (e.g. non-1710 
athletes and people with jobs that require them to be predominantly sedentary), 1711 




(336)] and fat-free mass - specifically skeletal muscle metabolism - is the primary 1713 
determinant of any inter-individual differences in RMR (337). DIT represents a 1714 
smaller component of daily energy expenditure and is estimated to be ~ 10 % of 1715 
total daily energy intake, although the diet composition can alter that percentage 1716 
(338). Indeed, the energy required (as a percentage of energy ingested) to digest 1717 
and absorb fats, carbohydrates, alcohol and protein is ~ 0-3 %, 5-10 %, 15-27 % 1718 
and 20-30 %, respectively (338). The component of daily energy expenditure that 1719 
shows the highest variation in most non-athletic cohorts is PAEE, with variance 1720 
of > 1,300 kcal·day-1 (339). PAEE represents the energy necessary to exert 1721 
physical forces on our environment and is primarily determined by the energy 1722 
expended during activities of daily living, but when performed regularly, exercise 1723 
can also make a contribution of > 20 % of average daily PAEE (340).  1724 
 1725 
To facilitate body mass losses and to alleviate the presence of obesity, an energy 1726 
deficit must be created and sustained by increasing energy expenditure and/or 1727 
reducing energy intake (151). Whole-body fat mass losses at 0.5-1.0 kg·week-1 1728 
are thought to be sustainable and because the energy density of the adipose 1729 
tissue is approximately 7.1 kcal·g-1, to achieve this rate of fat mass loss an energy 1730 
deficit of around 500 kcal·day-1 would be required (341).However, the magnitude 1731 
of the deficit needed to incur a meaningful reduction in obesity prevalence is 1732 
complicated by changes in body mass which can alter the energy cost associated 1733 
with RMR. For example, an increasing prevalence of obesity at the population 1734 
level can theoretically be explained by a positive energy balance of 7 kcal·day-1 1735 
(341). However, to have maintained this energy surplus at an individual level 1736 
through increased energy intake alone (i.e. assuming no decrement in PAEE), a 1737 
more substantial increase in energy intake of ~ 200 kcal·day-1 would theoretically 1738 
be required to account for increases in energy expenditure attributed to an 1739 
increase in RMR (341). The two sides of the energy balance equation are also 1740 
regulated by various interlinking factors, which all contribute to a highly-evolved 1741 
feedback system designed to preserve a state of energy balance (151). As such, 1742 
any acute deviation away from a state of energy balance may alter subsequent 1743 




regulatory system(s) involved in a maintenance of energy balance are thought to 1745 
be biased towards weight gain. For example, in response to a decrease in energy 1746 
availability over 3 days, RMR and sympathetic activity decrease and muscular 1747 
work becomes more efficient in an attempt to align energy expenditure to energy 1748 
intake [which would be conducive to long-term survival via maintenance of energy 1749 
balance (342)]. However, in that study, a week of overfeeding with a 50 % energy 1750 
surplus did not result in a clear adaptive increase in energy expenditure.  1751 
 1752 
Similarly, associations have been shown between an infrequent consumption of 1753 
breakfast at rest (a negative energy balance) and risk of adiposity (a sustained 1754 
positive energy balance), suggesting that compensation is likely to occur for the 1755 
energy deficit created from the omission of breakfast (343, 344). It has since been 1756 
shown that if healthy humans omit breakfast at rest they compensate through a 1757 
higher energy intake at lunch (345). Although energy intake up to and including 1758 
lunch remained higher with breakfast consumption versus omission (1246 ± 380 1759 
versus 929 ± 317 kcal, p<0.01) this difference of ~ 300 kcal was less than the 1760 
700 kcal provided in the breakfast. In healthy humans, consuming 700 kcal before 1761 
1100 over 6 weeks also results in a higher self-reported energy intake relative to 1762 
when fasting is continued until midday (2730 ± 573 versus 2191 ± 494 kcald-1, 1763 
p<0.01) but the difference of ~ 540 kcal was again less than the energy provided 1764 
in the breakfast (328). Similar results have been reported for humans with obesity 1765 
(329). In these studies, the omission of breakfast also decreased morning PAEE 1766 
and resulted in a lower 24-h PAEE in the healthy humans (328, 329). This could 1767 
be important if a reduction in energy intake (e.g. with breakfast omission) was 1768 
implemented as a weight loss strategy. For example, (in humans without obesity) 1769 
a compensation for breakfast omission over a period of 24 h via a higher post-1770 
breakfast energy intake of ~ 150 kcal and a lower daily PAEE of ~ 450 kcal would 1771 
create an energy deficit of only ~ 100 kcal relative to when a 700 kcal breakfast 1772 
was consumed. As such, if this difference in energy balance was always apparent 1773 
with the omission versus the consumption of breakfast, a specific decrease in fat 1774 
mass would require a longer time period to occur, as the overall energy deficit is 1775 




mass of only ~ 15 g·day-1 or ~ 0.1 kg·week-1 (341). Although even small changes 1777 
to energy balance can alter fat mass over a sufficient period of time (346), this 1778 
clearly highlights the important role of compensation for acute energy deficits in 1779 
a context of long term changes in fat- and/or body-mass.  1780 
 1781 
At the population level, associations exist between low physical activity levels and 1782 
a higher risk of obesity (347). However for weight loss in the initial months of an 1783 
intervention, exercise training can be less effective than energy restriction via diet 1784 
(348). Changes in body-mass in response to exercise training also shows some 1785 
apparent inter-individual variability [ranging from losses of 9.5 to gains of 2.6 kg 1786 
after 12 weeks of exercise, designed to expend 2500 kcal·week-1 (349)] although 1787 
this may be partly due to measurement errors or intra-individual variability (350). 1788 
PAEE is suggested to be sustained if overweight men start to regularly exercise 1789 
(340), so an increase in energy intake may be most accountable for this modest 1790 
and variable weight loss response. The nutrient-status of participants prior to 1791 
exercise is often unreported in exercise training studies and this may alter post-1792 
exercise compensation. Carbohydrate balance (dietary intake versus utilisation), 1793 
is proposed to be important in this regard, as liver and muscle glycogen stores 1794 
are thought to be tightly regulated, due to their small storage capacity (17, 351). 1795 
As such, when these stores are utilised, behaviours that alter energy balance 1796 
might change to favour their replenishment (17, 351). If carbohydrate balance is 1797 
indeed a regulator of energy balance, reducing rates of carbohydrate utilisation 1798 
during exercise may help prevent compensation for the exercise energy deficits. 1799 
 1800 
When energy balance is manipulated with pre-exercise breakfast consumption 1801 
versus omission in healthy men, no clear differences in energy intake at a mixed 1802 
macronutrient lunch are reported (15). If breakfast (444 kcal; 60 % carbohydrate; 1803 
23 % fat; 17 % protein) was then accounted for, exercise and breakfast omission 1804 
produced a more negative energy balance after the lunch compared to exercise 1805 
and breakfast consumption. Similarly, if healthy men run for 60 min but without 1806 
eating breakfast, ad libitum energy intake over 24 h is lower than when exercise 1807 




during morning fasting may be attributable to having less time in the day to eat. 1809 
However in the second study, a lower energy intake with exercise and breakfast 1810 
omission was partly attributable to a lower energy intake at post-exercise meals 1811 
(16). This suggests that healthy men do not compensate with a higher energy 1812 
intake for the energy deficit created by omitting breakfast prior to performing 1813 
exercise, potentially facilitating a more negative energy balance relative to when 1814 
breakfast is consumed. However, in the work of Bachman et al. (16) post-exercise 1815 
energy-expenditure was not measured and so energy balance was not reported. 1816 
A more negative energy balance after lunch with breakfast omission and exercise 1817 
has also been attributed to a negative whole-body fat balance, with carbohydrate 1818 
balance being similar to exercise with breakfast consumption (15). This is in line 1819 
with a theory (discussed in Chapter 5), that carbohydrate stores in the body are 1820 
tightly regulated (17, 352). Thus, sparing carbohydrate utilisation and inducing 1821 
less severe fluctuations to carbohydrate balance with breakfast omission before 1822 
exercise, may protect against energy compensation for the exercise-induced 1823 
energy deficit. In contrast, an increased rate of carbohydrate use during exercise 1824 
may increase the likelihood of a higher energy intake post-exercise (353, 354). 1825 
More evidence that carbohydrate status (and specifically liver glycogen status) 1826 
regulates energy balance is reports that mice overexpressing hepatic protein 1827 
targeted to glycogen, (which increases glycogen synthesis by activating glycogen 1828 
synthase and inhibiting glycogen phosphorylase), show a reduced energy intake, 1829 
a higher energy expenditure and lower fat masses versus wild-type mice (355). 1830 
Vagotomy (an operation where one or more branches of the vagus nerve are cut) 1831 
also abolished these effects in mice without altering the liver glycogen content, 1832 
suggesting a mediating role for the vagal nerve in co-ordinating any cross-talk 1833 
between the liver and the brain regarding the carbohydrate status of the liver. 1834 
 1835 
If increasing carbohydrate utilisation during exercise does stimulate an increased 1836 
post-exercise energy intake, exercising before versus after breakfast (i.e. altering 1837 
meal timing) may also be more effective for creating a negative energy balance. 1838 
Regularly exercising before breakfast may also increase the capacity of skeletal 1839 




non-exercise activity (356). One study did report that if exercise was performed 1841 
prior to breakfast, fat mass losses in 3 weeks were greater than if carbohydrates 1842 
were consumed before- and during-exercise, despite the same nutrition being 1843 
provided to both groups (357). During hyper-caloric high-fat feeding, exercise 1844 
training before and not after breakfast may protect against body mass gains when 1845 
compared to a non-exercise (control) group (11). However, changes in body 1846 
composition do not typically differ after exercise training performed before versus 1847 
after breakfast (12, 358, 359), although it should be noted that the length of the 1848 
training in many of these studies (~ 4-6 weeks) may be insufficient to allow the 1849 
detection of small differences in body composition across exercise groups. As 1850 
there is incomplete compensation in energy intake for an omission of breakfast 1851 
before exercise, this model (i.e. breakfast omission and exercise and not altered 1852 
breakfast timing) is most likely to create the conditions for a more negative energy 1853 
balance (and larger decreases in body mass over time) compared to exercise 1854 
and breakfast consumption. Studying energy balance with pre-exercise breakfast 1855 
omission versus consumption over 24 h (and then longer) is now important.   1856 
 1857 
CONCLUDING STATEMENTS 1858 
Obesity is often accompanied by decreased peripheral insulin sensitivity, which 1859 
is likely to be partly explained by defects relating to lipid metabolism in skeletal 1860 
muscle. Exercise training improves many aspects of metabolic health, but finding 1861 
ways to maximise these effects is important. Regularly exercising before versus 1862 
after nutrient-intake can augment adaptations in skeletal muscle that might be 1863 
important for both lipid metabolism and insulin sensitivity. Each bout of exercise 1864 
before versus after nutrient-intake also increases lipid flux during the activity and 1865 
this acute response may be important for any changes in insulin sensitivity with 1866 
regular training. Finally, omitting versus consuming breakfast prior to exercise 1867 
might create a more negative daily energy balance, which may have implications 1868 
for the long-term regulation of body mass if this stimulus is regularly repeated. 1869 
However, the metabolic and energy balance responses to exercise before versus 1870 




GENERAL AIMS OF THIS THESIS 1872 
Accordingly, the general aims of this thesis were: 1873 
1) To explore the effects of nutrient-exercise interactions on substrate 1874 
metabolism during and post-exercise. 1875 
2) To explore the effects of nutrient-exercise interactions on the regulation of 1876 
post-exercise postprandial glucose metabolism and potential underlying 1877 
regulatory mechanisms in healthy men.  1878 
3) To investigate the effects of nutrient-exercise interactions on intramuscular 1879 
signalling responses in healthy men.  1880 
4) To explore the effects of nutrient-exercise interactions on training 1881 
responsiveness in humans classified as overweight and obese, with a 1882 
specific focus on glucose metabolism and oral glucose insulin sensitivity.   1883 
5) To explore the effects of nutrient-exercise interactions during exercise 1884 
training in humans classified as overweight or obese on skeletal muscle 1885 
adaptations. 1886 
6) To assess the effects of nutrient-exercise interactions on energy and 1887 
substrate balances over a period of 24 h. 1888 
7) To assess the effects of nutrient-exercise interactions for changes in body 1889 
mass and components of human behaviour that regulate energy balance 1890 




CHAPTER 2 - GENERAL METHODS 1892 
 1893 
This chapter describes the experimental methods that were used consistently 1894 
throughout this thesis. The studies received ethical approval from the Research 1895 
Ethics Approval Committee for Health (REACH) for the University of Bath and/or 1896 
the National Health Service (South West) Research Ethics Committee. Written, 1897 
informed consent was gained from participants prior to them embarking upon any 1898 
given study. All studies were undertaken at the University of Bath in accordance 1899 
with the Declaration of Helsinki. 1900 
 1901 
PARTICIPANTS 1902 
Participants were primarily recruited from the staff and student population at the 1903 
University of Bath or the surrounding area (i.e. Bath and North East Somerset) 1904 
by email, posters or word of mouth. After contacting the research team to express 1905 
an interest in a particular study, prospective participants were provided written 1906 
information about the requirements of the study and the benefits and risks of 1907 
taking part and were given opportunities to ask any questions they had. If they 1908 
decided to take part, the participants completed a signed statement of informed 1909 
consent form and a health history questionnaire to confirm their eligibility for the 1910 
study and to help ensure their safety and wellbeing throughout their involvement. 1911 
In Chapters 3-5, participants were mainly recruited from the University of Bath 1912 
and were healthy, physically active men. The inclusion criteria were: 1913 
 1914 
• Males, aged 18-49 years 1915 
• Recreationally active 1916 
• Non-smokers 1917 
• Able and willing to safely comply with all study procedures 1918 
• Able to provide written informed consent for participation 1919 
• No bleeding disorder or taking medication which impacts blood coagulation 1920 
• No use of substances which may have posed undue risk to the participant or 1921 




• No contraindications to exercise testing, as determined by using a readiness for 1923 
exercise questionnaire (i.e. the Physical Activity Readiness Questionnaire)  1924 
• No known history of metabolic or cardiovascular disease 1925 
• Not currently dieting and having been weight-stable for the preceding 3 months 1926 
(< 5 % change in body mass)  1927 
• No plans to change diet or physical activity behaviours outside of the study 1928 
• No aversion to any of the foods provided in the study 1929 
• Additional inclusion criteria were also included for the participants who opted to 1930 
have muscle biopsy samples (for the research described in Chapters 3 and 6). 1931 
These were; no known tendency towards keloid scarring and no known sensitivity 1932 
or allergy to any local anaesthetic medicines  1933 
 1934 
In Chapter 6 participants were recruited from the staff and student population at 1935 
the University of Bath or the local surrounding area and were classified as 1936 
overweight or obese and sedentary. The inclusion criteria (where differing from 1937 
above) were: 1938 
 1939 
• Males, aged 18-65 years 1940 
• Classified as overweight according to the body mass index (BMI) > 25 kg·m-2 1941 
• Self-reported non-exercisers when exercise was defined to them as ‘continuous 1942 
physical activity lasting longer than 30 mins and of sufficient intensity for you to 1943 
perceive a notable increase in your heart rate and/or a sweat response’  1944 
 1945 
ANTHROPOMETRY 1946 
For anthropometric data, measurements were made in duplicate and averaged, 1947 
but if these deviated by > 1 %, a third measure was also recorded. Stature was 1948 
measured to the nearest 0.1 cm using a wall-mounted stadiometer (Seca Ltd, 1949 
Birmingham, UK), with participants barefoot and in the Frankfurt plane and after 1950 
inhalation of a breath. Body mass was measured with participants wearing light 1951 
clothing only, to the nearest 0.1 kg using electronic weighing scales (BC543 1952 
Monitor, Tanita, Tokyo, Japan). The body mass index (BMI) was calculated as 1953 




hip circumference were assessed to the nearest 0.1 cm using a non-elastic tape 1955 
measure (SECA 201, Hamburg, Germany) and the waist-to-hip circumference 1956 
was calculated. Waist circumference was taken at the midpoint between the lower 1957 
margin of the last palpable rib and the top of the iliac crest and hip circumference 1958 
was measured at the widest part of the buttocks. For Chapters 3 and 5, a dual 1959 
energy x-ray absorptiometry (DEXA) scan was completed to quantify fat- and fat 1960 
free-mass (Discovery, Hologic, Bedford, UK). The principle of DEXA is that the 1961 
distribution of bone, fat and non-bone or -fat tissues can be estimated from pixels 1962 
on a planar image, according to their propensity for radiographic attenuation at 1963 
two frequencies (360). This approach has some limitations for assessing body 1964 
composition, for example, fat-free mass estimations are susceptible to changes 1965 
in hydration status and the scan gives a cross-sectional image in the frontal plane 1966 
and so does not account for trunk thickness in the sagittal plane, which might 1967 
underestimate central adiposity. However, it provides data that cannot be derived 1968 
from more simple measures of body composition. To improve scan accuracy, 1969 
quality control checks were completed before each DEXA scan, which included 1970 
scanning a spine phantom with known radiographic attenuation properties and 1971 
checks to monitor background radiation. Scans were performed with participants 1972 
wearing light clothing, having adhered to the pre-trial controls as detailed below, 1973 
and having consumed 568 mL of water 1 h prior and voided immediately prior, to 1974 
help control for hydration status. They were positioned centrally on the scanning 1975 
bed in a supine position, with legs apart, feet turned inwards, arms as wide as 1976 
possible and hands in a mid-prone position. This was to ensure that the gap 1977 
between their arms and trunk was sufficient to allow regions of interest to be 1978 
defined on the analysis software (QDR for Windows, Hologic, UK). Scans were 1979 
analysed for fat- and fat-free mass to the nearest 0.1 kg, percentage body fat and 1980 
fat mass index (fat mass [kg] divided by the square of the participant’s height [m]). 1981 
 1982 
STANDARDISATION PROTOCOLS 1983 
For laboratory-based trials, the ambient temperature, barometric pressure and 1984 
humidity were assessed using a portable weather station (Technoline WS 6730, 1985 




controlled so that for each participant all trials were performed in similar ambient 1987 
conditions (details are provided in each experimental chapter). For all laboratory-1988 
based trials participants were asked to abstain from alcoholic and caffeinated 1989 
drinks for 24 h prior to testing. Food intake ceased at 8 pm on the evening prior 1990 
to each trial and participants fasted overnight for a minimum of 12 h, consuming 1991 
only water ab libitum during this period. They recorded the composition of their 1992 
evening meal on the day before the first main trial for a given study and replicated 1993 
the meal for subsequent trials in accordance with procedures for standardising 1994 
glucose tolerance testing (361). Participants were asked to refrain from strenuous 1995 
physical activity for 24 h prior to trials but to otherwise maintain their habitual 1996 
lifestyle. Weighed food and fluid records and/or questioning by a researcher 1997 
assessed their compliance to these controls. In Chapters 3 and 5, participants 1998 
also completed a physical activity diary and were given a physical activity monitor 1999 
(ActiheartTM; Cambridge Neurotechnology, Papworth, UK) to wear for the day 2000 
before each trial, as reported in the chapters. Water consumption was ad libitum 2001 
on the first trial for a given study and was replicated for subsequent trials.  2002 
 2003 
EXPIRED GAS SAMPLES 2004 
Estimating rates of substrate utilisation during rest and exercise was pertinent to 2005 
the aims of this thesis and was assessed using indirect calorimetry from expired 2006 
gas samples. The respiratory quotient (RQ) is the quantity of CO2 produced 2007 
versus O2 consumed at the tissue level. Indirect calorimetry assesses whole body 2008 
O2 consumption and CO2 production by using measures of gas exchange at the 2009 
lungs, as an approximate measure of the RQ. This indirect measure of the RQ is 2010 
referred to as the respiratory exchange ratio (RER). At the whole-body level, the 2011 
ratio of CO2 produced versus O2 consumed depends on the ratio of substrates 2012 
being oxidised, because the RQ of glucose is 1.00 (6 mol of O2 are consumed 2013 
and 6 mol of CO2 are produced for each mole [180 g] oxidised) and for palmitoyl-2014 
stearoyl-oleoyl-glycerol (PSOG), a triglyceride that is similar in composition to the 2015 
composition of human adipose tissue, the RQ is 0.70 (78 mol of O2 are consumed 2016 
and 55 mol of CO2 produced for each mole [861 g] oxidised) (88). It is possible 2017 




sustained positive energy (particularly carbohydrate) balance (27, 362), because 2019 
of net de novo lipogenesis, where lipid production is exceeding lipid oxidation at 2020 
the whole-body level. This is because the process of de novo lipogenesis has an 2021 
RQ of ~ 5.6, due to a net consumption of oxidising equivalents (88). Substrate 2022 
utilisation represents the sum of oxidation and any endogenous interchange of 2023 
substrates, such as de novo lipogenesis. Whilst humans have the capacity to 2024 
convert carbohydrates and proteins into lipids, we lack the enzymes necessary 2025 
for the reverse, so fatty acids can only be oxidised or stored, meaning that 2026 
substrate utilisation is equivalent to oxidation. However, for carbohydrates, this is 2027 
not always the case, so in this thesis the term substrate utilisation has been used. 2028 
However, in the conditions studied (the absence of a sustained positive energy 2029 
or carbohydrate balance) carbohydrate utilisation can be interpreted as oxidation.  2030 
  2031 
Continuous breath-by-breath gas analysis 2032 
Incremental cycling tests were undertaken to assess substrate utilisation rates, 2033 
peak oxygen uptake (V̇O2 peak) and peak power output (PPO). The protocols 2034 
were adapted from previous research that assessed substrate utilisation rates 2035 
across different exercise intensities and durations (363). Tests were performed 2036 
at a self-selected cadence using an electronically-braked ergometer (Excalibur 2037 
Sport, Lode Groningen, Netherlands). Participants were allowed to adjust the 2038 
saddle and handlebar heights to a preferred position, which were replicated for 2039 
any further cycling in a given study. For Chapters 3 and 4, the initial power output 2040 
was set at 50 Watts (W) and this was increased by 50 W every four min for an 2041 
initial four stages. Thereafter, the intensity was increased by 20 W every min until 2042 
volitional exhaustion. A two-phase protocol was chosen to increase the accuracy 2043 
of the test when assessing substrate utilisation during the initial stages as indirect 2044 
calorimetry requires steady state expired O2 and CO2 concentrations, and then 2045 
to facilitate the attainment of volitional exhaustion quickly, to reduce the likelihood 2046 
that localised muscle fatigue was the reason for test termination. Heart rate (HR; 2047 
Polar Electro Oy, Kempele, Finland), ratings of perceived exertion [RPE; from 6 2048 
(no exertion) to 20 (maximal exertion) (364)] and continuous breath-by-breath 2049 




(TrueOne2400, ParvoMedics, Sandy, USA) was turned on 60 min prior to testing 2051 
to allow for the temperature of the O2 and CO2 sensors to stabilise. The volume 2052 
and gas analysers were calibrated with a 3 L calibration syringe (Hans Rudolph, 2053 
Kansas City, USA) and a known concentration of a calibration gas (16.04 % O2, 2054 
5.06 % CO2; BOC Industrial Gases, Linde AG, Munich, Germany). During tests 2055 
participants breathed through a mouthpiece that was connected to a two-way, 2056 
non-rebreathing valve (model 2730, Hans Rudolph, Kansas City, Missouri), which  2057 
was itself connected to the analyser via falconia tubing (Baxter, Woodhouse & 2058 
Taylor Ltd, Macclesfield). After the test, PPO was calculated as the work rate of 2059 
the last completed stage, plus the fraction of time in the final non-completed 2060 
stage, multiplied by the relevant W increment. Oxygen uptake (V̇O2) and carbon 2061 
dioxide production (V̇CO2) were averaged over the last min of each stage and 2062 
used to assess substrate utilisation rates. V̇O2 peak was calculated as the highest 2063 
average V̇O2 measured over a rolling 30 s period. At least two criteria needed to 2064 
be achieved for a valid V̇O2 peak measure; a HR < 10 beats·min-1 of age predicted 2065 
maximal (220 - age), a respiratory exchange ratio (RER) > 1.05, an RPE > 17 or 2066 
an increase in V̇O2 of < 5 ml·kg-1·min-1 despite further increments in the exercise 2067 
intensity (365). In Chapter 6, the protocol was slightly modified to account for an 2068 
expected lower fitness level of individuals not accustomed to exercising, whereby 2069 
the test started at 50 W and the work rate increased by 25 W every three min.  2070 
 2071 
Douglas bag analysis 2072 
During rest and exercise, with the exception of the exercise tests, Douglas bags 2073 
were used to collect samples of expired air. The sensor (Mini MP 5200, Servomex 2074 
Group Ltd., Crowborough, UK) was turned on 60 min prior to testing to allow for 2075 
the temperature of the O2 and CO2 sensors to stabilise and was then calibrated 2076 
using a two-point calibration (99.99 % Nitrogen, 0 % O2, 0% CO2 and 16.04 % 2077 
O2, 5.06 % CO2 calibration gases: BOC Industrial Gases, Linde AG, Munich, 2078 
Germany). Participants were provided with a mouthpiece one min before each 2079 
sample was collected as a stabilisation period. Expired air samples were 2080 
collected into 200 L Douglas bags (Hans Rudolph, Kansas City, USA) with the 2081 




tubing and measurements of ambient O2 and CO2 concentrations were recorded 2083 
(366). Expired O2 and CO2 concentrations were measured in a known volume of 2084 
each sample for two min, or longer if values were not stable, using paramagnetic 2085 
and infrared transducers in the sensor. The ambient temperature and barometric 2086 
pressure were recorded as detailed previously, so that expired air volumes could 2087 
be corrected to standard temperature and pressure for dry gases. The volume 2088 
and temperature of expired air samples were measured using a dry gas meter 2089 
(Harvard Apparatus) and a digital thermistor (HI98509 Checktemp 1, Hanna 2090 
Instruments Ltd, Bedford, UK), respectively. The Haldane transformation was 2091 
used to calculate inspired gas volumes and to determine V̇O2 and V̇CO2 (367).  2092 
 2093 
Rates of lipid and carbohydrate utilisation were estimated from V̇O2 and V̇CO2 2094 
values via stoichiometric equations, primarily based on the formulae reported by 2095 
Keith Frayn (88). The equation used for lipids was based on the oxidation of 2096 
palmytoyl-stearoyl-oleoyl glycerol [PSOG], because this triglyceride is similar to 2097 
the overall composition of human adipose tissue. For carbohydrate utilisation, 2098 
calculations were also based on work by Frayn (88) but adjustments were made 2099 
to account for glycogen utilisation during exercise. Specifically, it was assumed 2100 
that there was an equal contribution of glucose and glycogen to carbohydrate 2101 
utilisation at 40-50 % V̇O2 peak, but with 20 % and 80 % contributions respectively 2102 
at exercise intensities of > 50 % V̇O2 peak (67). The underlying calculations are 2103 
explained subsequently in this chapter and the equations used were:  2104 
 2105 
1) Lipid utilisation for rest and exercise (gmin-1): 1.67 × V̇O2 - 1.67 × V̇CO2 2106 
2) CHO utilisation for rest (gmin-1): 4.542 x V̇CO2 - 3.201 x V̇O2 2107 
3) CHO utilisation for exercise at 40-50 % V̇O2peak (gmin
-1): 2108 
4.344  x V̇CO2 - 3.061 x V̇O2 2109 
4) CHO utilisation for exercise at 50-75 % V̇O2 peak (gmin
-1):   2110 
4.210  x V̇CO2 - 2.962 x V̇O2 2111 
 2112 
Substrate utilisation rates were only determined for exercise at intensities below 2113 




from indirect calorimetry at higher exercise intensities (67). Energy expenditure 2115 
was calculated assuming that lipids, glucose and glycogen yield 9.42, 3.74 and 2116 
4.15 kcal·g-1 of energy, respectively (67). The precise mixture of lipid sources 2117 
utilised is generally unknown, so caloric equivalents from 6.8 to 9.8 kcal·g-1 have 2118 
been previously cited (67). However, the most commonly applied constants are 2119 
from 9-9.75 kcal·g-1 which is within 3-4 % of the value of 9.42 kcal·g-1 used here. 2120 
 2121 
In Chapters 3 and 5, protein utilisation was accounted for in the measures of 2122 
carbohydrate and lipid utilisation (88, 368). Before protein is utilised for energy it 2123 
is first catabolised into amino acids and deaminated. The resultant amino acid 2124 
can be utilised, but nitrogen and sulphur are excreted in urine, sweat and faeces. 2125 
To measure protein utilisation, urinary nitrogen excretion was first estimated from 2126 
urine urea concentrations. The total volume of urine produced during a given trial 2127 
was recorded and a representative 1 mL of this sample was stored at -80 ºC. 2128 
Urine urea concentrations in mmol·L-1 were measured as detailed subsequently. 2129 
The concentration was divided by 35,700 to yield a urea concentration in g·mL-1 2130 
and then multiplied by 0.47 to yield nitrogen in g·mL-1. This assumes nitrogen 2131 
comprises 47 % of urea, but this is an estimate as urea accounts for ~ 90 % of 2132 
the nitrogen excreted in urine. This value was multiplied by the total urine volume 2133 
(mL) to estimate urinary nitrogen losses in g. Although, different values are used 2134 
to calculate protein utilisation in g·min-1 from urinary nitrogen losses in g·min-1, 2135 
the commonly applied value of 6.25 g of protein per g of urinary nitrogen was 2136 
applied here, as nitrogen comprises ~ 16 % of protein (67).  2137 
 2138 
In Chapters 4 and 6, protein utilisation was assumed to have made a negligible 2139 
contribution to energy metabolism for within-laboratory testing. Trial days in those 2140 
studies were shorter (~ 3 h) and protein utilisation was unlikely to have made a 2141 
meaningful contribution to metabolism as trials were mostly resting, meals were 2142 
carbohydrate-based and any exercise was moderate-intensity and relatively short 2143 
duration. During rest protein utilisation is ~ 1.4 g·h-1 for healthy men making it a 2144 
small contributor to energy metabolism (369). In a bolus, considerable doses of 2145 




values (370) and even high-intensity exercise does not always stimulate protein 2147 
utilisation above rest (369). As such, the absence of any correction for protein 2148 
utilisation is unlikely to have meaningfully altered estimations of whole-body lipid 2149 
or carbohydrate utilisation when it was not measured. In addition, for accurate 2150 
measures of protein utilisation using nitrogen excretion, trial days should be of 2151 
sufficient length for the sample to be reflective of daily nitrogen excretion (371). 2152 
 2153 
GLUCOSE TOLERANCE AND INSULIN SENSITIVITY 2154 
Although variations exist, some methods are most commonly used for assessing 2155 
glucose tolerance or peripheral insulin sensitivity (372). These involve measuring 2156 
blood glucose and insulin concentrations during fasting or after a physiological 2157 
challenge such as an oral glucose tolerance test. Peripheral insulin sensitivity can 2158 
be directly assessed with a hyperinsulinaemic-euglycemic clamp, whereby insulin 2159 
is infused at a constant rate to maintain hyperinsulinemia and blood glucose is 2160 
maintained at around 5.0 mmol·L-1 using a second infusion, with a higher glucose 2161 
infusion rate indicating heightened peripheral insulin sensitivity. Although less 2162 
common, a hyperinsulinaemic-hyperglycaemic clamp can also be used, whereby 2163 
glucose concentrations are increased to induce hyperglycaemia and maintained 2164 
through an infusion, with a higher infusion rate indicating high peripheral insulin 2165 
sensitivity (372). However, the gold-standard method for assessing whole-body 2166 
glucose tolerance is the oral glucose tolerance test (OGTT), where a 75 g glucose 2167 
bolus is ingested and followed by blood sampling every 10-15 min for ~ 120 min. 2168 
After 120 min, blood glucose concentrations of 7.8 to 11.0 mmol·L-1 suggests 2169 
impaired glucose tolerance and concentrations of > 11.0 mmol·L-1 suggests T2D 2170 
(372). In this test, the rate of blood glucose appearance is dependent on gastric 2171 
emptying, intestinal absorption and liver function, so it is more representative of 2172 
free-living situations (meal ingestion) than infusion-based methodologies (372). 2173 
For example, gastro-intestinally derived hormones such as GLP-1 are secreted 2174 
from intestinal enteroendocrine cells after meal consumption and can potentiate 2175 
insulin secretion (40), but this would not be apparent when glucose or insulin are 2176 
only infused peripherally. Therefore, the OGTT mimics the glucose and insulin 2177 




In addition, many indices of insulin sensitivity have been developed and validated 2179 
against a hyperinsulinaemic-euglycemic clamp, using measures obtained from 2180 
an OGTT. These indices include, but are not limited to, the homoeostatic model 2181 
assessment of insulin resistance [HOMA2-IR; fasting plasma glucose (mmol·L-1) 2182 
x fasting plasma insulin (pmol·L-1) / 22.5 (373)], the Quantitative Insulin Sensitivity 2183 
Check Index [QUICKI; 1 / log fasting blood insulin (µU·ml-1) + log fasting blood 2184 
glucose (mg·dL-1) (374)], the Matsuda Insulin Sensitivity Index (ISIMATSUDA; 2185 
10,000 / √ fasting blood glucose (mgdL-1) x fasting blood insulin (mIUmL-1) x 2186 
mean glucose over 120 min (mgdL-1) x mean insulin over 120 min (mIUmL-1) 2187 
(296)], the Cederholm Insulin Sensitivity Index (ISICEDERHOLM; 75000 + fasting 2188 
blood glucose (mmolL-1) - blood glucose at 120 min (mmolL-1) x 0.19 x 180 x 2189 
1.15 x body mass / 120 x log mean blood insulin over 120 min (mIUmL-1) x mean 2190 
blood glucose over 120 min (mmolL-1) (375)] and the oral glucose insulin 2191 
sensitivity index [OGIS; calculated as per http://webmet.pd.cnr.it/ogis/ (376)].  2192 
 2193 
In contrast to some OGTT-derived insulin sensitivity indices, such as ISIMATSUDA, 2194 
which are based on more simple empirical formulas, the OGIS was developed as 2195 
a physiologically representative glucose-insulin model. This method provides an 2196 
index of insulin sensitivity calculated via a model-derived formula from the OGTT 2197 
glucose and insulin concentrations from 0 min, 90 min and 120 min. Specifically, 2198 
a single compartment glucose model is used to estimate blood glucose clearance 2199 
rates after accounting for body surface area, similar to the hyperinsulinemic-2200 
euglycemic clamp. The index was validated against the clamp using 104 humans 2201 
with and without obesity and T2D. The authors reported that (a) the OGIS showed 2202 
a stronger correlation with the clamp method than other commonly-used insulin 2203 
sensitivity indices (b) there was no mean difference between the glucose 2204 
clearance rates derived from the clamp and the OGIS index and that (c) the OGIS 2205 
showed good intra-individual reproducibility. However, the index has only been 2206 
validated in resting and fasting conditions and thus if the mechanisms governing 2207 
the glucose-insulin relationship and the modelling from which the index was 2208 




In this thesis, fasting and OGTT-derived blood glucose and insulin concentrations 2210 
were measured. An OGTT was chosen to permit a simultaneous assessment of 2211 
whole-body oral glucose tolerance and an estimation of oral glucose insulin 2212 
sensitivity and because it was feasible given other constraints within each study. 2213 
Although the OGTT has been commonly used in physiology research, different 2214 
methods are used to obtain blood samples and include sampling from antecubital 2215 
veins (15), capillaries (377) or heated dorsal hand veins (329). Arterial blood best 2216 
represents the exposure of the peripheral tissues to metabolites and hormones 2217 
in the blood, so when knowledge of peripheral exposure to glucose or insulin is 2218 
important, arterial blood samples are appropriate. However, due to the  increased 2219 
risks associated with arterial catheterisation (378) other methods have been used 2220 
to provide samples reflective of arterial blood, such as the heated-hand technique 2221 
(379-385), which was used throughout this thesis.  2222 
 2223 
BLOOD SAMPLING AND TREATMENT 2224 
Upon arrival at the laboratory and after 10-15 min of rest, participants placed their 2225 
dominant hand into a heated-air box set to 55°C (Mass Spectrometry Facility; The 2226 
University of Vermont & University of Vermont Medical Center, Burlington, USA). 2227 
After 10-15 min, an intravenous catheter (BD Venflon Pro, BD, Helsingborg, 2228 
Sweden) was placed retrograde into a heated dorsal hand vein and a 10 mL 2229 
baseline blood sample was drawn. Blood was then sampled according to the 2230 
design of each study. Cannulae were kept patent via flushing of a 0.9 % sodium 2231 
chloride infusion (B.Braun, Melsungen, Germany) and the first 3 mL of drawn 2232 
samples was discarded to avoid any confounding influence of saline dilution on 2233 
the measured concentrations of metabolites or hormones in the sample. Plasma 2234 
was obtained by dispensing blood into ethylenediaminetetraacetic acid-coated 2235 
tubes (BD Oxford, UK) which were centrifuged for 10 min at 4 °C and 3500 g 2236 
(Heraeus Biofuge Primo R, Kendro Laboratory Products Plc., UK). Plasma was 2237 




Automatic analyser (Daytona) 2239 
Various metabolites were measured in plasma using an automated analyser 2240 
(Daytona; Randox Lab, Crumlin, UK). Before any analysis, the analyser was 2241 
calibrated using a two-point linear calibration system with a blank and a sample 2242 
with a known concentration of the metabolite. After calibration and at frequent 2243 
intervals during the analysis, standard samples were measured to act as a quality 2244 
control check. Before analysis, plasma samples were removed from the -80 ºC 2245 
freezer and thawed on ice for 60 min before measurement. Plasma glucose 2246 
concentrations were assessed in a colorimetric assay that measures glucose 2247 
after enzymatic oxidation by glucose oxidase, which produces gluconic acid and 2248 
hydrogen peroxide. The hydrogen peroxide then reacts with phenol and 4-2249 
aminophenazone in a reaction catalysed by peroxidase to produce a red-violet 2250 
quinoneimine dye. The intensity of the colour produced is measured at 505 nm 2251 
and is proportional to the sample glucose concentration up to 34.1 mmol·L-1. For 2252 
plasma lactate concentrations up to 15.0 mmol·L-1, lactate in the sample was 2253 
converted to pyruvate and hydrogen peroxide by lactate oxidase, before the same 2254 
hydrogen peroxide reaction as per the measurement of glucose.  2255 
 2256 
Plasma triglyceride (TAG) concentrations were measured using a colorimetric 2257 
assay, whereby enzymatic hydrolysis of TAG by lipases forms glycerol and fatty 2258 
acids. The glycerol is then converted to glycerol-3-phosphate by glycerol kinase 2259 
and glycerol-3-phosphate is then oxidised by glycerol-3-phosphate oxidase to 2260 
form dihydroxyacetone and hydrogen peroxide. Finally, quinoneimine is formed 2261 
from the hydrogen peroxide, 3-aminophenzane and 4-cholorophenol in a reaction 2262 
catalysed by peroxidase and is measured at 505 nm up to TAG concentrations 2263 
of 12.7 mmol·L-1. However, as this assay measures the glycerol component of 2264 
TAG it can overestimate TAG concentrations if substantial glycerol is present in 2265 
the sample. To avoid this potential measurement issue, glycerol concentrations 2266 
were independently measured on the analyser to provide a glycerol-blanked TAG 2267 
concentration. Concentrations of β-hydroxybuturate were assessed in an assay 2268 
that oxidises β-hydroxybuturate to acetoacetate in a reaction that is catalysed by 2269 




NADH and the resultant change in absorbance is measured and correlated with 2271 
the β-hydroxybuturate in a sample up to concentrations of 0.10-5.75 mmol·L-1. 2272 
Finally, to allow for protein utilisation to be estimated, urine urea concentrations 2273 
were measured. In this assay, urea is hydrolysed by urease to produce ammonia 2274 
and CO2, before the ammonia then combines with α-oxoglutarate and NADH in 2275 
a reaction catalysed by glutamate dehydrogenase to form glutamate and NAD+. 2276 
A change in absorbance can then be measured and correlated with the urea 2277 
concentration in the sample. 2278 
 2279 
Enzymatic colorimetric assays 2280 
Plasma non-esterified fatty acid (NEFA) concentrations were determined via a 2281 
commercially available assay using an enzymatic colorimetric principle (Alpha 2282 
Laboratories Ltd; Hampshire, UK). Briefly, 5 μL of each sample was pipetted into 2283 
a well and incubated for 5 min at 37 °C in the presence of 200 μL of an Acyl-CoA 2284 
synthetase, coenzyme A and adenosine 5-triphosphate disodium salt mixture. 2285 
This converts NEFA in the sample to acyl-CoA, adenosine monophosphate and 2286 
pyrophosphoric acid (PPi). The absorbance at 550 nm was measured to serve 2287 
as a blank (SPECTROstar plate reader, BMG Labtech, Aylesbury, UK). Then, a 2288 
reagent containing acyl-CoA oxidase and peroxidase was added before a 5 min 2289 
incubation. This was to oxidise the acyl-CoA to yield 2 3-trans-Enoyl-CoA and 2290 
hydrogen peroxide. Finally, in a reaction catalysed by peroxidase, the hydrogen 2291 
peroxide yields a blue pigment after oxidation condensation with 3-Methyl-N-2292 
Ethyl-N (β-Hydroxyethyl)-Aniline and 4-amino-antipyrine. The absorbance was 2293 
read again at 550 nm and the reading was subtracted from the blank for a final 2294 
absorbance. The concentration of NEFA in each sample was determined using 2295 
the relationship between standard concentrations and the final absorbance. 2296 
 2297 
Enzyme-linked immunoassays (ELISA) 2298 
Enzyme-linked immunosorbent assay kits (ELISAs) were used to measure 2299 
insulin, leptin (both Mercodia AB; Uppsala, Sweden), fibroblast growth factor 21 2300 
(FGF21; BioVendor Research & Diagnostic Products Czech Republic) and 2301 




concentrations using the direct sandwich technique. For insulin, 25 μL of plasma 2303 
was added to wells coated with a monoclonal antibody directed towards the 2304 
antigenic site on insulin. A second monoclonal antibody was added which was 2305 
labelled with horseradish peroxidase (HRP), which provides the enzyme activity 2306 
to convert the substrate to a fluorescent product. The mixture was left for 60 min 2307 
at room temperature on a plate shaker at 900 rpm. After washing to remove any 2308 
unbound antibody, tetramethyl benzidine (TMB) was added in a 200 μL solution 2309 
and left for 15 min to start the HRP reaction. The reaction was stopped by adding 2310 
a 50 μL sulfuric acid mixture and the absorbance was measured at 450 nm with 2311 
the aforementioned plate reader. The concentration of insulin in each sample was 2312 
determined with the relationship between insulin concentrations of standards and 2313 
absorbance values for concentrations up to 200 mU·L-1.  2314 
 2315 
To measure leptin a similar assay was performed, but antibodies were directed 2316 
against antigenic sites specific to leptin. During an initial incubation leptin in the 2317 
sample reacted with peroxidase-conjugated anti-leptin antibodies and after 2318 
washing, bound conjugate was detected using the TMB reaction, before reading 2319 
the absorbance at 450 nm for  concentrations up to 100,000 ng·mL-1.  2320 
 2321 
For I-FABP concentrations, 100 μL of plasma was pipetted into wells coated with 2322 
I-FABP antibodies. After a 60 min incubation at room temperature, 100 μL of 2323 
biotinylated tracer antibody was then added, which bound to captured I-FABP. 2324 
After a 60 min incubation, 100 μL streptavidin-peroxidase was added and after a 2325 
third 60 min incubation, the TMB reaction was initiated, before being terminated 2326 
30 min later with oxalic acid. The absorbance was read at 450 nm and I-FABP 2327 
concentrations in each sample were assessed using the absorbance values and 2328 
a standard curve for concentrations from 47-3,000 pg·mL-1.  2329 
 2330 
FGF-21 concentrations were measured by adding plasma to wells coated with a 2331 
polyclonal FGF-21 antibody. Following a 60 min incubation, 100 μL of a biotin-2332 
labelled polyclonal FGF-21 antibody was added and incubated for 60 min. Then, 2333 




were added. In this assay the TMB reaction was stopped using sulphuric acid 2335 
before absorbances were read at 450 nm and 630 nm (readings at 630 nm were 2336 
subtracted from those at 450 nm) to detect concentrations up to 1920 pg·mL-1. 2337 
 2338 
Precision of analysis 2339 
To minimise inter-assay variation, all samples were analysed in batch against the 2340 
same standards and controls after all data collection was completed. For blood 2341 
analysis, all samples for a participant were measured on the same plate or same 2342 
run on the Daytona. If concentrations were outside of the standard curve for a 2343 
given assay, they were diluted as per the kit instructions and then re-analysed. 2344 
Samples were measured in duplicate unless otherwise stated. Inter- and intra-2345 




  2347 
Table 2.1. Coefficient of variations for biochemical analytical techniques 
 Method Used 
  Coefficient of Variation (%) 
Intra-assay Inter-assay 
Glucose Photometric (Daytona)   
Chapters 3 and 5  3.2 ± 1.6 3.8 ± 2.8 
Chapter 4  2.9 ± 1.3 5.9 ± 1.3 
Chapter 6  2.5 ± 1.2 3.8 ± 3.5 
Triglycerides Photometric (Daytona)   
Chapter 3  1.4 ± 0.2 4.0 ± 0.3 
Chapter 4  3.4 ± 1.1 4.0 ± 1.1 
Chapter 6  3.4 ± 1.2 4.1 ± 3.7 
Lactate Photometric (Daytona)   
Chapter 3  1.0 ± 0.1 4.8 ± 1.7 
Chapter 4  3.4 ± 1.2 3.7 ± 0.6 
Total Cholesterol Photometric (Daytona)    
Chapter 6  1.2 ± 1.0 4.3 ± 4.1 
HDL Cholesterol Photometric (Daytona)   
Chapter 6  2.6 ± 3.4 3.9 ± 0.8 
LDL Cholesterol Photometric (Daytona)   
Chapter 6  0.8 ± 0.5 5.0 ± 4.9 
Glycerol Photometric (Daytona)   
Chapter 6  1.7 ± 0.0 4.7 ± 4.0 
Insulin ELISA   
Chapter 3  5.9 ± 2.2 10.0 ± 3.2 
Chapter 4  3.7 ± 0.8 6.5 ± 2.9 
Chapter 6  3.9 ± 1.3 9.9 ± 3.5 
NEFA ELISA   
Chapter 3  8.9 ± 3.3 10.5 ± 3.2 
Chapter 6  7.9 ± 1.2 10.2 ± 2.9 
IFAB-P ELISA   
Chapter 3  6.0 ± 2.2 - 
FGF-21 ELISA   
Chapter 5  - - 
Leptin ELISA   
Chapter 5  5.8 ± 4.8 7.1 ± 5.0 
C-peptide ELISA   
Chapter 6  4.3 ± 1.8 17.8 ± 3.2 
HDL= High density lipoprotein; LDL= Low density lipoprotein; NEFA= Non-esterified 





BLOOD GLUCOSE FLUX 2348 
To provide data on blood glucose flux during- and post-exercise, glucose tracers 2349 
([U13-C]-glucose ingestion with an infusion of [6,-6- 2H2]-glucose) were utilised in 2350 
Chapters 3 and 5. The principles of this method are discussed elsewhere (29) 2351 
but some important considerations are outlined below. Isotopes are atoms that 2352 
are chemically identical but have different molecular weights due to a different 2353 
number of neutrons in their nucleus. The common isotopes of major elements 2354 
[hydrogen (H), carbon (C), nitrogen (N) and oxygen (O)], are 1H, 12C, 12N and 16O, 2355 
and these are stable and non-radioactive. However, there are other stable 2356 
isotopes, that can be administered safely to humans, which are less common 2357 
(e.g. 2H, 13C, 15N, and 18O). These have the same chemical properties as the 2358 
more common isotopes but can be distinquished with mass spectrometery, due 2359 
to differences in their mass to charge ratio. For example, each glucose molecule 2360 
has six carbons and each carbon atom has ~ 1.1 % of chance of being 13C, so 2361 
only 6.6 % of naturally occurring glucose has one 13C. The underlying principle of 2362 
tracer methods is that when a known amount of a tracer is added to a system, 2363 
sampling from the pool (e.g. plasma) where the tracer is mixed to measure tracer 2364 
dilution, provides information about the flux of a tracee (e.g. glucose) of interest 2365 
in that pool. If the pool size is large relative to flux of the tracee, a priming dose 2366 
can be used to label the sampling pool with the tracee, to reduce the infusion time 2367 
needed to achieve tracer: tracee steady state at detectable concentrations.  2368 
 2369 
A fundamental principle of using stable isotopes is that the label used in a given 2370 
tracer does not re-appear in the sampling pool after it has been removed with the 2371 
tracee as re-cycling would result in the rate of appearance of the tracee being 2372 
underestimated (29). The total rate of blood glucose appearance is typically 2373 
determined using hydrogen (2H [deuterium] or 3H [tritium]) as opposed to carbon 2374 
isotopes. In Chapter 3, [6, 6-2H2]-glucose was chosen as an infusate, where two 2375 
hydrogen atoms attached to carbons at position 6 are deuterium. This is because 2376 
only carbon-labeled glucose can be recycled during gluconeogenesis (GNG) of 2377 
pyruvate and lactate from the Cori cycle (386). Hydrogen isotopes can be labelled 2378 




glucose metabolism. These processes can occur in the liver, which also has the 2380 
enymes needed to reverse each stage of glucose phosphorylation. Thus, whilst 2381 
GNG may not be a consideration with a hydrogen versus a cabon label, it is still 2382 
possible to understimate hepatic glucose production (HGP) with recycling of the 2383 
hydrogen label in the liver. If glucose is labelled on the 2nd carbon, the hydrogen 2384 
label is lost in the conversion of glucose-6-phosphate to fructose-6-phosphate 2385 
and labelling on the 3rd carbon is lost with cleavage of fructose-1,6-bisphosphate 2386 
to glyceraldehyde-3-phosphate and dihydroxyacetone phosphate. However, 2387 
when glucose is labelled on the 6th carbon, the label can only be lost after entry 2388 
into the TCA cycle, which is non-reversable (387). Blood glucose appearance 2389 
rates from [6,6-2H]-glucose therefore represents the appearance of glucose from 2390 
hepatic glycogen or GNG and not glucose cycle activity, as the label on the 6th 2391 
carbon cannot be lost in reversible steps of glucose metabolism. Using [6,6-2H2]-2392 
glucose as a tracer helps to overcome issues with futile cycling as this tracer can 2393 
be distinguished from the [6-2H1]-glucose product of recycling in analysis (388).  2394 
 2395 
Combining a [6,6-2H2]-glucose infusion with the oral ingestion of a second tracer 2396 
also provides data on the appearance of glucose from a meal. First, the infused 2397 
tracer can be used to estimate the total rate of blood glucose appearance and 2398 
the appearance of the ingested glucose can be estimated by multiplying the rate 2399 
of appearance of the ingested tracer in the plasma by the tracer: tracee ratio of 2400 
the meal. HGP is calculated as the total glucose appearance rate minus the rate 2401 
of appearance of ingested glucose. Finally, plasma glucose disposal rates can 2402 
be estimated by substracting the change in blood glucose concentrations from 2403 
the total rate of glucose appearance. Universally labelled [U13-C]-glucose was the 2404 
chosen oral tracer in Chapter 3, because there is no net loss of carbon during 2405 
glycolysis, so this versus a hydrogen label avoids issues with label recycling in 2406 
the liver. Using [U-13C]-glucose instead of an isotope with fewer carbon labels 2407 
also helps to avoid issues with recycling from GNG as for universally labelled 2408 
glucose to reappear in the blood, two triply labeled 3-carbon precursors would 2409 
need to have combined to form [U-13C]-glucose (389). Choosing an appropriate 2410 




the endogenous metabolism of the tracee of interest and the infusion rate also 2412 
dictates the quantity and cost of the tracer required. In Chapter 3, the prime and 2413 
infusion rates were based on prior research with a similar participant cohort and 2414 
protocol (390). Previous work was also used to inform the decision to modify the 2415 
infusion rate during exercise (391) and the OGTT (390) to account for expected 2416 
changes in HGP and to reduce alterations in the tracer-to-tracee ratio in order to 2417 
obtain more accurate measures of glucose flux (29).  2418 
 2419 
Preparation of tracers 2420 
For the OGTT, 73 g of glucose was first weighed as 81 g of dextrose monohydrate 2421 
corrected for water content (Myprotein, Northwich, UK). Then, 2 g of [U13-C]-2422 
glucose (99 %; Cambridge Isotope Laboratories, MA, USA) was weighed to the 2423 
nearest 0.01 g with electronic weighing scales (AX124/E Adventurer Analytical 2424 
Balance, Ohaus, Parsippany, USA) and added with 300 mL of plain water. The 2425 
infusate and prime were freshly made for each trial. A spreadsheet was prepared 2426 
with desired tracer weights and saline volumes which were calculated from the 2427 
desired infusion rate, the MW of [6,6-2H2]-glucose, the MW of sodium chloride, 2428 
the expected length of the infusion, an estimation for the volume of distribution of 2429 
glucose in the blood as 4 % of the participants body mass and an estimated 2430 
fasting plasma glucose concentration of 4.5 mmol·L-1. Tracer preperation was 2431 
completed under a sterlie fume hood and work surfaces, material packaging and 2432 
equipment were sprayed with 70 % ethanol. The desrired mass of [6,6-2H2]-2433 
glucose was weighed seperately for infusates and primes to the nearest 0.01 g 2434 
and the actual mass was recorded. Then, a needle was attached to a 60 mL 2435 
sterile syringe and used to add the desired volume of saline for the infusate and 2436 
prime and the actual volume was recorded. A second syringe was used to 2437 
aspirate the solution for the infusate and prime and was attached to a 3-way 2438 
stopcock, a 0.2 micron syringe filter and an intravenous infusion extension line 2439 
(for the prime, the syringe was only attached to the filter). The spreadsheet was 2440 
updated with the actual weights recorded so that the required pump rate could be 2441 




(Alaris™ PK Syringe Pump, BD, Wokingham, UK) and the infusate syringe was 2443 
weighed after each trial to ensure the infusion rate prescribed was accurate. 2444 
 2445 
Sample preparation 2446 
Plasma [U13C]-glucose and [2H2]-glucose enrichments were determined via gas 2447 
chromatography-mass spectrometry (GC-MS). First, the glucose was extracted 2448 
from samples using methanol-chloroform and hydrochloric acid, dried under 2449 
nitrogen gas and derivatised to ensure samples were sufficiently volatile and 2450 
thermally stable for GC-MS analysis (392). Specifically, 150 μL of plasma was 2451 
added to 3 mL of a methanol: chloroform mixture (2.3:1 ratio), vortexed for 10 min 2452 
using a plate shaker (MidiMix, Denley) and left on ice for 10 min. This was then 2453 
centrifuged at 3000 g and 4 ºC for 15 min (IEC Centra-CL3R, Thermo Electron 2454 
Corporation, Massachusetts, US). The top layer containing glycerol, glucose and 2455 
NEFA was removed using a pipette and transferred into a new tube (borosilicate 2456 
glass and threaded end with phenolic caps; Thermo Fisher Scientific, 2457 
Massachusetts, US). Thereafter, 2 mL of chloroform and 1 mL of hydrochloric 2458 
acid was added, before 10 min of vortexing and centrifuging at 3000 g at 4ºC for 2459 
10 min. The top layer with glycerol and glucose was transferred into a new tube 2460 
and the supernatant was evaporated under nitrogen at 70 ºC (Multivap 118 2461 
Nitrogen Evaporator; Organomation, Massachusetts, US and QBT4 dry block 2462 
heating system; Grant Instruments, Cambridge, UK). The pellet produced was 2463 
resuspended in 200 μL of a 1:3 hexafluorobenzene: ethyl acetate solution and 2464 
incubated at 70 ºC for 10 min. The solution was centrifuged at 3000 g and 25 ºC 2465 
for 5 min and evaporated under nitrogen. The sediment was resuspended in 100 2466 
μL of ethyl acetate, vortexed for 10 min, left at room temperature for 15 min and 2467 
transferred to a vial for GC (glass inserts; Macherey-Nagel, Düren, Germany).  2468 
 2469 
Gas chromatography mass spectrometry (GC-MS) 2470 
The [6,6-2H2]- and [U-13C]-glucose enrichments were determined using Agilent 2471 
Technologies gas chromatography and mass selective detectors (GC; Agilent 2472 
Technologies 6890N, UK; mass selective detector; Agilent Technologies 5973). 2473 




resultant gases could be carried down the chromatographic column by a carrier 2475 
gas and the different substances in the sample could be separated according to 2476 
their interactions with the coating of the column and carrier gas. The separated 2477 
substances emerged from the column into the mass spectrometer, where they 2478 
were ionized and separated according to their mass-to-charge (m/z) ratios. Data 2479 
analysis was completed on commercially available software (MSD ChemStation 2480 
analysis, Cheshire, UK). The glucose derivatives were acquired by using selected 2481 
ion monitoring at m/z 519, 521 and 525 for [12-C]-, [6,-62H2]-, and [U13-C]-glucose, 2482 
respectively and the area under each peak was calculated. Corrections were 2483 
made for the order in which the samples were loaded onto the GC and the plasma 2484 
enrichments of the isotopes were calculated via standard curves for [13-C]- and 2485 
[2H2]-glucose and expressed relative to enrichments for [12-C]-glucose. A baseline 2486 
sample from every trial was used to account for background isotopic enrichments.  2487 
 2488 
Data modelling and calculations  2489 
To reduce any impact of analytical variability on calculations of plasma glucose 2490 
flux, plasma glucose concentrations and enrichments were curve fitted using a 2491 
3rd Order Polynomial (393). Plasma glucose flux was assessed with Radziuk’s 2492 
two-compartment non-steady state model (394, 395). First, the total plasma 2493 













2) Rd (t) =RaTOTAL-V1∙Ġ(t) -k21∙V1∙G(t) +k12∙Q2(t) 2497 
 2498 
Where F is the [6,6-2H2] infusion, V1 is the glucose volume of distribution [4 % of 2499 
the participant’s body mass as this results in less variable estimations of glucose 2500 
flux for an OGTT compared to if larger values are used (29)],  E1(t) is the [2H2]-2501 
glucose enrichment (mole percent excess) at time t, Ė1 (t) is the change in E over 2502 
time (derivate of E), G(t) is the plasma glucose concentration at time t, Ġ(t) is the 2503 
change in G over time (derivate of G),  k12 and k21 are fixed constants between 2504 




are the amounts of tracer and tracee in the peripheral compartment respectively, 2506 
evaluated by integrating the two-compartment model.  2507 
 2508 
The [U13C]-glucose enrichment of the OGTT and RaTOTAL were then used to 2509 
assess the rate of appearance of glucose from the OGTT (RaOGTT) in plasma. In 2510 
the subsequent equations, r1 represents the ratio of the infusion [2H2] and oral 2511 
[U13C]-glucose tracer enrichments in plasma, ṙ(t) is the change in r over time 2512 
(derivate of r), g is the [U13C]-glucose in plasma, qoiv is the amount of [U13C]-2513 
glucose in the peripheral pool (evaluated by integrating the two-compartment 2514 





















In the 1950’s and 60’s Steele et al developed dual tracer methods for studying 2520 
glucose flux in a single-pool model (396-398). Since then, others have used the 2521 
principle of the method to study glucose flux but have addressed some limitations 2522 
associated with a single pool model. The problem with the single-pool model, 2523 
where the tracee and the tracer are uniformly distributed in a steady state, is that 2524 
this does not represent many physiological scenarios. For example, during an 2525 
OGTT there is a large influx of glucose into the blood and the glucose crosses, 2526 
and can be extracted, by many tissues prior to this (399, 400). Thus, at least two 2527 
pools are present for glucose in this condition; a rapidly equilibrating inaccessible 2528 
pool and the sampling pool (plasma). A failure to account for this second pool 2529 
increases errors in the estimations of glucose flux and especially HGP (399, 400). 2530 
A potential solution to this problem is the use of a pool fraction, which assesses 2531 
the sampling pool as a fraction of the volume of distribution of glucose in the body, 2532 
but the most appropriate value for a pool fraction can also vary under non-steady 2533 
state conditions (401). Alternatively, using a model with an accessible and non-2534 
accessible pool reduces errors with estimating plasma glucose flux, especially 2535 




HGP (401). A triple-tracer approach has also been used previously, where in 2537 
addition to an orally ingested tracer, two intravenous tracers (e.g. [6-3H]-glucose 2538 
and [6, 6-2H2]-glucose) are infused in patterns that minimise the change in their 2539 
ratio to the ingested tracer and glucose via HGP, respectively. Thus, calculations 2540 
of HGP become independent of modelling (400). However, there are large costs 2541 
with the purchase and analysis of a third tracer, and the dual tracer method when 2542 
implemented carefully can provides accurate estimations of plasma glucose flux. 2543 
 2544 
MUSCLE SAMPLING AND ANALYSIS 2545 
Throughout this thesis, skeletal muscle was sampled and primarily analysed for 2546 
the content and/or activity of proteins involved in glucose and/or lipid metabolism. 2547 
Samples were collected (~ 100 mg of wet weight) from the vastus lateralis using 2548 
a Bergstrom biopsy needle technique, which was adapted for suction (402) and 2549 
from separate skin incision sites, with these > 2 cm proximal to any prior incisions 2550 
on the same leg. Upon arrival at the laboratory participants rested for 15-20 min 2551 
in the supine position. The skin surrounding the sampling site was shaved before 2552 
being cleaned and sterilised with iodine (Videne, EcoLab, UK). A local 2553 
anaesthetic (2.5 mL of 1 % lidocaine, Hameln Pharmaceuticals Ltd., UK) was 2554 
injected under the skin using a 27 G needle and a second 2.5 mL dose of 2555 
lidocaine was injected onto the outside of the muscle facia (2-5 cm beneath the 2556 
skin surface) using a 21 G needle. A 3 mm incision at the anterior aspect of the 2557 
thigh was made with a blade (Swann Morton, size 11), iodine was applied and 2558 
pressure placed on the incision. Samples were taken using a 5-mm Bergstrom 2559 
biopsy needle (402) which was vertically inserted into the incision to a depth of at 2560 
least 1 cm beyond the fascia. A vacuum was created using a 100 mL syringe 2561 
attached to the needle to allow for the muscle to be snipped and this was repeated 2562 
2-3 times to obtain a sample. After removal of the needle, the incision was sealed 2563 
with a proline stitch and steri-strips, then covered with a water-proof adhesive 2564 
dressing. Samples were extracted from the needle and cleaned in saline with 2565 
dissection of obvious blood or connective tissue. Cleaned samples were placed 2566 





Upon removal from storage and whilst still immersed in liquid nitrogen, each 2569 
sample was dissected to remove a fragment of muscle tissue (20-30 mg), which 2570 
was freeze-dried for 12 h at -40 °C and -10-1 mmHg (Edwards Modulyo; Thermo 2571 
Fisher Scientific, Massachusetts, US). Thereafter, any remaining visible blood or 2572 
connective tissue was removed with a small blade (Swann Morton, stainless 2573 
steel, size 11) before samples were powdered with an agate pestle and mortar. 2574 
Powder was divided into separate Eppendorf tubes and weighed to the nearest 2575 
0.01 g (2 mg dry weight per tube) using an analytical balance scale (Sartorius 2576 
AG, Göttingen, Germany), before powdered samples were again stored at -80°C. 2577 
 2578 
Assessment of protein content  2579 
Powdered samples were added, at 100 μL·mg-1, to ice cold lysis buffer as detailed 2580 
in the final sub-section of Chapter 2, with phosphatase (Thermo Fisher Scientific, 2581 
Massachusetts, US) and protease inhibitors (Merck Millipore, Massachusetts, 2582 
US). Samples were then homogenised with 30-40 passes of a hand-held dounce 2583 
homogeniser (VWR International Ltd, Leicester, UK), incubated for 60 min at 4°C 2584 
with rotation (Gallenkamp Vacuum Oven, Fistreem International Ltd, Leicester, 2585 
UK) and centrifuged for 10 min at 4°C and at 20,000 g (Eppendorf™ 5424 2586 
Microcentrifuge, Hamburg, Germany) to remove insoluble material. The protein 2587 
content of the resultant supernatant was measured using a bicinchoninic acid 2588 
assay. Samples were diluted at a ratio of 1:10 using 0.1 M sodium hydroxide 2589 
(NaOH) and a standard curve was freshly prepared with dilutions of a 1 mg·mL-1 2590 
bovine serum albumin (BSA) stock. Then, 10 μL of the standards and samples 2591 
were pipetted in duplicate onto a 96-well plate. To each well, 196 μL protein assay 2592 
reagent A (Thermo Fisher Scientific) and 4 μL copper(II) sulfate was added, 2593 
before a 30 min incubation at 37°C. This assay relies on two reactions; first, the 2594 
peptide bonds in protein reduce Cu2+ ions from the copper(II) sulfate to Cu+. The 2595 
amount of Cu2+ reduced is proportional to the amount of protein in the original 2596 
sample. Next, two molecules of BCA chelate with each Cu+ ion, which forms a 2597 
purple-coloured complex. The intensity of the colour produced in this reaction is 2598 




BMG Labtech, Aylesbury, UK). The protein content of each sample was then 2600 
calculated by comparing the obtained absorbance values to the standard curve. 2601 
 2602 
Western blots 2603 
Western blotting was first developed in 1979 and provides semi-quantitative data 2604 
about the content and/or activity status of proteins in a sample (403). First, the 2605 
different proteins in a sample were separated via gel electrophoresis. Linear tris-2606 
glycine sodium dodecyl sulphate (SDS)-polyacrylamide gels were casted in CBS 2607 
(VWR) gel cassettes to obtain 10 % polyacrylamide resolving gel overlaid with a 2608 
6% polyacrylamide stacking gel. Then, an equal amount of protein (~ 40 µg) was 2609 
loaded for each sample in a 50 µL volume into separate wells, with 8 µL of MW 2610 
markers (Thermo Fisher Scientific) in one well. Proteins were separated 2611 
according to their MW by SDS-polyacrylamide gel electrophoresis using an 2612 
electrical current applied at 200 V for ~ 1 h, whilst the gel was submerged in 2613 
electrophoresis buffer. Proteins were then electro-transferred using a semi-dry 2614 
transfer onto a nitrocellulose membrane (Gelman Sciences, Portsmouth, UK). 2615 
This uses the electrophoretic mobility of the proteins in order to transfer them 2616 
from the gel onto the membrane which is sandwiched between electrodes with 2617 
the aid of a conducting solution (SDS-Transfer Buffer). The nitrocellulose 2618 
membrane and filter papers (Bio-Rad Laboratories; Hercules, California, USA) 2619 
were cut to an appropriate size and soaked in SDS-transfer buffer, before being 2620 
placed on a transfer unit (Bio-Rad Laboratories; Hercules, California, USA). An 2621 
electric current was created at 75 mA to facilitate the movement of the proteins 2622 
from the gel onto the membrane. Membranes were washed to remove any 2623 
transfer buffer before staining in a 0.1% Ponceau S solution in 3 % Trichloroacetic 2624 
acid (TCA) and imaging using a chemiluminescent imager (EpiChemi II 2625 
Darkroom, UVP, Upland, US) to assess transfer efficiency. Then, membranes 2626 
were washed in Tris-buffered saline (TBS) and cut according to the MW of the 2627 
protein of interest and incubated for 30 min in a blocking solution (5 % non-fat dry 2628 
milk in TBS-T; Marvel, Premier International Foods Ltd, UK) to reduce nonspecific 2629 
binding of the detection antibody. This was followed by washing (4 x 5 min) to 2630 




for ~ 12 h at 4°C with primary antibodies diluted ~ 1:1000 in TBS-T with 1 % BSA, 2632 
against the protein of interest. All of the primary antibodies used and the suppliers 2633 
are detailed in the relevant chapters of this thesis. Thereafter, membranes were 2634 
washed with TBS-T (5 x 5 min) and incubated in anti-species IgG horseradish 2635 
peroxidase-conjugated secondary antibodies (1:4000 dilution) in the blocking 2636 
solution. The secondary antibody used depends on the animal in which the 2637 
primary antibody was raised. For example, for a mouse monoclonal antibody, an 2638 
anti-mouse IgG secondary antibody from a non-mouse host is combined with 2639 
horseradish peroxidase, which reacts with the chemiluminescence reagent.  2640 
 2641 
Membranes were then visualised on the chemiluminescent imager (EpiChemi II 2642 
Darkroom, UVP, Upland, US). Multiple images of the membranes were made with 2643 
a CCD cooled camera, which measures the quantity of light produced from the 2644 
chemiluminescent reaction. Images were taken with various exposure times to 2645 
allow capturing images with optimal intensity of the protein bands. The volume of 2646 
pixels in each band were quantified using appropriate software (as detailed in the 2647 
relevant chapters of this thesis). Images were inverted to produce an image with 2648 
black bands on a white background and the intensity of the picture was adjusted 2649 
to allow the bands of interest to be more identified easily. For each band, a 2650 
background correction was completed at ~ 10 % of the intensity of each band, 2651 
with manual adjustments made to ensure that the entire width and peak of each 2652 
band was accounted for in the analysis. Due to the semi-quantitative nature of 2653 
the method all samples from a participant were included on the same gel and 2654 
quantification was done using the same software and by the same researcher. 2655 
After imaging, membranes were sometimes incubated for 30 min at 50°C in a 2656 
stripping solution (62.5 mM Tris pH 6.7, 2 %SDS, 100 mM 2-mercaptoethanol) to 2657 
allow for re-blotting of the same membrane with different primary antibodies. 2658 
 2659 
ENERGY BALANCE 2660 
Assessing energy intake 2661 
In Chapter 5, energy intake was assessed over 24 h including within-laboratory 2662 




meals for lunch within-laboratory and dinner (free-living). Meals were designed to 2664 
be homogenous to reduce the likelihood that a participant would overconsume or 2665 
preferentially consume one macronutrient (404). The macronutrient composition 2666 
of the meals was selected to reflect the high-carbohydrate diet typical to 2667 
developed countries (186). For within-laboratory meals, fresh portions were 2668 
continually provided to ensure that the participant finishing one portion was not 2669 
responsible for meal termination, and they were asked to eat until comfortably 2670 
full. For meals outside of the laboratory, participants were instructed to eat until 2671 
comfortably full, not to eat and/or drink anything not provided in the food package 2672 
(except water) and to bring remaining food back to the laboratory. For all meals, 2673 
the carbohydrate, fat and protein content (g) was taken from the manufacturer’s 2674 
label. Intake of a macronutrient was calculated as the g provided (cooked weight) 2675 
minus the g remaining after the meal. The energy consumed was estimated with 2676 
carbohydrates, fats and proteins giving 3.74, 9.42 and 4.09 kcal·g-1, respectively. 2677 
These values are equivalent to values that were used for the energy expended 2678 
with the utilisation of each substrate, so that calculations of energy/macronutrient 2679 
balances would be the same if expressed as g or kcal.  2680 
 2681 
In Chapter 6, participants were asked to keep a weighed diet record of their food 2682 
and fluid intake over a typical 4-day period at baseline and during the final week 2683 
of the intervention. The importance of maintaining their habitual diet during the 2684 
baseline monitoring period was outlined to participants and they were provided 2685 
the following instructions verbally and in writing; "Your lifestyle choices during this 2686 
free-living monitoring period are central to this study. We are interested in any 2687 
natural changes in your diet and/or physical activity habits, which you may or may 2688 
not make in response to the intervention. This monitoring period has been 2689 
carefully scheduled to avoid any pre-planned changes in these habits, such as a 2690 
holiday or diet/exercise plan. You should inform us immediately if unforeseen 2691 
factors external to the study may influence your lifestyle." As variation exists 2692 
between reported weekday and weekend energy intakes, a minimum of one 2693 
weekend day was included in the monitoring periods (405). Each participant 2694 




help reduce errors in estimations of food weights and they were asked to provide 2696 
packaging or photos of meals if weighing was impractical. Records were analysed 2697 
on Nutritics software for macronutrient intakes (Nutritics Ltd., Dublin, Ireland). The 2698 
composition of each food item was obtained from the manufacturer’s labels and 2699 
if this was not possible, the foods were analysed using the software database, or 2700 
comparable brands were used to provide necessary information and this was kept 2701 
constant across all records for a given participant. An average daily intake of each 2702 
macronutrient was calculated for the monitoring period and was then used to 2703 
calculate energy intake using aforementioned values for carbohydrate, fats and 2704 
proteins and with alcohol providing 7.10 kcal·g-1 (406). 2705 
 2706 
Accurately assessing energy intake in humans is one of the most difficult aspects 2707 
of energy balance research, because most methods depend on self-reporting, 2708 
which introduces observational, reporting and recall biases (407). In a laboratory 2709 
when researchers prepare and weigh food, it is possible to assess energy and 2710 
macronutrient intakes to the nearest ingested gram without any self-reporting. 2711 
However, even this method can be cofounded by observational biases, as energy 2712 
intakes can be 5-10 % lower if a participant is aware of being observed, in line 2713 
with social desirability to not over-consume (408). Providing researcher-weighed 2714 
meals is also less feasible in a free-living environment (407). One retrospective 2715 
method is the food frequency questionnaire, which asks questions about prior 2716 
meals (the frequency and portion size) over a given time period and often from a 2717 
pre-determined list of foods, although the list of foods and timescale used for the 2718 
assessment varies across studies (407). As this method is inexpensive and has 2719 
a low participant burden, it is typically used in epidemiological research, but it is 2720 
associated with issues such as a limited list of foods. A more personal approach 2721 
is where a participant interacts with an interviewer with the aim of capturing their 2722 
food and fluid intake and cooking methods from a previous day (24-h recall) or a 2723 
longer period. This typically provides more information than a food frequency 2724 
questionnaire but can still be influenced by recall bias and relies on estimated 2725 
portion sizes. To help avoid this potential source of error, participants are often 2726 




cited timescale is 7 days (to help account for day-to-day variability in energy 2728 
intakes) but the relatively high burden associated with recording often leads to 2729 
under-reporting or under-eating, so shorter records have also been used in an 2730 
attempt to improve the accuracy of diet records (405). The weighed diet record 2731 
method overcomes issues with recall bias, but dietary changes can occur (407). 2732 
Participants may consume pre-prepared food due to the ease of recording this 2733 
(compared to weighing ingredients) and their responses and/or diet may change 2734 
in line with social desirability (407).  2735 
 2736 
Validating methods of assessing energy intake is also difficult because every 2737 
measure is subjected to some bias. However, one study used covert observation 2738 
as a control, compared to weighed diet records, 24-h dietary recall and 12-day 2739 
food frequency questionnaires (407). The study was separated into phases when 2740 
the participants did not monitor energy intake and when they completed 3-day 2741 
weighed diet records and dietary recalls. However, researchers monitored energy 2742 
intakes throughout the whole study and the participants were not informed of this. 2743 
Based on a principle that energy cannot be created or destroyed, body mass 2744 
responds to changes in energy intake versus energy expenditure (18). To confirm 2745 
the validity of the energy intake data from covert observation, body mass and 2746 
energy expenditure via doubly-labelled water (as discussed subsequently in this 2747 
review) were assessed. There was no difference between the measured energy 2748 
expenditure and covertly-assessed energy intake and body mass also remained 2749 
unchanged, suggesting that the observation method could be used as a valid 2750 
control during that study. A 5.3 % reduction for energy intake occurred in the overt 2751 
versus the covert observation phases, supporting the idea that energy intakes 2752 
are lower when a participant is aware of being observed (408). Relative to covert 2753 
observation, the energy-intakes were decreased by ~ 5 % for the weighed diet 2754 
records ~ 10 % for 24-h diet recall and ~ 15 % for food frequency questionnaire 2755 
and 7-day diet recall. The magnitude of under-reporting for energy intake is also 2756 
often greater in humans with obesity and with increasing socioeconomic status 2757 
(409). Biomarkers such as blood lipid or vitamin concentrations have also been 2758 




reporting, but this is not currently possible for many foods (410). Finally, as eluded 2760 
to previously, when energy expenditure and body mass are measured over time, 2761 
inferences can be made about energy intake via a rearrangement of the energy 2762 
balance equation, but this does not allow macronutrient intakes to be assessed 2763 
(409). To conclude, although all methods available for assessing macronutrient 2764 
intakes are subjected to some biases, when assessed in a laboratory, providing 2765 
researcher-weighed meals without observing the participant provides the most 2766 
accurate data about energy and macronutrient intakes. In a free-living setting, a 2767 
weighed diet record is considered the most valid approach to measure energy 2768 
intakes and will be most accurate if the participants are aware of the importance 2769 
of accurately recording their food and fluid intakes (409). 2770 
 2771 
Assessing energy expenditure 2772 
In this thesis, total daily energy expenditure was measured as the summation of 2773 
resting metabolic rate (RMR), diet induced thermogenesis (DIT) and physical 2774 
activity energy expenditure (PAEE). RMR was assessed via indirect calorimetry 2775 
from a minumum of 3 x 5 min expired air samples collected into Douglas bags. 2776 
The participant rested in a semi-supine position for 15 min before the first sample 2777 
in accordance with the guidelines for measuring RMR (411). DIT was assumed 2778 
to be 10 % of recorded or measured energy intake (338). For within-laboratory 2779 
periods, PAEE was calculated as energy expenditure from indirect calorimetry 2780 
minus RMR. During free-living periods, PAEE was assessed with an ActiheartTM 2781 
monitor. The unit was fitted through adhesive ECG chest electrodes or a strap 2782 
and participants wore the monitor from 23:30 on the day prior to a measurement 2783 
period. If the monitor was not worn (e.g. when swimming) participants recorded 2784 
any physical activity performed. The monitor was initialised to long-term recording 2785 
with 1-min epochs and PAEE was calculated via branched-equation modelling. 2786 
Stature, body mass, age, sex and sleeping HR were entered in the software for 2787 
each participant. Mean sleeping HR was calculated by excluding the lowest and 2788 
highest recorded sleeping HR for a monitoring period, averaging the remaining 2789 
days and excluding days when the measured value was ± 10 % of this average. 2790 




entered into the software to derive an individually calibrated model, which 2792 
improves PAEE estimations (412, 413). Data were only considered to be of 2793 
useable quality and included in any subsequent analysis if > 90 % of the activity 2794 
trace was ‘not lost’ (i.e. non-wear time) with < 30 % of the HR trace extrapolated 2795 
by the software, whereby a 75 % weighting of PAEE towards accelerometry. In 2796 
Chapter 6, participants wore the ActiheartTM for 7-days as this period achieves 2797 
an 80 % reliability in activity counts for the monitor.  2798 
 2799 
Assessing energy expenditure involves measuring reactants and/or products of 2800 
the metabolism of glucose, lipid and protein molecules (88). 2801 
 2802 
1) 1 g Glucose + 0.746 L O2 → 0.746 L CO2 + 0.6 g H2O + Energy 2803 
2) 1 g Lipid + 2.029 L O2 → 1.430 L CO2 + 1.09 g H2O + Energy 2804 
3) 1 g Protein + 0.966 L O2 → 0.782 L CO2 + 0.45 g H2O + Energy 2805 
 2806 
However, these reactions are not 100 % efficient so some of the energy liberated 2807 
is lost as heat, instead of being transferred to ATP. This underpins the principle 2808 
of direct calorimetry, which is that the amount of heat lost by an organism at a 2809 
given time is proportional to the amount of energy being expended (414). Direct 2810 
calorimeters facilitate heat exchange within the system but not between the 2811 
system and the environment with water and air used as the mediums to allow 2812 
heat transfer, so that changes in their temperature can then be equated to an 2813 
energy parameter (414). Specialist and expensive equipment is however required 2814 
and although large chambers have been used to assess energy expenditure, they 2815 
are not most representative of free-living settings and can exert confounding 2816 
influences on activity behaviours (414). An alternative method is indirect 2817 
calorimetry, when oxygen uptake (V̇O2) and carbon dioxide production (V̇CO2) 2818 
are assessed from expired gas samples and sometimes combined with measures 2819 
of urinary nitrogen excretion. The principle of this method is that the fate of 2820 
ingested substrates is their oxidation to resynthesize ATP and to liberate energy 2821 
(88, 368). The oxidation of a given mass of glucose, fat or protein will utilise a 2822 




body level V̇O2 and V̇CO2 reflects O2 consumed and CO2 produced from 2824 
metabolism of all substrates at a given time. Analysis can then be completed to 2825 
isolate a contribution of each substrate to metabolism. It is first possible to isolate 2826 
a contribution of protein by measuring nitrogen excreted in urine as discussed 2827 
previously and shown in equation 4. This can be substituted into equation 3 to 2828 
derive CO2 produced and O2 consumed per g of nitrogen excreted (equation 5).  2829 
 2830 
4) Protein utilisation (g) = 6.25 x urinary nitrogen excretion (g) 2831 
5) 1 g Nitrogen [N] (g) + 6.038 L O2 → 4.888 L CO2 + 2.81 g H2O + Energy 2832 
 2833 
A 1:1 ratio of CO2 produced to O2 consumed is apparent with the utilisation of 2834 
glucose (88). Therefore, if the contribution of protein to metabolism is known or if 2835 
protein utilisation is assumed to be negligible any discrepancy between V̇O2 and 2836 
V̇CO2 must be explained by the utilisation of lipids and this has a ratio of 1: 0.695 2837 
for O2 consumed: CO2 produced. As such, the amount of lipid being utilised can 2838 
be determined from V̇O2 and V̇CO2 measures, before this value is then used to 2839 
calculate the contribution of carbohydrate to energy metabolism. This is outlined 2840 
in the subsequent equations, where equation 7 is subtracted from equation 6 2841 
for equation 8, which can be rearranged for equation 9, before this is substituted 2842 
into equation 6 to give equation 10, before rearranging to give equation 11.  2843 
 2844 
6) V̇O2= (0.746 x CHO [g]) + (2.029 x lipid [g]) + (6.038 x N [g]) 2845 
7) V̇CO2 =(0.746 x CHO [g]) + (1.430 x lipid [g]) + (4.888 x N [g]) 2846 
8) V̇O2 - V̇CO2= (0.599 x lipid [g]) + (1.150 x N [g]) 2847 
9) Lipid utilisation (g) = 1.67 (V̇O2- V̇CO2) - (1.92 x N [g]) 2848 
10) V̇O2= (0.746 x CHO [g]) + (3.388 x V̇O2) - (3.388 x V̇CO2) - (2.144 x N [g]) 2849 
11) CHO utilisation (g) = (4.542 x V̇CO2) - (3.201 x V̇O2) + (2.874 x N [g]) 2850 
 2851 
Once the amount of each substrate (g) that has been oxidised over a given time 2852 
period is determined, total energy expenditure can be calculated by multiplying 2853 
the amount of each substrate oxidised (g) by their caloric equivalents. Indirect 2854 




relative contribution of each substrate. However, the method relies on several 2856 
assumptions, including that V̇O2 and V̇CO2 is only attributable to these oxidation 2857 
reactions and as such any non-metabolic processes which consume or produce 2858 
O2 and/or CO2 or any inter-conversion of substrates will induce some error (67). 2859 
The most important of these assumptions are highlighted prior to Chapter 5 of 2860 
this thesis in relation to the data presented in that experimental chapter. 2861 
 2862 
Different methods use the principles of indirect calorimetry to assess substrate 2863 
and energy metabolism. Respiratory chambers can accurately measure V̇O2 and 2864 
V̇CO2 over several days but have cost and space constraints that are similar to 2865 
limitations for direct calorimetry (415). The Douglas bag method can also be used 2866 
to provide the same data without the impracticalities of cost and space but this is 2867 
still limited to laboratory settings (415, 416). Automated portable systems assess 2868 
expired and inspired O2 and CO2 concentrations and equate this to a volume 2869 
using an inline flow sensor (414). This method permits a greater flexibility in the 2870 
range of activities that can be assessed, but is still quite constrained to settings 2871 
that do not represent free-living physiology. Therefore, whilst these methods can 2872 
give accurate measurements of V̇O2 and V̇CO2, they are often restricted to the 2873 
controlled environments where energy expenditure can be assessed (415). This 2874 
is not a problem when assessing energy expenditure during rest or diet-induced 2875 
thermogenesis, but any measures of physical activity energy expenditure from 2876 
these methods should be interpreted in the context of a laboratory environment.  2877 
 2878 
The criterion method for assessing energy expenditure in a free living setting is 2879 
doubly-labelled water, which uses isotope tracers to assess V̇CO2 (417). When 2880 
combined with a set value for the respiratory exchange ratio of typically 0.85, this 2881 
method can estimate total energy expenditure over several days. Following the 2882 
ingestion of water composed of hydrogen (H) and O2 isotopes, several hours are 2883 
allowed for the isotopes to reach equilibrium in the body water pool before a 2884 
baseline (saliva, urine or blood) sample is collected. Over time, H and some O2 2885 
isotopes are lost as water, but some of the O2 atoms are incorporated into CO2 2886 




rate than the H isotope and the difference is due to CO2 production. Therefore, 2888 
measuring the depletion of the isotopes in subsequent samples of the body water 2889 
pool allows free-living energy expenditure to be estimated (417). One limitation 2890 
of the method is that it does not account for losses of the isotopes into molecules 2891 
other than water or CO2 and it does not account for changes in enrichment from 2892 
dietary changes, although these are likely to have a negligible effect under normal 2893 
physiological circumstances. However, the isotopes are also relatively costly and 2894 
without sampling at frequent intervals the data resolution is low, meaning that any 2895 
inferences about patterns or timing of physical activity are difficult to make (417). 2896 
Any change to the RER away from 0.85 with feeding and/or exercise can also 2897 
introduce errors, unless RER is frequently measured and accounted for.  2898 
 2899 
Recent technological advancements have facilitated a development of wearable 2900 
sensors that are now more commonly used to assess free-living physical activity 2901 
energy expenditure. By measuring accelerative forces, accelerometers can give 2902 
information about the duration, frequency and intensity of movements. However, 2903 
in isolation, accelerometers typically perform poorly against doubly-labelled water 2904 
for assessing energy expenditure (418). An alternative method to estimate 2905 
energy expenditure is by measuring HR, which is grounded on the linear 2906 
relationship between HR and V̇O2  (419). However, this method is also subject to 2907 
limitations, including inter-individual variation in the HR-V̇O2 relationship, due to 2908 
differences between people in, for example, age, fitness and the relative 2909 
efficiency of the movements being recorded (412). When an individual calibration 2910 
of the HR-V̇O2 relationship is performed, the agreement with doubly-labelled 2911 
water derived estimates of energy expenditure is improved (420). Despite this, 2912 
HR can still be influenced by other factors such as environmental temperature, 2913 
hydration status and stress which can result in errors in the energy expenditure 2914 
estimations in a free-living environment. Monitors have also been developed that 2915 
incorporate HR and accelerometry by using branched-equation modelling for 2916 
energy expenditure assessments (420). Energy expenditure estimations can be 2917 
made by classifying each min of activity into a category (i.e. low movement and 2918 




and HR) and weighting the estimate of energy expenditure towards either the HR 2920 
monitor or the accelerometer, accordingly (420). The Actiheart™ utilises a chest-2921 
worn HR sensor and an accelerometer to measure energy expenditure (421). To 2922 
initially validate this device, energy expenditure estimations for walking and 2923 
running were compared to indirect calorimetry. Combined HR-accelerometry 2924 
showed a better agreement with indirect calorimetry than either sensor used in 2925 
isolation and the standard error of the estimate was reduced by individualised 2926 
calibrations (412, 421). Estimations of energy expenditure from an ActiheartTM 2927 
are similar to those derived from doubly-labelled water (413) and with the monitor 2928 
information can also be obtained about the timing or intensity of physical activity.  2929 
 2930 
STATISTICAL ANALYSIS 2931 
An account of the statistical approach for each study is detailed in the relevant 2932 
chapter, but common methods are outlined here. Analyses was completed on 2933 
commercially available packages (IBM SPSS statistics V22 for windows, New 2934 
York, USA; Graph Pad Prism 7, La Jolla, CA, USA; and Microsoft Excel 2013). 2935 
Sample size estimations were made a priori, according to the outcomes of a given 2936 
study and were calculated to provide at least an 80 % probability of correctly 2937 
rejecting a null hypothesis. Statistical significance was accepted at p0.05.  2938 
 2939 
The total or incremental area underneath the concentration-time curve for plasma 2940 
metabolites and hormones were calculated using the trapezoid rule (422). These 2941 
values were divided by specific time periods for summary values. Data requiring 2942 
a single comparison of two means (paired differences for repeated measures) 2943 
were normality tested using Shapiro-Wilk tests. A t-test with a 2-sided significance 2944 
level was then applied for normally distributed data and non-normal data was 2945 
assessed with a Wilcoxon test or was log-transformed before analysis. If multiple 2946 
comparisons were necessary, two-way repeated measures or mixed-model 2947 
ANOVAs were used to assess any differences between trials or groups. This was 2948 
regardless of normality, as the type 1 error rate of ANOVA remains at p0.05, 2949 
even when the data are non-normally distributed within a physiological range 2950 




epsilon <0.75, with Huynh-Feldt corrections made for less severe asphericity. If 2952 
interaction effects (e.g. time x trial) were identified, t-tests were used to locate 2953 
variance between trials or groups, with Holm-Bonferroni step-wise adjustments 2954 
made to control for type I errors (424). Unless otherwise stated, all data in text, 2955 
figures and tables are means ± 95 % confidence intervals.  2956 
 2957 
Confidence intervals were normalised to remove between-subject variance from 2958 
an equation using the mean square error value from the corresponding statistical 2959 
general linear model if this was appropriate (425). These confidence intervals are 2960 
more reflective of differences between group or trial means than the variance of 2961 
individual participants around the mean. If data sets were incomplete, results 2962 
were sometimes extrapolated from measured values with the last observation 2963 
carried forward approach, but sensitivity analysis was completed with this data 2964 




BUFFERS AND STOCK SOLUTIONS FOR WESTERN BLOTTING 2966 
The following stock solutions were made in batch for western blot analysis and were 2967 
stored for up a maximum of two months and at room temperature. Unless stated 2968 
chemicals were purchased from Thermo Fisher Scientific (Massachusetts, US) or 2969 
Sigma-Aldrich Company Ltd (Gillingham, Dorset, UK). 2970 
 2971 
Lysis (RIPA) buffer: 1x concentrated stock 2972 
     From Stock  1 x (50 ml) 2973 
50 mM Tris (pH 7.4)   1 M Tris pH 7.4 2.5 mL 2974 
150 mM NaCl   2.5 M NaCl  3.0 mL 2975 
0.5 % Sodium deoxycholate    250 mg 2976 
0.1 % SDS    10 % SDS  500 μL 2977 
0.1 % NP-40    100 % NP-40 2978 
 2979 
SDS-sample buffer: 3x concentrated stock, final pH 6.8 2980 
187.5 mM Tris, 6 % SDS, 30 % glycerol 2981 
 2982 
Stacking Gel     Resolving Gel 2983 
     7 % 8% 10 % 12 %  6% 2984 
Acrylamide stock solution (mL) 17.5 20 25 30  3.4 2985 
Resolving gel buffer (mL)  25 25 25 25   - 2986 
Stacking Buffer (mL)    - - -  5.0 2987 
Double-distilled water (mL)  32.5 30 25 20  7.5 2988 
Ammonium persulphate (L) 500 500 500 500  100 2989 
TEMED (mL)    40 40 40 40  20 2990 
 2991 
Resolving gel buffer: 1.5 M Tris hydrochloride (Tris-HCl), 0.4 % (w/v) sodium 2992 
dodecyl sulfate (SDS), pH 8.8 2993 
 2994 
Final volume  250 mL 500 mL 1000 mL 2995 
Tris-HCL  45.43 g 90.86 g 181.7 g 2996 




Stacking gel buffer: 0.5 M Tris-HCl, 0.4 % (w/v) SDS, pH 6.8 2998 
 2999 
Final Volume  250 mL 500 mL 3000 
Tris-HCL  15.14 g 30.28 g 3001 
0.4% SDS  1 g  2 g 3002 
 3003 
Acrylamide solution: Ultra-Pure Protogel containing 30% acrylamide. Stored 3004 
away from light and at room temperature (National Diagnostics; Atlanta, US). 3005 
 3006 
Ammonium persulphate: 100 mg·mL-1, prepared freshly for each gel 3007 
 3008 
Electrophoresis running buffer (10x): 1 x buffer is 0.025 M Tris-HCl, 0.1 %: 3009 
(w/v) SDS, 0.2 M glycine, pH 8.3 3010 
 3011 
Final volume   2.5 L (10 x stock) 3012 
Tris-HCL   75.75 g 3013 
0.1% SDS   25 g 3014 
Glycine   360 g 3015 
 3016 
SDS-transfer buffer: pH 8.3 (for a volume of 2L mix with 1.6 L distilled water) 3017 
 3018 
Tris (48 mM)   11.63 g 3019 
Glycine (39 mM)  5.89 g 3020 
SDS    0.75 g (final percentage 0.0375%)  3021 
Methanol   400 mL 3022 
 3023 
Tris-buffered saline buffer TBS and TBS-T: 0.09% NaCl, 1M Tris-HCl, pH 7.4 3024 
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RELEVANCE TO THESIS  3058 
Requiring participants to fast overnight before laboratory-based exercise trials is 3059 
common procedure in an attempt to control for their metabolic status. However, 3060 
this standardisation may preclude the application of findings to situations most 3061 
representative of normal daily living for people living in developed countries. For 3062 
many humans, exercise is regularly performed in the evening (261) and in concert 3063 
with the high carbohydrate diet that is typically consumed in developed countries 3064 
(186), it is likely that the majority of exercise sessions are performed after eating 3065 
carbohydrates rather than in a fasted state. We also know that feeding before 3066 
exercise alters the glycaemic responses to exercise. Indeed, blood glucose fluxes 3067 
during exercise (272) and blood glucose concentrations after exercise (15) can 3068 
be increased if carbohydrate rich meals are consumed before exercise. However, 3069 
as discussed in Chapter 1, the mechanisms underpinning differences in glycemia 3070 
at post-exercise meals with altered pre-exercise feeding are not currently clear.  3071 
 3072 
Characterising blood glucose flux at meals consumed after exercise performed 3073 
in an overnight fasted state compared to after breakfast is important. This will 3074 
provide information regarding whether results from studies of exercise in a fasted-3075 
state can be applied to exercise more representative of normal daily living and 3076 
will advance our current understanding of post-exercise metabolism. Secondly, 3077 
investigating glycemic responses to food ingestion provides insights into mortality 3078 
risk (276). Given that most eating occasions in developed countries take place 3079 
whilst still in a postprandial state from previous meal(s), it is important to assess 3080 
postprandial responses to sequential meal consumption. Any glucose lowering 3081 
effect at post-exercise meals with exercise performed during morning fasting 3082 
compared to after prior meal consumption may help to protect against the risk of 3083 
T2D and CVD (276) and risk of macro- and microvascular complications in people 3084 
with T2D (278) with a repeated exposure to this stimulus. Some adaptations to 3085 
nutrient-exercise manipulations have also been suggested to be due to repeated 3086 
transient acute responses to exercise (426, 427). Therefore, characterising acute 3087 
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ABSTRACT  3090 
Aims: To characterize postprandial glucose flux after exercise in the fed versus 3091 
overnight fasted-state and to investigate potential underlying mechanisms. 3092 
Methods: In a randomized order, twelve men underwent breakfast-rest (BR; 3 h 3093 
semi-recumbent), breakfast-exercise (BE; 2 h semi-recumbent before 60-min of 3094 
cycling (50% peak power output) and overnight fasted-exercise (FE; as per BE 3095 
omitting breakfast) trials. An oral glucose tolerance test (OGTT) was completed 3096 
post-exercise (post-rest on BR). Dual stable isotope tracers ([U-13C] glucose 3097 
ingestion and [6,6-2H2] glucose infusion) and muscle biopsies were combined to 3098 
assess postprandial plasma glucose kinetics and intramuscular signalling, 3099 
respectively. Plasma intestinal fatty acid binding (I-FABP) concentrations were 3100 
determined as a marker of intestinal damage. Results: Breakfast before exercise 3101 
increased post-exercise plasma glucose disposal rates during the OGTT, from 3102 
44 g·120 min-1 in FE [35 to 53 g·120 min-1] (mean [normalized 95% CI]) to 73 3103 
g·120 min-1 in BE [55 to 90 g·120 min-1; p = 0.01]. This higher plasma glucose 3104 
disposal rate was, however, offset by increased plasma glucose appearance 3105 
rates (principally OGTT-derived), resulting in a glycemic response that did not 3106 
differ between BE and FE (p = 0.11). Plasma I-FABP concentrations during 3107 
exercise were 264 pg·mL-1 [196 to 332 pg·mL-1] lower in BE versus FE (p = 0.01). 3108 
Conclusion: Breakfast before exercise increases post-exercise postprandial 3109 
plasma glucose disposal, which is offset (primarily) by increased appearance 3110 
rates of orally-ingested glucose. Therefore, metabolic responses to fed-state 3111 





Postprandial glycemia is a strong predictor of future mortality and morbidity. Even 3114 
in people without diabetes, those with greater blood glucose excursions after 3115 
feeding are at an increased risk of cardiovascular disease (47, 48). This glycemic 3116 
response to food ingestion is dictated by blood glucose kinetics (i.e. the balance 3117 
between the rates of glucose appearance into blood and glucose disposal from 3118 
blood into peripheral tissues). Exercise potently increases glucose disposal from 3119 
the blood into skeletal muscle (52), and regular exercise is therefore 3120 
recommended as a lifestyle strategy to improve glycemic control.  3121 
 3122 
Habitual responses to exercise and nutrition are however, the culmination of not 3123 
only chronic adaptations, but also the acute effects of each exposure to these 3124 
daily behaviors (5, 6, 22). For example, each bout of exercise potently stimulates 3125 
post-exercise insulin sensitivity and muscle glucose uptake (52). However, 3126 
despite increases in blood glucose disposal rates, endurance-type exercise does 3127 
not always reduce postprandial glucose excursions in the post-exercise period 3128 
(20, 54). The finding that postprandial blood glucose concentrations are not 3129 
lowered post-exercise is because when exercise is performed (at least in the 3130 
fasted state), the increase in postprandial blood glucose disposal after exercise 3131 
can be offset - and even superseded - by increases in both endogenous and 3132 
meal-derived blood glucose appearance rates (34, 54). 3133 
 3134 
Whilst fasting prior to laboratory trials is common in order to control for baseline 3135 
metabolic status, these conditions may preclude the application of findings to 3136 
situations most representative of daily living. For example, most people living in 3137 
developed countries spend the majority of a typical day in the postprandial state 3138 
(13, 55). Therefore, most eating occasions and exercise sessions will take place 3139 
in the context of this postprandial situation (23). It has previously been shown by 3140 
others that plasma glucose fluxes during exercise (16), and by us that plasma 3141 
glucose concentrations after exercise (24), are elevated by pre-exercise feeding. 3142 
However, the effect of prior feeding on post-exercise plasma glucose flux has 3143 




regarding postprandial glucose kinetics under scenarios that are most 3145 
representative of daily living, and it may not be valid to generalize existing 3146 
observations of exercise in the fasted state. Moreover, an understanding of the 3147 
underlying mechanisms responsible for any differences in postprandial glucose 3148 
flux post-exercise, with prior feeding versus fasting, is still required. 3149 
 3150 
This study therefore aimed to characterize postprandial plasma glucose kinetics 3151 
after: 1) breakfast and rest; 2) breakfast and exercise and 3) overnight fasted-3152 
state exercise, while also exploring potential mechanisms (intramuscular 3153 
signaling and markers of intestinal damage) to explain any differences in glucose 3154 
flux between these conditions.  3155 
 3156 
METHODS 3157 
Ethical Approval 3158 
All trials were undertaken at the University of Bath (Bath, UK) in accordance with 3159 
the Declaration of Helsinki. The study was approved by the National Health 3160 
Service South-West Research Ethics Committee (reference: 15/SW/0006) and 3161 
registered at clinicaltrials.gov as NCT02258399. Written, informed consent was 3162 
obtained from all participants prior to their participation. 3163 
 3164 
Study Design 3165 
This study was a randomized cross-over design (randomization performed by 3166 
JTG with Research Randomizer version 3.0, http://www.randomizer.org/). 3167 
Preliminary testing was followed by three trials (separated by > 7 d), namely, 3168 
breakfast-rest (BR), breakfast-exercise (BE) and overnight fasted-exercise (FE). 3169 
A schematic for the study protocol is shown in Figure 1. For all trials participants 3170 
arrived at the laboratory after a 12 to 14-h overnight fast. In BR, a porridge 3171 
breakfast was consumed, followed by 3 h of rest, and then a 2-h oral glucose 3172 
tolerance test (OGTT). In BE, the same breakfast was consumed, before 2 h rest 3173 
and 60 min of cycling, prior to the OGTT. In FE, breakfast was omitted but the 3174 
trial otherwise replicated BE. By necessity of design (food intake/exercise) the 3175 




across the trials ([mean ± SD] ambient temperature [23.7 ± 0.5 °C on BR, 23.7 ± 3177 
0.6 °C on BE, 23.6 ± 0.7 °C on FE) and barometric pressure [734 ± 5 mmHg on 3178 
BR, 736 ± 6 mmHg on BE, 736 ± 5 mmHg on FE]; all p > 0.05).  3179 
 3180 
Figure 1. Schematic. An oral glucose tolerance test was conducted after 3181 
breakfast followed by rest (BR), breakfast followed by exercise (BE), or extended 3182 
overnight fasting followed by exercise (FE). Dual stable isotope tracers ([U-13C] 3183 
glucose ingestion and [6,6-2H2] glucose infusion) and muscle biopsies were used 3184 
to assess postprandial plasma glucose kinetics and intramuscular signaling. 3185 
 3186 
Participants 3187 
Twelve healthy and physically active men (self-reported as regular exercisers 3188 
engaging in at least 30 min of exercise a minimum of 3 times per week) were 3189 
recruited from Bath and North East Somerset, between May and November 2015. 3190 
Participant characteristics are shown in Table 1. Exclusion criteria included any 3191 
history of metabolic disease, or condition that may have posed undue personal 3192 
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Preliminary Testing 3195 
Participants were asked to refrain from strenuous physical activity for 24 h prior 3196 
to preliminary testing, but were asked to otherwise maintain their normal physical 3197 
activity behaviors. They abstained from alcoholic and caffeinated drinks for 24 h 3198 
prior to this visit. Food intake ceased at 8 pm on the evening before testing and 3199 
participants fasted overnight (minimum 12 h), consuming only water (ad libitum) 3200 
during this period. In addition, they were asked to consume 568 mL of water at 3201 
least 1 h prior to testing, and to void immediately prior to arriving at the laboratory. 3202 
Upon arrival, the participant’s stature was measured (Frankfurt plane) to the 3203 
nearest 0.1 cm using a stadiometer (Seca Ltd, Birmingham, UK). Body mass was 3204 
recorded to the nearest 0.1 kg (only light clothing permitted) using electronic 3205 
weighing scales (BC543 Monitor, Tanita, Tokyo, Japan). A whole-body dual 3206 
energy x-ray absorptiometry scan was completed to quantify fat and fat-free mass  3207 
Table 1. Participant Characteristics 
Age (y) 23 (3) 
Stature (cm) 179.8 (4.4) 
Body mass (kg) 76.3 (7.9) 
Body Mass Index (kg·m-2) 23.6 (2.90) 
Fat mass (kg)1 10.6 (3.7) 
Fat Mass Index (kg·m-2)1 3.26 (1.12) 
Body fat (%)1 14 (4) 
Fat free mass (kg)1 65.5 (6.4) 
V̇O2peak (L·min-1) * 4.00 (0.72) 
V̇O2peak (mL·kg·min-1) * 53 (10) 
Peak Power Output (W) 317 (67) 
HRMAX, (beats·min-1) 189 (10) 
Data are presented as means and (standard deviation). V̇O2peak = peak 
oxygen uptake. n = 12. *n = 11, due to technical difficulties with the breath-by-
breath analysis during one participant’s preliminary testing. 1 = derived by dual-




(DEXA; Discovery, Hologic, Bedford, UK). Participants performed an incremental 3208 
exercise test at a self-selected cadence on an electronically-braked ergometer 3209 
(Excalibur Sport, Lode Lode Groningen, Netherlands). They were permitted to 3210 
adjust the saddle and handlebar heights to their preferred position, which were 3211 
replicated for cycling during the exercise trials. The initial exercise intensity was 3212 
50 W and this was increased by 50 W every four min, for four stages.  Thereafter, 3213 
the intensity was increased by 20 W every min until volitional exhaustion. Heart 3214 
rate (Polar Electro Oy, Kempele, Finland) and continuous breath-by-breath 3215 
measurements were recorded throughout (TrueOne2400, ParvoMedics, Sandy, 3216 
USA). Volume and gas analyzers were calibrated with a 3 L calibration syringe 3217 
(Hans Rudolph, Kansas City, USA) and a calibration gas (balance nitrogen mix; 3218 
16.04% O2, 5.06% CO2; BOC Industrial Gases, Linde AG, Munich, Germany), 3219 
respectively. Peak power output (PPO) was calculated as the work rate of the last 3220 
completed stage, plus the fraction of time spent in the final non-completed stage, 3221 
multiplied by the work rate increment. Peak oxygen uptake (V̇O2 peak) was 3222 
calculated as the highest average V̇O2 over a rolling 30-s period.  3223 
 3224 
Main Trials  3225 
Participants refrained from strenuous physical activity, alcohol and caffeine for 24 3226 
h before all trials. They recorded the composition of their evening meal on the 3227 
day before the first main trial and replicated this meal for subsequent trials, in 3228 
accordance with procedures for standardizing postprandial glucose tolerance 3229 
testing (10). This pre-trial standardisation protocol has been previously shown to 3230 
be effective at producing overnight-fasted muscle glycogen concentrations, liver 3231 
glycogen concentrations and intramyocellular lipid that are standardised across 3232 
multiple trial days, in a similar population (21). To help ensure physical activity 3233 
standardization, participants completed a physical activity diary and wore a 3234 
physical activity monitor (ActiheartTM; Cambridge Neurotechnology, Papworth, 3235 
UK) for 24 h before all trials (pre-trial 24-h physical activity energy expenditure 3236 
[(mean ± standard deviation) 988 ± 500 kcal on BR, 1022 ± 521 kcal on BE, 992 3237 
± 313 kcal on FE; all p >0.05; n = 9]. Participants arrived at the laboratory at 0800 3238 




the subsequent trials. They were asked to void and all further urine samples were 3240 
collected for the remainder of the trial to allow for urinary nitrogen excretion to be 3241 
estimated from urine urea concentrations. Participants then placed their dominant 3242 
hand into a heated-air box (Mass Spectrometry Facility; The University of 3243 
Vermont & University of Vermont Medical Center, Burlington, USA) set to 55 °C. 3244 
After 20 min of rest, an intravenous catheter (BD Venflon Pro, BD, Helsingborg, 3245 
Sweden) was fitted into a heated dorsal hand vein (retrograde) and a 10-mL 3246 
baseline blood sample was drawn, before a 5-min expired gas sample was 3247 
collected. On the first main trial for each participant (see Figure 1), a baseline 3248 
muscle sample was taken from the vastus lateralis to allow for an assessment of 3249 
pathways involved in exercise and insulin signaling in muscle [5' AMP-activated 3250 
protein kinase (AMPK), acetyl-CoA carboxylase (ACC), protein kinase B (herein 3251 
referred to as Akt2), and Akt substrate of 160 kDa (AS160).   3252 
 3253 
In BE and BR, a porridge breakfast was then consumed within 10 min (3 h pre-3254 
OGTT) and in FE participants were allowed water only. The breakfast was 72 g 3255 
of instant refined oats (Oatso Simple Golden Syrup, Quaker Oats) and 360 mL of 3256 
semi-skimmed milk (Tesco), providing 431 kcal of energy ([1803 kJ]; 65 g CHO, 3257 
11 g FAT, 19 g PRO). The breakfast was high-carbohydrate (57% of energy 3258 
intake) and high glycemic-index [oatmeal, made from mix (Quaker Oats) has a 3259 
glycemic index of 69 (17)], as is commonly consumed in developed countries. 3260 
Due to the co-ingestion of milk, this breakfast would produce a high insulinemic 3261 
response (38, 46).  Breakfast consumption (or omission on FE) was followed by 3262 
2 h of rest, where participants remained in a semi-recumbent position, completing 3263 
resting activities (e.g. watching television), with expired gas samples collected 3264 
every 60 min. After 1 h 40 min of rest, (1 h 20 min pre-OGTT) a catheter was 3265 
inserted into an antecubital vein (the contralateral arm to the one used for blood 3266 
sampling). A primed infusion of [6,6-2H2]glucose was initiated and continued for 3267 
the remaining within-lab component of the trial (Cambridge Isotope Laboratories, 3268 
MA, USA; prime: 13.5 µmol.kg−1; infusion: 0.35 µmol.kg−1.min−1). After 20 min (60 3269 
min pre-OGTT), and on BE and FE only, participants began 60 min of cycling at 3270 




The cadence was self-selected (replicated for both exercise trials) and the power 3272 
output was monitored via a computerized system. In BR, participants remained 3273 
rested in the semi-recumbent position during this period. Expired gas samples 3274 
were collected every 15 min and blood samples were collected at 40 and 50 min 3275 
of exercise (20 and 10 min pre-OGTT). Immediately post-exercise (or post-rest 3276 
in BR) a muscle sample was taken from the vastus lateralis. Then a 2-h OGTT 3277 
was completed, with arterialized blood sampled at 10-min intervals and expired 3278 
gas sampled every 60 min. The OGTT was 73 g of glucose (81 g of dextrose 3279 
monohydrate corrected for water content; Myprotein, Northwich, UK) and 2 g of 3280 
[U-13C]glucose (99%; Cambridge Isotope Laboratories, MA, USA), to allow the 3281 
rate of appearance of the orally ingested glucose (RaOGTT) to be assessed. A final 3282 
muscle sample was taken post-OGTT (OGTT 120 min).  3283 
 3284 
Tracer approach, blood sampling and analysis 3285 
A dual-tracer approach was employed, where the tracer infusion rate was 3286 
doubled during exercise (on BE and FE) to account for an expected increase in 3287 
endogenous glucose production (1) and reduced to 80% of baseline at OGTT 20 3288 
min (all trials) to account for an expected suppression of endogenous glucose 3289 
production after oral glucose ingestion (9). This approach reduces changes in the 3290 
tracer-to-tracee ratio, thereby permitting more accurate estimations of glucose 3291 
kinetics (4). Arterialized blood was sampled from a heated dorsal hand vein at 3292 
baseline, at 60-min intervals during the initial 2-h rest period, at 40 and 50 min of 3293 
the exercise period (or post-rest in BR) and at 10-min intervals during the OGTT. 3294 
Whole blood was dispensed into ethylenediaminetetraacetic acid-coated tubes 3295 
(BD, Oxford, UK) which were first centrifuged (4 °C and 3500 g) for 10-min 3296 
(Heraeus Biofuge Primo R, Kendro Laboratory Products Plc., UK) to obtain 3297 
plasma. The plasma was then dispensed into 0.5 mL aliquots and immediately 3298 
frozen at -20 °C, before longer-term storage at -80 °C. 3299 
 3300 
Plasma glucose (intra-assay coefficient of variation [CV], 3.2%; inter-assay CV 3301 
3.8%), lactate (intra-assay CV, 1.0%; inter-assay CV 4.8%), and triglyceride 3302 




using an automated analyzer (Daytona; Randox Lab, Crumlin, UK) as per the 3304 
manufacturer’s instructions. Plasma insulin concentrations were measured using 3305 
a commercially available ELISA kit (Mercodia AB, Uppsala, Sweden; intra-assay 3306 
CV, 5.7%; inter-assay CV 9.9%). Plasma intestinal fatty acid binding protein (I-3307 
FABP) concentrations were measured as a marker of intestinal cell damage using 3308 
a commercially available ELISA kit (Hycult Biotech; intra-assay CV, 6.0%). 3309 
Plasma NEFA concentrations were determined using an enzymatic colorimetric 3310 
assay (WAKO Diagnostics; intra-assay CV, 8.9%; inter-assay CV 10.4%). For all 3311 
of these analyses, all plasma samples were analyzed in batch after all sample 3312 
collection was completed, and for a given participant all samples (from the three 3313 
trials) were run on the same plate. 3314 
 3315 
Plasma [U-13C]glucose and [2H2]glucose enrichments were determined by gas 3316 
chromatography-mass spectrometry (GC-MS: GC, Agilent 6890N; MS, Agilent 3317 
5973N; Agilent Technologies, Stockport, UK). Plasma glucose was extracted 3318 
using methanol-chloroform and hydrochloric acid, dried under nitrogen gas, and 3319 
then derivatised using the heptofluorobuyric acid method as previously described 3320 
(30). The glucose derivative was acquired by selected ion monitoring at mass-to-3321 
charge ratios (m/z) 519, 521 and 525 for [12C], [6,6-2H2]- and [U-13C]-glucose, 3322 
respectively. Glucose enrichments of [13C] and [2H2] in plasma were determined 3323 
using standard curves for [13C] and [2H2] glucose, and enrichments were 3324 
expressed relative to those at 519 (M+0). The baseline sample was used for 3325 
every trial to account for background isotopic plasma enrichments. To reduce any 3326 
impact of analytical variability on calculations of glucose kinetics, glucose and 3327 
enrichment data were curve fitted as previously described (63).  3328 
 3329 
Muscle sampling and analysis  3330 
Muscle samples were collected from the vastus lateralis under local anesthesia 3331 
(~5 mL of 1% lidocaine, Hameln Pharmaceuticals Ltd., Brockworth, UK). Samples 3332 
were taken from a 3-5-mm incision at the anterior aspect of the thigh with a 5-mm 3333 
Bergstrom biopsy needle technique adapted for suction (57). Samples were 3334 




longer-term storage at -80 °C. The order of dominant or non-dominant leg was 3336 
counterbalanced across trials for the OGTT 0 min and the 120 min samples. 3337 
Samples were taken from separate skin incision sites, with these > 2 cm proximal 3338 
to any previous incision on the same leg (59). For the OGTT 0 min sample (post 3339 
exercise [or rest in BR]) the incision was made prior to cycling (BE and FE) and 3340 
closed with Steristrips, to allow for an immediate sample post-exercise. 3341 
 3342 
Frozen wet tissue (20-30 mg) was freeze-dried, powdered, and dissected free of 3343 
visible blood and connective tissue and added to ice cold lysis buffer [50 mM Tris 3344 
(pH 7.4), 150 mM NaCl, 0.5% Sodium deoxycholate; 0.1% SDS and 0.1% NP-3345 
40] with a protease (Thermo Scientific) and phosphatase inhibitor cocktail 3346 
(Millipore). Samples were homogenized with a dounce homogenizer (~ 40 3347 
passes), incubated (60 min at 4 °C with rotation) and centrifuged for 10 min (4 °C 3348 
and 20,000 g). The protein content of the resultant supernatant was measured 3349 
via a bicinchoninic acid (BCA) protein assay kit (Thermo Scientific). For Western 3350 
blots, an equal amount of protein (40 µg) was loaded per lane for each sample 3351 
and separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis 3352 
(SDS-PAGE) on Tris-glycine SDS–polyacrylamide gels (7% for p-AMPKThr172, 3353 
total AMPK, p-ACCSer79 and total ACC, 10% for p-AktSer473 and total Akt2 and 8% 3354 
for p-AktThr308, p-AS160Thr642 and total AS160). Gels were electro-blotted using a 3355 
semi-dry transfer onto a nitrocellulose membrane. Membranes were washed in 3356 
Tris-buffered saline (0.09% NaCl, 100 mM Tris–HCl pH 7.4) with 0.1% Tween 20 3357 
(TBS-T) and incubated for 30-min in a blocking solution (5% non-fat dry milk in 3358 
TBS-T; Marvel, Premier International Foods Ltd, UK). The membranes were 3359 
incubated overnight at 4 °C with primary antibodies against p-AMPKThr172, p-3360 
ACCSer79, p-AktSer473, p-AktThr308 and p-AS160Thr642 (Cell Signaling Technologies, 3361 
USA). In the morning, membranes were washed in TBS-T and incubated with a 3362 
1:4000 dilution of anti-species IgG horseradish peroxidase-conjugated secondary 3363 
antibodies made up in the aforementioned blocking solution. After further 3364 
washes, membranes were incubated in an enhanced chemiluminescence (ECL) 3365 
reagent and visualized using a chemiluminescent imager (EpiChemi II Darkroom, 3366 




at 50 °C in a stripping solution [62.5 mM Tris pH 6.7, 2%SDS, 100 mM 2-3368 
mercaptoethanol], before re-blotting for total AMPK, total ACC, total Akt2 (Cell 3369 
Signaling Technologies, USA) and total AS160 (Merck-Milliopore, UK). For these 3370 
analyses, all samples from each participant (all three trials) were run on the same 3371 
gel. Band densities were quantified using VisionWorksLS Image Acquisition and 3372 
Analysis Software for Windows (UVP, Upland, USA). For all of the signalling 3373 
molecules reported in this experiment a ratio of phosphorylated to total protein 3374 
was calculated and the results were expressed relative to the baseline sample. 3375 
 3376 
Substrate utilization 3377 
Expired gas samples were collected at baseline, during the initial 2-h rest period 3378 
and the OGTT at 60-min intervals (for 5 min), and at 15-min intervals (for 1 min) 3379 
during the exercise period (or rest in BR). For all samples, participants were 3380 
provided with the mouthpiece 1 min before gas collections for a stabilization 3381 
period. Samples were collected in 200 L Douglas bags (Hans Rudolph, Kansas 3382 
City, USA) through falconia tubing (Baxter, Woodhouse and Taylor Ltd, 3383 
Macclesfield, UK). Concurrent measures of inspired air were made to correct for 3384 
changes in ambient O2 and CO2 concentrations (7). Expired O2 and CO2 3385 
concentrations were measured in a known volume of each sample, using 3386 
paramagnetic and infrared transducers respectively (Mini HF 5200, Servomex 3387 
Group Ltd., Crowborough, East Sussex, UK). The sensor was calibrated using 3388 
concentrations of low (99.998% Nitrogen, 0% O2 and CO2) and high (balance 3389 
nitrogen mix, 16.04% O2, 5.06% CO2) calibration gases (both BOC Industrial 3390 
Gases, Linde AG, Munich, Germany).  Urinary nitrogen excretion was estimated 3391 
from urine urea concentrations, which were measured on an automated analyzer 3392 
(Daytona; Randox Lab, Crumlin, UK), to allow for protein oxidation to be 3393 
accounted for in calculations of substrate utilization rates. 3394 
 3395 
Calculations and statistical analysis 3396 
A sample size estimation was completed a priori with the total rate of plasma 3397 
glucose appearance as the primary outcome measure. Rose et al. (54) reported 3398 




µmol·kg-1 during an OGTT after rest versus after fasted exercise. Using this effect 3400 
size, and an alpha level of 0.05, we calculated that 12 participants were required 3401 
for an 80% probability of statistically detecting an effect in the RaTOTAL using a 3402 
crossover design with three trials and a two-tailed, one-way ANOVA.   3403 
 3404 
The total and incremental area underneath the concentration-time curve (AUC or 3405 
iAUC, respectively) for each plasma metabolites or hormones was calculated 3406 
using the trapezoid rule. The AUC or iAUC for each plasma metabolite or 3407 
hormone was then divided by either the duration of the total within-lab period 3408 
(300-min) or the OGTT observation period (120-min), as appropriate, to provide 3409 
a time-averaged value (mmol·L-1), which are used as summary measures. 3410 
Plasma glucose and insulin concentrations during the OGTT were used to 3411 
estimate insulin sensitivity (ISI) according to the equation of Matsuda (41): [FPG 3412 
and FPI are fasting plasma glucose and insulin concentrations, and MPG and 3413 







Plasma glucose kinetics were determined using Radziuk’s two-compartment non-3418 
steady state model (50, 51) and SAMM II software (SAAM II v2.3, The Epilson 3419 
Group, Charlottesville, VA, USA). This model reduces errors in estimations of 3420 
glucose kinetics that are apparent when using Steele’s (56) one compartment 3421 
model (53). The total rate of plasma glucose appearance (RaTOTAL) and glucose 3422 
disappearance (Rd) were calculated as follows:   3423 
 3424 













Equation 2: 3427 




Where F is the [6,6-2H2] infusion, V1 is the glucose volume of distribution [4% of 3429 
body mass (kg)], E1(t) the [2H2] plasma glucose enrichment (mole percent 3430 
excess) at time t, Ė1 (t) the change in E over time [derivate of E], G(t) the plasma 3431 
glucose concentrations at time t, Ġ(t) the change in G over time [derivate of 3432 
G],  k12 and k21 are fixed rate constants between the peripheral and the accessible 3433 
compartments (0.05 min-1 and 0.07 min-1 respectively) and q2iv and Q2 are the 3434 
amounts of the tracer [2H2] and tracee in the peripheral compartment respectively, 3435 
evaluated by integrating the two-compartment model.  3436 
 3437 
The [U-13C] enrichment of the orally ingested glucose and the RaTOTAL (from 3438 
Equation 1) were used to calculate the plasma rate of appearance of glucose from 3439 
the OGTT (RaOGTT). In these equations, r1 is the ratio of the infusion [2H2] and oral 3440 
[U-13C] glucose tracer concentrations in plasma, ṙ (t) is the change in r over time 3441 
[derivate of r], g is the [U-13C] glucose tracer in plasma, qoiv is the amount of the 3442 
[U-13C] tracer in the peripheral compartment (by integrating the two-compartment 3443 
model), and EOGTT is the [U-13C] enrichment of the OGTT. 3444 
 3445 






















The metabolic clearance rate was calculated as the Rd divided by the plasma 3451 
glucose concentrations for a given time point (G1) 3452 
 3453 
Equation 5: 3454 
Metabolic Clearance Rate = Rd(t) /G1 3455 
Rates of whole-body fat and carbohydrate utilization were calculated using the 3456 
expired gas samples and stoichiometric equations (31).  Adjustments were made 3457 




urinary urea nitrogen). Plasma glucose utilization was assumed to be equivalent 3459 
to the plasma glucose rate of disappearance (Rd) as has been confirmed 3460 
previously (32). Muscle glycogen utilization during exercise (BE and FE only) was 3461 
calculated as total carbohydrate utilization during exercise minus plasma glucose 3462 
utilization during exercise. Due to these methods, this estimate of muscle 3463 
glycogen utilization will include the utilization of other non-glucose carbohydrates 3464 
(e.g. lactate). Both the production and utilization of ketone bodies can influence 3465 
the respiratory exchange ratio and therefore theoretically complicate the 3466 
estimates of carbohydrate oxidation during exercise. However, during short-3467 
duration, moderate intensity exercise this effect is negligible (31). Within-lab, 3468 
energy expenditure was determined assuming that lipids, glucose and glycogen 3469 
give 9.42, 3.74 and 4.15 kcal·g-1 respectively (31).  3470 
 3471 
One-way, repeated measures ANOVA were used to assess differences between 3472 
trials at baseline and for summary measures (e.g. AUCs). If multiple comparisons 3473 
were necessary, two-way repeated measures ANOVAs (time x trial) was used to 3474 
identify differences between trials. Degrees of freedom for F values were 3475 
Greenhouse-Geisser corrected for epsilon < 0.75, with Huynh-Feldt corrections 3476 
used for less severe asphericity. If time x trial interaction effects were identified, 3477 
multiple paired t-tests were used to locate variance, with Holm-Bonferroni step-3478 
wise adjustments to control for inflated type I errors. Pearson r and Spearman R 3479 
were used to explore correlations between variables displaying normal and non-3480 
normal distribution, respectively. Unless otherwise stated, data in text, figures 3481 
and tables are means ± 95% confidence intervals, which were normalized by 3482 
removing between-subject variance (presented as 95% nCI) (39). All statistical 3483 
analyses were completed using IBM SPSS statistics version 22 for windows (IBM, 3484 
New York, USA), with the exception of the Holm-Bonferroni step-wise 3485 
adjustments and the calculation of normalized confidence intervals which were 3486 
completed using Microsoft Excel [2013]. Graph Pad Prism 7 software (La Jolla, 3487 
CA, USA) was used for preparation of the manuscript figures. A complete set of 3488 
muscle samples was only obtained from nine participants. Due to cannulation 3489 




OGTT 70 min and for a different participant’s BE trial the last sample was at 3491 
OGTT 60 min. For these trials (2 of 36) the group average was used for the 3492 
missing data. Sensitivity analysis was completed for all measures involving blood 3493 
samples and including/excluding these two participants did not influence any of 3494 
the primary outcome measures. For clarity, the n is presented in all legends. 3495 
 3496 
RESULTS 3497 
Plasma glucose kinetics 3498 
The plasma glucose disappearance rate (Rd) displayed a time x trial interaction 3499 
(F = 3.123, p = 0.05), whereby plasma glucose Rd was higher during exercise 3500 
versus rest (Figure 2A). Compared to extended overnight fasting, breakfast 3501 
ingestion prior to exercise further increased the plasma glucose Rd during and 3502 
post-exercise (i.e. during the OGTT; Figure 2A). A main effect of trial was 3503 
detected for the plasma glucose Rd during the OGTT (F = 7.079, p = 0.01), 3504 
whereby the Rd was 45 g·120 min-1 in BR [95% nCI: 36 to 62 g·120 min-1] versus 3505 
73 g·120 min-1 in BE ([95% nCI: 55 to 90 g·120 min-1; p = 0.09 versus BR) and 44 3506 
g·120 min-1 in FE [95% nCI: 35 to 53 g·120 min-1]; p = 0.01 versus BE). Metabolic 3507 
clearance rates showed a main effect of trial, with the highest rates also apparent 3508 
in BE (Figure 2B; F = 7.849, p < 0.01 versus BR and FE). A main effect of trial 3509 
was detected for RaTOTAL during the OGTT ([g·120 min-1]; F = 3.915, p = 0.05) 3510 
which was highest in BE (Figure 2C). However, after post-hoc adjustment the 3511 
difference between trials was less apparent (p = 0.19 for BE versus BR and p = 3512 
0.09 for BE versus FE). A similar pattern was observed for the rate of appearance 3513 
of glucose from the OGTT in plasma (RaOGTT) and a trial x time interaction was 3514 
detected (Figure 2D; F = 3.134, p = 0.04). A main effect of trial was detected for 3515 
the total RaOGTT (F = 5.915, p = 0.02), which was 49 g·120 min-1 in BE [95% nCI: 3516 
44 to 53 g·120 min-1] (65% of the OGTT [59 to 71%]) versus 42 g·120 min-1 in BR 3517 
[95% nCI: 36 to 46 g·120 min-1] (56% of the OGTT [50 to 62%]; p = 0.11 versus 3518 
BE) and 41 g·120 min-1 in FE [95% nCI: 35 to 47 g] (55% of the OGTT [49 to 3519 
61%] p = 0.06 versus BE). The plasma enrichment of [2H2] - and [13C]-glucose 3520 





Plasma glucose concentrations 3523 
No difference between trials was detected for plasma glucose concentrations at 3524 
baseline (Figure 3A; p > 0.05). Thereafter, a trial x time interaction was apparent 3525 
(F = 2.957, p = 0.01). During the exercise period (rest in BR), plasma glucose 3526 
concentrations were higher in BR versus BE at 40 min, and in BR versus FE at 3527 
50 min (both p < 0.05). At OGTT 0 min, glucose concentrations were higher in 3528 
BR versus BE, and during the OGTT they were initially higher in BR versus BE 3529 
and in BR versus FE (all p < 0.05), but no further differences were then detected 3530 
(Figure 3A). Peak plasma glucose concentrations were higher in BR versus BE 3531 
(p = 0.03), but not different in BE versus FE (Table 2; p > 0.05). A main effect of 3532 
trial was detected for the within-lab (300-min) glucose AUC which was higher in 3533 
BR versus BE (Table 2; p = 0.05). However, no main effect of trial was detected 3534 





Figure 2. Plasma glucose disposal rate (Rd) (A), metabolic clearance rate  (B), 3537 
the total rate of plasma glucose appearance (RaTOTAL) (C), the rate of appearance 3538 
of glucose in plasma from the oral glucose tolerance test (RaOGTT) (D), and the 3539 
plasma enrichments of [2H2]-glucose (E) and [13C]-glucose (F) before and during 3540 
an oral glucose tolerance test that was conducted after breakfast followed by rest 3541 
(BREAKFAST-REST), breakfast followed by exercise (BREAKFAST-EX), or 3542 
extended overnight fasting followed by exercise (FASTED-EX). Data are means 3543 
± normalized 95% confidence intervals. n = 12 healthy men. a = difference 3544 
between breakfast rest versus breakfast exercise; b = breakfast rest versus fasted 3545 





Figure 3. Plasma glucose (A), plasma insulin (B), plasma non-esterified fatty 3548 
acids (NEFA; C), plasma β-hydroxybuturate (D) plasma triglyceride (E), and 3549 
plasma intestinal fatty acid binding protein (IFAB-P; F) concentrations before and 3550 
during an oral glucose tolerance test that was conducted after breakfast followed 3551 
by rest (BREAKFAST-REST), breakfast followed by exercise (BREAKFAST-EX), 3552 
or extended overnight fasting followed by exercise (FASTED-EX). Data are 3553 
means ± normalized 95% confidence intervals. n = 12 healthy men. a = difference 3554 
between breakfast rest versus breakfast exercise; b = breakfast rest versus 3555 





Figure 4. The time-averaged (120-min) plasma glucose (A) and plasma insulin 3558 
(B) incremental area under the curves (iAUC) and the Matsuda insulin sensitivity 3559 
index (C; ISIMATSUDA) for an oral glucose tolerance test conducted after breakfast 3560 
followed by rest (BREAKFAST-REST), breakfast followed by exercise 3561 
(BREAKFAST-EX), or extended overnight fasting followed by exercise (FASTED-3562 
EX). Data are means ± normalized 95% confidence intervals, with individual data 3563 




Plasma insulin concentrations 3565 
At baseline, there was no difference between trials for plasma insulin 3566 
concentrations (Figure 3B; p > 0.05). Main effects of time (F = 4.351, p < 0.01) 3567 
and trial (F = 7.986, p < 0.01) were detected, but there was no trial x time 3568 
interaction effect (F = 2.395, p = 0.07). Peak (and time to peak) plasma insulin 3569 
concentrations are shown in Table 2. A main effect of trial was detected for the 3570 
within-lab (300-min) insulin AUC which was higher in BR versus BE (p < 0.01), 3571 
but not different in BE versus FE (Table 2; p = 0.10). A main effect of trial was 3572 
apparent for the insulin OGTT iAUC [Figure 4B; (120-min) F = 5.132, p = 0.02] 3573 
which was lower in BE versus BR [by 27.34 pmol·L-1 (95% nCI: 12.10 to 45.80 3574 
pmol·L-1); p = 0.02] and lower in BE versus FE [by 28.67 pmol·L-1 (95% nCI: 10.21 3575 
to 47.12 pmol·L-1); p = 0.04]. There was a main effect of trial for the ISIMATSUDA 3576 
insulin sensitivity index (Figure 4C; F = 22.790, p < 0.01), which was higher in 3577 
BE versus BR [by 8.45 au, (95% nCI: 6.42 to 10.47 au); p < 0.01] and in BE 3578 
versus FE [by 6.49 au (95% nCI: 2.93 to 8.51 au); p < 0.01]. 3579 
 3580 
Plasma non-esterified fatty acid (NEFA) concentrations 3581 
A main effect of trial (F = 4.314, p = 0.04) was detected for plasma NEFA at 3582 
baseline, with concentrations of 0.30 mmol·L-1 in BR (95% nCI: 0.25 to 0.35 3583 
mmol·L-1), 0.45 mmol·L-1 in BE (95% nCI: 0.36 to 0.53 mmol·L-1; p = 0.03 BE 3584 
versus BR) and 0.36 mmol·L-1 in FE (95% nCI: 0.31 to 0.44 mmol·L-1; p = 0.12 3585 
FE versus BR and BE). Thereafter, a time x trial interaction effect was apparent 3586 
(Figure 3C; F = 11.438, p < 0.01), where plasma NEFA concentrations were 3587 
lowered by breakfast consumption in BR and BE, and remained lower during the 3588 
exercise in BE versus FE, before increasing during the initial OGTT period in BE 3589 
and FE versus BR. A main effect of trial was detected for the total within-lab  3590 
plasma NEFA (300-min) AUC and the NEFA OGTT (120-min) AUC which in both 3591 
instances was lower in BR versus BE and FE (Table 2; all p < 0.01).   3592 
 3593 
Other plasma metabolites  3594 
No differences were detected between trials at baseline for plasma β-3595 




interaction effect was apparent (F = 6.310, p < 0.01) where concentrations were 3597 
lowered by breakfast in BR and BE. Plasma β-hydroxybuturate concentrations 3598 
remained lower during exercise in BE versus FE, but increased during the OGTT 3599 
with BE and FE versus BR. However, with post-hoc adjustment, the differences 3600 
between trials for plasma β-hydroxybuturate concentrations became less clear 3601 
(all p > 0.05). The within-lab (300-min) β-hydroxybuturate AUC was lower with 3602 
BR versus BE (p = 0.03), but did not differ in BE and FE (Table 2; p = 0.35).  No 3603 
baseline differences were detected for triglyceride concentrations (Figure 3E, p 3604 
> 0.05) but a time x trial interaction effect was apparent (F = 3.994, p < 0.01). 3605 
There was an effect of trial for the within-lab (300-min) and OGTT (120-min) 3606 
triglyceride AUC, which tended to be lower in FE versus BE, but with post-hoc 3607 
adjustment this difference between trials was less clear (Table 2; p > 0.05). 3608 
Plasma lactate concentrations at baseline were not different across trials (p > 3609 
0.05) but were lower in BR versus BE and FE in the exercise period (rest in BR) 3610 
and at OGTT 0 min, but were then higher in BR versus BE during the OGTT (time 3611 
x trial; F = 20.305, p < 0.01). No effect of trial was detected for the total within-lab 3612 
(300-min) lactate AUC, but a main effect of trial was detected for the lactate OGTT 3613 
(120-min) AUC, which higher in BR versus BE (Table 2; p < 0.01).  3614 
 3615 
Plasma intestinal fatty acid binding protein (I-FABP) concentrations 3616 
There was no difference between trials at baseline for plasma I-FABP 3617 
concentrations (Figure 3F; p > 0.05), but these were lower after breakfast (time 3618 
x trial interaction effect; F = 6.844, p < 0.01) in BR and BE versus FE (both p < 3619 
0.05). During and post-exercise (or rest in BR), I-FABP concentrations were lower 3620 
in BR and BE versus FE and remained lower in BR versus FE until OGTT 20 min 3621 
(all p < 0.05). The within-lab (300-min) I-FABP AUC was lower in BR and BE 3622 
versus FE (Table 2; p = 0.01 and p = 0.05 respectively).  3623 
 3624 
Activation of exercise and insulin signalling pathways in skeletal muscle 3625 
Time x trial interaction effects were apparent for AMPKThr172 (ratio p-AMPK to 3626 
total-AMPK) and ACCSer79 (ratio pACC to total ACC) phosphorylation, if 3627 




Figure 5B, F = 5.881, p = 0.02, respectively). Compared to the breakfast-rest trial 3629 
(BR), skeletal muscle AMPKThr172 phosphorylation was higher post-exercise (or 3630 
post-rest in BR) in the breakfast and exercise (BE) trial [by 1.9 fold (95% nCI: 0.9 3631 
to 2.8 fold); p = 0.04] and was also higher in BE versus the fasted-exercise (FE) 3632 
trial [by 1.0 fold (95% nCI: 0.2 to 2.0 fold); p = 0.01]. A similar pattern was 3633 
apparent for ACC phosphorylation, which was higher post-exercise (or post-rest 3634 
in BR) in BE versus BR [by 6.7 fold (95% nCI: 5.4 to 8.0 fold); p = 0.03] but did 3635 
not differ between BE and FE (p = 0.09). By OGTT 120 min, ACCSer79 and 3636 
AMPKThr172 phosphorylation had returned to baseline levels in all three trials (all 3637 
p > 0.05). No time x trial interaction (F = 2.110, p = 0.16) nor a main effect of trial 3638 
(F = 0.098, p = 0.83) was detected for AktSer473 (ratio p-AktSer473 to total-Akt2) 3639 
phosphorylation (Figure 6A). A main effect of time (F = 9.907, p = 0.01) was 3640 
observed, where AktSer473 phosphorylation was elevated at OGTT 120 min in all 3641 
trials. Similarly no time x trial interaction (F = 1.533, p = 0.25) nor a main effect of 3642 
trial (F = 0.484, p = 0.56) was detected for AktThr308 (ratio p-AktThr308 to total-Akt2) 3643 
phosphorylation (Figure 6B). A main effect of time (F = 10.598, p = 0.01) was 3644 
also detected for this phosphorylation site, whereby AktThr308 phosphorylation was 3645 
elevated at OGTT 120 min in all trials. For AS160Thr642 phosphorylation (ratio p-3646 
AS160Thr642 to total-AS160), a time x trial interaction was detected (Figure 6C; F 3647 
= 4.430, p = 0.03), where the AS160Thr642 phosphorylation was not different with 3648 
BR and BE at any time, was higher pre-OGTT in BE compared to FE (p = 0.04), 3649 




  3651 
Table 2. Peak plasma concentrations, time to peak concentrations, and the time-
averaged area under the curve (AUC) for various metabolites and hormones measured 
during the total within-lab period (300-min) and/or during an oral glucose tolerance test 
observation (120-min) that was conducted after breakfast followed by rest (Breakfast-
Rest), breakfast followed by exercise (Breakfast-Exercise), or extended overnight 








Peak glucose conc. (mmol·L 1) 10.62 (9.98, 11.25) 9.65 (9.27, 10.03) a 9.82 (9.44, 10.45) p=0.03 
Time to peak glucose (min) 36 (24, 47) 49 (36, 62) 49 (36, 61) p=0.12 
Glucose AUCTOTAL (mmol·L-1) 6.41 (6.21, 6.60) 6.05 (5.90, 6.15) a 6.07 (5.93, 6.27) p=0.01 
Peak insulin conc. (pmol·L-1) 286 (231, 341) 209 (148, 269) 282 (222, 337) p=0.07 
Time to peak insulin (min) 38 (26, 49) 56 (47, 65) a 43 (33, 54) p=0.03 
Insulin AUCTOTAL (pmol·L-1) 88 (79, 97) 62 (54, 71) 
aa 76 (67, 85) p<0.01 
NEFA AUCTOTAL(mmol·L-1) 0.16 (0.12, 0.19) 0.28 (0.24, 0.33)aa 0.37 (0.31,0.42)bb p<0.01 
NEFA AUCOGTT (mmol·L-1) 0.10 (0.06, 0.14) 0.24 (0.20, 20.29) 
aa 0.26 (0.22, 0.31) bb p<0.01 
Triglyceride AUCTOTAL (mmol·L-1) 0.85 (0.79, 0.91) 0.81 (0.75, 0.86) 0.75 (0.70, 0.79) p=0.03 
Triglyceride AUCOGTT (mmol·L-1) 0.84 (0.77, 0.92) 0.79 (0.72, 0.86) 0.70 (0.64, 0.77) p=0.02 
Lactate AUCTOTAL (mmol·L-1) 1.05 (0.96, 1.13) 1.19 (1.08, 1.30) 1.16 (1.07, 1.27) p=0.06 
Lactate AUCOGTT (mmol·L-1) 1.12 (1.04, 1.20) 0.97 (0.89, 1.04) 
aa 1.03 (0.96, 1.11) p=0.02 
β-hydroxybuturate AUC (mmol·L-1) 0.03 (0.00, 0.06) 0.08 (0.06, 0.13) a 0.14 (0.09, 0.19) b p=0.03 
I-FABP AUCTOTAL (pg·mL-1) 279 (242, 317) 304 (267, 366) 415 (353, 476) 
b cc p<0.01 
Data are means and (normalized 95% confidence intervals). conc. = concentration; 
AUCTOTAL = the time-averaged area underneath the concentration-time curve for the total 
within-lab period (300-min); AUCOGTT = the time-averaged area underneath the 
concentration-time curve for the oral glucose tolerance test (120-min); I-FABP = 
intestinal fatty acid binding protein. n = 12 healthy men a represents a difference 
between breakfast rest and breakfast exercise, b a difference between breakfast rest 
and fasted exercise and c a difference between  breakfast exercise  and  fasted exercise 





Figure 5. The phosphorylation of 5' AMP-activated protein kinase (A; phospho 3653 
AMPKThr172, ratio p-AMPK to total-AMPK) and the phosphorylation of acetyl-CoA 3654 
carboxylase (B; phospho ACCSer79, ratio p-ACC to total-ACC) before (PRE-3655 
OGTT) and after (POST-OGTT) an oral glucose tolerance test that was 3656 
conducted after breakfast followed by rest (BREAKFAST-REST [BR]), breakfast 3657 
followed by exercise (BREAKFAST-EX [BE]), or extended overnight fasting 3658 
followed by exercise (FASTED-EX [FE]). All samples were taken from the vastus 3659 
lateralis. Samples were normalized to the baseline muscle sample for each 3660 
participant (collected in the resting fasted state on the first main trial for each 3661 
participant). Data are means ± normalized 95% confidence intervals. n = 9 3662 





Figure 6. The phosphorylation of Akt2 (A; phospho AktSer473, ratio p-Akt Ser473 to 3665 
total-Akt2 and B; phosphor AktThr308, ratio p-AktThr308 to total-Akt2) and the 3666 
phosphorylation of AS160 (C; AS160Thr642, ratio p-AS160Thr642 to total-AS160) 3667 
before (PRE-OGTT) and after (POST-OGTT) an OGTT that was conducted after 3668 
breakfast followed by rest (BREAKFAST-REST [BR]), breakfast followed by 3669 
exercise (BREAKFAST-EX [BE]), or extended overnight fasting followed by 3670 
exercise (FASTED-EX [FE]). All samples were taken from the vastus lateralis. 3671 
Samples were normalized to the baseline muscle sample for each participant 3672 
(collected in the resting fasted state on the first main trial for each participant). 3673 




Substrate utilization 3675 
Across the duration of the trial carbohydrate utilization was higher in BE versus 3676 
BR (Figure 7; by 514 kcal, [95% nCI: 452 to 576 kcal] and higher in BE versus 3677 
FE (by 124 kcal, [95% nCI: 18 to 230 kcal], both p < 0.01). This difference in 3678 
carbohydrate utilization between BE and FE was derived from a higher utilization 3679 
of plasma glucose and other carbohydrate sources (i.e. muscle glycogen, but 3680 
also plasma lactate) in BE (p = 0.02 and p = 0.04 respectively). Within-lab fat 3681 
utilization did not differ between BR and BE (p = 0.25), but was higher in FE 3682 
versus BE (by 138 kcal, [95% nCI: -6 to 224 kcal], p = 0.03). Muscle glycogen 3683 
utilization during exercise (g·kg body mass-1) was positively correlated (R = 0.64, 3684 
p < 0.01) with skeletal muscle ACCSer79 phosphorylation (ratio p-ACC to total-3685 





Figure 7. Substrate utilization after breakfast followed by rest (BREAKFAST-3688 
REST), breakfast followed by exercise (BREAKFAST-EX), or extended overnight 3689 
fasting followed by exercise (FASTED-EX). Within-lab substrate utilization was 3690 
calculated assuming that the plasma glucose disappearance rate was equivalent 3691 
to plasma glucose utilization. Glycogen utilization during exercise (on breakfast 3692 
exercise and fasted exercise only) was calculated as total carbohydrate utilization 3693 
(from indirect calorimetry) minus plasma glucose utilization during exercise. This 3694 
estimate of muscle glycogen utilization will therefore include the utilization of 3695 
other non-glucose (e.g. lactate) carbohydrates. GLU = glucose; M-GLY = muscle 3696 
glycogen; PRO = protein. Data are presented as means ± normalized 95% 3697 




DISCUSSION  3699 
This is the first study to assess the effect of pre-exercise feeding on postprandial 3700 
plasma glucose kinetics after exercise. Our data demonstrate that pre-exercise 3701 
feeding increases plasma glucose disposal during meals consumed after 3702 
exercise, despite lower insulinemia in this condition. Characterizing glucose flux 3703 
at meals is important because this determines postprandial glycemia; a predictor 3704 
of cardiovascular disease risk (47, 48). Previous work has only studied 3705 
postprandial glucose flux after fasted-state exercise. As most people consume 3706 
food and perform exercise while still in a postprandial period from a prior meal 3707 
(13, 23, 55) our results describe the physiological responses to feeding that are 3708 
more readily applicable to scenarios that are representative of normal daily living. 3709 
Moreover, our data demonstrate that metabolic responses to exercise conducted 3710 
in an overnight fasted state and to meals that are consumed post-exercise cannot 3711 
be easily extrapolated to conditions where breakfast has been consumed. 3712 
 3713 
The disposal of plasma glucose (the disappearance rate) into skeletal muscle is 3714 
elevated after exercise, via insulin-dependent and -independent pathways (25). 3715 
We observed a higher postprandial plasma glucose disposal rate with breakfast 3716 
versus fasting before exercise. The higher postprandial plasma glucose rate of 3717 
disposal with pre-exercise breakfast ingestion was apparent despite lower 3718 
insulinemia in the breakfast-exercise trial. At rest, breakfast consumption 3719 
improves glucose tolerance and insulin sensitivity at subsequent meals [known 3720 
as the “second-meal effect” (5, 20, 26)]. Mechanisms likely relate to delayed 3721 
gastric emptying (19), a potentiation of early phase insulinemia at the second 3722 
meal (37) and enhanced glucose uptake into muscle due to increased GLUT4 3723 
trafficking (18). Our findings show that breakfast ingestion (versus fasting) prior to 3724 
exercise enhances subsequent glucose disposal at post-exercise meals in the 3725 
presence of lower insulinemia, suggesting that the second-meal effect is 3726 
maintained even if exercise is performed between meals. Whilst the effects of 3727 
pre-exercise feeding on the metabolic responses during subsequent exercise is 3728 
well characterised (15, 43), our data therefore provide new insights regarding 3729 




Molecular insulin-signaling pathways are instrumental mediators of glucose 3731 
disposal in response to exercise and/or nutrition (11). We therefore determined 3732 
the activation status of key proteins involved in glucose uptake in skeletal muscle 3733 
[the primary site of postprandial glucose disposal (14)]. Akt activation (Thr308 and 3734 
Ser473 phosphorylation) two hours after OGTT began, was unaffected by prior 3735 
exercise or prior breakfast ingestion. However, the timing of muscle sampling 3736 
could be responsible for this result. It is possible that differences in Akt activation 3737 
between trials may have been apparent earlier in the postprandial period, as peak 3738 
Akt phosphorylation can be variable, occurring as early as 30 min after an OGTT 3739 
(35). Thus, despite the lack of a measurable difference, we cannot rule out a role 3740 
for insulin signaling in the glucose disposal responses we observed. Distal 3741 
proteins within the insulin signalling pathway can be activated after exercise, 3742 
without detectable differences in Akt phosphorylation (61). We therefore 3743 
measured AS160Thr642 activation as this phosphorylation site has been previously 3744 
shown to be activated by both insulin and exercise stimulation (58). However, our 3745 
data show that AS160Thr642 phosphorylation was not different two hours post-3746 
OGTT with breakfast versus fasting before exercise, providing further evidence 3747 
that differences in early stages of the activation of the insulin signalling pathway 3748 
were not responsible for the higher plasma glucose disposal rate we observed 3749 
when breakfast was ingested before exercise. 3750 
 3751 
AMPK activity also plays a key role in muscle glucose uptake and stimulates 3752 
GLUT4 translocation (27). The greater post-exercise skeletal muscle AMPK 3753 
activation with breakfast prior to exercise may have contributed to the higher 3754 
glucose disposal rate in that trial. This AMPK response seems to be specific to 3755 
skeletal muscle, as we have previously shown that post-exercise adipose tissue 3756 
AMPK content is unaffected by pre-exercise feeding (12). The increase in skeletal 3757 
muscle AMPK activity with pre-exercise feeding that we report in the present 3758 
study may seem surprising given that the ingestion of large amounts (> 200 g) of 3759 
carbohydrate before and during exercise can blunt AMPK signaling in muscle (3, 3760 
29). This blunting is partly because low muscle glycogen concentrations stimulate 3761 




participants in our study may explain why we did not observe an elevated AMPK 3763 
response in our fasted-exercise trial. For example, when smaller carbohydrate 3764 
doses are ingested before and/or during exercise (~ 120 g or less) the exercise 3765 
induced increase in the phosphorylation of AMPK and ACC is not always 3766 
suppressed compared to when a placebo is ingested (2, 36, 58), although in one 3767 
study this result was apparent despite a suppression of α2-AMPK activity when 3768 
carbohydrate was ingested (2). 3769 
 3770 
The heightened AMPK response observed in the current study with breakfast 3771 
before exercise may be explained by the type of carbohydrate ingested before 3772 
exercise (high-glycemic index) in the breakfast-exercise trial, as this can stimulate 3773 
muscle glycogen use during exercise, especially when no carbohydrate is 3774 
ingested during the activity (62). Thus, the high-glycemic index breakfast with a 3775 
modest carbohydrate content in the present study, may have stimulated muscle 3776 
glycogen utilization during exercise without supplying sufficient carbohydrate to 3777 
replace additional glycogen utilization, resulting in lower post-exercise muscle 3778 
glycogen concentrations with breakfast versus fasting before exercise. This could 3779 
explain the enhanced exercise-induced AMPK response if breakfast was 3780 
consumed prior to exercise. However, we had insufficient tissue to measure 3781 
muscle glycogen concentrations in all participants, so our data only provide rates 3782 
of muscle glycogen utilization (which was higher with feeding versus fasting 3783 
before exercise). Nevertheless, in the two participants for whom we had sufficient 3784 
tissue to perform glycogen analyses, these data agreed with the tracer-derived 3785 
calculations of muscle glycogen utilization (data not shown) and AMPK signaling 3786 
via western blotting. Consistent with this, the present data demonstrated that 3787 
post-exercise ACCSer79 phosphorylation – as a marker of activation of the AMPK 3788 
pathway - positively correlated with muscle glycogen utilization during exercise. 3789 
Thus, together our results suggest that the increased post-exercise plasma 3790 
glucose disposal rates with pre-exercise feeding versus fasting may have been 3791 
mediated through enhanced AMPK signaling, which is itself a consequence of 3792 
altered fuel use during exercise. AMPK signaling and resulting muscle glycogen 3793 




The higher plasma glucose disposal rate (despite lower plasma insulin 3795 
concentrations), that we observed in the breakfast-exercise trial, may be due to 3796 
differences in GLUT4 trafficking downstream of the signalling proteins we 3797 
measured. Insulin-stimulated GLUT4 translocation and insulin sensitivity of 3798 
skeletal muscle are increased in vitro, if muscle is pre-treated with insulin, without 3799 
differences in AktSer473 or AktThr308 activation, or the transport activity of GLUT4 3800 
(18). This suggests priming of skeletal muscle by prior insulin exposure enhances 3801 
subsequent insulin action. Pre-treatment with insulin and exercise augments this 3802 
response, possibly because insulin (33) and exercise (28) stimulate GLUT4 3803 
translocation from different intracellular stores (8, 49). As such, in this work, prior 3804 
breakfast and exercise (the multiple stimuli in BE), may have enhanced skeletal 3805 
muscle GLUT4 translocation during the OGTT. Although technically challenging 3806 
future work should now quantify GLUT4 trafficking with fed versus fasted state 3807 
exercise to confirm this. It is also possible that hepatic glucose disposal accounts 3808 
for some of the increase in glucose disposal following BE versus FE. Similarly to 3809 
skeletal muscle, insulin-stimulated hepatic glucose uptake is enhanced by prior 3810 
exposure to insulin in dogs (44, 45). Thus, assuming that this response persists 3811 
in humans and after exercise, priming of the liver by prior breakfast could also 3812 
contribute to greater glucose disposal during meals consumed post-exercise. 3813 
 3814 
The increases in post-exercise glucose disposal with prior breakfast consumption 3815 
were, however, offset by alterations in plasma glucose appearance. As such, 3816 
postprandial glucose concentrations did not differ between the two exercise trials. 3817 
Postprandial plasma glucose appearance rates are determined by three main 3818 
factors: 1) the appearance of glucose from the meal; 2) residual appearance of 3819 
glucose from previous meals; and/or 3) liver glucose output (glycogenolysis or 3820 
gluconeogenesis). We showed that alterations in the postprandial plasma 3821 
glucose appearance rate (RaTOTAL) after exercise with prior breakfast was mostly 3822 
driven by increased appearance of glucose from the post-exercise OGTT. These 3823 
alterations in the RaTOTAL suggest that differences in gut function (i.e. increased 3824 
intestinal damage or absorptive capacity) and/or splanchnic blood flow altered 3825 




factors related to intestinal absorption and splanchnic handling of glucose, rather 3827 
than just glucose metabolism by skeletal muscle.  3828 
 3829 
There are several potential mechanisms which may explain the differences in 3830 
glucose appearance rates due to intestinal absorption and/or splanchnic handling 3831 
of glucose. Plasma I-FABP concentrations are used as a marker of damage to 3832 
intestinal epithelial cells (60). We noted lower plasma I-FABP concentrations in 3833 
the breakfast-exercise versus fasted-exercise trial, despite increased plasma 3834 
glucose appearance rates of the orally-ingested glucose post-exercise. It is 3835 
therefore unlikely that increased intestinal damage was responsible for the higher 3836 
plasma glucose appearance rates we observed with feeding versus fasting 3837 
before exercise. The better maintenance of splanchnic perfusion during exercise 3838 
with prior feeding is a likely explanation for this response (15). If splanchnic 3839 
perfusion was better maintained during exercise with prior feeding, this may have 3840 
also directly facilitated higher OGTT-derived glucose appearance rates in that 3841 
trial versus the fasted-exercise trial. It should be acknowledged however, that this 3842 
intestinal damage response may be specific to cycling, and could differ with other 3843 
exercise modalities (e.g. running), within the context of pre-exercise feeding. An 3844 
alternative mechanism for higher appearance rate of orally-ingested glucose with 3845 
feeding before exercise could also be that apical glucose transporters were 3846 
primed by the prior breakfast ingestion (40). Although further underlying 3847 
mechanism(s) remain unclear, and should therefore be investigated with future 3848 
work, we showed that a major determinant of post-exercise glycemia (plasma 3849 
glucose appearance rates) are altered by pre-exercise feeding and that this is 3850 
unlikely to be explained by increases in intestinal damage.  3851 
 3852 
Our results show that the metabolic and intramuscular signaling responses to 3853 
exercise conducted in a fed state cannot be readily inferred from responses 3854 
observed with exercise in a fasted state. As well as a continual investigation of 3855 
the mechanisms responsible for differences in postprandial glucose metabolism 3856 
with altered pre-exercise feeding, future work should study whether the results 3857 




ingestion of fat and protein). Moreover, if the acute alterations in postprandial 3859 
metabolism translate into longer-term differences in insulin sensitivity with 3860 
repeated bouts of exercise in the fed versus fasted state and in populations with 3861 
obesity, should now be a focus for future work.  3862 
 3863 
To conclude, eating breakfast (versus fasting) before exercise increases post-3864 
exercise plasma glucose disposal rates but this is offset by increases in 3865 
appearance rates of (mainly) orally-ingested glucose, a result that does not 3866 
appear to be explained by a greater intestinal damage response to the exercise. 3867 
We showed that pre-exercise breakfast consumption lowers insulinema at meals 3868 
that are consumed post-exercise, providing new evidence that the second meal 3869 
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RELEVANCE TO THESIS  4086 
In physiology research, blood is frequently sampled to measure concentrations 4087 
of metabolites and hormones to assess glucose tolerance or insulin sensitivity 4088 
(215). However, studies aiming to answer broadly similar questions often use 4089 
different methods to obtain blood samples (Table 4.1). Whilst arteries are a 4090 
preferred sampling site for assessing the exposure of peripheral tissues to 4091 
glucose and insulin, antecubital veins are a more common blood sampling site, 4092 
largely due to risks associated with arterial cannulation, such as greater bleeding 4093 
from the sampling site and blood clots (378). However, heating the hand to 37 ºC 4094 
causes capillaries in the hand to vasodilate to disperse heat and this produces 4095 
venous blood from the veins of the heated hand that has a gaseous composition 4096 
that does not clearly differ from arterial blood (428). These are known as 4097 
‘arterialised’ or ‘arterialised-venous’ blood samples and provide concentrations of 4098 
metabolites (e.g. glucose) and hormones (e.g. insulin) that do not clearly differ to 4099 
concentrations in arterial samples that are collected simultaneously (380-382). 4100 
Despite this, many research studies continue to measure glucose and insulin in 4101 
non-arterialised venous blood (Table 4.1). This is a consideration if comparing 4102 
research studies that have used different blood sampling methods.  4103 
 4104 
For example, as outlined in Chapter 1, the ingestion of carbohydrates increases 4105 
blood glucose concentrations and insulin is secreted to regulate this response, 4106 
by suppressing glucose appearance from the liver and increasing blood glucose 4107 
disposal into the peripheral tissues (215). Systemic glucose and insulin are 4108 
transported in the blood to the periphery by arteries where insulin binds to the cell 4109 
membranes and increases glucose disposal into peripheral tissues, whereas 4110 
veins carry the blood back to the lungs after this interaction (194). Consequently, 4111 
concentrations of glucose and insulin are higher when measured in arterialised 4112 
versus venous blood (380-382) due to a partial removal of glucose by the 4113 
peripheral tissues for storage or oxidation and insulin binding to cell membranes 4114 
(194). If differences between blood sample methods were the same across all 4115 
testing conditions and populations, correction factors could be easily applied for 4116 




However, venous concentrations of metabolites and hormones can differ due to 4118 
an uptake or release of metabolites and hormones from the tissue beds in close 4119 
proximity to the sampling site. The magnitude of arterialised-venous differences 4120 
also depends on the context in which a sample was collected. The determining 4121 
factor is the interaction of tissues in proximity to the sampling site with the blood 4122 
(Figure 4.1). As such, when comparing blood sampled after a meal or a 4123 
hyperinsulinaemic-euglycaemic clamp, arterialised-venous differences for blood 4124 
glucose concentrations are often greater than during fasting, due to an increased 4125 
extraction of blood glucose by peripheral tissues (429). This may also vary across 4126 
populations, due to differences in the capacity of muscle for disposing of glucose 4127 
(430). Arterial-venous differences for concentrations of glucose may also depend 4128 
on the activity status of participants as exercise increases net glucose uptake into 4129 
active muscle (194) and can impair insulin sensitivity in non-active muscle (431). 4130 
 4131 
Figure 4.1. Different blood sampling methods produce different concentrations 4132 
of metabolites and hormones due to the location of the sample site in relation to 4133 
peripheral tissues. The magnitude of this difference between sampling methods 4134 
depends on the characteristics of participants and their feeding and activity status 4135 






Investigating whether prior exercise alters the magnitude of arterialised-venous 4138 
differences for blood glucose was important in this thesis. Consuming breakfast 4139 
before exercise was previously shown to increase blood glucose concentrations 4140 
at a post-exercise meal, compared to when breakfast was consumed at rest (15) 4141 
(Figure 4.2A). However, this blood glucose response to a post-exercise meal 4142 
with exercise versus rest was not shown in Chapter 3 (Figure 4.2B), despite both 4143 
studies recruiting young, physically active men and prescribing a similar duration 4144 
and intensity of exercise (1 h, moderate-intensity) in the same proximity to the 4145 
post-exercise meal (1 h prior). The exercise mode might explain this result, as 4146 
running was used in the first study, and cycling was used in Chapter 3 and this 4147 
may have altered the magnitude of the intestinal damage response to exercise 4148 
and consequently the blood glucose rate of appearance (292). In Chapter 3, 4149 
Table 4.1. Studies that validated commonly-applied insulin sensitivity indices or 
have manipulated the activity/nutritional status of participants and assessed oral 
glucose tolerance or insulin sensitivity from fasting or postprandial blood samples.  
 
Study details Blood sampling method Reported outcome 
Stumvoll et al., 2000 Venous (OGTT) Stumvoll (validation) 
Katz et al., 2000 Venous (Fasting) QUICKI (validation) 
Matsuda & DeFronzo, 1999 Unclear (OGTT) Matsuda (validation) 
Belfoire et al., 1998 Unclear (OGTT) Belfoire (validation) 
Cederholm & Wibell, 1990 Venous (OGTT) Cederholm (validation) 
Roberts et al., 2016 Arterialised (OGTT) Glucose AUC 
Wright et al., 2016 Unclear (OGTT) Matsuda & HOMA-IR 
Martin et al., 2016 Venous (OGTT) Glucose AUC 
Shephard et al., 2016 Venous (OGTT) Glucose AUC 
Campbell et al., 2015 Interstitial Fluid (Free Living) Glucose AUC 
Khattab et al., 2015 Unclear (OGTT) Glucose AUC 
Cermak et al., 2015 Venous (OGTT) Matsuda 
Gonzalez et al., 2015 Capillary (OGTT) Matsuda & HOMA2-IR 
Ross et al., 2015 Unclear (OGTT) Matsuda 
Gonzalez & Stevenson, 2014 Arterialised (Mixed Meal) Glucose AUC 
Knudsen et al., 2014 Venous (OGTT) Glucose AUC 
Ortega et al., 2014 Venous (OGTT) Matsuda 
Mottola et al., 2013 Venous (OGTT) Matsuda 
Van Dijk et al., 2013 Venous (Mixed Meal) Glucose AUC 
Numao et al., 2013 Venous (OGTT) Matsuda & Stumvoll 
Gonzalez et al., 2013 Venous (Mixed Meal) Matsuda 
Walhin et al., 2013 Venous (OGTT) Matsuda 
Weinheimer et al., 2012 Unclear (OGTT) Matsuda & HOMA-IR 
Dunstan et al., 2012 Venous (Mixed Meal) Glucose AUC 




lower postprandial intestinal fatty acid binding protein concentrations in blood 4150 
were measured with breakfast consumption before exercise, suggesting a lower 4151 
intestinal damage response compared to breakfast omission before exercise. If 4152 
running induces a different intestinal damage response to cycling and with prior 4153 
breakfast consumption versus omission needs investigation. However, another 4154 
difference between the studies was the sampling method used to obtain blood, 4155 
with venous blood in previous work (15) and arterialised-venous blood sampled 4156 
in Chapter 3, evident by the higher measured systemic glucose concentrations 4157 
in Figure 4.2. If exercise alters the net uptake of blood glucose by the tissues in 4158 
proximity to the sampling site, this may explain why a heightened postprandial 4159 
blood glucose response to a post-exercise meal compared to rest was apparent 4160 
in previous work with venous blood (so after tissue-blood interactions) but not in 4161 
Chapter 3 with arterialised blood (so before tissue-blood interactions). However, 4162 
a study of arterialised-venous differences for blood glucose concentrations after 4163 





Figure 4.2. Postprandial blood glucose (A and B) and insulin (C and D) 4166 
concentrations after rest and exercise with prior breakfast consumption. In panels 4167 
A and C, data are means ± 95% confidence intervals (CI) for n=11 healthy men 4168 
and are redrawn from Gonzalez et al. (15). In panels B and D, data are redrawn 4169 
from Chapter 3 and are means ± normalised 95% CI for n=12 healthy men. ‘a’ 4170 
represents a difference between rest and exercise with p<0.05.  4171 
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Oral glucose tolerance and insulin sensitivity are common measures, but are 4174 
determined using various blood sampling methods, employed under many 4175 
different experimental conditions. This study established whether measures of 4176 
oral glucose tolerance and oral glucose-derived insulin sensitivity (ISI) differ when 4177 
calculated from venous versus arterialised blood. Critically, we also established 4178 
whether any differences between sampling methods are consistent across 4179 
distinct metabolic conditions (after rest versus after exercise). Ten healthy men 4180 
completed two trials in a randomised order, each consisting of a 120-min oral 4181 
glucose tolerance test (OGTT), either at rest or post-exercise. Blood was sampled 4182 
simultaneously from a heated hand (arterialised) and an antecubital vein of the 4183 
contralateral arm (venous). Under both conditions, glucose time-averaged area 4184 
under the curve was greater from arterialised compared to venous plasma but 4185 
importantly, this difference was larger after rest relative to after exercise (0.99 ± 4186 
0.46 versus 0.56 ± 0.24 mmolL-1 respectively; p < 0.01). OGTT-derived ISIMatsuda 4187 
and ISICederholm were lower when calculated from arterialised relative to venous 4188 
plasma and the arterialised-venous difference was greater after rest versus after 4189 
exercise (ISIMatsuda: 1.97 ± 0.81 versus 1.35 ± 0.57 au, respectively; ISICederholm : 4190 
14.76 ± 7.83 versus 8.70 ± 3.95 au, respectively; both p < 0.01). Venous blood 4191 
provides lower postprandial glucose concentrations and higher estimates of 4192 
insulin sensitivity, compared to arterialised blood. Most importantly, these 4193 
differences between blood sampling methods are not consistent after rest versus 4194 
post-exercise, preventing standardised venous-to-arterialised corrections from 4195 





Insulin resistance is the first detectable defect in the pathogenesis of metabolic 4198 
diseases [e.g. type 2 diabetes (T2D) (1)] and can, along with the associated 4199 
impairment in glucose tolerance, independently predict risk of cardiovascular 4200 
disease and mortality (2). Glucose tolerance and insulin sensitivity can be 4201 
quantified in vivo using an oral glucose tolerance test (OGTT). Indeed, the OGTT 4202 
is frequently employed in both clinical (to diagnose T2D) and research settings 4203 
(to assess the efficacy and/or effectiveness of exercise or dietary interventions 4204 
for altering blood glucose control). After an overnight fast, a 75 g glucose load is 4205 
ingested and followed by an observation period (usually 120 min) where blood 4206 
samples are collected to determine glucose concentrations. If combined with 4207 
insulin measurements, estimates of whole-body insulin sensitivity can be derived 4208 
that are more representative of free-living physiology than other measures such 4209 
as the hyperinsulinemic-euglycemic clamp (3-6). 4210 
 4211 
However, guidelines for the OGTT provide no clear consensus or justification of 4212 
the most appropriate method for blood sampling. Consequently, oral glucose 4213 
tolerance and OGTT-derived estimates of insulin sensitivity are determined from 4214 
blood sampled from antecubital veins (7), capillaries (8), heated dorsal hand 4215 
veins (9), and glucose concentrations in the interstitial fluid (9). In some 4216 
instances, the blood sampling method (i.e. the sample site used) is not reported, 4217 
including in the validation of a commonly cited (> 2500 times) oral glucose derived 4218 
insulin sensitivity index (5). Arterial blood best represents the exposure of 4219 
peripheral tissues such as skeletal muscle to systemic metabolites and 4220 
hormones. When knowledge of peripheral exposure to glucose and insulin is 4221 
required, arterial samples may therefore be preferable. However, due to the 4222 
potential risks associated with arterial cannulation (10), alternative methods are 4223 
often used to provide blood reflective of arterial samples (commonly referred to 4224 
as arterialised-venous or arterialised blood), including the heated-hand technique 4225 
(11-17). Nonetheless, many studies derive oral glucose tolerance and insulin 4226 
sensitivity from non-arterialised venous blood from an antecubital vein, under 4227 




(7). Some guidelines provide corrections for venous to capillary plasma for an 4229 
OGTT, but only at rest (18). However, concentrations of metabolites or hormones 4230 
in a vein can differ due to their net uptake or release from tissue beds, which 4231 
depends on environment, nutritional and/or metabolic factors. For example, a 4232 
bout of endurance-type exercise increases insulin sensitivity and glucose uptake 4233 
in active muscle (19) and can impair insulin sensitivity in non-exercised muscle 4234 
(20). This prohibits venous-to-arterialised corrections, or direct comparisons 4235 
between studies that have used different, but common, methods for obtaining 4236 
blood samples (i.e. arterialised blood from a heated hand vein versus blood from 4237 
an antecubital vein). 4238 
 4239 
A comparison of arterialised and venous blood, for estimates of glucose tolerance 4240 
and OGTT-derived insulin sensitivity, under different metabolic conditions (i.e. 4241 
when prior exercise has been completed) has never been performed. As such, 4242 
the aim of this study was to: 1) establish if OGTT-derived insulin sensitivity indices 4243 
differ when calculated from arterialised versus venous blood samples and 2) 4244 
investigate whether prior lower-limb exercise influences the magnitude of any 4245 
differences between arterialised and venous concentrations of glucose or insulin. 4246 
 4247 
METHODS 4248 
Trial Design 4249 
This study adopted a cross-over design, whereby participants completed 4250 
preliminary measures followed by exercise and rest trials in a randomised order 4251 
(randomisation performed by RME using an online tool: randomizer.org), 4252 
separated by an interval of 7-21 days. On main trial days, an hour of moderate-4253 
intensity cycling or rest (lying recumbent on a bed) was followed by an oral 4254 
glucose tolerance test (OGTT), during which blood samples were collected 4255 
simultaneously from a pre-heated dorsal hand vein (arterialised) and an 4256 
antecubital vein of the contralateral arm (venous). All trials were completed at the 4257 
University of Bath (Bath, UK) in accordance with the Declaration of Helsinki. The 4258 
study was approved by the Research Ethics Approval Committee for Health at 4259 





Ten self-reported physically active and healthy men (mean ± SD: age: 23 ± 3 4262 
years; body mass: 76.9 ± 5.7 kg; height: 181.6 ± 4.5 cm; body mass index: 23.3 4263 
± 1.8 kgm-2; V̇O2 peak: 52.7 ± 8.9 mlkg-1min-1) were recruited from the staff and 4264 
student population at the University of Bath, between November 2015 and April 4265 
2016. Exclusion criteria included any history of metabolic disease, or any 4266 
condition that might have posed undue personal risk to the participant or 4267 
introduced bias to the experiment. Written, informed consent was obtained from 4268 
all participants prior to testing.  4269 
 4270 
Preliminary Testing 4271 
Upon arrival at the laboratory, height was measured to the nearest 0.1 cm with a 4272 
stadiometer (Seca Ltd, Birmingham, UK), with participants barefoot in the 4273 
Frankfurt plane. Body mass was measured with participants in light clothing and 4274 
to the nearest 0.1 kg using electronic weighing scales (BC543 Monitor, Tanita, 4275 
Tokyo, Japan). An incremental cycling test was then completed at a self-selected 4276 
cadence on an electronically-braked ergometer (Excalibur Sport, Lode, 4277 
Groningen, Netherlands). Participants were allowed to adjust the saddle and 4278 
handlebar heights to their preferred position. The initial power output was set at 4279 
50 W and was increased by 50 W every four min, for four stages. Thereafter, the 4280 
power output was increased by 20 W every min until volitional exhaustion. Heart 4281 
rate was monitored throughout (Polar Electro Oy, Kempele, Finland) and breath-4282 
by-breath measurements were recorded using an online gas analysis system 4283 
(TrueOne2400, ParvoMedics, Sandy, USA). The volume and gas analysers used 4284 
were calibrated with a 3 L calibration syringe (Hans Rudolph, Kansas City, USA) 4285 
and known concentrations of a calibration gas (16.04 % O2; 5.06 % CO2) 4286 
respectively. Maximal power output (MPO) was taken as the work rate of the last 4287 
completed stage, plus the fraction of time in the final non-completed stage, 4288 
multiplied by the work rate increment. Peak oxygen uptake (V̇O2 peak) was taken 4289 




Main Trials 4291 
Participants arrived at 0800 ± 1 hour, after a minimum 10 hour overnight fast and 4292 
having refrained from strenuous physical activity and caffeine for 24 hours. They 4293 
were asked to record their evening meal and physical activity on the day before 4294 
the first trial and replicate this for the second visit, in line with standard procedures 4295 
for postprandial glucose tolerance testing (21). Upon arrival, participants placed 4296 
their dominant hand into a heated-air box set to a constant temperature of 55°C 4297 
(Mass Spectrometry Facility; The University of Vermont & the University of 4298 
Vermont Medical Center, Burlington, USA). After 20 minutes, intravenous 4299 
cannulae (BD Venflon Pro, BD, Helsingborg, Sweden) were fitted in the heated 4300 
dorsal hand vein (retrograde) and the antecubital fossa of the contralateral arm 4301 
(antegrade). A simultaneous baseline 5 mL blood sample was drawn from each 4302 
site to be used as a baseline sample. Cannulae were kept patent via flushing of 4303 
a 0.9 % sodium chloride infusion (B.Braun, Melsungen, Germany) and the first 2 4304 
mL of each sample was thus discarded.  Plasma was obtained by dispensing 4305 
whole blood into ethylenediaminetetraacetic acid-coated tubes (BD, Oxford, UK) 4306 
which were centrifuged for 10 minutes (4°C and 3500 g) (Heraeus Biofuge Primo 4307 
R, Kendro Laboratory Products Plc., UK). Samples were dispensed into 0.5 mL 4308 
aliquots and immediately frozen at -20°C, before longer-term storage at -80°C. 4309 
On the exercise trial, participants completed 60 minutes of cycling on an 4310 
ergometer (Monark 894 E, Monark, Vansbro, Sweden) at 50 % MPO. On the rest 4311 
trial, they remained in the recumbent position throughout this period and were 4312 
permitted to complete resting activities (i.e. watching television or reading).  4313 
 4314 
In both trials, an OGTT was then performed. Participants ingested 82 g of 4315 
dextrose powder (Myprotein, Northwich, UK) dissolved in 300 mL of water 4316 
(equivalent to 75 g of anhydrous glucose).  Whole blood (5 mL) was collected 4317 
immediately prior to (OGTT 0 minute) and every 15 minutes post-ingestion of the 4318 
glucose load from the heated dorsal hand vein and the antecubital vein of the 4319 
contralateral arm simultaneously, and processed via aforementioned 4320 
methodology. Expired gas samples were collected at baseline and hourly during 4321 




exercise (and same time points in the rest trial). Gas samples were collected into 4323 
200 L Douglas Bags (Hans Rudolph, Kansas City, USA) via falconia tubing 4324 
(Baxter, Woodhouse and Taylor Ltd, Macclesfield, UK). Concurrent 4325 
measurements of inspired air composition were made, to correct for changes in 4326 
ambient O2 and CO2 concentrations. Expired O2 and CO2 concentrations were 4327 
measured in a known volume of each sample via paramagnetic and infrared 4328 
analysers (Mini HF 5200, Servomex Ltd., UK).  4329 
 4330 
Data Analysis  4331 
Plasma glucose, lactate and triglyceride concentrations were measured on an 4332 
automated analyser (Daytona; Randox Lab, Crumlin, UK) according to 4333 
manufacturer’s instructions. Plasma insulin concentrations were determined 4334 
using a commercially available ELISA (Mercodia AB, Uppsala, Sweden; intra-4335 
assay CV, 3.7 %; inter-assay CV 6.5 %). Samples were analysed in batch after 4336 
all data collection was completed, and for every participant, all samples from both 4337 
trials were analysed on the same plate. Energy expenditure and substrate 4338 
utilisation were determined for rest, exercise and during the OGTT via indirect 4339 
calorimetry. Assuming urinary nitrogen excretion to be negligible, substrate 4340 
utilisation was calculated using stoichiometric equations and adjusted for 4341 
exercise values to account for the contribution of glycogen (22). At rest, these 4342 
calculations assume that glucose provides all of the carbohydrate required for 4343 
metabolism. Adjustments were then made for estimations of carbohydrate 4344 
oxidation during moderate-intensity exercise, where metabolic requirements are 4345 
met by glucose and glycogen, which typically provide a 20 and 80% contribution 4346 
respectively (22). Energy expenditure was determined assuming that lipids, 4347 
glucose and glycogen provide 9.42, 3.74 and 4.15 kcalg-1 (22). 4348 
 4349 
Statistical Analysis 4350 
A sample size estimation was performed using fasting glucose concentrations 4351 
sampled from arterialised and venous blood (mean ± SD: 4.70 ± 0.19 versus 4.52 4352 
± 0.19 mmolL-1, for arterialised versus venous, respectively) (13). Using the 4353 




chance of detecting a statistical difference between arterialised and venous blood 4355 
for glucose with an α-level of 0.05. The area underneath the concentration-time 4356 
curve (AUC) for the plasma glucose and plasma insulin OGTT responses was 4357 
calculated using the trapezoid rule.  The total AUC (mmol120minL-1) was divided 4358 
by the duration of the OGTT observation period (120 min) to provide a time-4359 
averaged AUC (mmolL-1), which was used as a summary measure for the 4360 
reported postprandial responses. Insulin sensitivity indices were calculated as 4361 
described in the relevant table or figure (4-6, 23, 24). For comparisons of multiple 4362 
means, a two-way repeated measures trial (exercise or rest) x sample method 4363 
(arterialised or venous) ANOVA was employed. Where significant trial x sample 4364 
method interactions were detected, t-tests were performed to locate variance, 4365 
and corrected for multiple comparisons using Sidak’s multiple comparison test. A 4366 
Pearson r was used to correlate the arterialised-venous difference after rest 4367 
against the arterialised-venous difference after exercise. Data are presented as 4368 
means ± SD in text and means ± 95 % confidence intervals in figures unless 4369 
otherwise stated. All statistical analysis was completed using a commercially 4370 
available software package (GraphPad Software, Inc, CA, USA). In one 4371 
participant’s exercise trial the 105 minute and 120 minute post OGTT blood 4372 
samples were not collected from both sampling methods, and for these time 4373 
points (1 % of samples collected across the study) the last observation carried 4374 





Energy expenditure and substrate utilisation  4377 
The exercise was completed as prescribed, except for one participant for whom 4378 
the intensity was decreased to 45 % MPO for the final 30 minutes due to his 4379 
inability to maintain an intensity of 50 % MPO. The exercise intensity was 4380 
equivalent to 63 ± 5 % V̇O2 peak. In the rest trial, energy expenditure was 5.68 ± 4381 
0.55 kJmin-1 in the hour before the OGTT and rates of carbohydrate and fat 4382 
oxidation were 0.14 ± 0.07 and 0.09 ± 0.04 gmin-1, respectively. In the exercise 4383 
trial, energy expenditure during cycling was 51.00 ± 5.51 kJmin-1 and 4384 
carbohydrate and fat oxidation rates were 2.21 ± 0.41 and 0.38 ± 0.16 gmin-1 4385 
respectively. During the OGTT, no difference was detected between trials in 4386 
energy expenditure or substrate oxidation (all p > 0.05). 4387 
 4388 
Plasma glucose concentrations 4389 
At baseline, there was no difference in plasma glucose concentrations measured 4390 
in arterialised compared to the venous samples in the rest (5.31 ± 0.35 versus 4391 
5.27 ± 0.28 mmolL-1 respectively, p > 0.05) or exercise trials (5.25 ± 0.47 versus 4392 
5.18 ± 0.37 mmolL-1 respectively, p > 0.05). Immediately prior to the OGTT, 4393 
plasma glucose concentrations were higher in arterialised compared to venous 4394 
samples after rest (Table 1; p = 0.02) but not after exercise (p > 0.05). After rest, 4395 
glucose concentrations were higher at 30 and 45 minutes post-OGTT in 4396 
arterialised relative to venous plasma (Figure 1A; all p < 0.05). In the exercise 4397 
trial glucose concentrations did not differ between arterialised or venous plasma 4398 
at any time post-glucose ingestion (Figure 1B; all p > 0.05). Glucose AUC was 4399 
higher when calculated from arterialised relative to venous plasma after rest and 4400 
after exercise (Figure 3A; both p < 0.01). However, the arterialised-venous 4401 
difference was greater after rest (0.99 ± 0.46 mmolL-1) relative to after exercise 4402 
(0.56 ± 0.24 mmolL-1) (Figure 3A; p < 0.01). When analysed independently, 120 4403 
minute post-OGTT glucose concentrations were higher in arterialised relative to 4404 
venous plasma, and in both trials (Table 2; p < 0.05). When recommended 4405 
adjustments for venous to capillary plasma were applied [venous plasma + 1.1 4406 




plasma (Table 1; p < 0.05). For the plasma glucose AUC, the magnitude of the 4408 
arterialised-venous difference after rest was correlated with the magnitude of the 4409 
arterialised-venous difference after exercise (r = 0.800, p < 0.01).  4410 
 4411 
Plasma insulin concentrations  4412 
At baseline, there was no difference in plasma insulin concentrations measured 4413 
in arterialised relative to the venous samples in the rest (21.26 ± 4.26 versus 4414 
20.49 ± 4.47 pmolL-1 respectively, p > 0.05) or exercise trials (22.39 ± 6.78 versus 4415 
21.55 ± 5.93 pmolL-1 respectively, p > 0.05). Thereafter, there were no difference 4416 
in plasma insulin concentrations measured in arterialised compared to venous 4417 
samples at any time point in the rest (Figure 2A) or exercise trials (Figure 2B; 4418 
both p > 0.05). The time-averaged insulin AUC was higher in arterialised plasma 4419 
relative to venous plasma after rest and after exercise (Figure 3B; both p < 0.01). 4420 
No trial x sample method interaction was detected, indicating that the arterialised-4421 
venous difference was similar across the two trials (17.7 ± 16.8 versus 11.2 ± 6.7 4422 
pmolL-1 for rest versus exercise, p = 0.13). For the plasma insulin AUC, the 4423 
arterialised-venous difference after rest was correlated with the arterialised-4424 
venous difference after exercise (r = 0.790, p < 0.01). When data from both trials 4425 
were pooled, the arterialised-venous difference for insulin AUC was correlated 4426 





Figure 1. Plasma glucose concentrations during an oral glucose tolerance test 4429 
(OGTT) after rest (A) or after exercise (B). Data are samples collected 4430 
simultaneously from a pre-heated dorsal hand vein (arterialised) and the 4431 
antecubital fossa of a contralateral arm (venous). Values are mean ± 95% 4432 
confidence intervals. * Denotes significant differences between arterialised and 4433 
venous samples with p < 0.05. n = 10. 4434 
 4435 
Figure 2. Plasma insulin concentrations during an oral glucose tolerance test 4436 
(OGTT) after rest (A) or after exercise (B). Data are samples collected 4437 
simultaneously from a pre-heated dorsal hand vein (arterialised) and the 4438 
antecubital fossa of a contralateral arm (venous). Values are mean ± 95% 4439 





Insulin sensitivity indices  4442 
The OGTT-derived ISIMatsuda was lower if calculated from arterialised compared 4443 
to venous plasma in both trials (Figure 3C; p < 0.01). A trial x sample method 4444 
interaction indicated that the arterialised-venous difference was greater after rest 4445 
(1.97 ± 0.81 au) compared to after exercise (1.35 ± 0.57 au) trial (Figure 3C; p = 4446 
0.03). Similarly, the ISICederholm was lower if calculated from arterialised relative to 4447 
Table 1. Plasma concentrations and time-averaged area under concentration time 
curve for metabolites and insulin sensitivity indices for an oral glucose tolerance test. 
             Rest             Exercise 
 Arterialised Venous       Arterialised  Venous 
OGTT 0 glucose (mmolL-1) 5.43 (0.24) 5.24 (0.26) * 4.88 (0.47) 4.95 (0.53) † 
Peak glucose (mmolL-1) 9.55 (0.90) 8.17 (0.89) ** 8.98 (0.62) 8.30 (0.47) ** † 
120 min glucose (mmolL-1) 6.50 (1.08) 5.84 (0.96) ** 6.23 (1.04) 5.85 (0.73) * 
Correct glucose (mmolL-1) 6.50 (1.08) 6.94 (0.96) ** 6.23 (1.04) 6.95 (0.73) ** 
OGTT 0 insulin (pmolL-1) 20 (6) 18 (5) * 20 (5) 19 (6) 
Peak insulin (pmolL-1) 319 (179) 290 (152) ** 247 (121) 223 (97) ** 
120 min insulin (pmolL-1) 71 (42) 67 (36) 51 (28) 58 (37) † 
OGTT 0 Lactate (mmolL-1) 0.67 (0.18) 0.68 (0.17) 1.43 (0.74) 1.39 (0.59) 
Lactate AUC (mmolL-1) 0.95 (0.24) 0.99 (0.22) 1.09 (0.28) 1.11 (0.25) 
OGTT 0 TAG (mmolL-1) 0.59 (0.16) 0.62 (0.15) 0.67 (0.16) 0.72 (0.13) ** 
TAG AUC (mmolL-1) 0.56 (0.18) 0.57 (0.17) 0.63 (0.17) 0.64 (0.17) 
ISI Stumvoll (au) 0.12 (0.01) 0.13 (0.01) ** 0.12 (0.01) 0.12 (0.01) 
HOMA2-IR (au) 0.39 (0.12) 0.34 (0.11) * 0.37 (0.11) 0.36 (0.12) 
QUICKI-IR (au) 0.41 (0.02) 0.42 (0.03) * 0.42 (0.03) 0.43 (0.04) 
Data are samples collected simultaneously from a pre-heated dorsal hand vein (arterialised) and the 
antecubital fossa of the contralateral arm (venous). Values are mean (standard deviation). n = 10. 
TAG = Triglyceride.* equals a significant difference between arterialised and venous blood samples 
with p < 0.05. ** equals a significant difference between arterialised and venous blood samples with 
p < 0.01. † equals a significant sample method versus trial interaction with p < 0.05. ISIStumvoll = 0.226 
- [0.0032 x BMI (kgm-2)] - [0.000064 x plasma insulin at OGTT 120 (mIUml1)] - [0.0037 x plasma 
glucose at OGTT 90 (mmolL-1)]. QUICKI-IR = 1/ [log plasma insulin at OGTT 0 (mIUml-1) + log 





venous plasma after rest and after exercise (Figure 3D; both p < 0.01). The 4448 
arterialised-venous difference was also greater after rest compared to after 4449 
exercise (14.76 ± 7.83 au versus 8.70 ± 3.95 au; Figure 3D; p < 0.01). There was 4450 
a small but statistically significant difference for ISIStrumvoll after rest, with 4451 
calculated values lower when derived from arterialised, relative to venous plasma 4452 
(p < 0.01). After exercise, a similar trend was observed, but the difference 4453 
between sampling methods did not reach statistical significance in this instance, 4454 
and no significant trial x sample method interaction effect was detected for this 4455 
outcome (Table 1; both p = 0.08). The HOMA2-IR index was higher if calculated 4456 
from arterialised relative to venous plasma at rest (Table 1; p = 0.02) but no 4457 
difference was detected between sample methods after exercise (p > 0.05). The 4458 
QUICKI-IR index was lower if calculated from arterialised, relative to venous 4459 
plasma after rest (Table 1; p = 0.01). A similar trend was also apparent after 4460 
exercise, but the difference between sampling methods did not reach statistical 4461 
significance in this instance (p = 0.12).  No significant trial x sample method 4462 
interaction effect was detected for HOMA2-IR or QUICKI-IR (p > 0.05).  4463 
 4464 
Other Metabolites 4465 
Immediately prior to the OGTT, plasma lactate concentrations were not different 4466 
in arterialised relative to venous samples, and this was apparent in both the 4467 
exercise and rest trials (Table 1; both p > 0.05). Lactate AUC was not significantly 4468 
different if calculated from arterialised or venous plasma after rest or after 4469 
exercise (Table 1; both p > 0.05). Prior to the OGTT, plasma triglyceride 4470 
concentrations were not affected by the sample method used after rest (Table 1; 4471 
p > 0.05), but after exercise concentrations were higher in venous relative to 4472 
arterialised samples (p < 0.01). Triglyceride AUC was unaffected by sample 4473 
method after rest and exercise (Table 1; both p > 0.05). No trial x sample method 4474 





Figure 3. Time averaged area under the plasma glucose (A) and insulin (B) 4477 
concentration time curves, and ISI Matsuda (C) and ISI Cederholm (D) indices 4478 
after rest or exercise. Data are samples collected simultaneously from a pre-4479 
heated dorsal hand vein (arterialised) and the antecubital fossa of a contralateral 4480 
arm (venous). Values are mean ± 95% confidence intervals. n = 10. ISIMatsuda = 4481 
10,000 / [baseline glucose (mgdL-1) x baseline insulin (mIUmL-1)] x [mean 4482 
glucose over 120 minutes (mgdL-1) x mean insulin over 120 minutes (mIUmL-4483 
1)]. ISICederholm = 75000 + [baseline glucose (mmolL-1) - glucose at OGTT 120 4484 
(mmolL-1)] x 0.19 x 180 x 1.15 x Body Mass (kg) / [120 x log mean insulin over 4485 





This study demonstrates that venous blood samples produce different values with 4488 
respect to both glucose tolerance and insulin sensitivity indices, compared to 4489 
arterialised blood samples. Furthermore, if assessing whole-body glucose 4490 
tolerance, differences between sampling methods are not consistent under 4491 
different metabolic conditions (e.g. when a prior bout of endurance-type exercise 4492 
is performed, compared to rest) and so no single venous-to-arterialised correction 4493 
factor can always be applied. 4494 
 4495 
It has been known for decades that post-meal blood glucose concentrations can 4496 
predict future risk of metabolic diseases (25). Thus, glucose tolerance and OGTT-4497 
derived insulin sensitivity indices are widely used in research to assess disease 4498 
risk and responses to lifestyle or pharmacological interventions. Whilst arteries 4499 
are the preferred site for determining peripheral exposure to metabolites or 4500 
hormones, antecubital veins are a common site for postprandial blood sampling, 4501 
due to risks associated with arterial cannulation. Nonetheless, it has been known 4502 
since at least the 1920’s that heating the hand to approximately 37ºC causes the 4503 
cutaneous capillary beds to vasodilate as part of a homeostatic mechanism to 4504 
radiate heat (26). This results in the dorsal veins of a heated hand providing 4505 
concentrations of metabolites (e.g. glucose, non-esterified fatty acids, amino 4506 
acids and lactate) and hormones (e.g. insulin and glucagon) that are consistent 4507 
with arterial blood (11-17). Even increasing ambient temperature produces higher 4508 
postprandial concentrations of glucose and insulin if sampled in venous blood, 4509 
due to partial arterialisation (27, 28). The data presented here also show that 4510 
postprandial glucose concentrations are higher if measured in arterialised, 4511 
relative to venous plasma, but importantly the magnitude of this difference is 4512 
influenced by the activity status of participants at the time when the OGTT is 4513 
performed. This means that when glucose tolerance or insulin sensitivity are 4514 
assessed with an OGTT, it is essential to report the blood sampling procedure 4515 
that is used, as this could influence the interpretation of reported findings and will 4516 
allow for more appropriate comparisons between studies that have used different 4517 




concentrations were higher in arterialised relative to venous plasma after rest, but 4519 
there was no difference between sample methods when a prior bout of exercise 4520 
was performed. After rest, differences were detected when indices of insulin 4521 
resistance that use fasting concentrations of glucose and insulin were calculated 4522 
from arterialised versus venous plasma (i.e. HOMA2-IR and QUICKI), but the 4523 
absence of a trial x sample method interaction suggests that the arterialised-4524 
venous difference is uninfluenced by activity status. In line with previous results, 4525 
we showed that in both trials the postprandial glucose AUC was greater if 4526 
calculated from arterialised, relative to venous plasma. Importantly, these novel 4527 
data demonstrate that the arterialised-venous difference was lower if the OGTT 4528 
was performed after a bout of exercise, compared to after rest. Therefore, when 4529 
assessing glucose tolerance, venous samples cannot be adjusted by a consistent 4530 
correction to provide an equivalent to arterial concentrations. Estimates of insulin 4531 
sensitivity, including ISIMatsuda and ISICederholm, were also influenced by the sample 4532 
method used, with venous blood providing higher values. The magnitude of the 4533 
arterialised-venous difference was also greater after rest relative to after 4534 
exercise, again preventing consistent corrections being applied.   4535 
 4536 
These results also have implications when determination of absolute glucose 4537 
concentrations is required, such as when assessing hypo- and hyperglycaemia. 4538 
For example, peak postprandial plasma glucose concentrations and associated 4539 
measures (i.e. time-to-peak) has implications for risk of metabolic disease and 4540 
are often included as intervention outcomes (29). Our results demonstrate that 4541 
120 minute post-OGTT and peak plasma glucose concentrations are higher in 4542 
arterialised relative to venous plasma. If suggested corrections are applied to 4543 
obtain capillary concentrations from venous plasma (18), corrected venous 4544 
glucose concentrations are greater than those measured in arterialised blood. As 4545 
such, these corrections may need to be revisited.  4546 
 4547 
It is beyond the scope of this work to establish the underlying mechanisms for the 4548 
smaller arterialised-venous difference in glucose AUC after exercise compared 4549 




non-exercising forearm (20), potentially due to lipid deposition in non-exercise 4551 
muscle (30). This may have reduced glucose uptake across the forearm, reducing 4552 
the difference in concentrations between the arterialised and venous samples in 4553 
the exercise condition. The smaller difference could also be explained by an 4554 
increase in forearm blood flow post-exercise (31).  Also of interest is the 4555 
exploratory observation that participants with larger arterialised-venous 4556 
differences for the plasma glucose and insulin AUC after rest, tended to have 4557 
larger arterialised-venous differences for these outcomes after exercise. It is 4558 
plausible that this may be attributable to differences between the participants in 4559 
forearm muscle mass, and/or the anatomy of their vasculature, but this was not 4560 
possible to ascertain from the current study. 4561 
 4562 
To conclude, venous blood provides lower postprandial glucose concentrations 4563 
and higher estimates of insulin sensitivity than arterialised samples, when 4564 
common indices are applied. Moreover, the variation in plasma glucose 4565 
concentrations between venous and arterialised samples is different after 4566 
exercise compared to after rest, and thus corrections cannot readily be applied 4567 
across all conditions. These results indicate that the method used for blood 4568 
sampling (i.e. heating the hand for arterialised blood or sampling from an 4569 
antecubital vein) is an important consideration when comparing studies that 4570 
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RELEVANCE OF FINDINGS FOR THESIS 4653 
In Chapter 4, arterialised-venous differences for postprandial plasma glucose 4654 
concentrations were higher after rest than exercise, so one consistent correction 4655 
factor for blood glucose concentrations cannot be easily applied across these 4656 
conditions. It is possible that the blood sample method used was also responsible 4657 
for differences with results from Chapter 3 versus previous work of glycaemia 4658 
after exercise (15), as discussed prior to Chapter 4. Therefore, using data from 4659 
Chapter 4 and two-way (exercise or rest x time) ANOVAs the effect of using 4660 
arterialised versus venous blood for detecting differences in postprandial blood 4661 
glucose concentrations after exercise or rest was explored (Figure 4.3). 4662 
 4663 
Figure 4.3. Plasma glucose (A [arterialised] and B [venous]) and plasma insulin 4664 
(C [arterialised] and D [venous]) concentrations after rest or exercise. Data are 4665 
means ± 95% confidence intervals; n=10 healthy men.  4666 
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Figure 4.4. Plasma glucose AUC (A) and insulin AUC (B) after rest or exercise 4668 
in arterialised and venous blood. Data are means ± 95% confidence intervals; 4669 
n=10 healthy men. 4670 
 4671 
These data are different to the results presented in Chapter 4, (where the main 4672 
comparison was arterialised-venous differences with rest versus exercise) as 4673 
they now show the differences between rest and exercise with arterialised versus 4674 
venous blood. The aim of this sub-analysis was to establish whether a difference 4675 
in postprandial glycaemia after exercise versus after rest would be clearer using 4676 
venous compared to arterialised blood as this may explain the difference with 4677 
results in Chapter 3 and previous work (15). As shown in Figures 4.3 and 4.4, a 4678 
significant difference in postprandial blood glucose concentrations after exercise 4679 
versus rest was not apparent when using arterialised or venous blood samples. 4680 
Nonetheless, it is possible that this analysis was not sufficiently powered to detect 4681 
a difference between exercise and rest in this regard, as the sample method x 4682 
trial interaction effect approached significance (p=0.09) and Figure 4.4A shows 4683 
a trend for plasma glucose concentrations to be higher after exercise versus rest 4684 
in venous blood (p=0.22 rest versus exercise) whilst this was much less clear in 4685 
arterialised blood (p=0.80 rest versus exercise). The measurement of glucose in 4686 
venous (versus arterialised) blood could thus explain the post-exercise second 4687 
meal effect (i.e. higher postprandial blood glucose concentrations) in studies with 4688 
prior fasted cycling versus fasting at rest. Lipid deposition in the non-exercising 4689 
forearm may explain this result [and the lower glucose disposal rate in this tissue 4690 
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at a meal consumed after fasted lower-limb exercise versus fasting at rest (431)] 4691 
as discussed in Chapter 4. Finally, the work of Gonzalez et al. (15) where an 4692 
increase in post-exercise postprandial blood glucose concentrations (in venous 4693 
blood) was reported with breakfast consumption and exercise (versus breakfast 4694 
at rest) but not fasting and exercise (versus fasting at rest) may be explained by 4695 
the use of running instead of cycling exercise. This may alter blood glucose flux 4696 
via splanchnic perfusion, intestinal damage (glucose appearance rates) and/or 4697 
muscle damage (glucose disposal rates). More research is needed to investigate 4698 
arterialised-venous differences for blood glucose concentrations in the context of 4699 
these nutrient-exercise interactions and with different exercise modes.  4700 
 4701 
In addition to sampling from a heated dorsal hand vein and an antecubital vein of 4702 
the non-heated arm, blood was also sampled at the same time points from an 4703 
antecubital vein of the heated arm in Chapter 4. In Chapter 6, the effects of 4704 
exercise training before versus after breakfast for postprandial glycaemia was 4705 
studied and arterialised blood sampled. However, cannulating a dorsal hand vein 4706 
can be challenging in humans with obesity and this was not always achieved. In 4707 
these instances, the cannula was placed in an antecubital vein of the heated arm 4708 
and a correction was applied for plasma glucose concentrations during rest, using 4709 
data in Table 4.2 and Figure 4.3 (heated hand to heated arm). The magnitude 4710 
of the difference between these sample sites was notable at ~ 0.80 mmol·L-1 for 4711 
glucose at 30 min post-OGTT, in the context of the differences between groups 4712 
for the pre- to post-intervention changes in glucose concentrations for the same 4713 
OGTT time point in Chapter 6 ([mean ± 95 % CI] 0.46 ± 0.70 control versus -0.56 4714 
± 0.63 mmol·L-1 exercise). In Chapter 4, plasma insulin concentrations were not 4715 
statistically different at any time point during the OGTT after rest or exercise in 4716 
arterialised versus venous blood (Table 4.3). Non-significant differences were 4717 
also less meaningful in the context of difference between groups for the pre- to 4718 
post-intervention changes in insulin concentrations at the same OGTT time point 4719 
in Chapter 6 (80 ± 53 pmol·L-1 for control versus -185 ± 170 pmol·L-1 for exercise). 4720 
A correction factor for sample methods was therefore not applied for plasma 4721 




heated hand and partially-arterialised blood from the heated arm would also likely 4723 
be smaller in magnitude than differences with arterialised versus venous blood.  4724 
 4725 
Figure 4.5.  Plasma glucose concentrations during an oral glucose tolerance test 4726 
(OGTT) after rest with arterialised blood (heated dorsal hand vein), partially-4727 
arterialised blood (antecubital vein of the heated arm) and non-areterialised blood 4728 
(antecubital vein of the non-heated arm) (A) and the glucose AUC (B) after rest 4729 
or exercise during morning fasting. Data are means ± normalised 95% confidence 4730 
intervals for n=10 healthy men. In Panel A ‘a’ is a difference between heated-4731 
hand and non-heated arm, ‘b’ a difference between heated hand and heated arm 4732 
and ‘c’ a difference between heated arm and non-heated arm with p<0.05.  4733 
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Table 4.2. Plasma glucose concentrations from a heated hand, an antecubital 
vein from the heated arm and an antecubital vein from the non-heated arm during 
an oral glucose tolerance test during rest. Data are means and normalised 95% 
confidence intervals; 10 healthy men. * is a difference between sample methods 
















      
0 5.43 (0.16) 5.31 (0.16) -0.12 5.24 (0.14) -0.20 * 
15 7.19 (0.39) 6.67 (0.16) -0.52 6.44 (0.37) -0.76 * 
30 9.14 (0.31) 8.54 (0.39) -0.60 * 7.60 (0.40) -1.54 * 
45 8.88 (0.43) 8.11 (0.31) -0.77 7.37 (0.43) -1.51 * 
60 7.94 (0.35) 7.44 (0.43) -0.49 6.99 (0.45) -0.94 * 
75 7.29 (0.28) 6.74 (0.35) -0.55 6.50 (0.48) -0.79 * 
90 7.17 (0.25) 6.72 (0.28) -0.44 6.17 (0.49) -1.00 * 
105 6.97 (0.26) 6.43 (0.26) -0.55 6.00 (0.35) -0.98 * 
120 6.50 (0.13) 6.15 (0.13) -0.35 5.84 (0.28) -0.67 * 
Table 4.3. Plasma insulin concentrations from a heated hand 
and an antecubital vein from the non-heated arm during an 
oral glucose tolerance test at rest. Data are means and 










    
0 20 (1) 18 (1) -2 
15 169 (40) 116 (40) -53 
30 295 (25) 240 (25) -55 
45 230 (14) 213 (14) -17 
60 175 (6) 173 (6) -2 
90 115 (6) 111 (6) -4 
120 71 (6) 67 (6) -4 




CHAPTER 5 - BREAKFAST-EXERCISE & ENERGY BALANCE 4735 
 4736 
Skipping breakfast before exercise creates a more negative 24-h energy 4737 
balance: A randomized controlled trial in healthy physically active men. 4738 
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RELEVANCE TO THESIS 4763 
The results in Chapter 3 showed that the metabolic and intramuscular responses 4764 
to endurance-type exercise after breakfast cannot be inferred from the responses 4765 
observed following exercise during morning fasting. Eating breakfast prior to 4766 
exercise increased blood glucose disposal rates at a meal consumed after 4767 
exercise, but this was offset by increases in the appearance rate of mainly meal-4768 
derived glucose. Consuming carbohydrate before exercise also increases blood 4769 
glucose flux (272) and glucose concentrations (264, 270) as well as whole-body 4770 
carbohydrate utilisation rates during exercise (264, 270), compared to when the 4771 
exercise is performed during morning fasting. A difference in substrate utilisation 4772 
and glycaemia during exercise with altered pre-exercise feeding may also have 4773 
implications for the regulation of post-exercise energy balance. The concepts 4774 
outlined here were introduced during Chapter 1 of this thesis, but a more detailed 4775 
discussion is now provided as context for the work in Chapter 5.  4776 
 4777 
Numerous factors influence the regulation of energy balance and many of these 4778 
are co-ordinated by neuroendocrine pathways in the hypothalamus (433, 434). 4779 
Whilst not a primary focus of this thesis, it is proposed that afferents within the 4780 
gastrointestinal (GI) tract can be stimulated by mechanical and chemical stimuli 4781 
following meals, which may alter appetite and subsequent eating behaviours 4782 
(435). For example, increasing mechanical stress in the stomach can decrease 4783 
subsequent energy intake (436). This effect may also be potentiated by signals 4784 
emitted after nutrients enter the GI lumen. Ghrelin is an orexigenic hormone that 4785 
stimulates hunger and meal initiation when humans are fasting, and research in 4786 
rodents also suggests that this effect may be mediated by its actions within the 4787 
hypothalamus (437). During a 24-h fast, ghrelin secretion in healthy humans has 4788 
peaks that align with expected meal times (438) and the administration of ghrelin 4789 
versus saline in humans can stimulate an increase in energy intake (439, 440). 4790 
Anorexigenic peptides, including glucagon-like peptide 1 (GLP-1), peptide 4791 
tyrosine tyrosine (PYY), pancreatic polypeptide and oxyntomodulin can also be 4792 
secreted from the GI tract (in humans) in response to nutrient intake and also 4793 




mediating role for the hypothalamus (441). These GI-derived peptides are also 4795 
secreted in response to the presence of specific nutrients in the intestine which, 4796 
along with differences in their energy density and gastric emptying rates, explains 4797 
why in humans, some foods have a greater satiating effect than others (442).  4798 
 4799 
Leptin is a protein that is secreted from the adipose tissue, and in humans, blood 4800 
leptin concentrations are positively correlated with fat mass (443). Leptin may 4801 
have a role in the protection of further fat mass losses after longer-term diet or 4802 
exercise induced energy deficits, which reduce blood leptin concentrations likely 4803 
due to a loss of fat mass (444). A decrease in leptin concentrations following an 4804 
energy deficit may be a mechanism to preserve fat stores, with leptin acting in a 4805 
negative feedback loop, with the aim of maintaining the stability of adipose tissue. 4806 
Fasting blood leptin concentrations are ~ 20-50 % lower after exercise training 4807 
(340), but this response is less clear if additional food is provided (445). Lowering 4808 
blood leptin concentrations decreases satiety and increases sensations of hunger 4809 
in humans (446) and rodent research suggests that leptin acts by binding to the 4810 
hypothalamic arcuate nucleus (447). If humans classified as overweight undergo 4811 
weight loss, neural activity in brain regions relating to the regulatory, emotional 4812 
and cognitive control of appetite are altered in response to external cues in a 4813 
manner consistent with an increased desire to eat, yet this response can be 4814 
ameliorated by leptin administration (448). Taken together, these studies provide 4815 
convincing evidence of a hormonal regulation of energy balance in humans. 4816 
 4817 
Energy balance may be regulated by negative feedback, whereby the induction 4818 
of an energy deficit may stimulate behaviour change to restore energy balance 4819 
(17). Changes to substrate balance may also contribute to a regulation of energy 4820 
balance (351). Alterations to blood glucose flux [the glucostatic theory (449)] 4821 
and/or glycogen availability [the glycogenostatic theory (352)] have both been 4822 
proposed as possible regulators of energy balance. The glycogenostatic theory 4823 
has received the most attention and suggests that because glycogen stores in 4824 
the body have a smaller storage capacity than lipid stores [< 3000 kcal in a lean 4825 




the induction of a negative carbohydrate balance may stimulate energy intake 4827 
and/or decrease energy expenditure to favour glycogen replenishment.  4828 
 4829 
A number of studies in humans support a relationship between energy balance 4830 
and whole-body carbohydrate balance. In one study, 24-h substrate utilisation in 4831 
67 men and 45 women was assessed using a respiratory chamber and ad libitum 4832 
energy intake measured over the next 3 days (450). Carbohydrate utilisation 4833 
(r=0.40; p<0.01) and carbohydrate balance (r=-0.34; p<0.01) over 24 h predicted 4834 
subsequent energy intake. It has also been shown that trained people who often 4835 
typically display a relatively low rate of carbohydrate utilisation during intensity-4836 
matched exercise are less likely to compensate for an exercise-induced energy 4837 
deficit than untrained people (451, 452). Although demonstrating causality is 4838 
difficult, this raises the possibility that substrate utilisation during exercise may be 4839 
a regulator of post-exercise energy balance. In another study, healthy men cycled 4840 
for 90 min at 60 % V̇O2peak, before an ab libitum lunch. The men who relied more 4841 
heavily on carbohydrate as a substrate for exercise energy metabolism had a 4842 
more positive net energy balance after lunch versus their resting trial, whereas 4843 
the men with a lower rate of carbohydrate utilisation had a more negative energy 4844 
balance versus their rest trial (453). However, the energy cost of exercise was 4845 
also higher in men with a lower rate of carbohydrate use which contributed to that 4846 
difference in energy balance. Correlations between carbohydrate use during 4847 
exercise and energy intake post-exercise are reported elsewhere [r=0.76, p<0.01 4848 
(353) and r=0.57, p=0.02 (354)]. Nonetheless, in the first of those two studies all 4849 
participants cycled at 90 W so the relative exercise intensity may have differed 4850 
(and confounded the reported association) and in the second study, the exercise 4851 
session was designed to expend 400 kcal for all of the participants, but the 4852 
calculation was based on age-predicted HR and there were differences between 4853 
the participants in the actual exercise-induced energy deficit of (mean ± SD) 4854 
445.2 ± 54.0. Despite this, research more specific to this thesis has shown that 4855 
in healthy men, the energy deficit from breakfast omission prior to exercise is 4856 
incompletely compensated for at lunch (15) or over 24 h (16). The lower 24-h 4857 




to the breakfast, but to meals and snacks later in the day (16). That finding may 4859 
also be explained by the smaller permutations to carbohydrate balance if exercise 4860 
is performed during morning fasting compared to after breakfast. 4861 
 4862 
Although the aforementioned studies have limitations and so must be interpreted 4863 
cautiously, there is a considerable body of evidence to suggest that carbohydrate 4864 
utilisation during exercise may regulate aspects of post-exercise energy balance. 4865 
Whether the carbohydrate status of one store (i.e. muscle or liver glycogen) is a 4866 
more potent regulator of energy balance is less clear. The post-exercise period 4867 
is typically characterised by increased peripheral insulin sensitivity and glycogen 4868 
synthase activity in exercised muscle (454). This directs ingested carbohydrates 4869 
towards storage and reflects a biological drive to restore muscle glycogen. If the 4870 
depletion of muscle glycogen does stimulate energy intake, one mechanistic link 4871 
could be that cellular sensors such as AMPK convey information about glycogen 4872 
availability to the hypothalamus (455). After exercise, AMPK activity is typically 4873 
elevated in exercised skeletal muscle and increased further when the activity is 4874 
performed with a reduced muscle glycogen content (313, 456). AMPK activity 4875 
regulates aspects of metabolism in skeletal muscle (e.g. driving an increase in 4876 
lipid utilisation) and AMPK also mediates the effects of adipocyte‐ or GI‐derived 4877 
hormones in the hypothalamus (457, 458). In mice, fasting increases (and feeding 4878 
inhibits) AMPK activity in the hypothalamus and if adenoviruses expressing active 4879 
AMPK are injected into the basal medial hypothalamus of mice, hypothalamic 4880 
AMPK activity increases and is associated with an increased energy intake and 4881 
gains in body mass (458). However, if mice perform exercise hypothalamic AMPK 4882 
activity is not always increased (459), so any link between AMPK activity and the 4883 
regulation of energy balance after exercise is currently not clear.  4884 
 4885 
Interleukin-6 (IL-6) is a peptide that is secreted from active skeletal muscle during 4886 
exercise (248). IL-6 production may also be modulated by the glycogen content 4887 
of exercising muscles (460), leading to speculation that IL-6 operates as a cellular 4888 
energy sensor (461). IL-6 increases lipolysis in the adipose-tissue and stimulates 4889 




IL-6 concentrations during exercise (461). As such, if substrate utilisation during 4891 
exercise does regulate energy balance responses post-exercise, IL-6 secretion 4892 
may help to explain this association, with a link to muscle glycogen. Whole-body 4893 
IL-6 knockout mice appear to be susceptible to obesity and show increased fat 4894 
masses (462). In a human study, men and women with obesity performed 12 4895 
weeks of endurance-type exercise, with or without infusions of an IL-6 receptor 4896 
antagonist, tocilizumab. This study suggested that IL-6 signalling was required 4897 
for exercise training to reduce visceral fat mass, because when tocilizumab was 4898 
administered, the exercise-induced decrease in visceral fat mass was diminished 4899 
(463). Nonetheless, these findings may be best interpreted as evidence of a role 4900 
for substrate utilisation per se during exercise in the regulation of energy balance 4901 
as opposed to a mechanistic link between muscle glycogen status and energy 4902 
balance. This is because evidence of an association between plasma IL-6 levels 4903 
and post-exercise appetite is lacking (464) and because low muscle glycogen 4904 
concentrations would be expected to increase IL-6 secretion and stimulate lipid 4905 
utilisation, thereby decreasing carbohydrate utilisation. This would then, in theory, 4906 
decrease the likelihood of compensation after exercise, which is in contrast to 4907 
suggestions that lowering muscle glycogen concentrations increases subsequent 4908 
energy intake. In addition to a lack of a clear mechanistic link between muscle 4909 
glycogen status and behaviours that contribute to energy balance after exercise, 4910 
large reductions in muscle glycogen concentrations (~ 50 %) achieved with diet 4911 
and exercise does not always stimulate a clear increase in energy intake (465).  4912 
 4913 
Large variance in liver glycogen availability may be more robustly defended than 4914 
muscle glycogen because liver glycogen is a substantive source of glucose for 4915 
the systemic circulation and for vital organs including the brain during fasting (30). 4916 
A manipulation of whole-body carbohydrate balance via diet modifications over 4917 
1-2 days using isoenergetic diets but with varying fat and carbohydrate contents 4918 
does not substantially change subsequent energy intake responses (466, 467). 4919 
However, in a longer study, a low, moderate or high fat diet (20 %, 40 % or 60 % 4920 
of kcal) was consumed ad libitum for a week and an association between the 4921 




(467). If dietary carbohydrate is restricted, the liver glycogen content is decreased 4923 
due to increased glycogenolysis, to help maintain blood glucose concentrations 4924 
via increased HGP, especially as muscle glycogen does not contribute to blood 4925 
glucose maintenance due to a lack of glucose-6-phosphatase (468). Despite this, 4926 
with prolonged dietary carbohydrate restriction, the muscle glycogen content is 4927 
likely to also be decreased, as muscle glycogen is utilised during physical activity 4928 
and not restored unless carbohydrate is ingested (303). Therefore, investigating 4929 
whether liver glycogen has a specific role in the regulation of energy balance in 4930 
humans is difficult, because it is hard to manipulate liver glycogen status over 4931 
longer than a single overnight fast without also altering muscle glycogen status. 4932 
Nonetheless, in mice, a link between liver glycogen status and energy balance 4933 
has been shown. Mice that have high levels of liver glycogen show protection 4934 
from body mass gains, which was attributed to a reduction in energy intake (469). 4935 
Furthermore, mice that overexpress hepatic protein targeted to glycogen, which 4936 
increases liver glycogen concentrations by both activating glycogen synthase and 4937 
inhibiting glycogen phosphorylase, show a lower energy intake, increased energy 4938 
expenditure and lower subcutaneous fat mass, compared to wild type mice (355).  4939 
 4940 
A plausible link between liver glycogen status and alterations in energy balance 4941 
behaviours is that signals about energy availability from the liver are transmitted 4942 
to the brain via the hepatic vagus nerve. In support of this, when hepatic branch 4943 
vagotomy (HBV) was performed on mice overexpressing hepatic protein targeted 4944 
to glycogen, HBV blunted the effect of increased liver glycogen accumulation on 4945 
energy intake, which was apparent when sham operations were performed (355). 4946 
This was explained by the theory that a higher liver glycogen content maintains 4947 
hepatic ATP levels which is a signal of energy availability and inhibits the firing of 4948 
hepatic vagal afferents and an activation of the nucleus tractus solitarius resulting 4949 
in a suppression of appetite and a decrease in energy intake (470). However, 4950 
HBV operations can also inhibit the innervation of parts of the GI tract that may 4951 
alter the secretion of appetite-regulating peptides, which somewhat complicates 4952 
any interpretation of those mechanistic results (470). It is also possible that liver 4953 




changes in endocrine signalling. Specifically, fibroblast growth factor 21 (FGF21) 4955 
is a protein primarily produced by the liver and is responsive to alterations in liver 4956 
carbohydrate status. In rodents carbohydrate ingestion increases hepatic FGF21 4957 
mRNA expression and plasma FGF21 concentrations (471) and the increase in 4958 
plasma FGF21 concentrations can be associated with a reduction in meal size, a 4959 
reduction in sweet-seeking behaviours and decreases in body mass (471). This 4960 
response also seems to be enhanced with fructose-containing sugars, providing 4961 
a possible link to the liver because fructose-containing sugars can increase liver 4962 
glycogen synthesis to a greater extent than glucose (471). However, in humans 4963 
there is currently limited evidence linking hepatic glycogen availability or FGF21 4964 
to energy balance behaviours, so more research is warranted. 4965 
 4966 
Finally, as discussed previously, leptin is an important hormone in the regulation 4967 
of appetite and energy balance in humans. An acute (~ 3 day) decrease in 4968 
carbohydrate availability and 4 weeks of a low carbohydrate diet (relative to when 4969 
an isocaloric high carbohydrate diet is consumed) lowers fasting plasma leptin 4970 
concentrations (472, 473). An acute bout of exercise typically decreases glucose 4971 
uptake in the adipose tissue (474), which may be important as leptin secretion 4972 
from the adipose tissue can be altered depending on blood glucose availability 4973 
[e.g. infusing glucose at ~ 4 g·h-1 prevents a fall in leptin during periods of fasting 4974 
(475)]. Exercise also increases AMPK activation within the adipose tissue (476), 4975 
which may supress leptin secretion via mTOR signalling (477). Despite this, whilst 4976 
the consumption of a modest amount of carbohydrate before exercise alters 4977 
metabolism during exercise, it does not clearly alter the exercise-induced change 4978 
in the mRNA expression or the content of AMPK in the adipose tissue versus 4979 
exercise in the fasted-state (14). However, as hyperinsulinemia stimulates leptin 4980 
secretion (478), any link between carbohydrate utilisation during exercise and 4981 
plasma leptin concentrations may be explained by plasma insulin concentrations 4982 
(472). Overall, if carbohydrate utilisation during exercise is indeed a regulator of 4983 
post-exercise energy balance in humans, the current evidence suggests that this 4984 
relationship may be explained by changes to the liver glycogen content (i.e. liver 4985 




One of the limitations with the previous human studies investigating whether liver 4987 
or muscle glycogen availability is a more important regulator of energy balance, 4988 
is the absence of direct glycogen measurements, with inferences made only from 4989 
estimations of substrate balances at a whole-body level [where a positive  4990 
carbohydrate balance favours carbohydrate storage as glycogen and a negative 4991 
carbohydrate balance favours net glycogen utilisation (479)]. As such, to provide 4992 
further insights into the tissue-specific regulation of post-exercise energy balance 4993 
in Chapter 5, substrate balances were assessed using indirect calorimetry and 4994 
researcher-weighed meals, but were also combined with the glucose flux data 4995 
from Chapter 3. As such, during exercise the utilisation of carbohydrate derived 4996 
from the liver versus skeletal muscle was estimated. Plasma glucose utilisation 4997 
was assumed to be equivalent to the plasma glucose rate of disposal, as this has 4998 
been confirmed previously (480). As blood glucose utilisation during fasted-state 4999 
exercise is almost completely derived from the liver (30), an estimation of liver 5000 
glucose utilisation was made. Then, by subtracting this value from whole-body 5001 
carbohydrate utilisation rates, muscle glycogen utilisation was also estimated.  5002 
 5003 
This estimation of blood glucose disposal rates has limitations if tracer: tracee 5004 
steady-state is not achieved, but this can be avoided by using non-steady-state 5005 
modelling and frequent blood sampling (399). The protocol used in Chapter 3 5006 
was designed to assess glucose flux post-exercise, so blood was sampled more 5007 
infrequently during exercise. Despite this, the blood glucose appearance values 5008 
of (mean ± SD) of 3.75 ± 1.45 mg·kg-1·min-1 in Chapter 3 do not clearly differ to 5009 
values from research assessing liver glycogen utilisation during exercise with 13C 5010 
magnetic resonance spectroscopy (MRS) and glucose tracer methods (481). One 5011 
potential limitation with the tracer method that was used in Chapter 3 to estimate 5012 
muscle glycogen utilisation is that whole-body carbohydrate utilisation rates (from 5013 
which this measure was partly derived) can be altered by any utilisation of ketone 5014 
bodies such as β-hydroxybuturate (BHB). However, with the concentrations of 5015 
BHB that we report in Chapter 3, the utilisation of BHB (482) and the effect on 5016 
carbohydrate utilisation rates (88) is likely to be negligible. Another consideration 5017 




and muscle glycogen utilisation, but also the utilisation of lactate. In Chapter 3, 5019 
plasma lactate concentrations for fasted-exercise were 2.79 ± 1.00 mmol·L-1. 5020 
With similar blood lactate concentrations during fasted cycling in healthy men, 5021 
lactate made a contribution to whole-body carbohydrate utilisation of ~ 25 % 5022 
(483). In that study, further increasing plasma lactate concentrations resulted in 5023 
a higher rate of lactate utilisation (from 7 to 9 mg·kg-1·min-1) but this seemed to 5024 
be almost completely accounted for by a decrease in plasma glucose utilisation, 5025 
measured via tracer methods. As such, it is unlikely that the estimation of muscle 5026 
glycogen utilisation during exercise in Chapter 5 would have been meaningfully 5027 
influenced by the absence of a measure of lactate utilisation, even if this did differ 5028 
across participants, as blood glucose utilisation was assessed and accounted for 5029 
in the estimations of muscle glycogen utilisation.  5030 
 5031 
Alternative methods of assessing glycogen utilisation also have limitations. The 5032 
measurement of glycogen concentrations has historically involved the chemical 5033 
analysis of biopsy samples (268). However, if measuring glycogen in this way, 5034 
the measured concentration is only representative of the tissue that is sampled 5035 
and the site of sampling within the muscle. The biopsy procedure is also invasive 5036 
and can induce a catecholamine response and influence the concentrations of 5037 
various blood metabolites in unaccustomed participants (484). Obtaining a liver 5038 
biopsy sample is also difficult and is rarely performed outside of a clinical setting 5039 
(485). A non-invasive alternative to biopsy derived measures of muscle or liver 5040 
glycogen is 13C MRS, which measures the magnitude of a signal corresponding 5041 
to the quantity of 1-13C glucose in the glycogen-bound form. Some nuclei are 5042 
electrically charged, so if a magnetic field is applied using a probe positioned on 5043 
skin adjacent to a muscle of interest, an energy transfer occurs at a wavelength 5044 
corresponding to a specific radio frequency. When the nuclei spin returns to its 5045 
basal level, energy is then emitted at the same frequency. A signal that matches 5046 
this frequency is measured in order to yield an MRS spectrum for the nucleus 5047 
concerned. One limitation of this method for measuring glycogen is that only 13C 5048 
is detected, as the nuclei of 12C do not possess the magnetic moment required to 5049 




measurements, as dietary carbohydrates have different 13C/12C enrichments. 5051 
However, these differences in 13C abundance are small relative to changes in the 5052 
liver and muscle glycogen content with exercise (486), so can likely be neglected 5053 
as a confounding factor for glycogen measurements with this method. However, 5054 
a measure of glycogen concentrations before and after exercise only provides 5055 
net- and not absolute-rates of glycogen utilisation, which may be important as 5056 
glycogenesis can occur during exercise (487). As such, the tracer methods used 5057 
in Chapter 5 are appropriate for measuring absolute rates of glycogen utilisation. 5058 
 5059 
Another limitation with previous human studies assessing the effect of differences 5060 
in substrate utilisation during exercise on post-exercise energy balance, is the 5061 
absence of measures of subsequent free-living energy expenditure. Indeed, most 5062 
studies have only measured energy intake and/or energy expenditure, but in a 5063 
controlled environment. During periods of fasting, compensatory reductions in 5064 
free-living energy expenditure can occur and this has been attributed to a 5065 
reduction in non-exercise physical activity (328). In lean adults, extending an 5066 
overnight fast to midday decreases morning and 24-h physical activity energy 5067 
expenditure compared to when breakfast is consumed (328). In humans with 5068 
obesity, physical activity is also lower during the morning with breakfast omission 5069 
versus consumption (329). It is therefore surprising that an assessment of energy 5070 
expenditure outside of a controlled laboratory environment has never been 5071 
completed with exercise and breakfast omission versus consumption. Thus, one 5072 
of the aims of Chapter 5 was to investigate whether breakfast consumption 5073 
versus omission before exercise alters post-exercise energy intake and energy 5074 
expenditure over 24 h. A second aim was to investigate the role of muscle or liver 5075 
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ABSTRACT  5078 
Background: At rest, breakfast omission lowers daily energy intake, but also 5079 
lowers energy expenditure, attenuating any effect on energy balance. The effect 5080 
of breakfast omission, on energy balance when exercise is prescribed, is unclear. 5081 
Objective: The aim was to assess the effect of pre-exercise breakfast omission 5082 
versus consumption on 24-h energy balance. Methods: Twelve healthy active 5083 
young men (age 23 ± 3 years, body mass index 23.6 ± 2.0 kg·m-2) completed 5084 
three trials in a randomized order (separated >1 week): a breakfast of oats and 5085 
milk (431 kcal; 65 g CHO, 11 g FAT, 19 g PRO) followed by rest (BR); breakfast 5086 
before exercise (BE; 60 min cycling at 50% peak power output); and overnight-5087 
fasting before exercise (FE). The 24-h energy intake was calculated from 5088 
breakfast, and an ad libitum lunch, snacks and dinner. Indirect calorimetry with 5089 
heart-rate-accelerometry were used for substrate utilization and 24-h energy 5090 
expenditure. A [6,6-2H2]-glucose infusion was used to investigate tissue-specific 5091 
carbohydrate utilization. Results: Energy balance (24 h) was -400 kcal 5092 
(normalized 95 % confidence intervals: -230 to -571 kcal) with exercise and 5093 
breakfast omission (FE), and this was significantly lower than the rest trial (BR; 5094 
492 [332 to 652] kcal) and also the exercise but with prior breakfast consumption 5095 
(BE; 7 [-153 to 177] kcal; both P<0.01 versus FE). Plasma glucose utilization in 5096 
FE (mainly representing liver glucose utilization), was positively correlated with 5097 
energy intake compensation at lunch (r= 0.62, P= 0.03), suggesting a role for liver 5098 
carbohydrate use in post-exercise energy balance regulation. Conclusion: 5099 
Neither exercise energy expenditure nor the restricted energy intake via breakfast 5100 
omission were completely compensated for post-exercise. In healthy men, pre-5101 
exercise breakfast omission creates a more negative daily energy balance and 5102 





Obesity is an escalating global epidemic, and is a consequence of a chronic 5105 
positive energy imbalance. In addition to reducing calorie intake, regular exercise 5106 
is a commonly proposed strategy for facilitating weight loss or weight 5107 
maintenance (1). This is because exercise increases energy expenditure and 5108 
thus alters energy balance, thereby potentially favoring the conditions for 5109 
reductions in body and fat mass. Despite this, exercise training interventions often 5110 
report smaller than expected fat and body mass losses (2,3). This modest 5111 
response can be explained by compensation of energy balance behaviours 5112 
(either the activity stimulating energy intake and/or decreasing physical activity 5113 
outside of the prescribed exercise), and this reduces the energy deficit created 5114 
by the exercise energy expenditure (4). A similar example of this compensation, 5115 
is that breakfast omission at rest (i.e. reduced energy intake) decreases morning 5116 
non-exercise physical activity in lean humans and humans with obesity (5,6).  5117 
 5118 
In particular, altering carbohydrate balance may have implications for subsequent 5119 
energy balance (7). Endogenous carbohydrate stores (liver and muscle glycogen) 5120 
have a smaller storage capacity than lipid stores [< 3000 kcal in a lean 75 kg male 5121 
versus > 100,000 kcal for lipids (8,9)]. Due to this limited storage capacity, the 5122 
Glycogenostatic theory (7) proposes that endogenous carbohydrate stores are 5123 
closely regulated, and because of this, glycogen depletion may increasingly 5124 
stimulate compensatory energy intake in order to favour the replenishment of 5125 
these stores. For example, in humans there is some (albeit limited) evidence that 5126 
individuals who display high(er) rates of carbohydrate utilization when exercising 5127 
are more likely to compensate with a higher post-exercise energy intake 5128 
(8,10,11). Whilst short-term (1-3 days) alterations in glycogen availability with 5129 
exercise or diet does not always result in measurable compensation in energy 5130 
intake (8), mice overexpressing hepatic protein targeted to glycogen (which 5131 
increases liver glycogen concentrations) also display reduced energy intake and 5132 
increased energy expenditure (12). If carbohydrate metabolism is indeed a driver 5133 
of subsequent energy intake, any strategies that attenuate carbohydrate use 5134 




energy intake  (thereby reducing any erosion of the exercise-induced energy 5136 
deficit). One strategy that reduces the rate of whole-body carbohydrate utilization 5137 
during exercise is pre-exercise fasting (i.e. breakfast omission) (13). Furthermore, 5138 
since breakfast omission under resting conditions does not result in energy intake 5139 
compensation at lunch (14,15) any potential protection against a subsequent 5140 
higher energy intake (by a lower carbohydrate utilization during exercise when 5141 
fasting) is unlikely to be compromised due to the lower pre-exercise food intake 5142 
(i.e. with the omission of breakfast). 5143 
 5144 
If moderate intensity (55% V̇O2peak) endurance-type exercise is performed in the 5145 
overnight fasting state, whole-body carbohydrate utilization is lower (and fat 5146 
utilization is higher) compared to exercise after breakfast (13). Interestingly, 5147 
humans do not fully compensate with energy intake at a subsequent meal if 5148 
breakfast is omitted before exercise (15,16), which extends observations made 5149 
with breakfast consumption during resting conditions (5). These findings are 5150 
consistent with a role for carbohydrate balance in the regulation of energy 5151 
balance. However, an objective assessment of daily energy balance (when 5152 
energy intake and energy expenditure are assessed in a free-living setting) after 5153 
exercise with prior breakfast consumption versus omision has never been 5154 
conducted. This limitation is especially important in light of findings that the 5155 
omision of breakfast at rest decreases sedentary and light (i.e. non-exercise) 5156 
physical activity (5,6). Whether the carbohydrate status (content or rate of 5157 
utilization) of a specific tissue (liver or muscle glycogen) is a more potent regulator 5158 
of post-exercise energy balance also remains unknown. Indeed, no study has 5159 
specifically assessed a relationship between muscle or liver carbohydrate 5160 
utilization and post-exercise energy balance in humans. Investigating this 5161 
response would provide insights into the regulation of post-exercise energy 5162 
balance, and this information could be applied to refine exercise and nutritional 5163 
strategies (e.g. pre-exercise fasting to lower liver glycogen concentrations versus 5164 





Therefore, the aim of this experiment was to investigate the role of carbohydrate 5167 
availability during exercise on net energy balance over 24 h. In addition, the 5168 
application of glucose tracer methods (to assess hepatic glucose output and 5169 
utilization) combined with indirect calorimetry, was implemented to address a 5170 
secondary aim of exploring the tissue-specific regulation of energy balance.  5171 
 5172 
METHODS 5173 
Ethical Approval 5174 
These results were collected as part of a wider study (17), but none of the data 5175 
have been previously published. The study was completed at the University of 5176 
Bath (Bath, UK) as per the Declaration of Helsinki. Ethical approval was given by 5177 
the National Health Service South-West Research Ethics Committee 5178 
(15/SW/0006). The trial was registered at clinicaltrials.gov (NCT02258399). Prior 5179 
to participation, written and informed consent was obtained from all participants. 5180 
 5181 
Study Design 5182 
This study adopted a randomized cross-over design (randomization by JTG using 5183 
Research Randomizer version 3.0, http://www.randomizer.org/). Preliminary 5184 
testing was followed by three trials (7-30 d apart), which were breakfast followed 5185 
by rest (BR), breakfast followed by exercise (BE) and overnight fasting followed 5186 
by exercise (FE), in a random and counterbalanced order. A protocol schematic 5187 
is shown in Figure 1. For all trials participants arrived at the laboratory at 0800 ± 5188 
1 h having fasted overnight (12-14 h). In BR, upon arrival at the laboratory, a 5189 
porridge breakfast was consumed, followed by 3 h of rest, and a 2-h oral glucose 5190 
tolerance test (OGTT). In BE, the breakfast was consumed, before 2 h rest and 5191 
60 min of cycling, and the OGTT. In FE, breakfast was omitted but the trial 5192 
otherwise replicated BE. After the OGTT, participants were provided an ad libitum 5193 
lunch (within-lab) and a researcher-weighed food package, for consumption over 5194 
the remaining 24-h trial (free-living). Daily energy expenditure was assessed via 5195 
indirect calorimetry (for within-laboratory components) and heart-rate with 5196 
accelerometry (free-living after leaving the laboratory). All trials were completed 5197 





Figure 1. Schematic. Twelve healthy young, physically active men completed 5200 
three trials in a randomized order: breakfast followed by rest (BR), breakfast 5201 
followed by exercise (BE), or overnight fasting followed by exercise (FE). Daily 5202 
energy intake was determined by an ad libitum lunch, snacks and dinner meals. 5203 
Indirect calorimetry (within-lab) and heart-rate-accelerometry (free-living) were 5204 
used to assess substrate use and daily energy expenditure. A [6,6-2H2]-glucose 5205 
infusion was used to assess tissue-specific carbohydrate utilization. 5206 
 5207 
Participants 5208 
Twelve healthy and physically active men were recruited from Bath (UK) and the 5209 
surrounding area, between May and November 2015. Participant characteristics 5210 
are shown in Table 1. The main exclusion criteria for participants included them 5211 
having a history of metabolic disease, or any condition that may have posed 5212 
undue personal risk to the participant or introduced bias to the study. Participants 5213 
were also asked to confirm that they were not taking any medication that may 5214 
have influenced any of the reported outcomes. The participant’s stature was 5215 
measured to the nearest 0.1 cm using a stadiometer (Seca Ltd, Birmingham, UK) 5216 
and their body mass was recorded to the nearest 0.1 kg using electronic weighing 5217 
scales (BC543 Monitor, Tanita, Tokyo, Japan). A whole-body dual energy x-ray 5218 
absorptiometry scan was completed to quantify fat and fat-free mass (DEXA; 5219 
Discovery, Hologic, Bedford, UK). An incremental exercise test was completed 5220 
on an electronically-braked ergometer (Excalibur Sport, Lode Groningen) (17).  5221 
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Main Trials  5223 
Participants abstained from alcoholic and caffeinated drinks for 24 h prior to all 5224 
trials. Food intake ceased at 2000 h on the evening before trials and participants 5225 
then fasted overnight (minimum 12 h), consuming only water (ad libitum) during 5226 
this period. The final meal consumed by the participants on the evening before 5227 
all trials was provided (Spinach and Ricotta Cannelloni [Tesco]) to ensure the 5228 
energy and macronutrient intake across participants was standardized (592 kcal 5229 
of energy ([2,479 kJ]; 51 g CHO, 32 g FAT, 25 g PRO). Participants were also 5230 
asked to refrain from strenuous physical activity for 24 h prior to trials, but were 5231 
allowed to otherwise maintain their normal physical activity behaviours (replicated 5232 
for subsequent trials). To help ensure this standardization, participants recorded 5233 
an activity diary and wore a physical activity monitor (ActiheartTM; Cambridge 5234 
Neurotechnology, Papworth, UK). There were no differences between trials in 5235 
Table 1. Participant Characteristics. Values are means ± SDs, n=12.  
Age (y) 23 (3) 
Stature (cm) 179.8 (4.4) 
Body mass (kg) 76.3 (7.9) 
Body Mass Index (kg·m-2) 23.6 (2.0) 
Fat mass (kg)1 10.6 (3.7) 
Fat Mass Index (kg·m-2)1 3.26 (1.12) 
Body fat (%)1 14 (4) 
Fat free mass (kg)1 65.5 (6.4) 
Resting metabolic rate (kcal·day-1) 2091 (101) 
V̇O2peak (L·min-1) * 4.00 (0.72) 
V̇O2peak (mL·kg·min-1) * 53 (10) 
Peak Power Output (W) 317 (67) 
HRMAX, (beats·min-1) 189 (10) 
V̇O2peak = peak oxygen uptake. *n = 11, due to technical difficulties with the 




pre-trial physical activity energy expenditure as previously reported (17). 5236 
Participants arrived at the laboratory at 0800 ± 1 h and this time was replicated 5237 
for subsequent trials. They voided and all further urine samples were collected 5238 
for urine urea concentrations and estimations of urinary nitrogen excretion. An 5239 
intravenous catheter (BD Venflon Pro, BD, Helsingborg, Sweden) was placed 5240 
retrograde into a dorsal hand vein that had been heated for 20 min using a 5241 
heated-air box set to 55°C. A baseline blood sample (10 mL) was drawn, before 5242 
a 5-min expired gas sample was collected. In BE and BR, a porridge breakfast 5243 
was then consumed, but in FE participants were only permitted water. This was 5244 
followed by 2 h of rest (activities such as reading whilst semi-recumbent were 5245 
allowed), with 5-min expired gas samples collected hourly. During this period, a 5246 
catheter was inserted into an antecubital vein and a primed variable-rate infusion 5247 
of [6,6-2H2]glucose was initiated. After the 2-h rest period (in BE and FE only), 5248 
participants began 60 min of cycling at 50 % peak power output (PPO) on an 5249 
ergometer (Lode Corival, Lode B.V, Groningen, Netherlands). In BR, participants 5250 
continued to rest during this period. Expired gases were collected every 15 min 5251 
for 2 min and blood was sampled at 40 and 50 min of exercise (rest in BR). Then 5252 
a 2-h OGTT was completed, with blood sampled every 10 min and 5-min expired 5253 
gas samples collected hourly. Muscle biopsy samples were collected pre-and 5254 
post-OGTT as detailed elsewhere (17). Participants were given a researcher-5255 
weighed ad libitum lunch. After lunch, participants left the laboratory with a 5256 
researcher-weighed food package and wore an ActiheartTM for the remainder of 5257 
the 24-h trial.  5258 
 5259 
Test meals 5260 
Prior to participation participants confirmed they had no allergies or aversions to 5261 
any of the foods provided. The breakfast was 72 g of instant refined oats (Oatso 5262 
Simple Golden Syrup, Quaker Oats) and 360 mL of semi-skimmed milk (Tesco), 5263 
providing 431 kcal of energy ([1803 kJ]; 65 g CHO, 11 g FAT, 19 g PRO). Lunch 5264 
was oats (Everyday Value® Tesco), whole milk (Tesco), maltodextrin, whey 5265 
protein isolate (both Myprotein, Northwich, UK), olive oil (Tesco), and water, 5266 




overconsumption (18). The meal provided 150 kcal of energy per 100 g of cooked 5268 
food ([626 kJ]; 20 g CHO; 5 g FAT; 5 g PRO) and was terminated when 5269 
participants said that they felt ‘comfortably full’. Fresh, warmed portions were 5270 
continually provided to ensure that the participant finishing a portion was not 5271 
responsible for meal termination. Participants ate the lunch meal in isolation and 5272 
every attempt was made to avoid cues that may have influenced their eating 5273 
behaviors (the television was switched off and their mobile phones were not 5274 
present during the meal).  Remaining food was removed and weighed out of the 5275 
sight of participants. The free-living food package comprised: [1] a pasta meal, of 5276 
pasta, tomato sauce, cheddar cheese and olive oil (prepared by the researchers), 5277 
providing 151 kcal of energy per 100 g of cooked food ([632 kJ]; 20 g CHO; 6 g 5278 
FAT; 5 g PRO) [2] 4 x 35 g snack bars (GoAhead®; 367 kcal [1536 kJ] per 100 g; 5279 
74 g CHO, 8 g FAT; 3 g PRO) and [3] 2 x 180 mL chocolate milk flavor drinks 5280 
(Mars® Milk; 63 kcal [264 kJ] per 100 mL; 10 g CHO; 2 g FAT; 3 g PRO). 5281 
Participants were instructed to eat until they were ‘comfortably full’, not to eat or 5282 
drink anything not provided by this food package (water was ad libitum) and to 5283 
bring any remaining food to the laboratory the next morning. The carbohydrate, 5284 
fat and protein intake was taken as grams provided minus grams remaining.  5285 
 5286 
Blood sampling and analysis 5287 
Whole blood was dispensed into ethylenediaminetetraacetic acid-coated tubes 5288 
(BD, Oxford, UK) which were centrifuged (4°C and 3500 g) for 10-min (Heraeus 5289 
Biofuge Primo R, Kendro Laboratory Products Plc., UK) for plasma. This was 5290 
dispensed into 0.5 mL aliquots and frozen at -20°C, before longer-term storage 5291 
at -80°C. Plasma glucose concentrations (intra-assay coefficient of variation [CV], 5292 
3.2 %; inter-assay CV 3.8 %) were measured on an automated analyzer 5293 
(Daytona; Randox Lab, Crumlin, UK). Plasma leptin and FGF21 concentrations 5294 
were measured with commercially available ELISAs (Mercodia AB, Uppsala, 5295 
Sweden; intra-assay CV 5.8 %, inter-assay CV 7.1 % for leptin and BioVendor 5296 
Research & Diagnostic Products; Karasek, Czech Republic; run in singular for 5297 
FGF21). Blood samples were analyzed in batch after all sample collection was 5298 




Plasma [2H2]-glucose enrichments were determined via gas chromatography-5300 
mass spectrometry as described elsewhere (17) (GC, Agilent 6890N; MS, Agilent 5301 
5973N; Agilent Technologies, Stockport, UK). Radziuk’s two-compartment non-5302 
steady state model was used to assess plasma glucose flux (19, 20).  5303 
 5304 
Energy expenditure and substrate utilization 5305 
Indirect calorimetry was used to assess energy expenditure and substrate 5306 
utilization from expired gas samples (21). An average of the baseline expired gas 5307 
sample from the trials was used for resting metabolic rate. Urinary nitrogen 5308 
excretion was estimated from urine urea concentrations, which were measured 5309 
on an automated analyzer (Daytona; Randox Lab, Crumlin, UK). This allowed 5310 
protein utilization to be accounted for in calculations of carbohydrate and lipid 5311 
utilization. Free-living physical activity energy expenditure was assessed (from 5312 
when the participant left the laboratory until 24 h post breakfast consumption [or 5313 
omission]) using an ActiheartTM, which integrates accelerometer and HR signals 5314 
(22). Physical activity energy expenditure was calculated using branched-5315 
equation modelling (23) with measured energy expenditure and heart rate values 5316 
from exercise and from rest entered into the ActiheartTM software for an 5317 
individually calibrated model (24,25). Data were considered to be of a useable 5318 
quality if >90 % of the activity trace was ‘not lost’ with <30 % of the HR trace 5319 
extrapolated by the software. Daily energy expenditure was calculated from 5320 
indirect calorimetry (for within-lab), and the ActiheartTM data (for free-living).   5321 
 5322 
Calculations and statistical analysis 5323 
A sample size calculation was completed based on previous research, where a 5324 
difference in energy balance (in-lab) between a FE and BE trial was (mean ± SD) 5325 
1580 ± 1410 kJ (15). With an α-level of 0.05, 12 participants were required to 5326 
provide an 80% chance of detecting a statistically significant difference in energy 5327 
balance with a repeated measures ANOVA and 3 trials. The total (AUC) and 5328 
incremental (iAUC) area under the concentration-time curves for plasma FGF-21 5329 
and plasma leptin were calculated using the trapezoid rule. This was divided by 5330 




Whole-body fat and carbohydrate utilization rates were calculated via 5332 
stoichiometric equations (21), with adjustments made to account for protein 5333 
utilization and the utilization of muscle glycogen during exercise (21). Within-lab, 5334 
energy expenditure was determined with lipids, glucose and glycogen giving 5335 
9.42, 3.74 and 4.15 kJ·g-1 of energy respectively (21). At these exercise 5336 
intensities, plasma glucose utilization during exercise can be assumed to be 5337 
equivalent to the plasma glucose rate of disposal (26). Muscle glycogen utilization 5338 
was calculated as total carbohydrate utilization minus plasma glucose utilization 5339 
during exercise (this estimate includes the utilization of all non-glucose 5340 
carbohydrates [e.g. lactate]). To account for excess post-exercise oxygen 5341 
consumption in BE and FE, estimates of substrate utilization and energy 5342 
expenditure were adjusted using similar research (27). To assess whether the 5343 
carbohydrate status of specific tissues (i.e. liver or muscle) were predictors of 5344 
post-exercise energy intake, plasma glucose and muscle glycogen utilization 5345 
during exercise in the FE trial, was correlated with compensation in energy intake 5346 
at lunch (energy intake on FE minus energy intake on BR, normalized to resting 5347 
metabolic rate [as this measure best reflects the energy requirements of rest]). 5348 
Only data from the FE trial was included in this analysis because if fasting, plasma 5349 
glucose utilization during exercise primarily represents the utilization of glucose 5350 
from hepatic sources but during BE, plasma glucose utilization during exercise 5351 
reflects liver glucose utilization and glucose from the pre-exercise breakfast.  5352 
 5353 
All data were first tested for normality by using a Shapiro-Wilk test. One-way, 5354 
repeated measures ANOVAs were used to detect differences between trials at 5355 
baseline and for summary measures. For multiple comparisons, two-way 5356 
repeated measures ANOVAs (time x trial) were employed. Degrees of freedom 5357 
were Greenhouse-Geisser corrected for epsilon <0.75, with Huynh-Feldt 5358 
corrections used for less severe asphericity. If time x trial interaction effects were 5359 
identified, multiple paired t-tests (with Holm-Bonferroni step-wise adjustments) 5360 
were used to locate the variance between trials. Pearson r were used to explore 5361 
correlations. Unless otherwise stated, data are means ± normalized (n) 95 % 5362 




available packages (Graph Pad Prism 7, La Jolla, CA, USA; Microsoft Excel 5364 
[2013] and IBM SPSS statistics version 22 for windows [IBM, New York, USA]). 5365 
For three participants, ActiheartTM data did not satisfy the inclusion criteria for 5366 
useable data and these people were excluded from some analysis.  5367 
 5368 
RESULTS 5369 
Energy intake 5370 
There was no meaningful compensation through energy intake at lunch, for the 5371 
energy deficit created by exercise as the mean difference in energy intake in BR 5372 
versus BE was 11 kcal [n95%CI: -182 to 203 kcal] P>0.05; [Figure 2A]). The 5373 
omission of breakfast pre-exercise was partially compensated for with lunch 5374 
energy intake on FE versus BE (Figure 2A) but this difference of 166 kcal (n95 % 5375 
CI: -27 to 308 kcal) was less than the energy in the breakfast (~ 430 kcal). Thus, 5376 
when accounting for breakfast, within-lab energy intake did not significantly differ 5377 
in BR and BE, but was significantly higher in BE versus FE (265 [123 to 407] kcal; 5378 
P<0.01]. There was some compensation for the energy deficit created by 5379 
exercise via free-living energy intake in BE, but the omission of breakfast prior to 5380 
exercise, did not result in any further compensation with energy intake in a free-5381 
living environment (Figure 2A). Thus, daily energy intake was significantly higher 5382 
in BE versus BR (245 [81 to 362] kcal; P<0.01] and in BE versus FE (393 [276 to 5383 
510] kcal; P<0.01]. The total plasma glucose rate of disposal (Rd) during FE 5384 
(representing plasma glucose [primarily from hepatic sources] utilization during 5385 
exercise) was positively correlated with compensation in lunch energy intake in 5386 
FE versus BR when normalized to resting metabolic rate (Figure 3A). The total 5387 
plasma glucose rate of appearance during exercise in FE was also correlated 5388 
(r=0.67, P=0.02) with compensation in lunch energy intake (normalized to resting 5389 
metabolic rate). A similar relationship was apparent when the plasma glucose 5390 
rate of disposal during FE was correlated with compensation in lunch energy 5391 
intake when energy intake data were not normalized (r=0.61, P=0.04) or 5392 
normalized to DEXA-derived fat free mass (r=0.57, P=0.05). Muscle glycogen 5393 
and whole body lipid utilization and energy expenditure during exercise in FE 5394 





Figure 2. Daily energy intake (A) and energy expenditure (B). Data are means ± 5397 
normalized 95 % CI for n = 12 (9 for free-living energy expenditure) healthy young 5398 
men. For (A), a represents a difference in free-living energy intake with breakfast 5399 
rest and breakfast exercise with P<0.05 and b a difference in lunch energy intake 5400 
in breakfast exercise versus fasted exercise with P<0.05. For (B) a shows a 5401 
difference for within-lab energy expenditure with breakfast rest and both exercise 5402 
trials with P<0.05.  5403 
 5404 
Energy expenditure and substrate utilization 5405 
The exercise was completed as prescribed and the intensity was 61 ± 3 % V̇O2 5406 
peak (mean ± SD). Energy expenditure during cycling was 683 kcal in BE (n95 % 5407 
CI: 664 to 702 kcal) and 697 kcal in FE (n95 % CI: 678 to 715 kcal; P=0.28 versus 5408 
BE). Carbohydrate utilization was significantly higher in BE (536 [510 to 561] kcal) 5409 
versus FE (478 [452 to 503] kcal, P<0.01), but whole-body lipid utilization was 5410 
significantly lower in BE  (138 [102 to 175] kcal) compared to FE (212 [176 to 5411 
248] kcal; P<0.01). During the OGTT, no difference between the trials in energy 5412 
expenditure or substrate use was detected. There was no clear difference 5413 
between any trials for free-living physical activity (Figure 2B). Thus, daily energy 5414 
expenditure was significantly lower with BR versus BE and FE, but did not 5415 
significantly differ in BE versus FE (Figure 2B).  5416 
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Figure 3. The plasma glucose rate of disappearance (Rd) (A), muscle glycogen 5418 
utilization (B), whole-body lipid utilization (C) and energy expenditure (D) during 5419 
fasted exercise versus lunch energy intake compensation (lunch energy intake 5420 
after fasted exercise minus lunch energy intake after rest) normalized to resting 5421 
metabolic rate. Data are Pearson r. n = 12 healthy young men.  5422 
 5423 
Energy and substrate balance 5424 
Consuming breakfast but performing exercise (BE) resulted in a lower within-lab 5425 
energy balance versus rest (BR), which was primarily driven by a difference in 5426 
carbohydrate balance (Figure 4A). The omission of breakfast prior to exercise 5427 
(FE) resulted in a lower within-lab energy balance compared to BE, primarily via 5428 
the induction of a significantly lower fat balance, as no significant difference in 5429 
carbohydrate balance was apparent in FE versus BE (Figure 4A). The same 5430 
pattern between trials was shown over 24 h (Figure 4B), where a higher energy 5431 





Figure 4. Within-lab (A) and daily energy balance (B) Data are means ± 5434 
normalized 95 % CI for n = 12 (9 for daily energy balance) healthy young men. 5435 
PRO = protein; CHO = carbohydrate.  For (A), a represents a difference in CHO 5436 
balance between breakfast rest and breakfast exercise with P<0.05 and b a 5437 




Plasma leptin and fibroblast growth factor 21 (FGF-21) concentrations 5439 
At baseline there were no differences for plasma leptin, nor FGF-21 5440 
concentrations (Figure 5). A time x trial interaction effect was detected for plasma 5441 
leptin, but with post-hoc adjustment there was no significant difference at any 5442 
time point, and no main effect of trial was apparent for the leptin AUC (P=0.21). 5443 
No time x trial interaction effect was observed for FGF-21, and there was no main 5444 
effect for the FGF-21 AUC (P=0.07). 5445 
 5446 
Figure 5. Plasma leptin (A) and FGF-21 (B) concentrations. Data are means ± 5447 




DISCUSSION  5449 
This is the first study to assess the effect of pre-exercise feeding versus fasting 5450 
on all components of energy balance over 24 h, with inclusion of within-lab and 5451 
free-living periods. We showed that breakfast omission before exercise (FE) is 5452 
not fully compensated for with post-exercise energy intake, and not compensated 5453 
for at all with subsequent free-living energy expenditure, creating a more negative 5454 
daily energy balance versus breakfast consumption prior to exercise (BE). Our 5455 
results also demonstrate that plasma glucose utilization during FE demonstrated 5456 
a stronger relationship with energy intake compensation, than muscle glycogen 5457 
utilization, whole-body lipid utilization or exercise energy expenditure. Plasma 5458 
glucose utilization was also the only carbohydrate source to demonstrate a 5459 
positive relationship with energy intake compensation. As plasma glucose during 5460 
exercise when fasting is primarily derived from hepatic sources, this result 5461 
supports a potential role for liver carbohydrate status in the regulation of post-5462 
exercise energy balance. These data offer new insights into responses to feeding 5463 
and exercise that are applicable to typical daily living (29, 30). 5464 
 5465 
We showed that the energy deficit created by exercise was not compensated for 5466 
through a higher energy intake at an ad libitum lunch in an exercise versus rest 5467 
trial (BE versus BR), but was partially compensated for with a higher energy 5468 
intake later in the day (in a free-living setting). In contrast, breakfast omission 5469 
before exercise (FE) was partially compensated for at lunch, but not further 5470 
compensated for later in the day. These findings suggest that the compensation 5471 
for the energy deficits created by exercise and pre-exercise breakfast omission 5472 
likely occur over different time periods. The energy intake responses we report 5473 
with pre-exercise breakfast omission are in line with previous observations that 5474 
when healthy men perform 60-min of running after breakfast, evening and 24-h 5475 
energy intake are higher versus exercise before breakfast (16). As fasting prior 5476 
to exercise reduces carbohydrate utilization during exercise (13), these results 5477 
are consistent with a theory that the status of endogenous carbohydrate stores 5478 
(i.e. liver and muscle glycogen) may play a role in energy balance regulation (7). 5479 




energy balance comes from our current, and prior observations (15) that the more 5481 
negative within-lab energy balance in the FE trial was attributable to a negative 5482 
fat balance, as carbohydrate balance was similar to the BE trial.  5483 
 5484 
The ability to fully apply these energy intake findings to daily living is, however, 5485 
incomplete without an assessment of free-living energy expenditure. Here, we 5486 
also demonstrate that pre-exercise breakfast ommission is not fully compensated 5487 
for via non-exercise physical activity energy expenditure, when using objective 5488 
measures of physical activity in a free-living environment. Thus, we provided a 5489 
more complete picture of energy balance after breakfast versus fasting before 5490 
exercise. Indeed, the physical activity monitor we used has been validated in 5491 
laboratory and free-living settings (and versus doubly-labelled water) (25, 31, 32). 5492 
Our results show that [1] even with the inclusion of a free-living component, 5493 
fasting prior to exercise creates a more negative daily energy balance compared 5494 
to if a pre-exercise breakfast is consumed and that [2] whole-body carbohydrate 5495 
balance may contribute to energy balance regulation (at least post-exercise).  5496 
 5497 
Previously, it was unclear if a specific carbohydrate store was a primary regulator 5498 
of post-exercise energy balance. Here, we show that plasma glucose disposal 5499 
rates and plasma glucose appearance rates during exercise in FE (which 5500 
primarily represents the mobilization and utilization of glucose from hepatically 5501 
derived sources, as no carbohydrate was ingested before/during exercise in FE) 5502 
were the only carbohydrate related outcomes (not muscle glycogen utilization) to 5503 
demonstrate a positive relationship with energy intake compensation.  This is the 5504 
first evidence of a link between tissue-specific carbohydrate utilization during 5505 
exercise and energy balance in humans. In our fasting exercise trial, participants 5506 
with higher rates of plasma glucose disposal consumed more energy at lunch, 5507 
relative to their rest trial. This finding that a more rapid utilization of plasma 5508 
glucose during exercise in FE (and a likely higher rate of utilization of 5509 
carbohydrate from hepatic sources) may increase post-exercise energy intake, is 5510 
consistent with research showing that a higher liver glycogen content in mice is 5511 




result suggests that the liver glycogen content may be a regulator of energy 5513 
balance, and is consistent with the correlation we report because higher liver 5514 
glucose utilization rates would be expected to deplete the liver glycogen content 5515 
during exercise to a greater extent. Future studies should confirm this relationship 5516 
using a direct measure of net hepatic glycogen utilization, like 13C magnetic 5517 
resonance spectroscopy. 5518 
 5519 
A possible link between the liver carbohydrate status and post-exercise energy 5520 
intake regulation may be explained by concentrations of circulating hormones. 5521 
For example, exercise increases liver FGF-21 secretion (34), which may 5522 
influence subsequent energy intake (35). It is also suggested that blood leptin 5523 
concentrations may help to regulate carbohydrate metabolism and energy 5524 
balance during periods of fasting (36). During rest, higher plasma leptin 5525 
concentrations after a lunch meal have been previously observed in a breakfast 5526 
versus morning fasting trial (14). This may be accounted for by a slow release of 5527 
leptin in response to breakfast and/or a diurnal shift in leptin release with morning 5528 
fasting (14). However, whilst confirming that exercise increases plasma FGF-21 5529 
concentrations, we showed that neither plasma FGF-21, nor plasma leptin 5530 
concentrations, were altered by pre-exercise breakfast omission (FE) versus pre-5531 
exercise breakfast consumption (BE). The postprandial leptin response we 5532 
observed after exercise was, however, similar to the response observed with 5533 
breakfast ommission at rest. Alternatively, a higher rate of liver carbohydrate 5534 
utilization may influence energy balance via a liver-brain neural network (the 5535 
hepatic branch of the vagus nerve) to the central nervous system, as has been 5536 
demonstrated in rodents (12). Although future research needs to further 5537 
investigate any mechanisms linking overall and liver carbohydrate metabolism to 5538 
energy balance in humans, the evidence presented here is the first to 5539 
demonstrate that plasma glucose utilization during fasted exercise (and thus 5540 
carbohydrate use from hepatic sources) is positively correlated with post-exercise 5541 
energy intake in humans. Our results are most applicable to young physically 5542 
active men. However, as untrained individuals show increased liver glucose 5543 




may be more susceptible to a high post-exercise energy intake, which may make 5545 
it more difficult for these individuals to lose weight via exercise.  5546 
 5547 
Although the regulatory mechanisms remain unclear, this study provides novel 5548 
insights into the regulation of all behavioural components of daily energy balance 5549 
after pre-exercise breakfast omission (FE) versus breakfast consumption (BE). 5550 
Our findings must however be interpreted in light of the study design. Firstly, 5551 
although the protocol included a free-living period, participants were constrained 5552 
to a laboratory environment during the morning, and it is possible that behaviours 5553 
that alter energy balance may have changed in a free-living environment during 5554 
this time after fasting versus fed exercise. This restriction of physical activity likely 5555 
contributed to the positive 24-h energy balance observed in the BR trial. In 5556 
addition, participants also had a limited choice of food during the study and it is 5557 
possible that energy intake may have differed under more free-living conditions. 5558 
Our results also only relate to breakfast omission and not altered breakfast timing. 5559 
Despite this, under energy balanced conditions (with the consumption of 5560 
breakfast either pre- or post-exercise) energy intake at an ad libitum lunch does 5561 
not differ, despite alterations in substrate balance (38). In light of that result and 5562 
our current findings, future research should now investigate all components of 5563 
energy balance with altered timing of breakfast and in free-living settings (rather 5564 
than breakfast omission and the time restricted feeding with fasting prior to 5565 
exercise). Investigating energy balance responses to regular exercise in the 5566 
fasting versus fed state and with overweight populations should be another focus 5567 
for future work. This would provide insights as to whether the 24-h energy balance 5568 
responses we report here, translate into enduring changes in body mass or 5569 
composition with repeated bouts of exercise in the fasting versus fed state.  5570 
Finally, although this study lacks characterization of other gut hormones that have 5571 
been associated with energy intake, it has been shown that acylated ghrelin and 5572 
glucagon like peptide 1 (GLP-1) responses to exercise in the fasting versus fed 5573 
states do not differ to any meaningful degree (15, 39, 40). Plasma insulin 5574 
concentrations during and after exercise were also not altered to any great extent 5575 




To conclude, pre-exercise breakfast omission is not fully compensated for with 5577 
energy intake, nor at all with non-exercise energy expenditure post-exercise, 5578 
creating a more negative 24-h energy balance compared to when breakfast is 5579 
consumed before exercise. We also show that post-exercise energy intake 5580 
compensation is positively correlated with plasma glucose utilization when 5581 
exercise is performed when fasting, highlighting a possible role for liver 5582 
carbohydrate status in energy balance regulation. These results have important 5583 
implications for the regulation of post-exercise energy balance and suggest that 5584 
for healthy young men, a short-term energy deficit may be more easily attained if 5585 
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CHAPTER 6 - BREAKFAST-EXERCISE TRAINING STUDY  5705 
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Lipid metabolism links nutrient-exercise timing to insulin sensitivity in 5707 
overweight men. 5708 
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RELEVANCE TO THESIS 5740 
Nutrient availability before, during and after exercise potently alters metabolism 5741 
during- and in the hours after-exercise (10, 15). Specifically, exercise performed 5742 
in an overnight fasted-state increases lipid utilisation and also alters the activity 5743 
of proteins implicated in exercise adaptation for a number of hours post-exercise, 5744 
versus exercise after consuming carbohydrates. This raises the possibility that 5745 
nutrient-exercise timing could regulate health-related adaptions to exercise via 5746 
adaptations in skeletal muscle and/or altering lipid flux. Indeed, as discussed in 5747 
Chapter 1, a higher turnover of lipids derived from the adipose tissue has been 5748 
associated with a better regulation of metabolic health (167, 168) and a regular 5749 
utilisation of lipid stores in skeletal muscle is associated with increased peripheral 5750 
insulin sensitivity, potentially by alleviating an accumulation of lipid intermediates 5751 
that can interfere with intramuscular insulin signalling (9).  5752 
 5753 
Whilst characterising acute metabolic and intramuscular responses to exercise 5754 
can provide insights into the potential utility of exercise-nutrient interactions to 5755 
improve health outcomes, the acute responses to exercise and/or nutrition do not 5756 
consistently translate into the expected chronic adaptations with regular training. 5757 
One example is that exercise performed in a fasted state versus after consuming 5758 
carbohydrates can increase the expression or activity of proteins involved in lipid 5759 
metabolism and also increases the capacity for utilising lipids during exercise at 5760 
the whole-body level with repeated training (305, 306). These adaptations should, 5761 
in theory, improve exercise capacity or performance in endurance-type events by 5762 
reducing the reliance on endogenous carbohydrate stores. However, in most of 5763 
these studies, no clear differences are shown between exercise groups for the 5764 
changes in endurance-type exercise performance after training. As such, even if 5765 
a higher rate of lipid utilisation when breakfast is omitted versus consumed before 5766 
an acute bout of exercise creates the theoretical conditions for improvements in 5767 
insulin sensitivity, this needs to be confirmed with exercise training studies. The 5768 
fact that acute responses to exercise and/or nutrient ingestion do not consistently 5769 
translate into the expected enduring adaptations with repeated exposure to these 5770 




Indeed, there is currently a lack of exercise training studies investigating nutrient-5772 
exercise interactions in a context of metabolism and health. This is likely to be 5773 
important, because in the absence of marked weight loss, some exercise training 5774 
studies report a modest group-level effect for insulin sensitivity and also apparent 5775 
inter-individual variability in this regard (488, 489). This may be explained by 5776 
differences in the nutritional status of participants before exercise.  5777 
 5778 
If healthy men consume a hypercaloric (+ 30 % kcal), fat‐rich diet (50 % kcal), 5779 
whole-body glucose tolerance and oral-glucose tolerance test derived estimates 5780 
of peripheral insulin sensitivity are increased over 6 weeks versus a non-exercise 5781 
control group, if exercise is performed before breakfast, but not if carbohydrates 5782 
are consumed before/during exercise (11). This suggests that nutrient-exercise 5783 
timing mediates health-related adaptations to exercise. However, a high-fat diet 5784 
is not representative of the diet consumed by many people living in developed 5785 
countries and in that study, changes in oral-glucose insulin sensitivity may have 5786 
been due to increases in body mass in the control and fed-exercise groups, but 5787 
not in the fasted-exercise group. Nonetheless, that study, and other data from 5788 
lean, healthy men suggests that nutrient provision prior to and/or during exercise 5789 
alters adaptive responses to moderate-intensity exercise training (490). However, 5790 
humans classified as overweight or obese can display divergent metabolic 5791 
responses to feeding and fasting compared to lean humans (491). Therefore, in 5792 
order to understand the potential for nutrient-exercise timing to alter metabolic 5793 
health in individuals at risk of metabolic diseases, there is a need to study relevant 5794 
populations, such as people classified as overweight. Thus, the aim of the 5795 
research in Chapter 6 was to determine the effects of endurance-type exercise 5796 
training before versus after nutrient-intake on oral glucose insulin sensitivity in 5797 
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Context: Pre-exercise nutrient availability alters acute metabolic responses to 5801 
exercise, which could modulate training responsiveness. We hypothesised that 5802 
in men with overweight/obesity, acute exercise before versus after nutrient 5803 
ingestion would increase whole-body and intramuscular lipid utilization, 5804 
translating into greater increases in oral glucose insulin sensitivity over 6-weeks 5805 
of training.  5806 
Design and Participants: We showed in men with overweight/obesity 5807 
(mean±SD for BMI: 30.2±3.5 kgm-2 for acute, crossover study, 30.9±4.5 kgm-2 5808 
for randomized, controlled, training study) a single exercise bout before versus 5809 
after nutrient provision increased lipid utilisation at the whole-body level, but also 5810 
in both type I (p<0.01) and type II muscle fibres (p=0.02). We then used a 6-week 5811 
training intervention to show sustained, 2-fold increases in lipid utilisation with 5812 
exercise before versus after nutrient provision (p<0.01).  5813 
Main Outcome Measures: Postprandial glycemia was not differentially affected 5814 
by exercise training before vs after nutrient provision (p>0.05), yet plasma 5815 
insulinemia was reduced with exercise training before, but not after nutrient 5816 
provision (p=0.03), resulting in increased oral glucose insulin sensitivity when 5817 
training was performed before versus after nutrient provision (25±38 vs -21±32 5818 
mLmin-1m-2; p=0.01) and this was associated with increased lipid utilisation 5819 
during exercise (r=0.50, p=0.02). Regular exercise prior to nutrient provision 5820 
augmented remodelling of skeletal muscle phospholipids and protein content of 5821 
the glucose transport protein GLUT4 (p<0.05). 5822 
Conclusions: Experiments investigating exercise training and metabolic health 5823 
should consider nutrient-exercise timing, and exercise performed before versus 5824 
after nutrient intake (i.e., in the fasted state) may exert beneficial effects on lipid 5825 





Postprandial hyperinsulinemia and associated peripheral insulin resistance are 5828 
key drivers of metabolic diseases, such as type 2 diabetes (T2D) and 5829 
cardiovascular disease (1-3). Obesity and a sedentary lifestyle are independently 5830 
associated with changes in skeletal muscle that can reduce insulin sensitivity 5831 
(4,5) and increase hyperinsulinemia, contributing to elevated cardiovascular 5832 
disease risk (2). Therefore, increasing insulin sensitivity and reducing 5833 
postprandial insulinemia are important targets for interventions to reduce the risk 5834 
of metabolic disease. 5835 
 5836 
Regular exercise training represents a potent strategy to increase peripheral 5837 
insulin sensitivity and to reduce postprandial insulinemia (6). The beneficial 5838 
effects of exercise on oral glucose tolerance and insulin sensitivity can be 5839 
attributed to both an ‘acute phase’ (during and straight after each bout of exercise 5840 
performed) and the more enduring molecular adaptations that accrue in response 5841 
to regular exercise (7). A single bout of endurance-type exercise activates 5842 
contractile pathways in exercising muscle, which (independently of insulin) 5843 
translocate the glucose transporter, GLUT4, to the plasma membrane and T-5844 
tubules to facilitate increased transmembrane glucose transport (8-10). The 5845 
mechanisms that underlie the exercise-training induced increases in oral glucose 5846 
insulin sensitivity include an increase in the total amount of time spent in the 5847 
‘acute phase’ (7), but also other adaptations that occur, such as changes in body 5848 
composition (e.g. increased fat-free mass and reduced adiposity), an increased 5849 
mitochondrial oxidative capacity (11), adaptations relating to glucose transport 5850 
and insulin signaling pathways (12), and alterations to the lipid composition of 5851 
skeletal muscle (13,14).  5852 
 5853 
Despite the potential for exercise to increase whole-body and peripheral insulin 5854 
sensitivity, there can be substantial variability in the insulin sensitizing effects of 5855 
fully-supervised exercise training programs (15). Crucially, this inter-individual 5856 
variability for postprandial insulinemia following exercise training has also been 5857 




some of this variability to exercise is true inter-individual variability (16). 5859 
Nutritional status and thus the availability of metabolic substrates alters 5860 
metabolism during and following exercise (17-20). Carbohydrate feeding before 5861 
and during exercise suppresses whole-body and skeletal muscle lipid utilization 5862 
(21,22) and blunts the skeletal muscle mRNA expression of genes involved in 5863 
exercise-adaptation for many hours post-exercise (23-25). This raises the 5864 
possibility that nutrient-exercise interactions may regulate adaptive responses to 5865 
exercise and thereby contribute to the apparent individual variability in exercise 5866 
responsiveness via skeletal muscle adaptation and/or pathways relating to 5867 
substrate metabolism. 5868 
       5869 
Emerging data in lean, healthy men suggests that nutrient provision affects 5870 
adaptive responses to exercise training (26,27). However, feeding and fasting 5871 
may exert different physiological responses in people who are overweight or 5872 
obese compared to lean individuals.  For example, extended morning fasting 5873 
versus daily breakfast consumption upregulates the expression of genes involved 5874 
in lipid turnover in adipose tissue in lean, but not in obese humans (28). 5875 
Therefore, in order to fully understand the potential for nutrient-exercise timings 5876 
to alter metabolism, exercise-adaptations and metabolic health in individuals at 5877 
increased risk of metabolic disease, there is a need to study the most relevant 5878 
populations, such as individuals classified as overweight or obese (29). It is 5879 
currently unknown whether nutrient provision before versus after exercise affects 5880 
adaptations to exercise training in these populations. 5881 
 5882 
To this end, the aim of the present work was to assess the acute and chronic 5883 
effects of manipulating nutrient-exercise timing on lipid metabolism, skeletal 5884 
muscle adaptations, and oral glucose insulin sensitivity in men with overweight 5885 
or obesity. We hypothesized that nutrient-exercise interactions would affect the 5886 
acute metabolic responses to exercise, with increased whole-body and 5887 
intramuscular lipid utilization with exercise before versus after nutrient provision. 5888 




nutrient provision would result in greater training-induced increases in oral 5890 
glucose insulin sensitivity in men classified as overweight or obese. 5891 
 5892 
METHODS 5893 
Ethical Approval 5894 
This project comprised two experiments. We first assessed the acute metabolic 5895 
and mRNA responses to manipulating nutrient-exercise timing (Acute Study), 5896 
followed by a 6-week randomized controlled trial to assess the longer-term (i.e. 5897 
training) adaptations in response to nutrient-exercise timing (Training Study). All 5898 
participants provided informed written consent prior to participation. Potential 5899 
participants were excluded if they had any condition, or were taking any 5900 
medication, known to alter any of the outcome measures. The studies were 5901 
registered at https://clinicaltrials.gov (NCT02397304 and NCT02744183, 5902 
respectively). Protocols were approved by the National Health Service Research 5903 
Ethics Committee (15/WM/0128 & 16/SW/0260, respectively) and experiments 5904 
were conducted in accordance with the Declaration of Helsinki. 5905 
 5906 
Acute Study 5907 
In the Acute Study, 12 sedentary, men classified as overweight or obese were 5908 
recruited from the Birmingham region of the UK. The main exclusion criteria 5909 
included being regularly physically active, having hypertension or possible 5910 
(undiagnosed) T2D. Participant characteristics are shown in Table 1.  5911 
 5912 
This was a randomised cross-over study where on one visit (breakfast-exercise 5913 
or BR-EX), a standardised breakfast (cornflake cereal with skimmed milk, 5914 
wholemeal toast, sunflower spread and strawberry jam) was consumed upon 5915 
arrival at the laboratory (and following 48 h of diet control). The breakfast provided 5916 
25% of estimated daily energy requirements [calculated as resting metabolic rate 5917 
(RMR) multiplied by a physical activity factor of 1.53 (30)] and was 65% 5918 
carbohydrate, 20% fat and 15% protein. After a 90-min period of rest, 60 min of 5919 
cycling exercise was then performed at 65% peak oxygen uptake (V̇O2 peak). 5920 




determine whole-body substrate utilisation rates. Blood was sampled in the 5922 
overnight-fasted state, at 45 min post breakfast and immediately before exercise 5923 
was performed (90 min post breakfast), every 30 min during exercise and at 60 5924 
min intervals during a 3-h post-exercise recovery. In a subset of participants (n=8) 5925 
vastus lateralis muscle was sampled pre- and immediately post-exercise to 5926 
assess fiber-type specific intramuscular triglyceride (IMTG) and mixed-muscle 5927 
glycogen utilization. A third muscle sample (taken at 3 h post-exercise) was used 5928 
to assess the intramuscular gene expression (mRNA) responses to exercise 5929 
(n=7). On the other visit (exercise-breakfast or EX-BR) the participants completed 5930 
the same protocol, but the breakfast was consumed immediately after the post-5931 
exercise muscle sample. The primary outcome for the Acute Study was 5932 
intramuscular lipid utilisation during exercise performed before versus after 5933 
nutrient ingestion.  5934 
 5935 
Training Study 5936 
To assess longer-term adaptive (i.e. training) responses to altering nutrient-5937 
exercise timing (Training Study) we recruited 30, overweight and obese, 5938 
sedentary men (self-reported non-exercisers) from the Bath region of the UK 5939 
(Table 1). This was a single-blind, randomized, controlled trial, with participants 5940 
allocated to a no-exercise control group (CON; n=9) a breakfast before exercise 5941 
group (BR-EX; n=12) or an exercise before breakfast group (EX-BR; n=9) for 6-5942 
weeks (Figure 1). The exercise was supervised moderate-intensity cycling 5943 
(Monark Exercise AB, Vansbro, Sweden) performed 3 times per week, starting at 5944 
50% peak power output [PPO] (weeks 1-3) and increasing to 55% PPO (weeks 5945 
4-6). The duration of the exercise sessions progressed from 30- (week 1) to 40- 5946 
(week 2) to 50-min (weeks 3-6). All sessions were supervised at the University of 5947 
Bath. During every one of the 336 exercise training sessions, 1-min expired gas 5948 
samples were collected every 10 min to assess substrate utilization and heart 5949 
rate (Polar Electro Oy, Kempele, Finland) and ratings of perceived exertion (31) 5950 
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Table 1. Participant characteristics 
 Study 1 Study 2 - Training Study 
 Acute Study CON BR-EX EX-BR p-value  
n 12 9 12 9  
Body Mass (kg) 95.1 (13.6) 101.1 (19.5) 95.2 (12.4) 98.0 (18.8) 0.73 
BMI (kg·m-2) 30.2 (3.5) 31.8 (5.8) 30.3 (3.9) 30.8 (4.1) 0.75 
Waist Circumference 
(cm) 
105.7 (11.6) 107.7 (14.8) 103.9 (8.9) 104.7 (11.6) 0.63 
Hip Circumference (cm) 110.9 (6.5) 110.8 (8.4) 111.4 (7.1) 111.6 (8.5) 0.32 
Waist-to-Hip Ratio 0.95 (0.08) 0.97 (0.06) 0.93 (0.04) 0.94 (0.05) 0.31 
V̇O2peak (ml·kg-1·min-1) 29.1 (5.3) 32.6 (7.7) 34.3 (5.6) 32.4 (4.0) 0.71 
PPO (W) 156 (39) 204 (47) 208 (26) 203 (22) 0.73 
Physical Activity Level 
(PAL) 
- 1.71 (0.16) 1.68 (0.16) 1.68 (0.11) 0.90 
Data are means (SD) for overweight or obese men. BMI = Body Mass Index; 
V̇O2peak = peak oxygen uptake; PPO = peak power output; CON = control; BR-EX 
= breakfast-exercise; EX-BR = exercise-breakfast. Physical Activity Level (PAL) 





Figure 1. Protocol schematic for the training study. 5954 
 5955 
Participants ate their evening meal before 2000 h the evening prior to any 5956 
exercise sessions. Participants in BR-EX were given a drink in an opaque bottle 5957 
made from 1.3 g carbohydrate·kg body mass-1 maltodextrin (MyProtein, 5958 
Northwich, UK) with vanilla flavoring (20% carbohydrate solution) for 5959 
consumption 2-h before exercise. They were asked not to eat or drink anything 5960 
else (except water ad libitum) in this period and confirmed they had consumed 5961 
the drink before exercising. After exercise, they were provided a taste matched 5962 
placebo (water and vanilla flavoring) to consume 2-h after exercise and were 5963 
asked not to consume anything else during this period. Participants in EX-BR 5964 
were given the same drinks, but with the order of the drinks reversed. Participants 5965 
in CON were given the same drinks for three days per week during the 5966 
intervention, with the carbohydrate drink as breakfast (0800-0900 h) and the 5967 
placebo for consumption with their lunch (1100-1300 h). These participants were 5968 
asked not to consume anything else between the drinks. There were no other diet 5969 
controls in the intervention. Blinding of the groups was deemed successful, 5970 




difference between the carbohydrate and placebo drinks or could not identify 5972 
which contained carbohydrate. Five participants determined which drink had 5973 
carbohydrate (CON n=1, BR-EX n=2, EX-BR n=1), but this is within the proportion 5974 
that could do so at random. 5975 
 5976 
Pre- and post-intervention, an oral glucose tolerance test (OGTT), a vastus 5977 
lateralis muscle sample (fasting, rested state) and an exercise test (to assess 5978 
V̇O2 peak and the capacity for lipid utilization during exercise in the fasted-state) 5979 
were undertaken. Post-intervention tests were between 24 h to 48 h (for muscle 5980 
sampling) and 48 h to 72 h (for OGTT) after the last exercise training session, to 5981 
reduce any residual effects of the last exercise bout performed on these 5982 
measurements. The primary outcome for the Training Study was the pre- to 5983 
post-intervention change in the glycaemic and insulinemic responses to the 5984 
OGTT, which were also used to derive an index of oral glucose insulin sensitivity 5985 
(as described subsequently). 5986 
 5987 
Pre-trial standardizations 5988 
For both studies, the participants were asked to maintain their normal physical 5989 
activity behaviors and to abstain from alcoholic and caffeinated drinks for 24 h 5990 
prior to all main laboratory trials. Food intake ceased at 2000 h ± 1 h on the 5991 
evening before testing and participants fasted overnight (minimum of 10 h). For 5992 
all trials, participants arrived at the laboratory at 0800 ± 1 h, with the exact time 5993 
replicated for subsequent trials. For the Acute Study, participants were provided 5994 
with a standardized weight maintaining diet (50% carbohydrate, 35% fat, 15% 5995 
protein) based on their estimated energy requirements (RMR multiplied by the 5996 
physical activity factor of 1.53 as stated previously) for consumption for 48 h prior 5997 
to main trials. For the Training Study, they recorded the composition of their 5998 
evening meal on the day before a pre-intervention trial and replicated this meal 5999 
for the post-intervention trial, in line with guidelines for testing postprandial 6000 
glycemic control (32). We have shown that this protocol produces fasting muscle 6001 
and liver glycogen and fasting intramuscular lipid concentrations that are 6002 




Anthropometry  6004 
Stature was measured to the nearest 0.1 cm using a stadiometer (Seca Ltd, 6005 
Birmingham, UK). Body mass was measured to the nearest 0.1 kg using 6006 
electronic weighing scales (Acute Study: OHaus Champ II Scales, USA; 6007 
Training Study: BC543 Monitor, Tanita, Japan). Waist and hip circumferences 6008 
were measured to the nearest 0.1 cm and according to the World Health 6009 
Organization guidelines. 6010 
 6011 
Exercise tests 6012 
Participants completed exercise tests on an electronically-braked ergometer. In 6013 
the Acute Study, the starting intensity was 35 W, and this was increased by 35 6014 
W every 3 min until volitional exhaustion. In the Training Study, the starting 6015 
intensity for the exercise test was 50 W which was increased by 25 W every 3 6016 
min. Heart rate (Polar Electro Oy, Kempele, Finland) and continuous breath-by-6017 
breath measurements were recorded (Acute Study: Oxycon Pro, Jaeger, 6018 
Wurzburg, Germany; Training Study: TrueOne2400, ParvoMedics, Sandy, 6019 
USA). Volume and gas analyzers were calibrated using a 3-L calibration syringe 6020 
(Hans Rudolph, Kansas City, USA) and a calibration gas (16.04% O2, 5.06% CO2; 6021 
BOC Industrial Gases, Linde AG, Germany). Peak power output (PPO) was 6022 
calculated as the work rate of the final completed stage, plus the fraction of time 6023 
in the final non-completed stage, multiplied by the W increment. V̇O2 peak was 6024 
the highest measured V̇O2 over a 30 s period, using methods and attainment 6025 
criteria previously reported (34). 6026 
 6027 
Blood sampling and analysis 6028 
In the Acute Study, 10 mL blood was sampled from an antecubital forearm vein 6029 
and 6 mL was dispensed into ethylenediaminetetraacetic acid-coated tubes (BD, 6030 
Oxford, UK) and centrifuged (4°C at 3500 rpm) for 15 min (Heraeus Biofuge 6031 
Primo R, Kendro Laboratory Products Plc., UK). Resultant plasma was dispensed 6032 
into 0.5 mL aliquots and frozen at -20°C, before longer-term storage at -80°C.  A 6033 
proportion of the sample (4 mL) was allowed to clot in a plain vacutainer prior to 6034 




and NEFA using an ILAB 650 Clinical Chemistry Analyzer (Instrumentation 6036 
Laboratory, Warrington, UK). Serum insulin concentrations were measured with 6037 
an ELISA kit (Invitrogen; Cat#KAQ1251) and Biotek ELx800 analyzer (Biotek 6038 
Instruments, Vermont, USA).  6039 
 6040 
In the Training Study, prior to blood sampling participants placed their dominant 6041 
hand into a heated-air box set to 55°C. After 15 min of rest, a catheter was placed 6042 
(retrograde) into a dorsal hand vein and 10-mL of arterialized blood was drawn 6043 
for a baseline sample in the overnight-fasted state (35). Then a 75-g OGTT was 6044 
completed and arterialized blood sampled every 15 min for 2 h and processed 6045 
(as detailed above) for plasma. Plasma glucose (intra-assay CV: 2.50%), 6046 
glycerol, triglyceride (glycerol-blanked), and total- HDL- and LDL-cholesterol 6047 
concentrations were measured using an automated analyzer (Daytona; Randox 6048 
Lab, Crumlin, UK). Plasma insulin (Mercodia AB; reference #10-1113-01) and C-6049 
peptide (Sigma Aldrich; reference #EZHCP-20K) concentrations were measured 6050 
using commercially available ELISA kits (intra-assay CV for insulin: 3.86% and 6051 
for C-peptide: 4.26%). Non-esterified fatty acid (NEFA) concentrations were 6052 
assessed via an enzymatic colorimetric kit (WAKO Diagnostics; references #999-6053 
34691/#991-34891; intra-assay CV: 7.95%). All analysis was done in batch and 6054 
for a given participant all samples were included on the same plate.  6055 
 6056 
Muscle sampling  6057 
All vastus lateralis skeletal muscle samples were collected under local anesthesia 6058 
(~ 5 mL 1% lidocaine, Hameln Pharmaceuticals Ltd., Brockworth, UK) and from 6059 
a 3-6-mm incision at the anterior aspect of the thigh using a 5-mm Bergstrom 6060 
biopsy needle technique adapted for suction. For the Acute Study, samples were 6061 
collected pre- and immediately post-exercise and at 3 h post-exercise. To enable 6062 
the analysis of the IMTG content ~ 15-20 mg of each sample was embedded in 6063 
Tissue-Tek OCT (Sigma Aldrich, Dorset, UK) on cork disc and frozen in liquid 6064 
nitrogen cooled isopentane, before being transferred into an aluminium cryotube 6065 
and stored at -80°C. Remaining muscle (for glycogen and gene expression 6066 




samples were collected pre- and post-intervention with participants in a fasted, 6068 
resting state, with both samples collected from their dominant leg. Muscle was 6069 
extracted from the needle and frozen in liquid nitrogen, before storage at -80 °C. 6070 
Frozen wet muscle (80-100 mg) was freeze-dried and powdered, with visible 6071 
blood and connective tissue removed. Ice cold lysis buffer (50 mM Tris [pH 7.4], 6072 
150 mM NaCl, 0.5% Sodium deoxycholate; 0.1% SDS and 0.1% NP-40) with 6073 
protease and phosphatase inhibitors was added. Samples were homogenized 6074 
with a dounce homogenizer, before a 60 min incubation (4°C with rotation) and 6075 
10 min centrifugation (4°C and 20,000 g). The protein content of the resultant 6076 
supernatant was measured using a bicinchoninic acid assay. 6077 
 6078 
Intramuscular triglyceride (Acute Study) 6079 
The muscle mounted in Tissue-Tek was cut into 5 μm thick transverse sections 6080 
with a cryostat at -25°C (Bright 5040, Bright Instrument Company; Huntingdon, 6081 
England) and collected onto an uncoated glass slide and frozen immediately after 6082 
sectioning. Each slide had 4 samples for a participant (pre- and post-exercise 6083 
both trials) to decrease variation in staining intensity between muscle sections 6084 
and slides were prepared and analyzed for each participant. For analysis, 6085 
cryosections were removed from the freezer and fixed immediately in 3.7% 6086 
formaldehyde for 60 min. Slides were then rinsed with distilled water (3 x 30 s) 6087 
and treated for 5 min with 0.5% Triton-X100 in phosphate-buffered solution (PBS; 6088 
137 mmol·L-1 sodium chloride, 3 mmol·L-1 potassium chloride, 8 mmol·L-1 sodium 6089 
phosphate dibasic, 3 mmol·L-1 potassium phosphate monobasic). The slides 6090 
were washed (3 x 5 min in PBS) and incubated for 2 h at room temperature with 6091 
anti-myosin heavy chain I antibody (MHCI; mouse IgM, Developmental Studies 6092 
Hybridoma Bank:  reference #A4.480) and anti-dystrophin antibody (mouse 6093 
IgG2b, Sigma Aldrich: reference #D8168) in 5% goat serum diluted in PBS (1:1 6094 
PBS dilution). This was followed by washes in PBS (3 x 5 min), after which 6095 
conjugated secondary antibodies [goat anti mouse (GAM) IgM conjugated to 6096 
AlexaFluor 633 for MHCI; Thermo Fisher: reference #A21046; and GAM IgG2b 6097 
conjugated to AlexaFluor 594 for dystrophin; Thermo Fisher: reference #A21145] 6098 




PBS. Then, muscle sections were incubated in BODIPY 493/503 solution 6100 
(Thermo Fisher: reference #D3922) for 20 min at room temperature in a dark 6101 
room before washes (2 x 3 min in PBS). Stained sections were embedded in 6102 
Mowiol 4-88 mounting medium (Fluka: reference #81381) and covered with a 6103 
coverslip. Slides were left to dry overnight at room temperature before analysis 6104 
by confocal microscope in duplicate (DMIRE2, Leica Microsystems; 40x oil 6105 
objective; 1.25 NA). An argon laser 488 nm was used to excite BODIPY-493/503 6106 
(emission 510-652 nm), while a helium-neon 594 nm and 633 nm laser line were 6107 
used to excite Alexa Fluor 594 (dystrophin, emission 6680698 nm) and 6108 
AlexaFluor 633 (MHCI, emission 698-808 nm), respectively. Images were 6109 
scanned in projection of 4 lines in 1024x1025 pixels format. Quantification of the 6110 
lipid droplets was performed using Image J software and the intramuscular 6111 
triglyceride (IMTG) content of each sample was calculated as the percent area of 6112 
bodipy staining of the total fiber area ([BODIPY stained area [um2] / area of 6113 
muscle [um2]*100). 6114 
 6115 
Muscle glycogen (Acute Study) 6116 
Muscle glycogen concentrations were measured using a method described 6117 
previously (36). Briefly, 10-15 mg of frozen tissue was powdered and transferred 6118 
into a glass tube pre-cooled on dry ice. Thereafter, the samples were hydrolyzed 6119 
by adding a 500 µl of 2M HCL and then incubated for 2 h at 95 ºC. After cooling 6120 
to room temperature, 500µl 2M NaOH was added. Samples were centrifuged and 6121 
the supernatant was analyzed for glucose concentrations using an ILAB 650 6122 
Clinical Chemistry Analyzer (Instrumentation Laboratory, Warrington, UK). 6123 
 6124 
Gene expression (Acute Study) 6125 
The mRNA expression of 34 metabolic genes was analyzed using a custom RT2 6126 
Profiler PCR Array (Qiagen, USA). First, RNA was extracted from 20-40 mg of 6127 
powdered muscle tissue using Tri reagent (1 mL, Sigma Aldrich, UK, T9424). 6128 
After addition of chloroform (200 uL, Acros organics 268320025), tubes were 6129 
incubated at room temperature for 5 min and centrifuged for 10 min (4 oC at 12 6130 




and RNA was purified on Reliaprep spin columns (Promega, USA, Z6111) as per 6132 
manufacturer’s instructions. The LVis function of the FLUOstar Omega 6133 
microplate reader was used to measure RNA concentrations to ensure all 6134 
samples for each participant had the same amount of RNA (184 ng - 400 ng) and 6135 
samples were reverse transcribed to cDNA using the RT2 First Strand kit 6136 
(Qiagen, UK, 330401). Quantitative RT-PCR analysis was performed using 6137 
custom designed 384-well RT2 PCR Profiler Arrays (Qiagen) and RT2 SYBR 6138 
Green Mastermix (Qiagen) on a CFX384 Real-Time PCR Detection system 6139 
(BioRad). 2.8 ng cDNA was added to each well. All primers that were used are 6140 
commercially available (Table 2). The absence of genomic DNA, the efficiency 6141 
of reverse-transcription and the efficiency of the PCR assay were assessed for 6142 
each sample and conformed to manufacturer’s limits. Relative mRNA expression 6143 
was determined via the 2-∆∆CT method (37). Housekeeper genes (βactin [Refseq# 6144 
NM_001101]; ribosomal protein lateral stalk subunit P0 [Refseq# NM_001002] 6145 
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Table 2. List of genes analysed for mRNA expression 
Gene Qiagen catalogue 
number 
Refseq# 
CD36 Cat#PPH01356A NM_000072 
SLC27A1 Cat#PPH17902A NM_198580 
SLC27A4 Cat#PPH00471A NM_005094 
FABP3 Cat#PPH02460C NM_004102 
FABP4 Cat#PPH02382F NM_001442 
ACSL1 Cat#PPH19272A NM_001995 
ACSL6 Cat#PPH08013A NM_001009185 
CPT1B Cat#PPH20905B NM_001145134 
CPT2 Cat#PPH15572A NM_000098 
ACACA Cat#PPH02316A NM_000664 
ACACB Cat#PPH02301A NM_001093 
MLYCD Cat#PPH12795A NM_012213 
HADHA Cat#PPH10000B NM_000182 
GPAM Cat#PPH06361A NM_001244949 
DGAT1 Cat#PPH23420F NM_012079 
PNPLA2 Cat#PPH11403B NM_020376 
LIPE Cat#PPH02383A NM_005357 
PDK4 Cat#PPH07615A NM_002612 
PDK2 Cat#PPH00810A NM_001199898 
GYG1 Cat#PPH13614A NM_001184720 
GYS1 Cat#PPH00988C NM_001161587 
PRKAA1 Cat#PPH00043B NM_206907 
PRKAA2 Cat#PPH15207A NM_006252 
PRKAB2 Cat#PPH09415B NM_005399 
PRKAG1 Cat#PPH07190A NM_001206709 
PPARGC1A Cat#PPH00461F NM_013261 
PPARA Cat#PPH01281B NM_001001928 
PPARD Cat#PPH00455A NM_001171818 
UCP3 Cat#PPH06066A NM_003356 
IL6 Cat#PPH00560C NM_000600 
SLC2A4 Cat#PPH02326A NM_001042 
IRS1 Cat#PPH02328A NM_005544 
IRS2 Cat#PPH02297A NM_003749 




Western blotting (Training Study) 6148 
For western blots, 40 µg of protein was loaded for each sample and separated 6149 
via sodium dodecyl sulfate polyacrylamide gel electrophoresis on Tris-glycine 6150 
SDS–polyacrylamide gels (15% for OXPHOS and CPT-1, 10% CD36 and GLUT4 6151 
and 8% for AMPK, CHC22, CHC17, AkT and AS160). Gels were electro-blotted 6152 
(semi-dry transfer) onto a nitrocellulose membrane and were then washed in Tris-6153 
buffered saline (0.09% NaCl, 100 mM Tris–HCl pH 7.4) with 0.1% Tween 20 6154 
(TBS-T) and incubated for 30 min in a blocking solution (5% non-fat milk in TBS-6155 
T). Membranes were incubated overnight at 4 °C with primary antibodies against 6156 
OXPHOS (Abcam: reference #ab110411), CPT-1 (Abcam: reference 6157 
#ab134988), CD36 (Abcam: reference  #ab133625), GLUT4 [self-raised rabbit 6158 
polyclonal antibody against the C-terminus of GLUT4 (38)], CHC22 [SHL-KS, 6159 
affinity purified self-raised rabbit polyclonal against the CHC22 C-terminus cross-6160 
absorbed against the CHC17 C-terminus (39)],  CHC17 [TD.1 self-raised mouse 6161 
monoclonal against CHC17 terminal domain (40)] AMPKα (Cell Signalling 6162 
Technologies: reference #2532), Akt (Cell Signaling Technologies: reference 6163 
#3063), AS160 (Millipore: reference #07-741). It should be noted that the AMPKα 6164 
antibody recognises both α1 and AMPKα2 isoforms of the catalytic subunit and 6165 
does not detect the regulatory AMPK or AMPK subunits (41). Following 6166 
incubation with the primary antibodies, the membranes were washed in TBS-T 6167 
and incubated for 60 min in a 1:4000 dilution of anti-species IgG horseradish 6168 
peroxidase-conjugated secondary antibodies in the aforementioned blocking 6169 
solution. After further washes, membranes were incubated in an enhanced 6170 
chemiluminescence reagent and visualized (EpiChemi II Darkroom, UVP, 6171 
Upland, USA). The band densities were quantified using Image Studio Lite 6172 
software (Version 5.2; LI-COR, Nebraska, USA) and were normalized to either 6173 
GAPDH (Proteintech: reference #60004-1-Ig) or Actin (Sigma Aldrich: reference 6174 
#A2066), before the pre- to post-intervention change was calculated. Pre- and 6175 
post-intervention samples from any given participant were included on the same 6176 
gel. Citrate synthase activity was measured using a commercially available assay 6177 





Phospholipid composition (Training Study) 6180 
Samples were freeze-dried, powdered under liquid nitrogen, and transferred into 6181 
glass tubes containing 2 ml of methanol and butylated hydroxytoluene (0.01%) 6182 
and heptadecanoic acid (as an internal standard), followed by the addition of 4 6183 
mL of chloroform and 1.5 mL of water, before lipids were extracted. The lipid 6184 
containing fraction was transferred into thin-layer chromatography (TLC; 6185 
Kieselgel 60, 0.22 mm, Merck, Darmstadt, Germany) silica plates and lipids were 6186 
separated by TLC with a heptane: isopropyl ether: acetic acid (60:40:3, 6187 
vol/vol/vol) resolving solution. Lipid bands were made visible by spraying the 6188 
plates with a 0.2% solution of 3'7'-dichlorofluorescin in methanol and recognized 6189 
under ultraviolet light using standards on the plates. Then the gel bands 6190 
containing phospholipids were scraped off the plates, transferred into screw cap 6191 
tubes and transmethylated with BF3/methanol. The fatty acid methyl esters 6192 
(FAMEs) were then dissolved in hexane and analyzed by GLC. A Hewlett-6193 
Packard 5890 Series II gas chromatograph with Varian CP-SIL capillary column 6194 
(100 m, internal diameter of 0.25 mm) and flame-ionization detector were used. 6195 
In accordance with the retention times of standards, the individual long-chain fatty 6196 
acids quantification was performed. The content of phospholipids was estimated 6197 
as the sum of the total fatty acid species and expressed in nanomoles per 6198 
milligram of dry mass (42,43). 6199 
 6200 
Energy expenditure and intake (Training Study) 6201 
Average daily energy expenditure was calculated as the sum of the resting 6202 
metabolic rate (RMR), diet-induced thermogenesis (10% of self-reported daily 6203 
energy intake) and physical activity energy expenditure (PAEE). To assess RMR, 6204 
participants rested in a semi-supine position for 15 min before 4 x 5-min expired 6205 
air samples were collected (44). The participants were provided with the 6206 
mouthpiece 1 min prior to sample collections (as a stabilization period) which 6207 
were collected into a 200-L Douglas bag (Hans Rudolph, Kansas City, USA) via 6208 
falconia tubing (Baxter, Woodhouse and Taylor Ltd, Macclesfield, UK). 6209 
Concurrent measures of inspired air were also made to correct for changes in the 6210 




measured in a volume of each sample using paramagnetic and infrared 6212 
transducers (Mini HF 5200, Servomex Group Ltd., Crowborough, UK). The 6213 
sensor was calibrated with low (0% O2 and 0% CO2) and high (16.04% O2, 5.06% 6214 
CO2) calibration gases (BOC Industrial Gases, Munich, Germany). Substrate 6215 
utilization rates were then calculated via stochiometric equations (45,46). Energy 6216 
expenditure was calculated assuming that fatty acids, glucose and glycogen 6217 
provide 40.81 kJ·g-1, 15.64 kJ·g-1 and 17.36 kJ·g-1 of energy, respectively. To 6218 
measure free-living PAEE, participants wore an ActiheartTM monitor over 7 days 6219 
(Cambridge Neurotechnology, Papworth, UK). This monitor integrates 6220 
accelerometry and heart rate signals and has been validated as a measure of 6221 
energy expenditure (47-49). Energy expenditure and heart rate values from rest 6222 
and exercise were entered in the ActiheartTM software for an individually 6223 
calibrated model. Participants were also asked to keep a written record of their 6224 
food and fluid intake for 4 days over a typical 7-day period (including a weekend 6225 
day) pre- and during the last week of the intervention. Weighing scales were 6226 
provided to increase the accuracy of records.  Records were analyzed using 6227 
Nutritics software (Nutritics Ltd., Dublin, Ireland). The macronutrient composition 6228 
of each food was taken from the manufacturer’s labels, but if this was not possible 6229 
(e.g. fresh products) foods were analyzed via the software database or 6230 
comparable brands were used to provide the relevant information, and this was 6231 
kept constant across records.  6232 
 6233 
Statistics 6234 
In the Acute Study, the sample size was based upon data demonstrating an 6235 
attenuation of intramuscular lipid utilization during exercise with carbohydrate 6236 
intake before and during exercise with an effect size of d = 1.5. (22) We aimed to 6237 
recruit 12 participants assuming at least 8 participants would complete the study 6238 
with biopsies to provide >90% power with α set at 0.05. In the Training Study, a 6239 
sample size estimation was completed using data from a training study in healthy, 6240 
lean men (26). In that study, a change in the plasma glucose AUC for an oral 6241 
glucose tolerance test (OGTT) of -65±53 mmol·min·L-1 was shown in an EX-BR 6242 




participants were required for a >90% chance of detecting this effect. We 6244 
therefore recruited 30 participants to account for the possibility of an unequal 6245 
allocation of participants across three groups when using a stratified 6246 
randomization schedule. Participants were allocated to the CON (n=9), BR-EX 6247 
(n=12) or EX-BR (n=9) groups using this schedule, which was generated by JPW 6248 
and included a factor for Physical Activity Level (PAL) and the time-averaged 6249 
glucose AUC for the baseline OGTT which was assessed using a Freestyle 6250 
Freedom Lite Glucose Meter. This was to ensure an even distribution of less (PAL 6251 
<1.65) and more active (PAL >1.65) participants and participants with glucose 6252 
AUC values above or below 8 mmol·L-1. Data are presented as means ± 95% 6253 
confidence intervals (CI), except for participant characteristics (which are mean 6254 
± SD). A Shapiro-Wilk test was performed to test for normal distribution and if this 6255 
was not obtained, non-parametric tests (e.g. Wilcoxon matched-pairs signed rank 6256 
tests) were employed. In the Acute Study, differences between groups were 6257 
assessed with paired t-tests or a two-way repeated measures ANOVA (for 6258 
variables dependent on time). In the Training Study, one-way ANOVAs were 6259 
used to assess differences between groups at baseline and two-way mixed-6260 
design ANOVAs were used to assess differences between groups in response to 6261 
the intervention (group x time). If interaction effects were identified, independent 6262 
t-tests were used to locate variance, with Holm-Bonferroni step-wise adjustments 6263 
made. Correlations between variables were explored using Pearson r or 6264 
Spearman R for normal or non-normal distributions, respectively. A significance 6265 
level of p<0.05 was always used. The area under the concentration-time curve 6266 
(AUC) was calculated via the trapezoid rule and divided by the duration of an 6267 
observation period of interest for a time-averaged summary value. Plasma 6268 
glucose and insulin concentrations were used to assess oral glucose insulin 6269 
sensitivity (the OGIS index) as per instructions provided at; 6270 
http://webmet.pd.cnr.it/ogis/ (50). Statistical analyses were completed on IBM 6271 
SPSS statistics V 22 for windows (except for the Holm-Bonferroni adjustments 6272 
which were completed on Microsoft Excel) and Graph Pad Prism 7 was used to 6273 
prepare the figures. As we were unable to collect data from all participants for all 6274 





Exercise before nutrient ingestion increases whole-body and skeletal muscle lipid 6277 
utilization but does not differentially modulate muscle gene expression 6278 
In the Acute Study, exercising before versus after nutrient provision increased 6279 
the acute plasma glucose and serum insulin responses to food consumption 6280 
(Figure 2A and 2B). The plasma glucose AUC was 6.70 [6.00 to 7.39] mmol·L-6281 
1·330 min-1 with exercise before nutrient provision versus 5.91 [5.33 to 6.50] 6282 
mmol·L-1·330 min-1 with exercise after nutrient provision (p<0.01). The serum 6283 
insulin AUC was 86.9 [48.5 to 125.2] pmol·L-1·330 min-1 with exercise before 6284 
nutrient provision versus 55.3 [31.2 to 79.3] pmol·L-1·330 min-1 with exercise after 6285 
nutrient provision (p<0.01). Exercise performed before versus after nutrient 6286 
provision resulted in higher glycerol and non-esterified fatty acid (NEFA) 6287 
concentrations during the exercise (Figure 2C and 2D).  6288 
 6289 
Nutrient provision before exercise potently altered whole-body metabolism, 6290 
resulting in an increase in whole-body carbohydrate utilization (Figure 2E) and a 6291 
decrease in whole-body lipid utilization (Figure 2F). In skeletal muscle, glycogen 6292 
utilization during exercise (time effect, p<0.01) was independent of nutrient-6293 
exercise timing (time x trial interaction effect p=0.12; Figure 2G). However, the 6294 
type I muscle fibre intramuscular triglyceride (IMTG) content was only reduced 6295 
with exercise performed before nutrient provision (time x trial interaction: p=0.02; 6296 
Figure 2H and 2J). A similar pattern was observed for the type II muscle fibre 6297 
IMTG content (time x trial interaction: p=0.04; Figure 2I and 2J), although the 6298 
reduction with exercise before nutrient provision did not achieve statistical 6299 
significance after post-hoc corrections. Nonetheless, clear differences (both 6300 
p<0.05) in the net changes in the IMTG content were observed in both fibre types 6301 
with exercise before versus after nutrient provision (for type I: -3.44 [-1.61 to -6302 
5.26]% versus 1.44 [-1.46 to 4.34 ]% area covered by lipid staining and type II: -6303 
1.89 {-0.16 to -3.61]% versus 1.83 [0.50 to 3.17]% area covered by lipid staining 6304 





Of the 34 selected genes that are implicated in metabolic adaptations to exercise, 6307 
only 8 genes were altered by exercise, whereby IRS-1 and FATP1 were 6308 
decreased post-exercise compared to baseline (p<0.05) and IRS-2, PDK4, 6309 
PGC1, FATP4 and ACSL1 were increased post-exercise compared to baseline 6310 
(all p<0.05). However, only PPAR was differentially expressed by nutrient-6311 
exercise timing and was higher with breakfast before versus after exercise 6312 





Figure 2. Plasma glucose (A), serum insulin (B), plasma glycerol (C) and plasma 6315 
NEFA (D) concentrations and whole-body carbohydrate (E) and fat (F) utilization. 6316 
Muscle was sampled pre- and post-exercise (vastus lateralis) to assess mixed-6317 
muscle glycogen (G) and fiber-type specific intramuscular lipid (IMTG) utilization 6318 
(H & I). Panel J is images where IMTG (stained green) in combination with 6319 
dystrophin (to identify the cell border, stained red) is shown from muscle samples 6320 
of a representative participant for breakfast-exercise and exercise-breakfast 6321 
trials. White I shows type 1 fibers and all other fibers are assumed to be type II. 6322 
Yellow bars are scale (50 m). All data are presented as means ± 95% CI. For 6323 
panels A-F n=12, for panels G, H and I n=9. a difference with pre- versus post-6324 





Figure 3. Skeletal muscle mRNA expression responses to a bout of exercise 6327 
before versus after nutrient provision (in the form of breakfast) in overweight men. 6328 
n=8. Muscle was sample pre- and at 3 h post-exercise (vastus lateralis) to assess 6329 
the intramuscular gene expression responses to exercise. aeffect of exercise; b 6330 




Exercise training before nutrient provision leads to sustained increases in lipid 6332 
utilization  6333 
In the Training Study the compliance to the training was 100%, as all sessions 6334 
were completed as prescribed. The average exercise intensity was 62 ± 5% V̇O2 6335 
peak in BR-EX and 62 ± 4% V̇O2 peak in EX-BR (p=0.98) and the heart rate (HR) 6336 
response and average rating of perceived exertion (RPE) to the exercise training 6337 
were 140 ± 13 versus 134 ± 8 beats·min-1 in BR-EX versus EX-BR (p=0.18) and 6338 
13 ± 1 au versus 13 ± 1 au (6-20 rating scale) in BR-EX versus EX-BR; (p=0.54), 6339 
respectively. In the Training Study rates of whole-body lipid utilization were 6340 
around 2-fold higher with exercise before versus after nutrient provision and this 6341 
difference between the conditions was sustained throughout the whole 6-week 6342 
intervention (Figure 4A). As a consequence, regular exercise before (versus 6343 
after) nutrient provision increased cumulative whole-body lipid utilization (during 6344 
exercise) over a 6-week intervention, from 799 kcal [530 to 1069] in BR-EX to 6345 
1666 kcal [1260 to 2072] in EX-BR (p<0.01). This was accompanied by a 6346 
decrease in whole-body carbohydrate utilization during exercise (Figure 5A), as 6347 
reflected by a decrease in the respiratory exchange ratio (group effect, p<0.01; 6348 
Figure 5B). However, cumulative energy expenditure throughout the exercise 6349 
intervention did not differ with exercise performed before versus after nutrient 6350 
provision (Figure 5C; 7207 [6739 to 7676] kcal in BR-EX versus 6951 [6267 to 6351 
7635] kcal in EX-BR; p=0.48). 6352 
 6353 
Exercise training before nutrient provision leads to increased oral glucose insulin 6354 
sensitivity  6355 
The oral glucose tolerance test-derived estimate of peripheral insulin sensitivity 6356 
(the OGIS index; p=0.26), postprandial glycaemia (p=0.80) and postprandial 6357 
insulinemia (p=0.30) were similar between groups pre-intervention (Table 3). The 6358 
intervention-induced changes in postprandial glycaemia (time x group interaction, 6359 
p=0.54; Figure 4B) and fasting blood lipid profiles were unaffected by nutrient-6360 
exercise timing (pre- and post-intervention data are shown in Tables 3 and 4). 6361 
However, exercise training before, but not after nutrient intake reduced 6362 
postprandial insulinemia (time x group interaction p=0.03; Figure 4C).  Exercise 6363 




x group interaction p=0.03; Figure 4D with pre- and post-intervention data in 6365 
Table 3). The plasma C-peptide-to-insulin ratio was not differentially altered by 6366 
nutrient-exercise timing (time x group interaction, p=0.12; Figure 4E). The 6367 
change in the OGIS index in response to exercise training was positively and 6368 
moderately correlated with cumulative lipid utilization during exercise during the 6369 





Figure 4. Whole-body lipid utilization during every a 6-week exercise intervention 6372 
(A) and the change in the plasma glucose AUC (B), plasma insulin AUC (C), the 6373 
oral glucose insulin sensitivity index (OGIS; D) and the postprandial plasma C-6374 
peptide: insulin ratio (E) in control, breakfast-exercise and exercise-breakfast 6375 
groups. Panel F is a Pearson correlation between changes in the OGIS index and 6376 
cumulative lipid utilization throughout the training intervention. All data are means 6377 
± 95% CI. For control n = 9, for breakfast-exercise n = 12 and for exercise-6378 
breakfast n = 9 men classified as overweight or obese. The shaded area is the 6379 
95% confidence bands for the regression line. a difference between control versus 6380 





Figure 5. Energy expenditure (A), the respiratory exchange ratio (B) and whole-6383 
body carbohydrate utilisation rates (C) during every exercise session in a 6-week 6384 
training intervention and a Pearson correlation between cumulative energy 6385 
expenditure throughout the exercise training intervention with the changes in oral 6386 
glucose insulin sensitivity (the OGIS index) with exercise before versus after 6387 
nutrient intake (D). All data are presented as means ± 95% CI. For control n = 9, 6388 
for breakfast-exercise n = 12 and for exercise-breakfast n = 9 men classified as 6389 
overweight or obese. The shaded grey area represents the 95% confidence 6390 




  6392 
Table 3. Postprandial plasma metabolite concentrations for the control (CON; n=9), 
breakfast-exercise (BR-EX; n=12) and exercise-breakfast (EX-BR; n=9) groups. 
 Pre-intervention Post-intervention  
CON glucose AUC (mmol·L-1) 8.20 (1.36) 8.43 (0.89) 0.69 
BR-EX glucose AUC (mmol·L-1) 8.26 (0.90) 8.34 (1.35) 0.78 
EX-BR glucose  AUC (mmol·L-1) 8.52 (1.05) 8.14 (1.03) 0.27 
CON insulin AUC (pmol·L-1) 385 (221) 514 (382) 0.08 
BR-EX insulin AUC (pmol·L-1) 268 (109) 303 (135) 0.16 
EX-BR insulin AUC (pmol·L-1) 458 (441) 355 (254) 0.21 
CON C-peptide AUC (ng·mL-1) 6.59 (2.57) 7.32 (3.11) 0.18 
BR-EX C-peptide AUC (ng·mL-1) 5.25 (1.72) 5.54 (1.87) 0.34 
EX-BR C-peptide AUC (ng·mL-1) 6.81 (4.40) 6.03 (3.45) 0.28 
CON NEFA AUC (mmol·L-1) 0.17 (0.07) 0.19 (0.07) 0.52 
BR-EX NEFA AUC (mmol·L-1) 0.20 (0.08) 0.16 (0.06) 0.08 
EX-BR NEFA AUC (mmol·L-1) 0.14 (0.03) 0.13 (0.04) 0.48 
CON OGIS (mL·min-1·m-2) 401 (39) 372 (63) 0.19 
BR-EX OGIS (mL·min-1·m-2) 403 (31) 380 (34) 0.06 
EX-BR OGIS (mL·min-1·m-2) 374 (56) 399 (42) 0.08 
Data are means and (SD). Abbreviations: NEFA = non-esterified fatty acid, OGIS = oral glucose 
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Table 4. Fasting plasma metabolite concentrations for the control (CON; n=9), 





Δ from  
pre-intervention 
 time x 
group 
interaction 
CON glucose (mmol·L-1) 5.39 (0.49) 5.57 (0.66) 0.17 (-0.32, 0.66)  
F=1.413 
p= 0.26 BR-EX glucose (mmol·L
-1) 5.48 (0.33) 5.60 (0.47) 0.12 (-0.30, 0.54) 
EX-BR glucose (mmol·L-1) 5.72 (0.71) 5.46 (0.72) -0.27 (-0.67, 0.13) 
CON insulin (pmol·L-1) 95 (121) 81 (63) -14 (-7, 8)  
F=0.327 
p= 0.72 BR-EX insulin (pmol·L
-1) 43 (23) 43 (24) 0 (-14, 15) 
EX-BR insulin (pmol·L-1) 49 (43) 47 (35) -2 (-20, 14) 
CON HOMA-IR (au) 0.35 (0.04) 0.34 (0.03) -0.01 (-0.02, 0.00)  
F=0.458 
p=0.40 BR-EX HOMA-IR (au) 0.37 (0.03) 0.37 (0.04) 0.00 (-0.01, 0.01) 
EX-BR HOMA-IR (au) 0.37 (0.04) 0.37 (0.04) 0.01 (-0.02, 0.04) 
CON NEFA (mmol·L-1) 0.36 (0.16) 0.39 (0.11) 0.03 (-0.10, 0.15)  
F=1.021 
p=0.37 BR-EX NEFA (mmol·L
-1) 0.44 (0.15) 0.39 (0.10) -0.05 (-0.11, 0.15) 
EX-BR NEFA (mmol·L-1) 0.34 (0.09) 0.32 (0.10) -0.02 (-0.09, 0.05) 
CON TAG (mmol·L-1) 1.59 (0.77) 2.05 (0.70) 0.46 (-0.06, 0.98)  
F= 5.967 
p<0.01 BR-EX TAG (mmol·L
-1) 1.34 (0.84) 1.11 (0.42) -0.24 (-0.55, 0.76)a 
EX-BR TAG (mmol·L-1) 1.10 (0.31) 0.88 (0.36) -0.22 (-0.41, -0.03)b 
CON cholesterol (mmol·L-1) 4.41 (1.23) 4.59 (1.36) 0.19 (-0.74, 1.12)  
F=1.707 
p=0.20 BR-EX cholesterol (mmol·L
-1) 3.77 (1.34) 3.72 (1.21) -0.05 (-0.41, 0.30) 
EX-BR cholesterol (mmol·L-1) 3.74 (0.82) 3.24 (0.92) -0.51 (-0.95, -0.07) 
CON HDL cholesterol (mmol·L-1) 0.84 (0.17) 0.86 (0.20) 0.02 (-0.14, 0.18)  
F=1.634 
p=0.21 BR-EX HDL cholesterol (mmol·L
-1) 0.82 (0.31) 0.84 (0.33) 0.02 (-0.05, 0.10) 
EX-BR HDL cholesterol (mmol·L-1) 0.90 (0.23) 0.81 (0.26) -0.09 (-0.19, 0.01) 
CON LDL cholesterol (mmol·L-1) 3.36 (1.33) 3.56 (1.36) 0.20 (-0.50, 0.89)  
F=2.110 
p=0.14 BR-EX LDL cholesterol (mmol·L
-1) 2.71 (0.97) 2.70 (0.99) -0.01 (-0.31, 0.28) 
EX-BR LDLcholesterol (mmol·L-1) 2.72 (0.57) 2.31 (0.58) -0.41 (-0.80, -0.02) 
Data are means and (SD) except for change scores which are means and (95% CI). 
Abbreviations: HOMA-IR = the homeostatic model of insulin resistance, NEFA = non-
esterified fatty acid, TAG = triglyceride, HDL = high density lipoprotein, LDL = low density 
lipoprotein a = difference in change from pre- to post-intervention for CON versus BR-EX and 




Nutrient-exercise timing does not differentially alter body composition or 6394 
oxidative capacity 6395 
Exercise before versus after nutrient provision resulted in comparable changes 6396 
in body mass (time x group interaction, p=0.97; Figure 6A), a marker of central 6397 
adiposity (the waist to hip ratio; time x group interaction, p=0.17, Figure 6B), and 6398 
the peak capacity for whole-body lipid utilization (time x group interaction, p=0.14; 6399 
Figure 6C). Exercise training increased V̇O2 peak by ~ 3 mLkgmin-1 relative to 6400 
a no-exercise control (CON) group (time x group interaction, p=0.01) but the 6401 
magnitude of this increase in cardiorespiratory fitness was unaffected by nutrient 6402 
exercise timing (p=0.54 with breakfast-exercise versus exercise-breakfast). Self-6403 
reported daily energy intake was unaffected by exercise or nutrient-exercise 6404 
timing (time x group interaction, p=0.38; Table 5), and although daily energy 6405 
expenditure was increased in the exercise groups versus control group (time x 6406 
group interaction, p=0.01; Table 5), this increase was unaffected by nutrient-6407 





Figure 6. Body mass (A), the waist-to-hip ratio (B), whole-body oxidative capacity 6410 
(VO2peak; C) and peak fat utilization rates during an incremental exercise test 6411 
(D) at baseline, week 3 and week 6 of an intervention in control (no-exercise), 6412 
breakfast-exercise and exercise-breakfast groups. All data are presented as 6413 
means ± 95% CI. For control n = 9, for breakfast-exercise n = 12 and for exercise-6414 
breakfast n = 9 men classified as overweight or obese a difference between 6415 
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Table 5. Components of daily energy intake and daily energy expenditure pre- and 
post-intervention for the control (CON; n=9 [except for PAEE where n=8]), 
breakfast before exercise (BR-EX; n=12 [except for PAEE where n=10]) and 










CON RMR (kcal·d-1) 1997 (225) 2021 (232) 24 (-56, 104)  
F=1.791 
p=0.19 BR-EX RMR (kcal·d
-1) 1964 (167) 2074 (208) 110 (45, 174) 
EX-BR RMR (kcal·d-1) 1899 (228) 1967 (194) 68 (-13, 148) 
CON TEF (kcal·d-1) 283 (61) 292 (85) 9 (-29, 48)  
F=0.982 
p= 0.38 BR-EX TEF (kcal·d
-1) 292 (50) 288 (42) -4 (-19, 10) 
EX-BR TEF (kcal·d-1) 271 (55) 258 (44) -13 (-29, 4) 
CON PAEE (kcal·d-1) 1144 (298) 1077 (327) -67 (-215, 81)  
F=7.044 
p<0.01 BR-EX PAEE (kcal·d
-1) 986 (264) 1190 (343) 204 (56, 352) a 
EX-BR PAEE (kcal·d-1) 1006 (147) 1357 (324) 351 (126, 576) b 
CON CHO intake (kcal·d-1) 1180 (357) 1424 (600) 244 (-29, 517)  
F=0.977 
p=0.39 BR-EX CHO intake (kcal·d
-1) 1171 (317) 1272 (220) 101 (-51, 252) 
EX-BR CHO intake (kcal·d-1) 1133 (307) 1214 (234) 81 (-91, 252) 
CON FAT intake (kcal·d-1) 1148 (326) 1045 (311) -104 (-257, 49)  
F=0.347 
p=0.71 BR-EX FAT intake (kcal·d
-1) 1132 (307) 1091 (238) -41 (-156, 75) 
EX-BR FAT intake (kcal·d-1) 987 (320) 882 (172) -105 (-289, 79) 
CON PRO intake (kcal·d-1) 429 (97) 376 (89) -52 (-89, 15)  
F=1.517 
p=0.24 BR-EX PRO intake (kcal·d
-1) 511 (122) 446 (59) -65 (-118, -11) 
EX-BR PRO intake (kcal·d-1) 406 (97) 399 (117) -7 (-75, 62) 
CON ALC intake (kcal·d-1) 72 (95) 75 (154) 3 (-145, 152)  
BR-EX ALC intake (kcal·d-1) 111 (118) 69 (72) -42 (-101, 17) F=1.115 
EX-BR ALC intake (kcal·d-1) 185 (168) 90 (131) -94 (-191, 2) p=0.34 
Data are means and (SD) except for change scores which are means and (95% CI). 
Abbreviations: CHO = carbohydrate, PRO = protein, ALC = alcohol, RMR = resting 
metabolic rate, TEF = thermic effect of feeding, PAEE = physical activity energy 
expenditure. a denotes a difference in the change from pre-to post-intervention for CON 




Exercise training before nutrient provision increases phospholipid remodeling 6418 
There was a significant effect on global skeletal muscle remodeling with exercise 6419 
before versus after nutrient ingestion as quantified by the sum of changes in the 6420 
fatty acid content of all phospholipid species (p=0.01; Figure 7A). Nutrient 6421 
provision prior to exercise prevented this exercise-induced increase in skeletal 6422 
muscle phospholipid remodeling as the sum of changes was not different to a 6423 
non-exercise control group (p=0.41). No clear time x group interaction effects 6424 
were determined for any of the measured fatty acid species, except for the 6425 
proportion of 18:0, which increased with exercise before nutrient provision 6426 
compared to the control group (Table 6). The change in the overall saturated fatty 6427 
acid content of skeletal muscle phospholipids was moderately and positively 6428 
correlated with changes in postprandial insulinemia and the relationship was 6429 
robust to the exclusion of any single data point (Figure 7B). 6430 
 6431 
Figure 7. Pre-to-post intervention changes in the sum of all changes in the fatty 6432 
acid content of phospholipid species (A) and a Pearson correlation between 6433 
postprandial insulinemia with the change in the proportion of saturated fatty acids 6434 
in skeletal muscle phospholipids (B). All data are presented as means ± 95% CI. 6435 
For control n = 6, for breakfast-exercise n = 9 and for exercise-breakfast n = 5 6436 
men classified as overweight or obese. The shaded area represents the 95% 6437 
confidence bands for the regression line. b difference between breakfast-exercise 6438 
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Table 6. Skeletal muscle phospholipid composition in a control (CON; n=6), 





 time x group 
interaction 
CON 14:0 (% of total) 1.3 (0.5) 1.0 (0.3) 
F=0.493 
p=0.62 
BR-EX 14:0 (% of total) 0.8 (0.1) 0.7 (0.1) 
EX-BR 14:0 (% of total) 0.8 (0.4) 0.7 (0.1) 
CON 16:0 (% of total) 24.8 (2.3) 24.3 (1.0) 
F=1.537 
p=0.25 
BR-EX 16:0 (% of total) 22.4 (0.6) 21.7 (1.2) 
EX-BR 16:0 (% of total) 19.5 (1.5) 17.9 (1.4) 
CON 18:0 (% of total) 14.2 (0.3) 14.2 (0.5) 
F=7.205 
p<0.01 
BR-EX 18:0 (% of total) 14.6 (0.4) 15.2 (0.6) 
EX-BR 18:0 (% of total) 11.9 (0.8) 13.0 (0.8) a 
CON 20:0 (% of total) 0.13 (0.05) 0.09 (0.02) 
F=1.141 
p=0.34 
BR-EX 20:0 (% of total) 0.08 (0.02) 0.08 (0.04) 
EX-BR 20:0 (% of total) 0.10 (0.04) 0.10 (0.07) 
CON 22:0 (% of total) 0.21 (0.07) 0.20 (0.02) 
F=0.666 
p=0.53 
BR-EX 22:0 (% of total) 0.20 (0.04) 0.19 (0.04) 
EX-BR 22:0 (% of total) 0.20 (0.05) 0.23 (0.10) 
CON 24:0 (% of total) 0.15 (0.07) 0.14 (0.04) 
F=0.108 
p=0.90 
BR-EX 24:0 (% of total) 0.12 (0.08) 0.11 (0.06) 
EX-BR 24:0 (% of total) 0.16 (0.08) 0.13 (0.06) 
CON 16:1 (% of total) 0.82 (0.34) 0.70 (0.19) 
F=1.254 
p=0.31 
BR-EX 16:1 (% of total) 0.66 (0.12) 0.75 (0.26) 
EX-BR 16:1 (% of total) 0.66 (0.15) 0.62 (0.17) 
CON 18:1n9c (% of total) 7.9 (3.0) 7.1 (1.5) 
F=2.970 
p=0.08 
BR-EX 18:1n9c (% of total) 6.3 (0.6) 6.8 (0.6) 
EX-BR 18:1n9c (% of total) 6.6 (1.3) 6.6 (0.9) 
CON 18:2n6c (% of total) 33.6 (5.0) 34.5 (4.1) 
F=0.250 
p=0.78 
BR-EX 18:2n6c (% of total) 37.2 (2.2) 37.7 (2.5) 
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Table 6 (con) Skeletal muscle phospholipid composition in a control (CON; n=6), 





 time x group 
interaction 
CON C18n3 (% of total) 0.23 (0.06) 0.21 (0.05) 
F=1.842 
p=0.19 
BR-EX C18n3 (% of total) 0.25 (0.05) 0.29 (0.04) 
EX-BR C18n3 (% of total) 0.22 (0.03) 0.26 (0.02) 
CON 20:4n6 (% of total) 14.4 (0.8) 15.0 (1.0) 
F=1.862 
p=0.19 
BR-EX 20:4n6 (% of total) 14.9 (1.8) 14.0 (1.4) 
EX-BR 20:4n6 (% of total) 11.9 (1.3) 11.0 (1.7) 
CON 20:5n3 (% of total) 0.66 (0.21) 0.71 (0.18) 
F=0.245 
p=0.79 
BR-EX 20:5n3 (% of total) 0.71 (0.12) 0.73 (0.12) 
EX-BR 20:5n3 (% of total) 0.64 (0.18) 0.69 (0.18) 
CON 20:0 (% of total) 0.13 (0.05) 0.09 (0.02) 
F=1.141 
p=0.34 
BR-EX 20:0 (% of total) 0.08 (0.02) 0.08 (0.04) 
EX-BR 20:0 (% of total) 0.10 (0.04) 0.10 (0.07) 
CON 22:6n3 (% of total) 1.5 (0.4) 1.6 (0.5) 
F=0.077 
p=0.93 
BR-EX 22:6n3 (% of total) 1.6 (0.2) 1.6 (0.2) 
EX-BR 22:6n3 (% of total) 1.3 (0.5) 1.4 (0.3) 
CON 24:1 (% of total) 0.13 (0.08) 0.13 (0.05) 
F=0.021 
p=0.98 
BR-EX 24:1 (% of total) 0.10 (0.03) 0.10 (0.04) 
EX-BR 24:1 (% of total) 0.14 (0.09) 0.13 (0.08) 
Data are means and (SD). a denotes a difference in the change from pre-to 




Exercise training before nutrient provision augments intramuscular adaptations  6442 
Skeletal muscle AMPK protein levels increased ~3-fold with exercise training 6443 
performed before- but not after-nutrient provision versus a no-exercise control 6444 
group (Figure 8A). However, these increases did not translate into differential 6445 
changes in proteins including CD36 and CPT-1 which are involved in fatty acid 6446 
transport in skeletal muscle [both p>0.05; data available online (51)], or markers 6447 
of mitochondrial oxidative capacity, including the protein levels of the OXPHOS 6448 
complexes [all p>0.05; data available online (51)] or citrate synthase activity 6449 
(change from baseline: -2.1 molmin-1mg of protein-1 [-12.9 to 8.7] in CON, 7.6 6450 
molmin-1mg of protein-1 [-1.2 to 16.4] in BR-EX and 6.5 molmin-1mg of 6451 
protein-1 [0.2 to 12.8] in EX-BR; p>0.05). There were also no differential changes 6452 
in the content of insulin signaling proteins such as Akt2 or AS160 in response to 6453 
nutrient-exercise timing (p>0.05; Figure 8B). However, there was a ~2-fold 6454 
increase in skeletal muscle GLUT4 protein levels with exercise training performed 6455 
before (p=0.04), but not after nutrient provision (p=0.58) versus a non-exercise 6456 
control group (Figure 8A). There was also an increase in the protein levels of the 6457 
CHC22 clathrin isoform and its associated adaptor protein (GGA2) relative to the 6458 
CHC17 clathrin isoform, with exercise before versus after nutrient provision (both 6459 
p<0.05; Figure 8B). When we examined the CHC22 isoform alone [data not 6460 
shown but available online (51)]we noted baseline differences which may have 6461 
confounded the interpretation of these fold-changes due to regression to the 6462 
mean. We thus present the CHC22/CHC17 ratio (Figure 8B) to reflect GLUT4-6463 
associated clathrin-mediated membrane traffic relative to total clathrin-mediated 6464 





Figure 8. Pre-to-post intervention changes in the levels of energy-sensing 6467 
proteins and proteins involved in insulin-sensitive GLUT4 trafficking in skeletal 6468 
muscle (A and B). Representative immunoblots are shown (C) for each protein 6469 
(including those reported in text but not shown in this figure) from the same 6470 
participant as well as the loading controls used. All data are presented as means 6471 
± 95% CI and the dotted horizontal line represents the baseline (pre-intervention) 6472 
values. For control n = 6, for breakfast-exercise n = 9 and for exercise-breakfast 6473 
n = 5 men classified as overweight or obese. adifference between control versus 6474 
exercise-breakfast; bdifference between breakfast-exercise versus exercise-6475 





This is the first study to investigate the effect of nutrient-exercise interactions on 6478 
key aspects of metabolic health in people classified as overweight or obese. We 6479 
found that a single exercise bout performed before, but not after, nutrient 6480 
provision increased whole body and skeletal muscle lipid utilization. We then 6481 
used a 6-week training program to reveal sustained, 2-fold increases in lipid 6482 
utilization that were maintained throughout 6 weeks of exercise training 6483 
performed before versus after nutrient provision. An oral glucose tolerance test-6484 
derived estimate of peripheral insulin sensitivity (the OGIS index) increased with 6485 
exercise training before versus after nutrient provision and this was associated 6486 
with increased lipid utilization during the exercise training intervention. Exercise 6487 
training prior to nutrient provision also augmented remodeling of phospholipids 6488 
and increased the levels of energy sensing (i.e. AMPK) and glucose transport 6489 
proteins (i.e. GLUT4) in exercised skeletal muscle. These results indicate that 6490 
nutrient-exercise timing modulates training responsiveness in overweight men 6491 
and link lipid utilization during exercise to exercise-training-induced changes in 6492 
aspects of metabolic health. 6493 
 6494 
First, we showed that a single bout of exercise performed before versus after 6495 
nutrient intake increased whole-body lipid utilization. A blunting of intramuscular 6496 
triglyceride (IMTG) utilization has been shown in type I fibers of lean, healthy men 6497 
in response to carbohydrate ingestion before and during exercise, compared to 6498 
exercise in the fasted-state (22). Here, we demonstrated for the first time that 6499 
exercise before versus after breakfast consumption increases net IMTG 6500 
utilization in men classified as overweight or obese. Whilst the authors do 6501 
acknowledge that absolute IMTG content may have been underestimated due to 6502 
the analytical procedures used to estimate IMTG (i.e. use of Triton-X100 6503 
detergent, overnight drying of mounting medium), all samples were treated 6504 
consistently. We also showed that net skeletal muscle glycogen utilization and 6505 
acute skeletal muscle mRNA responses were largely unaffected by the same 6506 
exercise performed before versus after breakfast. This is important, because 6507 




muscle glycogen concentrations are therefore unlikely to have driven the training 6509 
responses we observed in the training study with the present method of nutrient-6510 
exercise timing.  6511 
 6512 
Altering substrate availability can also drive adaptive responses to exercise partly 6513 
by modulating acute mRNA expression in exercised skeletal muscle (52). 6514 
However, in the present study, only one measured gene was differentially 6515 
expressed in response to exercise before versus after nutrient provision. 6516 
Specifically, we observed less of an exercise-induced increase in skeletal muscle 6517 
PPAR expression with exercise before versus after nutrient provision, which is 6518 
surprising given that PPAR has been implicated in adaptations relating to 6519 
oxidative capacity and lipid utilization (53). However, previous research has also 6520 
shown no differential increase in PPAR expression in skeletal muscle when 6521 
exercise was performed with carbohydrate consumption before and during 6522 
exercise versus in the fasted state (54). The different response observed in the 6523 
present study might be because we assessed the effect of nutrient-exercise 6524 
timing (nutrient provision before versus after exercise) rather than the omission 6525 
versus ingestion of nutrients. This suggests that inferences cannot necessarily 6526 
be extrapolated from studies assessing the effects of nutrient ingestion versus 6527 
nutrient omission, to inform responses to models of nutrient-exercise timing.  6528 
 6529 
In the training study, we then showed that acute increases in whole-body lipid 6530 
utilization during a single bout of exercise performed before versus after nutrient 6531 
intake were sustained throughout 6-weeks of exercise training. Moreover, only 6532 
exercise training performed before nutrient intake reduced postprandial 6533 
insulinemia and increased the oral glucose tolerance test-derived estimate of 6534 
peripheral insulin sensitivity (i.e. the OGIS index). As the plasma C-peptide-to-6535 
insulin ratio was not differentially altered by nutrient-exercise timing, the reduction 6536 
in postprandial insulinemia with exercise performed before versus after nutrient 6537 
ingestion is likely to be due to a reduction in insulin secretion rather than an 6538 
increase in hepatic insulin extraction (55). It should also be noted that difference 6539 




equivalent to the difference between individuals classified as having a healthy 6541 
phenotype compared to individuals with impaired glucose tolerance (56). 6542 
 6543 
Exercise training before versus after nutrient provision also resulted in 6544 
augmented phospholipid remodeling in skeletal muscle. Moreover, the change in 6545 
the saturated fatty acid content of skeletal muscle phospholipids with exercise 6546 
correlated with the change in postprandial insulinemia. This supports prior 6547 
observations that a higher proportion of saturated fatty acids in skeletal muscle 6548 
phospholipids negatively correlates with insulin sensitivity (57). Single-leg 6549 
exercise training has been used to show increased polyunsaturated fatty acid 6550 
content of skeletal muscle phospholipids in an exercised versus non-exercised 6551 
leg (58). Since that change was independent of dietary intake, the reduction in 6552 
the saturated fatty content of phospholipids was likely due to a preferential 6553 
upregulation of saturated fatty acid oxidation as a result of the higher energy 6554 
expenditure (59,60). However, because this previous work involved changes in 6555 
energy expenditure across experimental conditions, the role of lipid utilization 6556 
independent of energy expenditure on phospholipid remodeling could not be 6557 
explored. Here, we showed that skeletal muscle remodeling was increased with 6558 
exercise performed before versus after nutrient provision, presumably due to 6559 
increased lipid utilization in that condition.  6560 
 6561 
AMPK is also nutrient sensitive and contributes to regulation of fatty acid 6562 
utilization (61), mitochondrial biogenesis (62) and the expression of proteins 6563 
involved in skeletal muscle glucose uptake, including GLUT4 and AS160 (63-65), 6564 
which are key players in whole-body insulin sensitivity (66). We observed greater 6565 
increases in the protein content of AMPK in skeletal muscle with exercise training 6566 
before versus after nutrient intake. The increase in the GLUT4 content of skeletal 6567 
muscle we observed with exercise before nutrient provision may be explained by 6568 
this heightened AMPK response and, in turn, may have contributed to increases 6569 
in the OGIS index following exercise training before versus after nutrient provision 6570 
(67). Skeletal muscle AMPK can be activated by increased fatty acid availability, 6571 




utilization can modulate AMPK and GLUT4 mRNA expression with different 6573 
exercise models (66). However, since we observed no difference in muscle 6574 
glycogen utilization with altered nutrient-exercising timing in the acute study, the 6575 
change in the GLUT4 content with exercise training before versus after breakfast 6576 
is likely to be attributable to repeated increases in fatty acid availability, potentially 6577 
through increases in the skeletal muscle AMPK content. The AMPK antibody we 6578 
used detects both isoforms of the catalytic subunits of AMPK (AMPKα1 and α2). 6579 
In human skeletal muscle, three different complexes have been described 6580 
[α2β2γ1, α2β2γ3, and α1β2γ1; (69)] and our antibody therefore captured all 6581 
complexes. Accordingly, we cannot speculate whether a specific heterotrimeric 6582 
AMPK complex is predominately contributing to the increase in AMPK content 6583 
that we report. As such, the effect of nutrient-exercise timing on AMPK activation 6584 
warrants continued investigation. 6585 
 6586 
The correct targeting and sequestration of GLUT4 into its intracellular insulin-6587 
responsive compartments is also important for insulin sensitivity in skeletal 6588 
muscle (70,71). Clathrin heavy chain isoform 22 (CHC22) plays a specialized role 6589 
in regulating GLUT4 sequestration in human skeletal muscle (72), protecting 6590 
GLUT4 from degradation (73) and making it more available for insulin-stimulated 6591 
release. We showed an increase in CHC22 protein levels in exercised muscle 6592 
(relative to the exercise effects on CHC17 protein levels) with exercise before 6593 
versus after nutrient provision. As the cognate clathrin CHC17 plays a 6594 
widespread membrane traffic role in many tissues, CHC17 levels provide a 6595 
benchmark for general membrane traffic changes compared to those in the 6596 
GLUT4 pathway (74). The relative increase in CHC22 levels we observed thus 6597 
suggests that exercise before nutrient provision not only augments GLUT4 6598 
protein levels, but potentially also the machinery necessary for the appropriate 6599 
sequestration and targeting of GLUT4 to its insulin-responsive compartment. This 6600 
may lead to improved GLUT4 translocation and contribute to the increases in the 6601 
OGIS index we observed with exercise training before versus after nutrient intake. 6602 
However, the CHC22 results reported here should be interpreted cautiously due 6603 




responses. Further work is therefore needed to investigate nutrient-exercise 6605 
interactions and their effect on CHC22 levels. In addition, the remodeling of 6606 
skeletal muscle phospholipids could have contributed to the ability of GLUT4 to 6607 
fuse to the muscle-plasma membrane via less rigid arrays of phospholipid 6608 
molecules in plasma membranes (75). 6609 
 6610 
The greater increase in AMPK content we observed with exercise before nutrient 6611 
provision did not further augment measured markers of mitochondrial biogenesis 6612 
in skeletal muscle in response to exercise training in overweight men. This is in 6613 
contrast to prior work demonstrating that carbohydrate ingestion before and 6614 
during exercise suppresses exercise-induced increases in the content of proteins 6615 
in skeletal muscle involved in fatty acid transport and oxidation (26). This further 6616 
highlights that the model of nutrient-exercise timing that we employed (breakfast 6617 
consumption before versus after exercise) might be distinct from other types of 6618 
nutrient timing. Although changes in skeletal muscle mitochondrial content and/or 6619 
oxidative capacity may be involved in regulating insulin sensitivity (76), the lack 6620 
of differential response with exercise before versus after nutrition provision in this 6621 
study suggests that these factors are unlikely to explain the changes in the OGIS 6622 
index with the current model of nutrient-exercise timing employed (i.e. exercise 6623 
before versus after breakfast). It is interesting that the intramuscular adaptations 6624 
and changes in the OGIS index that we observed occurred in the presence of 6625 
similar changes in body composition, self-reported daily dietary intake and total 6626 
daily energy expenditure with altered nutrient-exercise timing. Notwithstanding 6627 
other factors that may have contributed to the increases in oral glucose insulin 6628 
sensitivity with exercise before versus after nutrient ingestion, this highlights lipid 6629 
metabolism as a potentially important mechanism explaining the improvement in 6630 
OGIS with regular exercise performed before versus after breakfast.   6631 
 6632 
It should also be noted that the responses observed for OGIS were an interaction 6633 
between groups, and thus the response to exercise before nutrient provision is 6634 
an increase relative to the non-exercise control group and the exercise after 6635 




carbohydrate provision and although this is typical of breakfasts in developed 6637 
countries, it remains to be seen whether lower-carbohydrate meals produce 6638 
similar effects. Potential limitations in our work also include the absence of a non-6639 
exercise fasting group, which would have allowed us to explore a role of extended 6640 
morning fasting per se in the training study. However, our prior work has already 6641 
shown that extended morning fasting in an absence of exercise may impair insulin 6642 
sensitivity and increase postprandial insulinemia in obese humans (77).  6643 
 6644 
To summarize, the present data are the first to show that exercise training before 6645 
versus after carbohydrate (i.e. breakfast) consumption affects responsiveness to 6646 
exercise training in men classified as overweight or obese, including greater 6647 
remodeling of skeletal muscle phospholipids, adaptations of proteins involved in 6648 
nutrient sensing and glucose transport in skeletal muscle, and increases in and 6649 
index of oral glucose insulin sensitivity. These data suggest that exercising in a 6650 
fasted state can augment the adaptive response to exercise, without the need to 6651 
increase the volume, intensity, or perception of effort of exercise. These 6652 
responses may be linked to the acute increases in lipid utilization during every 6653 
bout of exercise performed in the fasted- versus the fed-state (a difference that 6654 
is sustained throughout a period of training over 6-weeks). These findings 6655 
therefore have implications for future research and clinical practice. For example, 6656 
exercise training studies should account for nutrient-exercise timing if aspects of 6657 
metabolic control are an outcome measure. Secondly, to increase lipid utilization 6658 
and oral glucose insulin sensitivity with training, endurance-type exercise should 6659 
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CHAPTER 7 - GENERAL DISCUSSION 6942 
 6943 
The aim of this thesis was to characterise the acute and training responses to 6944 
exercise performed during morning fasting (with breakfast omission or breakfast 6945 
consumption post-exercise) compared to exercise performed after consuming 6946 
breakfast, with a specific focus on substrate metabolism, postprandial glycemia, 6947 
intramuscular adaptations and energy balance. This first involved an application 6948 
of glucose tracer methods in combination with muscle sampling to investigate 6949 
postprandial blood glucose flux after a single bout of exercise. Consuming versus 6950 
omitting breakfast before a single bout of exercise increased plasma glucose flux 6951 
after a post-exercise meal, despite blood glucose concentrations not substantially 6952 
differing in those conditions. It was then shown that an energy deficit from omitting 6953 
breakfast before exercise is not compensated for over a 24 h period via either an 6954 
increase in energy intake or a decrease in energy expenditure in healthy men. 6955 
Finally, if the acute metabolic- and intramuscular-responses to altered nutrient-6956 
exercise timing translates into enduring adaptations with a repeated exposure to 6957 
these stimuli in overweight men was investigated. In that study, participants were 6958 
prescribed the same breakfast and training over 6 weeks, with the only difference 6959 
between the exercise groups being in the timing of carbohydrate consumption in 6960 
relation to exercise. In six weeks, exercise training before versus after nutrient-6961 
intake increased oral glucose insulin sensitivity and augmented key adaptive 6962 
responses to exercise in skeletal muscle. Therefore, for men classified as 6963 
overweight or obese, it is preferable to perform exercise sessions before versus 6964 
after consuming carbohydrates to heighten the metabolic benefits of training. This 6965 
finding could have important implications for future exercise recommendations. 6966 
 6967 
The acute and training study in this thesis had some differences, namely in the 6968 
population studied and if the main comparison was breakfast consumption versus 6969 
omission or altered breakfast timing (pre- versus post-exercise). Despite this, a 6970 
consistent finding was that glycaemic responses to post-exercise meals depends 6971 
on if breakfast is consumed before exercise. A previous study showed that when 6972 




were increased after a post-exercise meal versus breakfast consumption at rest, 6974 
but when breakfast was omitted before exercise this response was less apparent 6975 
versus breakfast omission and rest (15). Using glucose tracer methods in 6976 
Chapter 3, it was shown that plasma glucose flux is increased at post-exercise 6977 
meals with prior breakfast consumption versus omission, but clear differences in 6978 
blood glucose concentrations were not apparent in that chapter. One difference 6979 
between the research in this thesis and the previous work was in the sampling of 6980 
arterialised blood versus venous blood respectively, which alters the measured 6981 
concentrations of blood glucose (428). The magnitude of any arterialised-venous 6982 
differences also depends on the net uptake or release of metabolites from tissue 6983 
beds in proximity to the blood sampling site. This was studied in Chapter 4, where 6984 
performing prior exercise was shown to reduce postprandial arterialised-venous 6985 
differences for blood glucose concentrations compared to rest, which may explain 6986 
why a higher blood glucose response was shown with exercise versus rest with 6987 
venous blood (15), but not in Chapter 3, when arterialised blood was sampled.  6988 
 6989 
In Chapter 3, the increase in plasma glucose appearance rates with breakfast 6990 
consumption before exercise was primarily attributable to glucose from the post-6991 
exercise oral glucose tolerance test (OGTT). However, systemic intestinal fatty 6992 
acid binding protein concentrations, as a marker of intestinal damage, were lower 6993 
if breakfast was consumed versus omitted before exercise. That finding suggests 6994 
that exercise-induced intestinal damage was lessened in that trial and a better 6995 
maintenance of splanchnic perfusion during exercise with prior feeding is a likely 6996 
explanation (10). If splanchnic perfusion was better maintained during exercise 6997 
with prior feeding, this may have also facilitated the higher OGTT-derived plasma 6998 
glucose appearance compared to when breakfast was omitted before exercise, 6999 
which should now be investigated. A higher postprandial plasma glucose disposal 7000 
rate was also shown with breakfast consumption versus omission pre-exercise, 7001 
despite postprandial insulinemia being reduced. Intramuscular insulin-signaling 7002 
pathways mediate blood glucose disposal in response to exercise/nutrition (492). 7003 
However, Akt activation at Thr308 and Ser473 and AS160Thr642 phosphorylation 7004 




omission before exercise, suggesting that differences in the activation of proteins 7006 
in the early stages of intramuscular insulin signalling were not responsible for the 7007 
higher plasma glucose disposal rates if breakfast was consumed before exercise.  7008 
 7009 
However, heightened intramuscular AMPK signalling was apparent after exercise 7010 
with prior breakfast consumption versus omission, which may have contributed 7011 
to the higher blood glucose disposal rates in that trial (493). The ingestion of large 7012 
amounts (> 200 g) of carbohydrate before and during exercise can blunt AMPK 7013 
signaling in muscle (315, 494). However, when a carbohydrate dose (< 120 g) 7014 
more representative of a breakfast consumed in developed countries (186) is 7015 
consumed pre-exercise, net muscle glycogen utilisation during the exercise might 7016 
be increased, especially when no carbohydrate is ingested during the exercise 7017 
(293). This may be because exercise after a high-glycaemic index, carbohydrate-7018 
rich breakfast can facilitate lower blood glucose concentrations in the early stage 7019 
of the activity (273). A breakfast-induced increase in insulin concentrations may 7020 
stimulate carbohydrate utilisation and reduce net NEFA mobilisation from the 7021 
adipose-tissue. Then if exercise is started soon after, the availability of energy-7022 
deriving substrates in the blood may not be sufficient to meet the energy demands 7023 
of the activity, with a combination of these stimuli increasing muscle glycogen 7024 
utilisation, and in turn, the exercise-induced AMPK response (313).  7025 
 7026 
There is also evidence that pre-exercise muscle glycogen concentrations would 7027 
not be higher with breakfast consumption versus omission before exercise, 7028 
especially if the activity was commenced < 2 h after the meal. A series of studies 7029 
performed by Taylor et al. used 13C nuclear magnetic resonance spectroscopy to 7030 
show the slow time course for muscle-glycogen synthesis after consumption of a 7031 
mixed-macronutrient and ~ 60 % carbohydrate breakfast. In the first of these 7032 
studies (495) muscle glycogen concentrations initially decreased and then did not 7033 
start to rise above basal concentrations until ~ 2 h post-meal, with the increase 7034 
above basal concentrations not reaching significance until ~ 3 h post-meal. A 7035 
second study then confirmed this observation in healthy men and also showed 7036 




the predominant fate of the glucose taken up by skeletal muscle in the immediate 7038 
(< 2 h) post-breakfast period is oxidation, before a switch towards net glycogen 7039 
synthesis thereafter. This suggests that muscle glycogen concentrations may not 7040 
be higher prior to exercise performed < 2 h after consuming breakfast versus 7041 
breakfast omission. Thus, if muscle glycogen utilisation is indeed greater during 7042 
post-breakfast exercise (if no carbohydrate is ingested during exercise) muscle 7043 
glycogen concentrations could be lower after the activity is completed. In light of 7044 
the data in Chapter 3, muscle glycogen concentrations and AMPK signalling with 7045 
exercise after breakfast consumption versus omission should now be explored. 7046 
 7047 
In Chapter 3 it was shown that substrate metabolism during- and intramuscular 7048 
signalling after a single bout of exercise performed during fasting can be altered 7049 
by consuming a prior breakfast. Adaptations relating to postprandial metabolism 7050 
after exercise training may also depend on nutrient timing in relation to exercise 7051 
(8). If apparent, this may be attributable to higher rates of IMTG and/or adipose-7052 
tissue derived plasma NEFA utilisation during every bout of exercise performed 7053 
before versus after nutrient intake, and/or increases in the content and activity of 7054 
proteins involved in lipid metabolism after training (12, 13, 308). This is because 7055 
defects related to lipid metabolism and/or a low turnover of endogenous lipid 7056 
pools are likely to be apparent in obesity and have been associated with insulin 7057 
resistance (9). The only prior training study which investigated whole-body insulin 7058 
sensitivity under conditions of altered exercise-nutrient timing, suggested that 7059 
feeding carbohydrates before and during-exercise blunted the increases in oral 7060 
glucose insulin sensitivity compared to a non-exercise group, that was apparent 7061 
when exercise was performed before any carbohydrate was consumed (11). 7062 
However, that study was completed in healthy men during hyper-caloric, high-fat 7063 
feeding and so those results are not easily applied to obesity or situations most 7064 
representative of daily living in developed countries (186).  7065 
 7066 
In Chapter 6, it was shown that when men classified as overweight or obese start 7067 
exercise training, performing exercise sessions before versus after carbohydrate-7068 




measurable differences between the groups for changes in oxidative capacity at 7070 
a whole-body level (V̇O2 peak) or in skeletal muscle, changes in the capacity for 7071 
lipid utilisation at a whole-body level (peak fat utilisation rates during exercise) or 7072 
in skeletal muscle (the content of CPT-1 and CD36) or changes in body-mass, 7073 
self-reported energy intake or energy expenditure. However, a positive 7074 
relationship between the changes in oral glucose insulin sensitivity and 7075 
cumulative whole-body lipid utilisation during training was apparent, highlighting 7076 
a possible link between the turnover of endogenous lipid pools and insulin 7077 
sensitivity. In men classified as overweight or obese, consuming breakfast before 7078 
versus after exercise decreases blood NEFA and glycerol concentrations 7079 
(suggestive of a suppression of lipolysis in the adipose-tissue) during exercise 7080 
and blunts the utilisation of IMTG (as shown in Chapter 6). A higher turnover of 7081 
lipids from the adipose tissue has been associated with better metabolic health 7082 
(167, 168) and a regular utilisation of IMTG is associated with increased insulin 7083 
sensitivity, likely by alleviating any accumulation of lipid metabolites that interfere 7084 
with insulin signalling (9). This supports the correlation between cumulative lipid 7085 
utilisation and insulin sensitivity shown in Chapter 6, and suggests that for insulin 7086 
sensitivity, a regular turnover of endogenous lipid stores may be important.  7087 
 7088 
The phospholipid (PL) content of skeletal muscle may be a determinant of insulin 7089 
sensitivity (134). Previous research has shown that exercise training can result in 7090 
remodelling of the PL pool (325) likely due to an upregulation of saturated fatty 7091 
acid oxidation with a higher energy expenditure (326). However, as all prior work 7092 
has involved changes in energy expenditure a role of lipid utilisation independent 7093 
of energy expenditure in PL remodelling was unclear. In Chapter 6, exercising 7094 
before versus after breakfast was a greater stimulus for PL remodelling potentially 7095 
due to increased lipid utilisation (326) and/or an increased accumulation of 7096 
energy sensing proteins such as AMPK or PGC1α in skeletal muscle (327). In 7097 
addition, the GLUT4 content in the exercised muscle was increased to a greater 7098 
extent with exercise before, but not after breakfast versus a no-exercise group. 7099 
This is consistent with the increased GLUT4 protein content after exercise 7100 




exercise in healthy men (265). Eating breakfast before exercise may therefore 7102 
blunt adaptive responses relating to energy sensing in muscle, which could in 7103 
turn have implications for both PL remodelling (327) and the GLUT4 response to 7104 
the training (165). The apparent disparity between the acute and training studies 7105 
in this thesis for the post-exercise AMPK response suggests that acute responses 7106 
to exercise do not always translate into enduring training adaptations and/or that 7107 
responses to altered nutrient-exercise timing may be specific to the model that is 7108 
employed. In Chapter 6, an increase in the CHC22 protein levels in skeletal 7109 
muscle with exercise before versus after breakfast was also detected. CHC22 7110 
has a role in forming insulin-responsive GLUT4 vesicles and more research in 7111 
humans is now needed to clarify the role of nutrient-exercise timing for CHC22. 7112 
Collectively, the results in Chapter 6 showed that exercise training before versus 7113 
after nutrient-intake may be more efficacious for increasing oral glucose insulin 7114 
sensitivity in overweight humans and that this response may be linked to 7115 





Figure 7.1. Mechanisms by which exercising before versus after nutrient intake 7118 
may increase oral glucose tolerance test derived estimates of peripheral insulin 7119 
sensitivity in humans classified as overweight or obese. Over six weeks, exercise 7120 
performed before (versus after) breakfast resulted in increased lipid utilisation 7121 
during each exercise session (increased cumulative lipid utilisation), an increased 7122 
content of proteins involved in GLUT4 trafficking and insulin signalling and 7123 
remodelling of the phospholipid pool in exercised skeletal muscle. Markers of 7124 
mitochondrial oxidative capacity and capacity for lipid utilisation (CPT-1 or CD36 7125 
protein levels) did not clearly differ in skeletal muscle or when measured at a 7126 
whole-body level (i.e. peak oxygen uptake and fat utilisation rates during an 7127 
incremental exercise test) with exercise before versus after nutrient ingestion. In 7128 
this figure the dashed line shows that markers of mitochondrial oxidative capacity 7129 
were not differentially altered with nutrient-exercise timing despite oral glucose 7130 
insulin sensitivity increasing with exercise training before versus after breakfast. 7131 
 7132 
Abbreviations:  7133 
GLUT4 = glucose transporter 4 7134 
NEFA = non-esterified fatty acid 7135 
IMTG = intramuscular triglyceride 7136 
AMPK = 5' AMP-activated protein kinase 7137 
PGC1α = peroxisome proliferator activated receptor gamma coactivator 1 alpha 7138 
OXPHOS = oxidative phosphorylation complexes 7139 
CPT-1 = carnitine palmitoyltransferase I 7140 
FAT/CD36 = fatty acid translocase/cluster of differentiation 36 7141 
Akt = protein kinase B;  7142 
AS160 = Akt substrate of 160 kDa 7143 































A second aim of this thesis was to investigate changes in energy balance with 7145 
altered nutrient-exercise timing. Prior research demonstrated that the omission 7146 
of breakfast before exercise was incompletely compensated for via a higher post-7147 
exercise energy intake in healthy men (15, 16). A lower energy intake over 24 h 7148 
with pre-exercise breakfast omission has also been attributed to a lower energy 7149 
intake from post-exercise meals and snacks (16). This may be explained by the 7150 
glycogenostatic theory, which speculates that reducing carbohydrate utilisation 7151 
during exercise may help to protect against compensation through a higher post-7152 
exercise energy intake (17). The research in Chapter 5 showed that in healthy 7153 
men, the omission versus consumption of breakfast before exercise was not 7154 
compensated for with a higher post-exercise energy intake, nor a decreased 7155 
energy expenditure, creating a more negative 24-h energy balance. Men with 7156 
higher blood glucose disposal rates during fasted-exercise (suggesting a higher 7157 
rate of liver carbohydrate utilisation) also consumed more energy at lunch versus 7158 
their resting trial. This is consistent with the evidence that a higher liver glycogen 7159 
content in mice is associated with a lower energy intake and together suggests 7160 
that the liver glycogen content may be a regulator of post-exercise energy intake 7161 
compensation (355, 469). However, this finding needs to be confirmed with direct 7162 
measures of liver glycogen utilisation during exercise. The implications of these 7163 
findings and this research area was recently reviewed by Dr Mark Hopkins (497). 7164 
 7165 
Due to the incomplete compensation for breakfast omission prior to exercise, this 7166 
strategy might create the conditions for greater losses in body mass compared to 7167 
eating breakfast before exercise. However, any acute change in energy balance 7168 
over 24 h needs to persist over a prolonged time period for changes in body mass 7169 
(251). As adjustments in energy intake to energy deficits from exercise are 7170 
thought to be regulated over > 24 h (498, 499), more research is now needed to 7171 
investigate long-termer changes in energy balance and body mass with regular 7172 
exercise training and breakfast omission versus consumption. However, regularly 7173 
exercising in a fasted state and consuming breakfast after the exercise does not 7174 
appear to increase losses in body- or fat-mass over 4-6 weeks, relative to when 7175 




Chapter 6 was the first to assess changes in all components of energy balance 7177 
when manipulating nutrient-exercise timing during supervised exercise training in 7178 
men classified as overweight. Performing exercise increased average daily PAEE 7179 
compared to a non-exercise group, but no meaningful differences in average daily 7180 
self-reported energy intake, objectively measured energy expenditure, nor 7181 
changes in body mass or the ratio of waist-to-hip circumference were evident 7182 
between the two exercise groups. This suggests that exercising before versus 7183 
after breakfast might not create the conditions for greater losses in body mass 7184 
when the same nutrition is consumed post-exercise. Future research could now 7185 
establish whether the acute energy deficit created by omitting breakfast and 7186 
exercising translates into greater body mass losses over time.  7187 
 7188 
One potential concern with exercise during morning fasting is a detrimental effect 7189 
this could have for whole-body protein balance. Protein balance is determined by 7190 
rates of protein synthesis versus protein breakdown, with synthesis exceeding 7191 
breakdown following meals and the converse of this apparent during periods of 7192 
fasting, so that a balance is achieved over a typical day (500). After an overnight 7193 
fast the reduced availability of dietary amino acids and low circulating insulin 7194 
concentrations shifts this equilibrium towards protein breakdown (501). Fasting 7195 
for 72 h doubles rates of amino acid efflux from muscle versus a 10-h fast and 7196 
liberated amino acids can undergo gluconeogenesis, thus allowing protein to 7197 
contribute to energy metabolism (502). Whilst a 72-h fast is not representative of 7198 
daily living for most people in developed countries, exercise during fasting versus 7199 
after nutrient intake may alter protein balance, as fasting and exercise depress 7200 
muscle protein synthesis, with a positive protein balance only achieved if amino 7201 
acids availability is increased (503). In Chapter 3, a more negative 24-h protein 7202 
balance was shown with breakfast omission versus consumption before exercise 7203 
(mean [n95% CI]: 25 g [18 to 32] versus 35 g [25 to 44]; p=0.01) which is likely 7204 
due to an incomplete compensation in energy intake for the 19 g of protein in the 7205 
breakfast. The effect of only altering nutrient-exercise timing on protein balance 7206 
during exercise training should be studied, as ingesting protein in isolation before 7207 




As a higher turnover of endogenous lipid pools with exercise performed before 7209 
versus after nutrient intake might, at least partially, explain augmented health-7210 
related adaptations to training (167, 168), understanding any effect of protein 7211 
ingestion on lipid utilisation during exercise is important. Including whey protein 7212 
in meals (50 % protein, 40 % carbohydrate and 10 % fat) consumed during rest 7213 
does not suppress rates of lipid utilisation to the same extent as when an 7214 
isoenergetic carbohydrate-only meal is consumed, even in the presence of blood 7215 
insulin concentrations that do not clearly differ (505). In another cross-over study, 7216 
10 men performed 45 min of moderate-intensity cycling after prior muscle 7217 
glycogen depletion (506). They ingested 20 g of casein hydrolysate 45 min 7218 
before-, 10 g during- and 20 g post-exercise or a placebo. No clear differences 7219 
between those trials in whole-body lipid utilisation or blood NEFA concentrations 7220 
during exercise were shown, suggesting that if protein is consumed in isolation, 7221 
lipid metabolism may not be supressed versus exercise during fasting. Despite 7222 
this, a time x trial interaction effect was reported for blood glycerol, with lower 7223 
concentrations in the protein trial, which suggests that ingesting protein before- 7224 
and during-exercise blunts the net mobilisation of lipids from the adipose tissue 7225 
compared to fasted exercise. Also, (although the difference was not statistically 7226 
significant) lipid utilisation rates were ~ 0.10 g·min-1 lower with protein ingestion. 7227 
 7228 
In another study, 9 men cycled for 2 h at 70 % V̇O2 peak before breakfast or after 7229 
having consumed whey protein or a leucine-enriched whey gel providing 22 g 7230 
protein 60 min pre-, 22 g during- and 22 g post-exercise (507). In this study, 7231 
urinary nitrogen excretion was not measured so a contribution of protein to energy 7232 
metabolism was not accounted for, so these results should be interpreted with 7233 
caution. However, no clear differences were shown between trials for whole-body 7234 
lipid utilisation rates during exercise [(mean ± SEM); whey 0.37 ± 0.26, leucine 7235 
0.36 ± 0.24, fasted 0.34 ± 0.24 g·min-1] or for blood NEFA concentrations, despite 7236 
higher blood insulin concentrations in the protein trials. However, as mentioned, 7237 
a contribution of protein to energy metabolism was not accounted for, and when 7238 
a similar dose of protein is provided, protein utilisation is increased (508). As the 7239 




protein consumption before exercise would decrease the RER and potentially 7241 
result in an overestimation of lipid utilisation rates, when this is not accounted for. 7242 
Despite this, a study that did account for a utilisation of protein in estimations of 7243 
substrate utilisation also reported that consuming protein (20 g) after exercise 7244 
does not supress rates of whole-body lipid utilisation during subsequent rest or 7245 
exercise versus exercise during morning fasting, whereas whole-body lipid 7246 
utilisation rates during exercise were decreased when carbohydrate (40 g) was 7247 
ingested prior [(mean ± SD): fasting: 0.57 ± 0.13; protein 0.52 ± 0.08; 7248 
carbohydrate 0.44 ± 0.12 g·min-1 (509)]. Although confirmatory research is now 7249 
required, if stimulating a higher rate of lipid utilisation during exercise is important 7250 
for training-induced changes in oral-glucose insulin sensitivity (Chapter 6), eating 7251 
a protein-rich meal and avoiding dietary carbohydrates before exercise may be 7252 
an alternative option to exercising during a morning fast. Further investigations of 7253 
any differences in the stores of lipids utilised during exercise after an overnight 7254 
fast versus after protein ingestion would also be beneficial, in light of the results 7255 
in Chapter 6, showing a blunting of IMTG utilisation with exercise after breakfast.  7256 
 7257 
The extent to which the timing of exercise throughout the day mediates training 7258 
responses remains to be clarified in humans (and independent of nutrient status). 7259 
A study in mice used a transcriptomic and metabolic approach to investigate the 7260 
impact of a single bout of exercise performed in the morning compared to the 7261 
evening on skeletal muscle metabolism and suggested that global remodelling of 7262 
skeletal muscle may be altered by the timing of exercise during the day (510). 7263 
Many biological processes relating to energy metabolism are characterised by 7264 
daily variations controlled by a central clock located in the hypothalamus and 7265 
clocks located in peripheral tissues (511). The circadian clock in skeletal muscle 7266 
is proposed to play an important role in the regulation of muscle metabolism and 7267 
its regulation may be linked to energy sensors such as AMPK. Peripheral clocks 7268 
may also be sensitive to feeding (512) and dietary challenges (513). The rodent 7269 
study suggests that this regulation may extend to exercise, but this now needs to 7270 
be confirmed in humans. A recent study (514) in humans did suggest that (when 7271 




health benefits to performing exercise in the afternoon versus the morning for 7273 
individuals with T2D. However, in Chapter 6, when the timing of exercise per se 7274 
did not differ across exercise groups, nutrient-exercise interactions also mediated 7275 
adaptations to training. If the timing of exercise during the day also alters these 7276 
responses (in a fasted- versus fed-state), results from studies with exercise in the 7277 
morning may not be applied to exercise at other times. Together these studies all 7278 
demonstrate the sensitivity of exercise to the conditions in which it is performed.  7279 
 7280 
Moderate-intensity endurance-type exercise facilitates the biggest increase in 7281 
lipid utilisation versus rest and also the greatest difference in lipid utilisation with 7282 
exercise and prior breakfast consumption versus omission. Indeed, at higher 7283 
intensities carbohydrates are a greater contributor to metabolism, regardless of 7284 
whether the exercise is performed in the fed- versus fasted-state (249). As such, 7285 
if a higher rate of lipid utilisation with exercise before nutrient-intake is important 7286 
for adaptations related to health, this effect may be most apparent with moderate 7287 
intensity exercise. Nonetheless, future research could investigate the effects of 7288 
altered nutrient-timing with other forms of exercise that are commonly undertaken 7289 
in developed countries, as alternatives to endurance-type exercise. Secondly, 7290 
whether a minimal number of sessions per week need to be performed before 7291 
versus after nutrient-intake for greater increases in oral-glucose insulin sensitivity 7292 
should be studied (and whether increasing the overall exercise dose performed 7293 
reduces differences between exercise performed in the fasted versus fed-state). 7294 
Investigating any effects of changing the meal composition or the specific timing 7295 
of pre-exercise meals before exercise may also provide insights for people who 7296 
cannot (or prefer not to) exercise during morning fasts. Indeed, whole-body lipid 7297 
utilisation rates are higher with exercise performed before versus after consuming 7298 
carbohydrates but the magnitude of this difference can also depend on the meal 7299 
content (e.g. the glycaemic index) and the length of the fast between the last meal 7300 
consumed and the exercise bout (270). Finally, whether performing exercise 7301 
before versus after breakfast (with no carbohydrate consumed during exercise) 7302 




The research in this thesis focused on blood glucose regulation but acute bouts 7304 
of exercise before versus after eating may also be more efficacious for lowering 7305 
lipidemic responses to the meal, due to a greater activation of LPL in blood and 7306 
skeletal muscle after exercise (515, 516). In Chapter 6, glycerol-blanked fasting 7307 
blood triglyceride concentrations were lowered by performing exercise training 7308 
but the magnitude of this response did not differ with exercise performed before 7309 
versus after nutrient intake. Other studies that have manipulated nutrient-timing 7310 
in relation to exercise show either no change in fasting blood lipid concentrations 7311 
(13, 310) or decreases with training, but with the magnitude of this decrement 7312 
being similar (11, 12). However, future work could now investigate postprandial 7313 
lipidaemia with regular exercise performed before versus after breakfast.  7314 
 7315 
In this thesis only men were included to remove sex differences as a potential 7316 
confounding factor for key outcomes that were reported. During endurance-type 7317 
exercise of the same relative intensity, a contribution of lipids to metabolism is 7318 
often higher in women, particularly when sex differences in body composition and 7319 
cardiorespiratory fitness are accounted for (97, 517, 518). A higher rate of lipid 7320 
utilisation during exercise in women has been attributed to effects of oestrogens, 7321 
an increased expression of lipid metabolism proteins, a higher intramuscular lipid 7322 
content and an increased proportion of type I muscle fibres in women versus men 7323 
(519). Pre-menopausal women are also typically more insulin sensitive than men 7324 
matched for BMI and training status, likely due to differences in oestrogen and 7325 
adipokine secretion and/or the size of adipose-tissue depots (520). To complicate 7326 
this further, the contribution of lipids to metabolism and insulin sensitivity in 7327 
women changes during the menstrual cycle and whilst this can be accounted for 7328 
during a study, the length of the menstrual cycle is not always uniform. Although 7329 
confirmatory research is now required, there is no current evidence to suggest 7330 
that results from this thesis should not be applied to women, as omitting (versus 7331 
consuming) nutrients before exercise increases lipid utilisation in both sexes (67).  7332 
 7333 
Collectively, the research in this thesis has revealed that the timing of meals in 7334 




glucose metabolism. For meals consumed immediately after cycling exercise 7336 
consuming a prior breakfast increases plasma glucose appearance rates and 7337 
glucose disposal rates in healthy men, to the extent that a balance is achieved 7338 
and plasma glucose concentrations do not clearly differ versus when breakfast is 7339 
omitted. Performing exercise before nutrient intake increases fat utilisation during 7340 
the activity and this occurs in response to a single bout of exercise and is also 7341 
sustained throughout a period exercise training. With regular exercise training, 7342 
consuming nutrients after exercise and performing exercise during a morning fast 7343 
is more efficacious for improving oral glucose insulin sensitivity and augments 7344 
intramuscular adaptations relating to energy sensing, glucose transport and the 7345 
phospholipid composition in overweight men, compared to when carbohydrates 7346 
are ingested before the exercise. These changes may be due to a higher rate of 7347 
lipid utilisation during each bout of exercise performed and/or aspects relating to 7348 
energy sensing in exercised muscle. In healthy men, omitting versus consuming 7349 
breakfast before exercise may be most favourable for creating a negative energy 7350 
balance over that day. However, after 4-6 weeks of training, any changes in body 7351 
mass or behavioural components of energy balance do not consistently or clearly 7352 
differ with exercise before versus after (the same) nutrient intake. Therefore, for 7353 
changes in body mass, the energy deficit from exercise and/or breakfast omission 7354 
is the main consideration, whilst for the regulation of postprandial glycemia, the 7355 
specific timing of nutrient intake in relation to exercise has a mediating role, with 7356 
a heightened response to fasted- exercise. Important next steps include: 7357 
 7358 
1) Characterising substrate use during exercise performed before versus 7359 
after breakfast (with no carbohydrate ingested during exercise) in humans 7360 
with and without obesity, with a focus on IMTG and muscle glycogen (by 7361 
using tracer techniques, MRS and/or transmission electron microscopy). 7362 
2) Designing exercise interventions for health that include different exercise 7363 
modes and intensities (e.g. high intensity interval and moderate-intensity 7364 
endurance-type exercise) and periodising food intake accordingly.  7365 
3)  Investigating the long-term impact of omitting breakfast and exercising on 7366 
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